# Industria y Comercio

SUPERINTENDENCIA

P. C. T.

Delegatura de propiedad Industrial

División de Nuevas Creaciones

04120065

SOLICITUD

# PATENTE DE INVENCIÓN

21. **EXPEDIENTE No.** 04120065

54. **TÍTULO** Inhibidores de la peptido-Desformilasa.

51. **CLASIFICACIÓN INTERNACIONAL** A61K 31/16

71. **SOLICITANTE** Smithkline - Beecham Corporation.

**DOMICILIO** One franklin plaza, Philadelphia, Pa. 19101, Estado Unidos de América

74. **APODERADO** Carlos R. Olarte

22. **BOGOTÁ, D. C.,** Noviembre 29, 2004

(FORMA P-10)

SS

04/100.

# OLARTERAISBECK

Industria y Comercio
SUPERINTENDENCIA

SUPERINDUSTRIA Y COMERCIO
Radicacion : 04120065 00000000 Folios: 319
Fecha (AMD): 2004-11-29 17:36:04
Tramite : 811 PCT-PATENT 379 FASE NACI 411 PRESENTA
Dependencia: 2000 DIVISION DE NUEVAS CREACIONES

**FORMULARIO ÚNICO DE SOLICITUD DE PATENTE**
**PCT**
**ENTRADA EN FASE NACIONAL**

**(1) SOLICITUD DE:**

[X] Patente de Invención. [ ] Patente de Modelo de Utilidad.

[ ] Capítulo I. [X] Capítulo II.

**(2) SOLICITANTE (71)**

Nombre: SMITHKLINE BEECHAM CORPORATION
Dirección: One Frankline Plaza, Philadelphia PA 19101, Estados Unidos de América.
Nacionalidad o Domicilio: ESTADOUNIDENSE
Lugar de Constitución: ESTADOS UNIDOS DE AMERICA
Teléfono: _____ Fax: _____
E-mail: _____

IDENTIFICACIÓN
C.C. [ ] NIT [ ]
C.E. [ ] Otro [ ]
Cual _____
Número _____

**(3) REPRESENTANTE APODERADO**

Nombre: CARLOS R. OLARTE
Dirección: World Trade Center Torre A, Calle 100 No. 8A-37 Piso 10
Teléfono: 601-7700 Fax: 601-7799
E-mail: office@olarteraisbeck.com

IDENTIFICACIÓN
C.C. [x] NIT [ ]
C.E. [ ] Otro [ ]
Cual _____
Número 79.782.747 Btá
TP 74.295

**(4) INVENTOR (ES) (72)**

Nombre: KELLY AUBART, ANDREW B. BENOWITZ, SIEGFRIED B. CHRISTENSEN, JOSEPH M. KARPINSKI, JINHWA LEE, DOMINGOS J. SILVA.
Dirección: 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, Estados Unidos de América.
Nacionalidad o Domicilio: ESTADOUNIDENSE

**(5) PCT (86)**

Solicitud Internacional No. PCT/US03/17054 Fecha Mayo 30, 2003

Publicación Internacional No. WO 03/101442 Fecha Diciembre 11, 2003

**(6) Título (54)** INHIBIDORES DE LA PEPTIDO-DESFORMILASA (Folio 323)

**(7) Clasificación Internacional (51)** A61K 31/16

**(8) Prioridad** SI [X] N [ ]

| (33) País de Origen | (32) Fecha | (31) Número de Solicitud |
|---|---|---|
| US | Mayo 31, 2002 | 60/384,457 |
| | | |
| | | |
| | | |

**(9) Comprobante de pago No.** 87, 775 **Fecha** Noviembre 10, 2004

(10) **ANEXOS**

- [x] Comprobante de pago de la tasa de presentación de la solicitud.
- [ ] Documento que acredita la existencia y representación legal cuando el solicitante sea persona jurídica.
- [x] Poderes, si fuere el caso.
- [ ] Documento de cesión del inventor al solicitante o a su causante.
- [ ] Declaraciones.
- [x] Copia de la solicitud internacional. (Resumen, descripción, reivindicaciones, dibujos).
- [x] Traducción de la solicitud internacional al castellano. (Resumen, descripción, reivindicaciones, dibujos).
- [x] Copia del examen preliminar internacional efectuado por la Autoridad Internacional de Examen Preliminar (IPEA).
- [ ] Traducción del examen preliminar internacional efectuado por la IPEA.
- [ ] De ser el caso, copia del contrato de acceso.
- [ ] De ser el caso, documento que acredite la licencia o autorización de uso de conocimientos tradicionales de las comunidades indígenas.
- [ ] De ser el caso, certificado de depósito del material biológico.
- [ ] Arte final 12 x 12.
- [ ] De ser el caso, información sobre otras solicitudes de patente o títulos obtenidos en el extranjero por el mismo titular o su causante, relacionadas parcial o totalmente con la invención de esta solicitud.
- [ ] De ser el caso, modificaciones efectuadas a la solicitud internacional.
- [x] Otros. Búsqueda Internacional

(12) Solicito la concesión de la patente,

NOMBRE: CARLOS R. OLARTE FIRMA:

C.C. 79.782.747 Btá T.P. 74.295

3

SUPERINDUSTRIA Y COMERCIO
Radicacion : 04120065 00000000 Folios: 319
Fecha (AMD): 2004-11-29 17:36:04
Tramite : 811 PCT-PATENT 379 FASE NACI 411 PRESENTAN
Dependencia: 2020 DIVISION DE NUEVAS CREACIONES

NIT : 800176089-2

RECIBO OFICIAL DE CAJA : 4 - 87,775
FECHA : NOVIEMBRE 10 DE 2004

##### C O N S I G N A C I O N #####

| DEPOSITANTE | TIPO PAGO | BANCO | CUENTA | No. PAGO | FECHA PGO | Vr. PAGO |
|---|---|---|---|---|---|---|
| FREDERICK TORRES | CONSIGNACION | BANCO POPULAR | 050-00110-6 | 32717475 | 10/11/2004 | 722,000.00 |

##### C O N C E P T O #####

| CANT. | RENTISTICO | CONCEPTO | | TOTAL CONCEPTO |
|---|---|---|---|---|
| 1 | 90005-01-01 SOLICITUDES | 1 TRAMITES DE SOL. DE PATENTE DE IN | | 422,000.00 |
| | | TOTAL : | $ | 422,000. |

SON: CUATROCIENTOS VEINTIDOS MIL PESOS

RESPONSABLE : _____

RECIBO DE CAJA APLICADO AL ASUNTO No.

Traducción oficial del Inglés por Marlén Neira Castro, resolución 2117 del Ministerio de Justicia de Colombia

4

**APOSTILLA EN PODER DE REPRESENTACIÓN DE**

**SMITHKLINE BEECHAM CORPORATION**

**PODER DE REPRESENTACION**

Bilingüe inglés- español otorgado en Brentford, Middlesex, Inglaterra el 13 de agosto de 2003 y firmado por Peter John Giddings, Apoderado y Funcionario autorizado.

Certificado de Notario De Pinna en español certificando que Peter John Giddings es apoderado de Smithkline Beecham Corporation, firmado por James Kerr Milligan.

**APOSTILLA**

(Convención de la Haya del 5 de octubre de 1961)

1. País: Reino Unido de Gran Bretaña e Irlanda del Norte
   - Este documento Público
2. ha sido firmado por James Kerr Milligan
3. Quien ejerce funciones de Notario público
4. Lleva el sello del Notario público

CERTIFICADO

5. En Londres
6. El 14 agosto 2003
7. Por el Secretario de Estado Principal de su Majestad para Asuntos exteriores y de la Mancomunidad
8. No. G229470
9. Gran Sello de la Oficina de Asuntos exteriores y de la Mancomunidad
10. Firma legible de J. Garbrah- Por el Secretario de Estado

---

Si el documento se usa en un país que no pertenece a la Convención de la Haya del 5 de octubre de 1961 debe pasar por la sección consular de la Misión que representa el país.

Es traducción fiel del inglés, con copia archivo para confron[illegible]

COMO NOTARIA ONCE DE ESTE CIRCULO HAGO CONSTAR QUE ESTA COINCIDE CON EL ORIGINAL QUE TUVE A LA VISTA.

30 DIC 2003

BOGOTA, D.C. - COLOMBIA
ZULMA NAVARRO DE BAUTISTA
NOTARIA ONCE (11)

Marlen Neira C

MARLEN NEIRA CASTRO
Traductor e Intérprete Oficial
Inglés - Español - Inglés
Resolución No. 2117 del 7 Oct 1987

# DE PINNA
NOTARIES

Yo, el infrascrito, **JAMES KERR MILLIGAN**, Notario Público de la Ciudad de Londres, Inglaterra, por la Autoridad Real debidamente admitido y juramentado,

**C E R T I F I C O:**

**QUE** es auténtica la firma "P. Giddings" suscrita al pie del adjunto Poder, por ser del puño y letra del Señor Don **PETER JOHN GIDDINGS**, cuya identidad me consta, Apoderado de la corporación denominada **"SMITHKLINE BEECHAM CORPORATION"**, corporación legalmente constituída y existente de acuerdo con las leyes del Estado de Pensilvania, Estados Unidos de América, con domicilio social en 1, Franklin Plaza, Philadelphia, Pensilvania 19101, Estados Unidos de América;

**QUE** el citado Señor Don **PETER JOHN GIDDINGS** está debida y suficientemente autorizado para firmar documentos de esta clase, en virtud del Poder otorgado en su favor por la referida Sociedad fechado el 11 de julio de 2002, copia del cual he tenido a la vista.

**Y QUE** los objetos para los cuales se otorgó dicho Poder se encuentran dentro de los objetos o actividades de la citada Sociedad, de acuerdo con la Escritura Constitutiva y los Estatutos Sociales, los cuales he tenido a la vista.

**Y PARA QUE CONSTE** donde y como convenga y fuere necesario expido el presente Certificado que firmo y sello en dicha Ciudad de Londres, el día de hoy trece de agosto del año dos mil tres.

CONSULADO DE COLOMBIA
COTEJADO CON EL ORIGINAL QUE HE TENIDO A LA VISTA
30 OCT 2003
BOGOTÁ, D.C. - COLOMBIA
NOTARIA ONCE (11)

**JAMES KERR MILLIGAN**
**Notario Público de Londres, Inglaterra**

SCRIVENER NOTARIES

DE PINNA
85 Piccadilly London W1J 0LJ
Telephone: +44 (0)20 7355 5500 Facsimile: +44 (0)20 7355 0200 DX No. 42521 Piccadilly 1

**APOSTILLE**
(Hague Convention of 5 October 1961 / Convention de La Haye du 5 octobre 1961)

**UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND**

1. Country: United Kingdom of Great Britain and Northern Ireland
   Pays: Royaume-Uni de Grande-Bretagne et d'Irlande du Nord

   This public document / Le présent acte public

2. Has been signed by — James Kerr Milligan
   a été signé par

3. Acting in the capacity of — Notary Public
   agissant en qualité de

4. Bears the seal/stamp of — The Said Notary Public
   est revêtu du sceau/timbre de

   Certified/Attesté

5. at London/à Londres — 6. the/le 14 August 2003

7. by Her Majesty's Principal Secretary of State for Foreign and Commonwealth Affairs /
   par le Secrétaire d'Etat Principal de Sa Majesté aux Affaires Etrangères et du Commonwealth.

8. Number/sous No — G229470

9. Stamp:
   timbre:

10. Signature: J. Garbrah

*For the Secretary of State / Pour le Secrétaire d'Etat*

If this document is to be used in a country which is not party to the Hague Convention of 5 October 1961,
it should be presented to the consular section of the mission representing that country.

# OLARTERAISBECK

OLARTE RAISBECK & FRIERI, LTDA.
LEGAL & PROFESSIONAL SERVICES

WORLD TRADE CENTER – TORRE C
CALLE 100 NO. 8A-55 PISO 10
BOGOTA, COLOMBIA
TELEPHONE: +57-1 638-6200
FAX: +57-1 638-6201

www.olarteraisbeck.com


6

## Power of Attorney

The undersigned,

SmithKline Beecham Corporation

domiciled in

One Franklin Plaza, P O Box 7929, Philadelphia, PA 19101, United States of America

by means of these presents hereby grants to **Carlos R. Olarte, J. Ian Raisbeck and Ana María Frieri** full and sufficient Power of Attorney to file, prosecute, obtain, defend and enforce any and all of the company's **Patents, Utility Models and Industrial Designs** in the Republic of Colombia, to which end it empowers them to take all steps necessary before any administrative or judicial authority of any class for the objects stated, to file petitions, appeals, replies and oppositions, pay taxes and annuities, request testimonies, receive documents and securities, abandon applications and collect refimds. Sufficient power is hereby granted to receive notifications on behalf of the Company, to confer powers on those who are to represent the company judicially and extrajudicially, to answer in court in the matter of all claims and demands that may be presented in connection with the objects stated, giving them likewise power to substitute these presents and revoke such substitutions.

## Poder

El suscrito,

SmithKline Beecham Corporation

domiciliado en

One Franklin Plaza, P O Box 7929, Philadelphia, PA 19101, United States of America

por medio del presente otorga a **Carlos R. Olarte, J. Ian Raisbeck y Ana María Frieri** poder especial, amplio y suficiente para presentar, tramitar, obtener, defender y hacer respetar todas y cualquiera de **Patentes, Modelos de Utilidad y Diseños Industriales** de la compañía en la República de Colombia, a cuyo efecto los faculta para dar todos los pasos necesarios ante cualquier autoridad administrativa o judicial de cualquier jerarquía para cumplir con lo encomendado, elevar solicitudes, apelaciones, respuestas y oposiciones, pagar impuestos y anualidades, solicitar testimonios, recibir documentos y valores, desistir y percibir. Se concede poder bastante para recibir notificaciones a nombre de la compañía, otorgar poderes a quienes vayan a representar a la compañía judicial y extrajudicialmente, responder en juicio a todas las reclamaciones o demandas que por motivo de lo encomendado se presentaren, dándoles asimismo facultad para sustituir el presente y revocar dichas sustituciones.

Signature/Firma: _____

Peter John GIDDINGS as Attorney and Authorised Official

Date/Fecha: 13 August 2003

City,Country/Ciudad,País: Brentford, Middlesex, England

DESPACHO NOTARIO ONCE DE ESTE CIRCULO HAGO CONSTAR QUE ESTA FOTOCOPIA COINCIDE CON EL ORIGINAL QUE TUVE SIENDO A LA VISTA
30 DIC 2003
BOGOTÁ, D.C. - COLOMBIA
ZULMA NAVARRO DE BAUTISTA
NOTARIA ONCE (E)

# PCT

## REQUEST

**The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty**

**For receiving Office use only**

International Application No:

International Filing Date

Name of receiving Office and "PCT International Application"

Applicant's or agent's file reference
**P51358**

**Box No. I TITLE OF INVENTION**

**PEPTIDE DEFORMYLASE INHIBITORS**

**Box No. II APPLICANT**

Name and Address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)*

**SmithKline Beecham Corporation**
**One Franklin Plaza**
**Philadelphia, Pennsylvania 19103**
**United States of America**

Telephone No. **610-270-5019**

Facsimile No. **610-270-5090**

State *(i.e. country)* of nationality:
**United States of America**

State *(i.e. country)* of residence:
**United States of America**

This person is applicant for the purposes of: ☐ all designated States ☒ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental box

**Box No. III FURTHER APPLICANTS AND/OR (FURTHER) INVENTORS**

Name and Address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)*

**Aubart, Kelly M.**
**1250 South Collegeville Road**
**Collegeville, Pennsylvania 19426**
**United States of America**

This person is:
☐ applicant only
☒ applicant and inventor
☐ inventor only *(If this check-box is marked, do not fill in below)*

State *(i.e. country)* of nationality:
**United States of America**

State *(i.e. country)* of residence:
**United States of America**

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental box

☒ **Further applicants and/or (further) inventors are indicated on a continuation sheet**

**Box No. IV AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE**

The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as: ☒ agent ☐ common representative

Name and Address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country)*

Simon, Soma G.
SMITHKLINE BEECHAM CORPORATION
Corporate Intellectual Property, UW2220
709 Swedeland Road, P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939
United States of America

Telephone No.
610-270-5019

Facsimile No.
610-270-5090

Agent's Registration No. with the Office:

☐ Address for correspondence: Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent

## Continuation of Box No. III FURTHER APPLICANTS AND/OR (FURTHER) INVENTORS

*If none of the following sub-boxes is used, this sheet is not to be included in the request*

Name and Address *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (the is, country) of residence if no State of residence is indicated below.)*

**Benowitz, Andrew B.**
**1250 South Collegeville Road**
**Collegeville, Pennsylvania 19406**
**United States of America**

This person is:
☐ applicant only
☒ applicant and inventor
☐ inventor only *(if this check-box is marked, do not fill in below)*

State *(i.e. country)* of nationality: **United States of America**

State *(i.e. country)* of residence: **United States of America**

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental box

Name and Address *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (the is, country) of residence if no State of residence is indicated below.)*

**Christensen, Siegfried B., IV,**
**1250 South Collegeville Road**
**Collegeville, Pennsylvania 19426**
**United States of America**

This person is:
☐ applicant only
☒ applicant and inventor
☐ inventor only *(if this check-box is marked, do not fill in below)*

State *(i.e. country)* of nationality: **United States of America**

State *(i.e. country)* of residence: **United States of America**

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental box

Name and Address *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (the is, country) of residence if no State of residence is indicated below.)*

**Karpinski, Joseph M.**
**1250 South Collegeville Road**
**Collegeville, Pennsylvania 19426**
**United States of America**

This person is:
☐ applicant only
☒ applicant and inventor
☐ inventor only *(if this check-box is marked, do not fill in below)*

State *(i.e. country)* of nationality: **United States of America**

State *(i.e. country)* of residence: **United States of America**

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental box

Name and Address *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (the is, country) of residence if no State of residence is indicated below.)*

**Lee, Jinhwa**
**1250 South Collegeville Road**
**Collegeville, Pennsylvania 19426**
**United States of America**

This person is:
☐ applicant only
☒ applicant and inventor
☐ inventor only *(if this check-box is marked, do not fill in below)*

State *(i.e. country)* of nationality: **Korea**

State *(i.e. country)* of residence: **United States of America**

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental box

Name and Address *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (the is, country) of residence if no State of residence is indicated below.)*

**Silva, Domingos J.**
**1250 South Collegeville Road**
**Collegeville, Pennsylvania 19426**
**United States of America**

This person is:
☐ applicant only
☒ applicant and inventor
☐ inventor only *(if this check-box is marked, do not fill in below)*

State *(i.e. country)* of nationality: **Brazil**

State *(i.e. country)* of residence: **United States of America**

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental box

☐ Further applicants and/or (further) inventors are indicated on a continuation sheet

## Box No. V DESIGNATION OF STATES

The following designations are hereby made under Rule 4.9(a) *(mark the applicable check-boxes; at least one must be marked)*:

**Regional Patent**

☒ **AP** **ARIPO Patent:** GH Ghana, GM Gambia, KE Kenya, LS Lesotho, MW Malawi, MZ Mozambique, SD Sudan, SL Sierra Leone, SZ Swaziland ; TZ United Republic of Tanzania, UG Uganda, ZM Zambia, ZW Zimbabwe and any other State which is a Contracting State of the Harare Protocol and of the PCT

☒ **EA** **Eurasian Patent:** AM Armenia, AZ Azerbaijan, BY Belarus, KG Kyrgyzstan, KZ Kazakstan, MD Republic of Moldova, RU Russian Federation, TJ Tajikistan, TM Turkmenistan, and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT

☒ **EP** **European Patent:** AT Austria, BE Belgium, CH and LI Switzerland and Liechtenstein, CY Cyprus, CZ Czech Republic, DE Germany, DK Denmark,EE Estonia, ES Spain, FI Finland, FR France, GB United Kingdom, GR Greece, IE Ireland,IT Italy, LU Luxembourg, MC Monaco, NL Netherlands, PT Portugal, SE Sweden, SI Slovenia, SK Slovakia, TR Turkey and any other State which is a Contracting State of the European Patent Convention and of the PCT

☒ **OA** **OAPI Patent:** BF Burkina Faso, BJ Benin, CF Central African Republic, CG Congo, CI Côte d'Ivoire, CM Cameroon, GA Gabon GN Guinea, GQ Equatorial Guinea, GW Guinea Bissau, ML Mali, MR Mauritania, NE Niger, SN Senegal, TD Chad, TG Togo, and any other State which is a member State of OAPI and a Contracting State of the PCT *(if other kind of protection or treatment desired, specify on dotted line)*.....

**National Patent** *(if other kind of protection or treatment desired, specify on dotted line)*

| | | | | | |
|---|---|---|---|---|---|
| ☒ AE | United Arab Emirates | ☐ GH | Ghana | ☒ NO | Norway |
| ☒ AG | Antigua and Barbuda | ☐ GM | Gambia | ☒ NZ | New Zealand |
| ☒ AL | Albania | ☒ HR | Croatia | ☒ OM | Oman |
| ☐ AM | Armenia | ☒ HU | Hungary | ☒ PH | Philippines |
| ☐ AT | Austria | ☒ ID | Indonesia | ☒ PL | Poland |
| ☒ AU | Australia | ☒ IL | Israel | ☐ PT | Portugal |
| ☐ AZ | Azerbaijan | ☒ IN | India | ☒ RO | Romania |
| ☒ BA | Bosnia and Herzegovina | ☒ IS | Iceland | ☐ RU | Russian Federation |
| ☒ BB | Barbados | ☒ JP | Japan | ☒ SC | Seychelles |
| ☐ BG | Bulgaria | ☐ KE | Kenya | ☐ SD | Sudan |
| ☒ BR | Brazil | ☐ KG | Kyrgyzstan | ☐ SE | Sweden |
| ☐ BY | Belarus | ☒ KP | Democratic People's Republic | ☒ SG | Singapore |
| ☒ BZ | Belize | | of Korea | ☒ SI | Slovenia |
| ☒ CA | Canada | ☒ KR | Republic of Korea | ☐ SK | Slovakia |
| ☐ CH & LI | Switzerland and Liechtenstein | ☐ KZ | Kazakhstan | ☐ SL | Sierra Leone |
| ☒ CN | China | ☒ LC | Saint Lucia | ☐ TJ | Tajikistan |
| ☒ CO | Colombia | ☒ LK | Sri Lanka | ☐ TM | Turkmenistan |
| ☒ CR | Costa Rica | ☒ LR | Liberia | ☒ TN | Tunisia |
| ☒ CU | Cuba | ☐ LS | Lesotho | ☐ TR | Turkey |
| ☐ CZ | Czech Republic | ☒ LT | Lithuania | ☒ TT | Trinidad and Tobago |
| ☐ DE | Germany | ☐ LU | Luxembourg | ☐ TZ | United Republic of Tanzania |
| ☐ DK | Denmark | ☒ LV | Latvia | ☒ UA | Ukraine |
| ☒ DM | Dominica | ☒ MA | Morocco | ☐ UG | Uganda |
| ☒ DZ | Algeria | ☐ MD | Republic of Moldova | ☒ US | United States of America |
| ☒ EC | Ecuador | ☒ MG | Madagascar | ☒ UZ | Uzbekistan |
| ☐ EE | Estonia | ☒ MK | The Former Yugoslav Republic | ☒ VN | Vietnam |
| ☐ ES | Spain | | of Macedonia | ☒ YU | Yugoslavia |
| ☐ FI | Finland | ☒ MN | Mongolia | ☒ ZA | South Africa |
| ☐ GB | United Kingdom | ☐ MW | Malawi | ☐ ZM | Zambia |
| ☒ GD | Grenada | ☒ MX | Mexico | ☐ ZW | Zimbabwe |
| ☒ GE | Georgia | ☐ MZ | Mozambique | | |

Check boxes below reserved for designating States which have become party to the PCT after issuance of this sheet:

☐ ..... ☐ ..... ☐ .....

☐ ..... ☐ ..... ☐ .....

**Precautionary Designation Statement** In addition to the designations made above, the applicant also makes under Rule 4.9(b) all designations which would be permitted under the PCT except the designation(s) of none. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit. *(Confirmation of a designation consists of the filing of a notice specifying that designation and the payment of the designation and confirmation fees. Confirmation must reach the receiving Office within the 15-month time limit.)*

**Supplemental Box** *If the Supplemental Box is not used, this sheet need not be included in the request*

*1. If, in any of the Boxes, the space is insufficient to furnish all the information: in such case, write "Continuation of Box No...."[indicate the number of the Box] and furnish the information in the same manner as required according to the captions of the Box in which the space was insufficient; in particular*

*(i) If more than two persons are involved as applicants and/or inventors and no "continuation sheet" is available: in such case, write "Continuation of Box III" and indicate for each additional person the same type of information as required in Box No. III. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below;*

*(ii) if, in Box No. II or in any of the sub-boxes of Box No. III, the indication "the States indicated in the Supplemental Box" is checked: in such case, write "Continuation of Box No. II" or "Continuation of Box No. III" or "Continuation of Box Nos. II and No. III" (as the case may be), indicate the name of the applicant(s) involved and, nexxt to (each) such name, the State(s) (and/or, where applicable, ARIPO, Eurasion, European or OAPI patent) for the purposes of which the named person is inventor;*

*(iii)if, in Box No. II or in any of the sub-boxes of Box No. III, the inventor or the inventor/applicant is not inventor for the purposes of all designated States or for the purposes of the United States of America: : in such case, write "Continuation of Box No. II" or "Continuation of Box No. III" or "Continuation of Boxes Nos. II and III" (as the case may be), indicate the name of the inventor(s) and, next to (each) such name the State(s) (and/or, where applicable,ARIPO, Eurasian, European or OAPI patent) for the purposes of which the named person is inventor;*

*(iv)if, in addition to the agent(s) indicated in Box No. IV, there are further agents : in such case, write "Continuation of Box No. IV" and indicate for each further agent the same type of information as required in Box No. IV;*

*(v) if, in Box No. V, the name of any State (or OAPI) is accompanied by the indication "patent of addition," or "certificate of addition," or if, in Box No. V, the name of the United States of America is accompanied by an indication "Continuation" or "Continuation-in-part", in such case, write "Continuation of Box No. V" and the name of each State involved (or OAPI), and after the name of each such State (or OAPI), the number of the parent title or parent application and the date of grant of the parent title or filing of the parent application;*

*(vi)if, in Box VI, there are more than three earlier applications whose priority is claimed: in such case, write "Continuation of Box No. VI" and indicate for each additional earlier application the same type of information as required in Box No. VI.*

*(vii) if, in Box No. VI, the earlier application is an ARIPO application: in such case, write "Continuation of Box No. VI", specify the number of the item corresponding to that earlier application and indicate at least one country party to the Paris Convention for the Protection of Industrial Property for which that earlier application was filed.*

*2. If, with regard to the precautionary designation statement contained in Box No. V, the applicant wishes to exclude any State(s) from the scope of that statement: in such case, write "Designation(s) excluded from precautionary designation statement" and indicate the name of two-letter code of each State so excluded.*

*3. If the applicant claims, in respect of any designated Office, the benefits of provisions of the national law concerning non-prejudicial disclosures or exceptions to lack of novelty: in such case, write "Statement concerning non-prejudicial disclosures or exceptions to lack of novelty" and furnish the statement below.*

**Continuation of Box No. IV:**

Dinner, Dara L.
Dustman, Wayne J.
Fedon, Jason C.
Furman, Theodore R.
Gimmi, Edward R.
Hall, Linda E.
Hecht, Elizabeth J.
Henderson, Loretta J.
Kanagy, James M.
Kellerman, James
Kinzig, Charles M.
Lockenour, Andrea
Madden, Laura K.
Marjarian, William R.
McCarthy, Mary E.
Sieburth, Kathryn
Stein-Fernandez, Nora
Sutton, Jeffrey A.
Venetianer, Stephen
Winslow, Andrea

**All of SmithKline Beecham Corporation, address as indicated in Box No. IV.**

**Box No. VI PRIORITY CLAIM** ☐ Further priority claims are indicated in the Supplemental Box

Where earlier application is

| Filing Date of earlier application (day/month/year) | Number of earlier application | national application: country or member of WTO | regional application:* regional Office | international application: receiving Office |
|---|---|---|---|---|
| item (1) (31.05.02) 31 May 2002 | 60/384,457 | item (1) United States of America | | |
| item (2) | | | | |
| item (3) | | | | |

☐ **Further priority claims are indicated in the Supplemental Box.**

☒ The receiving Office is hereby requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) (*only if the earlier application was filed with the Office which for the purposes of the present international application is the receiving Office*) identified above as:

☐ all items ☒ item (1) ☐ item (2) ☐ item (3) ☐ item 4 ☐ item (5) ☐ other, see Supplemental Box

**Where the earlier application is an ARIPO application, it is mandatory to indicate in the Supplemental Box at least one country party to the Paris Convention for the Protection of Industrial Property for which that earlier application was filed (Rule 4.10(b)(ii)).....*

**Box No. VII INTERNATIONAL SEARCHING AUTHORITY**

Choice of International Searching Authority (ISA) (if two or more International Searching Authorities are competent to carry out the international search, indicte the Authority chosen; the two-letter code may be used):

ISA/US

Request to use results of earlier search; reference to that search (if an earlier search has been carried out by or requested from the International Searching Authority):

Date (day/month/year) Number Country (or regional Office)

**Box No. VIII DECLARATIONS**

| The following declarations are contained in Boxes Nos. VIII(I) to (v) (mark applicable check-boxes below and indicate in the right colmn the number of each type of declaration): | | | Number of declarations |
|---|---|---|---|
| ☐ | Box No. VIII(i) | Declaration as to the identity of the inventor | : |
| ☒ | Box No. VIII(ii) | Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent | :6 |
| ☒ | Box No. VIII(iii) | Declaration as to the applicant's entitlement, as at the international filing date, to claim the priority of the earlier application | :6 |
| ☒ | Box No. VIII(iv) | Declaration of inventorship (only for the purposes of the designation the United States of America) | :6 |
| ☐ | Box No. VIII(v) | Declaration as to non-prejudicial disclosures or exceptions to lack novelty | : |

**Box No. VIII(ii) DECLARATION: ENTITLEMENT TO APPLY FOR AND BE GRANTED A PATENT**
The declaration must conform to the standardized wording provided for in Section 212; see Notes to Boxes Nos. VIII, VIII(i) to (v) (in general and the specific Notes to Box No. VIII(ii). If this Box is not used, this sheet should not be included in the request.

Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent (Rules 4.17(ii) and 51*bis*.1(a)(ii)), in a case where the declaration under Rule 4.17(iv) is not appropriate:

SMITHKLINE BEECHAM CORPORATION is entitled to apply for and be granted a patent by virtue of the following:

an assignment from

**Aubart, Kelly M.**, 1250 South Collegeville Road, King of Prussia, PA 19426, dated 20 March 2003

**Benowitz, Andrew B.**, 1250 South Collegeville Road, King of Prussia, PA 19426, dated 20 March 2003

**Christensen, Siegfried B., IV**, 1250 South Collegeville Road, King of Prussia, PA 19426, dated 20 March 2003

**Karpinski, Joseph M.**, 1250 South Collegeville Road, King of Prussia, PA 19426, dated 20 March 2003

**Lee, Jinhwa**, 1250 South Collegeville Road, King of Prussia, PA 19426, dated 20 March 2003

**Silva, Domingos J.**, 1250 South Collegeville Road, King of Prussia, PA 19426, dated 20 March 2003

This declaration is made for the purposes of all designations.

☐ This declaration is continued on the following sheet, "Continuation of Box No. VIII(ii)".

**Box No. VIII(iii) DECLARATION: ENTTILEMENT TO CLAIM PRIORITY**

The declaration must conform to the standardized wording provided for in Section 213; see Notes to Boxes Nos. VIII, VIII(i) to (v) (in general) and the specific Notes to Box No. VIII(iii) and 51*bis*.1(a)(iii)

Declaration as to the applicant's entitlement, as at the international filing date, to claim the priority of the earlier application specified below, where the applicant is not the applicant who filed the earlier application or where the applicant's name has changed since the filing of the earlier application (Rules 4.17(iii) and 51*bis*.1(a)(iii)):

in relation to this international application,

SMITHKLINE BEECHAM CORPORATION is entitled to claim priority of earlier application No. 60/384,457 filed in the United States of America by virtue of the following:

an assignment from Inventors **Aubart, Kelly M.; Benowitz, Andrew B.; Christensen, Siegfried B., IV; Karpinski, Joseph M.; Lee, Jinhwa; and Silva, Domingos J.**, to SMITHKLINE BEECHAM CORPORATION, dated 20 March 2003.

This declaration is made for the purposes of all designations, except the designation of the United States of America.

☐ This declaration is continued on the following sheet, "Continuation of Box No. VIII(iii)".

**Box No. VIII(iv) DECLARATION: INVENTORSHIP (only for the purposes of the designation of the United States of America).** The declaration must conform to the following standardized wording provided for in Section 214; see Notes to Boxes Nos. VIII, VIII(i) to (v) (in general) and the specific Notes to Box No. VIII (iv). If this Box is not used, this sheet should not be included in the request.

**Declaration of Inventorship (Rules 4.17(iv) and 51*bis*.1(a)(iv))**
**for the purposes of the designation of the United States of America:**

I hereby declare that I believe I am the original, first and sole (if only one inventor is listed below) or joint (if more than one inventor is listed below) inventor of the subject matter which is claimed and for which a patent is sought.

This declaration is directed to the international application of which it forms a part (if filing declaration with application).

This application is directed to international application No. PCT/ (if furnishing declaration pursuant to Rule 26*ter*).

I hereby declare that my residence, mailing address, and citizenship are as stated next to my name.

I hereby state that I have reviewed and understand the contents of the above-identified international application, including the claims of said application. I have identified in the request of said application, in compliance with PCT Rule 4.10, any claim to foreign priority, and I have identified below, under the heading "Prior Application," by application number, country or Member of the World Trade Organization, day, month and year of filing, any application for a patent or inventor's certificate filed in a country other than the United States of America, including any PCT international application designating at least one country other than the United States of America, having a filing date before that of the application on which foreign priority is claimed.

Prior Applications; (prior to priority).....

I hereby acknowledge the duty to disclose information that is known by me to be material to patentability as defined by 37 C.F.R. §1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the PCT international filing date of the continuation-in-part.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the Uited States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name: **Kelly M. Aubart**

Residence: **1250 South Collegeville Road, Collegeville, PA 19426**

Mailing Address: GlaxoSmithKline, Corporate Intellectual Property - UW2220, P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Citizenship: **United States of America**

Inventor's Signature: Kelly Aubart Date: 3/20/03
(if not contained in the request, or if declaration is corrected or added under Rule 26*ter* after the filing of the international application. The signature must be that of the inventor, not that of the agent.)
(of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26*ter* after the filing of the international application)

Name: **Andrew B. Benowitz**

Residence: **1250 South Collegeville Road, Collegeville, PA 19426**

Mailing Address: GlaxoSmithKline, Corporate Intellectual Property - UW2220, P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Citizenship: **United States of America**

Inventor's Signature: Andrew B. Benowitz Date: 3/20/03
(if not contained in the request, or if declaration is corrected or added under Rule 26*ter* after the filing of the international application. The signature must be that of the inventor, not that of the agent.)
(of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26*ter* after the filing of the international application)

☐ This declaration is continued on the following sheet, "Continuation of Box No. VIII(iv)".

**Continuation of Box No. VIII(i) to (v) Declaration**

*If the space is insufficient in any of Boxes Nos. VIII(i) to (v) to furnish all the informatino, including in the case where more than two inventors are to be named in Box No. VIII (iv), in such case, write "Continuation of Box No. VIII " (indicate the item number of the Box) and furnish the information in the same manner as required for the purposes of the Box in which the space was insufficient. If additional space is needed in respect of two or more declarations, a separate continuation box must be used for each such declaration. If this Box is not used, this sheet should not be included in the request.*

Name: **Siegfried B. Christensen, IV**

Residence: **1250 South Collegeville Road, Collegeville, PA 19426**
Mailing Address: GlaxoSmithKline, Corporate Intellectual Property - UW2220, P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Citizenship: **United States of America**

Inventor's Signature: Siegfried B. Christensen Date: 3/20/03
(if not contained in the request, or if declaration is corrected or added under Rule 26*ter* after the filing of the international application. The signature must be that of the inventor, not that of the agent.)
(of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26*ter* after the filing of the international application)

Name: **Joseph M. Karpinski**

Residence: **1250 South Collegeville Road, Collegeville, PA 19426**
Mailing Address: GlaxoSmithKline, Corporate Intellectual Property - UW2220, P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Citizenship: **United States of America**

Inventor's Signature: Joseph Karpinski Date: 3/20/03
(if not contained in the request, or if declaration is corrected or added under Rule 26*ter* after the filing of the international application. The signature must be that of the inventor, not that of the agent.)
(of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26*ter* after the filing of the international application)

Name: **Jinhwa Lee**

Residence: **1250 South Collegeville Road, Collegeville, PA 19426**
Mailing Address: GlaxoSmithKline, Corporate Intellectual Property - UW2220, P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Citizenship: **Korea**

Inventor's Signature: Date: 3/20/03
(if not contained in the request, or if declaration is corrected or added under Rule 26*ter* after the filing of the international application. The signature must be that of the inventor, not that of the agent.)
(of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26*ter* after the filing of the international application)

Name: **Domingos J. Silva**

Residence: **1250 South Collegeville Road, Collegeville, PA 19426**
Mailing Address: GlaxoSmithKline, Corporate Intellectual Property - UW2220, P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Citizenship: **Brazil**

Inventor's Signature: Domingos Silva Date: 3/20/03
(if not contained in the request, or if declaration is corrected or added under Rule 26*ter* after the filing of the international application. The signature must be that of the inventor, not that of the agent.)
(of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26*ter* after the filing of the international application)

Sheet No. 10

| *This international application contains:* | | | This international application is accompanied by the following item(s) (mark the applicable check-boxes below and indicate in right column the number of each item): | Number of items |
|---|---|---|---|---|
| *(a) in paper form, the following number of sheets:* | | | | |
| request (including declaration sheets) | : | 10 | 1. ☒ fee calculation sheet : | 1 |
| | | | 2. ☒ separate signed power of attorney : | 2 |
| description (excluding sequence listings and/or tables related thereto) | : | 114 | 3. ☐ original general power of attorney : | |
| | | | 4. ☒ copy of general power of attorney : | 6 |
| claims | : | 23 | 5. ☐ statement explaining lack of signature : | |
| abstract | : | 01 | 6. ☐ priority document(s) identified in Box No. VI as item(s): : | |
| drawings | : | 00 | 7. ☐ translation of international application into (language): : | |
| **Sub-total number of sheets** | : | 148 | 8. ☐ separate indications concerning deposited microorganism or other biological materials : | |
| sequence listings | : | 0 | 9. ☐ sequence listings in computer readable *form (indicate type and number of carriers)* : | |
| tables related thereto : | : | 0 | (i) ☐ copy submitted for the purposes of international search under Rule 13*ter* only (and not as part of the international application) : | |
| (for both, actual number of sheets if filed in paper form, whether or not also filed in computer readable form; see (c) below) | | | (ii) ☐ *(only where check-box (b)(i) or (c)(I) is marked in left column)* additional copies including, where applicable, the copy for the purposes of international search under Rule 13*ter* : | |
| **Total number of sheets** | : | 148 | (iii) ☐ together with relevant statement as to the identity of the copy or copies with the sequence listings mentioned in left column : | |
| (b) ☐ only in computer readable form (Section 801(a)(i)) | | | 10. ☐ tables in computer readable form related to sequence listings (indicate type and number of carriers) : | |
| (i) ☐ sequence listings | | | (i) ☐ copy submitted for the purposes of international search under Section 802(b-*quarter*) only (and not as part of the international application) : | |
| (ii) ☐ tables related thereto | | | (ii) ☐ (only where check-box (b)(ii) or (c)(ii) is marked in left column) additional copies including, where applicable, the copy for the purposes of international search under Section 802 (b-*quarter*) : | |
| (c) ☐ also in computer readable form (Section 801(a)(ii)) | | | (iii) ☐ together with relevant statement as to the identity of the copy or copies with the tables mentioned in left column : | |
| (i) ☐ sequence listings | | | 11. ☐ other *(specify)*: : | |
| (ii) ☐ tables related thereto | | | | |
| **Type and number of carriers (diskette, CD-ROM, CD-R or other) on which are contained the** | | | | |
| ☐ sequence listings: | | | | |
| ☐ tables related thereto: | | | | |
| *(additional copies to be indicated under items 9(ii) and/or 10(ii), in right column)* | | | | |

| Figure of the drawings which should accompany the abstract: | Language of filing of the international application: |
|---|---|
| | |

**Box No. IX SIGNATURE OF APPLICANT, AGENT, OR COMMON REPRESENTATIVE**

*Must in each signature, indicate the name of the person signing and the capacity in which the person signs (if such is not obvious from reading the request).*

**SMITHKLINE BEECHAM CORPORATION**

By: _____

**Soma G. Simon**
Attorney for the Applicant

**For receiving Office use only**

| | | | |
|---|---|---|---|
| 1. | Date of actual receipt of the purported international application | | 2. Drawings: |
| 3. | Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application: | | ☐ received: |
| 4. | Date of timely receipt of the required corrections under PCT Article 11(2) | | ☐ not received: |
| 5. | International Searching Authority specified by the applicant: **ISA/** | 6. ☐ Transmittal of search copy delayed until search fee is paid | |

**For International Bureau use only**

| |
|---|
| Date of receipt of the record copy by the International Bureau |

*This Sheet Is Not Part Of And Does Not Count As A Sheet Of The International Application*

# PCT

## FEE CALCULATION SHEET
## Annex To The Request

For receiving office use only

International Application No:

Applicant's or Agent's file reference: P51358

Date Stamp of the Receiving Office

Applicant: SMITHKLINE BEECHAM CORPORATION

### CALCULATION OF PRESCRIBED FEES

1. TRANSMITTAL FEE . . . . . $240.00 T

2. SEARCH FEE . . . . . $700.00 S

International search to be carried out by ISA/US

*(If two or more International Searching Authorities are competent in relation to the international application, indicate the name of the Authority which is chosen to carry out the the international search)*

3. INTERNATIONAL FEE

Basic Fee

The international application contains 148 sheets.

first 30 sheets . . . . . $ 407.00 $b_1$

118 (Remaining Sheets) x $9.00 (additional amount) = 1,062.00 $b_2$

Add amounts entered at $b_1$ and $b_2$ and enter total at B . . . . . $1,469.00 B

Designation Fee

The international application contains 58 designations.

5 (number of designation fees payable) x $88.00 (amount of designation fee) = $ 440.00 D

Add amounts entered at B and D and enter total at I . . . . . $1,909.00 I

(Applicants from certain States are entitled to a reduction of 75% of the international fee. Where the applicant is (or all applicants are) so entitled, the total to be entered at I is 25% of the sum of the amounts entered at B and D.)

4. FEE FOR PRIORITY DOCUMENT . . . . . $ 15.00 P

5. TOTAL FEES PAYABLE

Add amounts entered at T, S, I and P, and enter total in the TOTAL box . . . . . $2,864.00 TOTAL

☐ The designation fee is not paid at this time

### MODE OF PAYMENT

☒ authorization to charge deposit account (see below)

☐ bank draft ☐ coupons

☐ cheque ☐ cash ☐ other *(specify):*

☐ postal money order ☐ revenue stamps

### DEPOSIT ACCOUNT AUTHORIZATION *(this mode of payment may not be available at all receiving Offices)*

The RO/ US

☒ is hereby authorised to charge the total fees indicated above to my deposit account

☒ is hereby authorised to charge any deficiency or credit any overpayment in the total fees indicated above to my deposit account

☒ is hereby authorised to charge the fee for preparation and transmittal of the priority document to the International Bureau of WIPO to my deposit account

19-2570
Deposit Account Number

30/5/03
Date *(day/month/year)*

Soma G. Simon

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 December 2003 (11.12.2003)

PCT

(10) International Publication Number
WO 03/101442 A1

(51) International Patent Classification[7]: A61K 31/16, 31/18, 31/44, 31/50, 31/505, 31/495, C07C 243/22, 311/16, C07D 213/77, 237/22, 239/42

(21) International Application Number: PCT/US03/17054

(22) International Filing Date: 30 May 2003 (30.05.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/384,457 31 May 2002 (31.05.2002) US

(71) Applicant *(for all designated States except US)*: SMITHKLINE BEECHAM CORPORATION [US/US]; One Franklin Plaza, Philadelphia, PA 19103 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: AUBART, Kelly, M. [US/US]; 1250 South Collegeville Road, Collegeville, PA 19426 (US). BENOWITZ, Andrew, B. [US/US]; 1250 South Collegeville Road, Collegeville, PA 19406 (US). CHRISTENSEN, Siegfried, B., IV [US/US]; 1250 South Collegeville Road, Collegeville, PA 19426 (US). KARPINSKI, Joseph, M. [US/US]; 1250 South Collegeville Road, Collegeville, PA 19426 (US). LEE, Jinhwa [KR/US]; 1250 South Collegeville Road, Collegeville, PA 19426 (US). SILVA, Domingos, J. [BR/US]; 1250 South Collegeville Road, Collegeville, PA 19426 (US).

(74) Agents: SIMON, Soma, G. et al.; SmithKline Beecham Corporation, Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US).

(81) Designated States *(national)*: AE, AG, AL, AU, BA, BB, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SC, SG, TN, TT, UA, US, UZ, VN, YU, ZA.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for all designations*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AU, BA, BB, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SC, SG, TN, TT, UA, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)*

— *of inventorship (Rule 4.17(iv)) for US only*

**Published:**

— *with international search report*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 03/101442 A1

(54) Title: PEPTIDE DEFORMYLASE INHIBITORS

(57) Abstract: Novel PDF inhibitors and novel methods for their use are provided.

# PEPTIDE DEFORMYLASE INHIBITORS

## FIELD OF THE INVENTION

The present invention relates to the use of novel antibacterial compounds, and pharmaceutical compositions containing these compounds as peptide deformylase inhibitors.

## BACKGROUND OF THE INVENTION

Bacterial initiator methionyl tRNA is modified by methionyl tRNA formyltransferase (FMT) to produce formyl-methionyl tRNA. The formyl methionine (f-met) is then incorporated at the N-termini of newly synthesized polypeptides. Polypeptide deformylase (PDF or Def) then deformylates primary translation products to produce N-methionyl polypeptides. Most intracellular proteins are further processed by methionine amino peptidase (MAP) to yield the mature peptide and free methionine, which is recycled. PDF and MAP are both essential for bacterial growth, and PDF is required for MAP activity. This series of reactions is referred to as the methionine cycle (Figure 1).





Figure 1. The methionine cycle.

To date, polypeptide deformylase homologous genes have been found in bacteria, in chloroplast-containing plants, in mice and in human. The plant proteins are nuclear encoded

but appear to carry a chloroplast localisation signal. This is consistent with the observation that chloroplast RNA and protein synthesis processes are highly similar to those of eubacteria. While there is limited information on protein expression of mammalian PDF gene homologs (Bayer Aktiengesellschaft, Pat. WO2001/42431), no functional role for such proteins has been demonstrated to date (Meinnel, T., Parasitology Today 16(4), 165-168, 2000).

Polypeptide deformylase is found in all eubacteria for which high coverage genomic sequence information is available. Sequence diversity among PDF homologs is high, with as little as 20% identity between distantly related sequences. However, conservation around the active site is very high, with several completely conserved residues, including one cysteine and two histidines which are required to coordinate the active site metal (Meinnel, T. et al., J. Mol. Biol. 267, 749-761, 1997).


PDF is recognized to be an attractive antibacterial target, as this enzyme has been demonstrated to be essential for bacterial growth in vitro (Mazel, D. et al., EMBO J. 13 (4), 914-923, 1994), is not believed to be involved in eukaryotic protein synthesis (Rajagopalan et al., J. Am. Chem. Soc. 119, 12418-12419, 1997), and is universally conserved in prokaryotes (Kozak, M., Microbiol. Rev. 47, 1-45, 1983). Therefore PDF inhibitors can potentially serve as broad spectrum antibacterial agents.

## SUMMARY OF THE INVENTION

The present invention involves novel antibacterial compounds represented by Formula (1) hereinbelow and their use as PDF inhibitors.

## DETAILED DESCRIPTION OF THE INVENTION

In one aspect of the present invention, there is provided a compound of formula (1):




(1)

wherein:

R is selected from the group consisting of:

$C_{2-6}$ alkyl (optionally substituted by alkoxy, halogen, or $C_{1-3}$ alkylsulfanyl); $C_{2-6}$ alkenyl (optionally substituted by alkoxy, halogen, or $C_{1-3}$ alkylsulfanyl); $C_{2-6}$ alkynyl (optionally substituted by alkoxy, halogen, or $C_{1-3}$ alkylsulfanyl); $(CH_2)_n$—$C_{3-6}$ carbocycle (optionally substituted by alkoxy, halogen, or $C_{1-3}$ alkylsulfanyl); and $(CH_2)_n$—R4, wherein R4 is selected from the group consisting of phenyl, furan, benzofuran, thiophene, benzothiophene, tetrahydrofuran, tetrahydropyran, dioxane, 1,4-benzodioxane or benzo[1,3]dioxole; R4 is optionally substituted by one or more substituent selected from Cl, Br, I, $C_{1-3}$ alkyl (optionally substituted by one to three F) and $C_{1-2}$ alkoxy (optionally substituted by one to three F);

R1 and R2 are independently selected from the group consisting of:


hydrogen, $C_{1-3}$ substituted alkyl, $C_{2-3}$ substituted alkenyl, $C_{2-3}$ substituted alkynyl, $(CH_2)_n$—$C_{3-6}$ substituted carbocycle, aryl, heteroaryl, and heterocyclic;

Y represents O, $CH_2$ or a covalent bond; and

n is an integer from 0 to 2;

or a salt, solvate, or physiologically functional derivative thereof.

In this invention the most preferred R2 group is hydrogen. In this invention the most preferred absolute configuration of compounds of the formula (1) is indicated below:




As used herein, the term "alkyl" refers to a straight or branched chain saturated hydrocarbon radical. Examples of "alkyl" as used herein include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, isopentyl, hexyl and the like.

As used herein, the term "substituted alkyl" refers to a straight or branched chain saturated hydrocarbon radical, optionally substituted with substituents selected from the group that includes $C_{1-3}$ alkyl (optionally substituted by one to three fluorines), $C_{2-3}$ alkenyl, $C_{2-3}$ alkynyl, $C_{1-2}$ alkoxy (optionally substituted by one to three fluorines), sulfanyl, sulfinyl,

sulfonyl, oxo, hydroxy, mercapto, amino, guanidino, carboxy, aminocarbonyl, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclic, aminosulfonyl, sulfonylamino, carboxyamide, ureido, nitro, cyano and halogen, multiple degrees of substitution being allowed.

As used herein, the term "alkenyl" refers to a straight or branched chain hydrocarbon radical having at least one carbon-carbon double bond. Examples of "alkenyl" as used herein include, but are not limited to, ethenyl and propenyl.

As used herein, the term "substituted alkenyl" refers to a straight or branched chain hydrocarbon radical having at least one carbon-carbon double bond, optionally substituted with substituents selected from the group which includes $C_{1-3}$ alkyl (optionally substituted by one to three F), amino, aryl, cyano and halogen, multiple degrees of substitution being allowed.

As used herein, the term "alkynyl" refers to a straight or branched chain hydrocarbon radical having at least one carbon-carbon triple bond. Examples of "alkynyl" as used herein include, but are not limited to, acetylenyl and 1-propynyl.

As used herein, the term "substituted alkynyl" refers to a straight or branched chain hydrocarbon radical having at least one carbon-carbon triple bond, optionally substituted with substituents selected from the group which includes $C_{1-3}$ alkyl (optionally substituted by one to three F), amino, aryl and halogen, multiple degrees of substitution being allowed.

As used herein, the term "halogen" refers to fluorine (F), chlorine (Cl), bromine (Br), or iodine (I), and "halo" refers to the halogen radicals fluoro, chloro, bromo and iodo.

As used herein, the term "carbocycle" refers to a non-aromatic cyclic hydrocarbon radical having from three to seven carbon atoms. For carbocycles with five- to seven-membered rings, a ring double bond is allowed. Exemplary "carbocycle" groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, and cycloheptyl.

As used herein, the term "substituted carbocycle" refers to a non-aromatic cyclic hydrocarbon radical having from three to seven carbon atoms, and which is optionally substituted with substituents selected from the group which includes $C_{1-3}$ alkyl (optionally substituted by one to three F), $C_{2-3}$ alkenyl, $C_{2-3}$ alkynyl, $C_{1-2}$ alkoxy (optionally substituted by one to three F), sulfanyl, sulfinyl, sulfonyl, oxo, hydroxy, mercapto, amino, guanidino, carboxy, aminocarbonyl, aryl, aryloxy, heteroaryl, heterocyclic, aminosulfonyl, sulfonylamino,

carboxyamide, nitro, ureido, cyano and halogen, multiple degrees of substitution being allowed. For carbocycles with five- to seven-membered rings, a ring double bond is allowed.

As used herein, the term "aryl" refers to an optionally substituted benzene ring or to an optionally substituted benzene ring fused to one or more optionally substituted benzene rings to form a ring system. Exemplary optional substituents include $C_{1-3}$ substituted alkyl, $C_{2-3}$ substituted alkenyl, $C_{2-3}$ substituted alkynyl, heteroaryl, heterocyclic, aryl, $C_{1-3}$ alkoxy (optionally substituted by one to three F), aryloxy, aralkoxy, acyl, aroyl, heteroaroyl, acyloxy, aroyloxy, heteroaroyloxy, sulfanyl, sulfinyl, sulfonyl, aminosulfonyl, sulfonylamino, carboxyamide, aminocarbonyl, carboxy, oxo, hydroxy, mercapto, amino, nitro, cyano, halogen, or ureido, multiple degrees of substitution being allowed. Such a ring or ring system may be optionally fused to one or more optionally substituted aryl rings (including benzene rings), carbocycle rings or heterocyclic rings. Examples of "aryl" groups include, but are not limited to, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, indanyl, anthracyl or phenanthryl, as well as substituted derivatives thereof.

As used herein, the term "heteroaryl" refers to an optionally substituted monocyclic five to six membered aromatic ring containing one or more heteroatomic substitutions selected from S, SO, $SO_2$, O, N, or N-oxide, or to such an aromatic ring fused to one or more optionally substituted rings, such as heteroaryl rings, aryl rings, heterocyclic rings, or carbocycle rings (e.g., a bicyclic or tricyclic ring system). Examples of optional substituents are selected from the group which includes $C_{1-3}$ substituted alkyl, $C_{2-3}$ substituted alkenyl, $C_{2-3}$ substituted alkynyl, heteroaryl, heterocyclic, aryl, $C_{1-3}$ alkoxy (optionally substituted by one to three F), aryloxy, aralkoxy, acyl, aroyl, heteroaroyl, acyloxy, aroyloxy, heteroaroyloxy, sulfanyl, sulfinyl, sulfonyl, aminosulfonyl, sulfonylamino, carboxyamide, aminocarbonyl, carboxy, oxo, hydroxy, mercapto, amino, nitro, cyano, halogen or ureido, multiple degrees of substitution being allowed. Examples of "heteroaryl" groups used herein include, but are not limited to, benzoimidazolyl, benzothiazolyl, benzoisothiazolyl, benzothiophenyl, benzopyrazinyl, benzotriazolyl, benzotriazinyl, benzo[1,4]dioxanyl, benzofuranyl, 9*H*-α-carbolinyl, cinnolinyl, 2,3-dihydro-[1,4]dioxino[2,3-b]-pyridinyl, furanyl, furo[2,3-b]pyridinyl, imidazolyl, imidazolidinyl, imidazopyridinyl, isoxazolyl, isothiazolyl, isoquinolinyl, indolyl, indazolyl, indolizinyl, naphthyridinyl, oxazolyl, oxothiadiazolyl, oxadiazolyl, phthalazinyl, pyridyl, pyrrolyl, purinyl, pteridinyl, phenazinyl, pyrazolyl, pyridyl, pyrazolopyrimidinyl,

pyrazolopyridinyl, pyrrolizinyl, pyridazyl, pyrazinyl, pyrimidyl, 4-oxo-1,2-dihydro-4H-pyrrolo[3,2,1-ij]-quinolin-4-yl, quinoxalinyl, quinazolinyl, quinolinyl, quinolizinyl, thiophenyl, triazolyl, triazinyl, tetrazolopyrimidinyl, triazolopyrimidinyl, tetrazolyl, thiazolyl, thiazolidinyl, and substituted versions thereof.

As used herein, the term "heterocyclic" refers to a three to seven-membered ring containing one or more heteroatomic moieties selected from S, SO, $SO_2$, O, N, or N-oxide, optionally substituted with substituents selected from the group which includes $C_{1-3}$ substituted alkyl, $C_{2-3}$ substituted alkenyl, $C_{2-3}$ substituted alkynyl, heteroaryl, heterocyclic, aryl, $C_{1-3}$ alkoxy (optionally substituted by one to three F), aryloxy, aralkoxy, acyl, aroyl, heteroaroyl, acyloxy, aroyloxy, heteroaroyloxy, sulfanyl, sulfinyl, sulfonyl, aminosulfonyl, sulfonylamino, carboxyamide, aminocarbonyl, carboxy, oxo, hydroxy, mercapto, amino, nitro, cyano, halogen, or ureido, multiple degrees of substitution being allowed. Such a ring can be saturated or have one or more degrees of unsaturation. Such a ring may be optionally fused to one or more other optionally substituted "heterocyclic" ring(s), aryl ring(s), heteroaryl ring(s), or carbocycle ring(s). Examples of "heterocyclic" moieties include, but are not limited to, 1,4-dioxanyl, 1,3-dioxanyl, pyrrolidinyl, pyrrolidin-2-onyl, piperidinyl, imidazolidine-2,4-dionepiperidinyl, piperazinyl, piperazine-2,5-dionyl, morpholinyl, dihydropyranyl, dihydrocinnolinyl, 2,3-dihydrobenzo[1,4]dioxinyl, 3,4-dihydro-2H-benzo[b][1,4]-dioxepinyl, tetrahydropyranyl, 2,3-dihydrofuranyl, 2,3-dihydrobenzofuranyl, dihydroisoxazolyl, tetrahydrobenzodiazepinyl, tetrahydroquinolinyl, tetrahydrofuranyl, tetrahydronaphthyridinyl, tetrahydropurinyl, tetrahydrothiopyranyl, tetrahydrothiophenyl, dihydroquinoxalinyl, tetrahydroquinoxalinyl, tetrahydropyridinyl, tetrahydrocarbolinyl, 4H-benzo[1,3]-dioxinyl, benzo[1,3]dioxonyl, 2,2-difluorobenzo-[1,3]-dioxonyl, 2,3-dihydro-phthalazine-1,4-dionyl, isoindole-1,3-dionyl, and the like.

As used herein, the term "alkoxy" refers to the group $-OR_x$, where $R_x$ is alkyl as defined above. Exemplary alkoxy groups useful in the present invention include, but are not limited to, methoxy, difluoromethoxy, trifluoromethoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, and t-butoxy.

As used herein the term "aralkoxy" refers to the group $-OR_xR_y$, where $R_x$ is alkyl and $R_y$ is aryl as defined above.

As used herein the term "aryloxy" refers to the group $-OR_x$, where $R_x$ is aryl as defined above.

As used herein, the term "mercapto" refers to the group -SH.

As used herein, the term "sulfanyl" refers to the group $-SR_x$, where $R_x$ is substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.

As used herein, the term "sulfinyl" refers to the group $-S(O)R_x$, where $R_x$ is substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.

As used herein, the term "sulfonyl" refers to the group $-S(O)_2R_x$, where $R_x$ is substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.

As used herein, the term "oxo" refers to the group =O.

As used herein, the term "hydroxy" refers to the group -OH.

As used herein, the term "amino" refers to the group $-NH_2$. The amino group is optionally substituted by substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.

As used herein, the term "cyano" refers to the group -CN.

As used herein, the term "aminosulfonyl" refers to the group $-S(O)_2NH_2$. The aminosulfonyl group is optionally substituted by substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.

As used herein, the term "sulfonylamino" refers to the group $-NHS(O)_2R_x$ where $R_x$ is substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.

As used herein, the term "carboxyamide" refers to the group $-NHC(O)R_x$ where $R_x$ is substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.

As used herein, the term "carboxy" refers to the group -C(O)OH. The carboxy group is optionally substituted by substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.

As used herein, the term "aminocarbonyl" refers to the group $-C(O)NH_2$. The aminocarbonyl group is optionally substituted by substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.

As used herein, the term "ureido" refers to the group $-NHC(O)NHR_x$ wherein $R_x$ is hydrogen, alkyl, carbocycle or aryl as defined above.

As used herein, the term "guanidino" refers to the group $-NHC(=NH)NH_2$.

As used herein, the term "acyl" refers to the group $-C(O)R_a$, where $R_a$ is alkyl, carbocycle, or heterocyclic as defined herein.

As used herein, the term "aroyl" refers to the group $-C(O)R_a$, where $R_a$ is aryl as defined herein.

As used herein, the term "heteroaroyl" refers to the group $-C(O)R_a$, where $R_a$ is heteroaryl as defined herein.

As used herein, the term "acyloxy" refers to the group $-OC(O)R_a$, where $R_a$ is alkyl, carbocycle, or heterocyclic as defined herein.

As used herein, the term "aroyloxy" refers to the group $-OC(O)R_a$, where $R_a$ is aryl as defined herein.

As used herein, the term "heteroaroyloxy" refers to the group $-OC(O)R_a$, where $R_a$ is heteroaryl as defined herein.

Also included in the present invention are pharmaceutically acceptable salts and complexes, such as the hydrochloride, hydrobromide and trifluoroacetate salts and the sodium, potassium and magnesium salts. The compounds of the present invention may contain one or more asymmetric carbon atoms and may exist in racemic and optically active forms. All of these compounds and diastereomers are contemplated to be within the scope of the present invention.

Preferred compounds useful in the present invention are selected from the group consisting of:

N-Hydroxy-N-[(R)-2-(N'-pyridin-2-yl-hydrazinocarbonyl)-heptyl]-formamide.

N-Hydroxy-N-{(R)-2-[N'-(3-methoxy-phenyl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-{(R)-2-[N'-(4-Cyano-phenyl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(2,6-Dimethyl-pyrimidin-4-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-[(R)-2-(N'-quinoxalin-2-yl-hydrazinocarbonyl)-heptyl]-formamide.

N-Hydroxy-N-((2*R*)-2-{N'-(3,4-dihydro-quinoxalin-2-yl)-hydrazinocarbonyl}-heptyl)-formamide.

N-Hydroxy-N-{(R)-2-[N'-(1,3,4-trimethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)-hydrazinocarbonyl]-heptyl}-formamide.

4-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-benzenesulfonamide.

N-Hydroxy-N-[(2*R*)-2-(cyclohexylmethyl)-3-oxo-3-{N'-[4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-propyl]-formamide.

N-Hydroxy-N-[(2*R*)-2-(cyclopentylmethyl)-3-oxo-3-{N'-[4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-propyl]-formamide.

N-{(R)-2-[N'-(Dimethyl-trifluoromethyl-pyrimidin-4-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(6-trifluoromethyl-pyridazin-3-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(6-trifluoromethyl-pyrimidin-4-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(9H-purin-6-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-{(R)-2-[N'-(5-Cyano-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-((2*R*)-2-{[N'-(pyrimidin-2-yl)-hydrazino]carbonyl}-heptyl)-formamide.

N-Hydroxy-N-((2*R*)-2-(cyclobutylmethyl)-3-oxo-3-{N'-[4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-propyl)-formamide.

N-Hydroxy-N-{(R)-2-[N'-(6-imidazol-1-yl-pyrimidin-4-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-[(R)-2-(N'-Benzo[1,2,4]triazin-3-yl-hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(7-methoxy-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-((R)-2-{N'-[6-(5-Chloro-pyridin-3-yl-oxy)-pyridazin-3-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-Hydroxy-N-[(2*R*)-2-({N'-[6-(1*H*-pyrrol-1-yl)-3-pyridazinyl]-hydrazino}-carbonyl)-heptyl]-formamide.

N-Hydroxy-N-((2*R*)-2-{[N'-(9-methyl-9*H*-purin-6-yl)-hydrazino]-carbonyl}-heptyl)-formamide.

N-Hydroxy-N-{(R)-2-[N-({6-morpholin-4-yl}-9H-purin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-{(R)-2-[N'-(6-Fluoro-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-((2*R*)-2-{[N'-(1-methyl-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-yl)-hydrazino]-carbonyl}-heptyl)-formamide.

N-{(R)-2-[N'-(4-Amino-6-isopropyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(2,5-Dimethyl-4-nitro-2H-pyrazol-3-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(3-Chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(6-Dimethylamino-9H-purin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-[(2*R*)-4-cyclopropyl-2-({N'-[4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-butyl]-formamide.

N-Hydroxy-N-((2*R*)-2-(cyclopropylmethyl)-3-oxo-3-{N'-[4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-propyl)-formamide.

N-Hydroxy-N-{(R)-2-[N'-methyl-N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid methyl ester.

2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid.

N-{(R)-2-[N'-(5-Fluoro-4-methoxy-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(4-Dimethylamino-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(2*R*)-2-[(N'-{6-[(2-hydroxyethyl)amino]-1,3-dihydro-2*H*-purin-2-ylidene}-hydrazino)-carbonyl]-heptyl}-formamide.

N-{(R)-2-[N'-(5-Fluoro-4-morpholin-4-yl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(5-Fluoro-4-methylamino-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid dimethylamide.

N-Hydroxy-N-{(R)-2-[N'-(3-oxo-3,4-dihydro-quinoxalin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-{(R)-2-Butoxy-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.

2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (2-fluoro-phenyl)-amide.

2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid tert-butylamide.

N-Hydroxy-N-((R)-2-{N'-[(1-piperidin-1-yl-methanoyl)-trifluoromethyl-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-{(R)-2-[N'-(5-Cyano-4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-[(2*R*)-2-({N'-[9-(4,4,4-trifluorobutyl)-1,9-dihydro-2*H*-purin-2-ylidene]-hydrazino}-carbonyl)-heptyl]-formamide.

N-Hydroxy-N-((R)-2-{N'-[(1-morpholin-4-yl-methanoyl)-trifluoromethyl-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid benzylamide.

N-Hydroxy-N-[(2*R*)-3-[N'-(1,2,4-benzotriazin-3-yl)-hydrazino]-2-(cyclohexylmethyl)-3-oxopropyl]-formamide.

N-Hydroxy-N-((2*R*)-2-(cyclohexylmethyl)-3-{N'-[7-(methyloxy)-1,2,4-benzotriazin-3-yl]-hydrazino}-3-oxopropyl)-formamide.

2-[2-((2R)-2-{[Formyl(hydroxy)amino]methyl}heptanoyl)hydrazino]-N-methyl-N-2-pyridinyl-4-(trifluoromethyl)-5-pyrimidinecarboxamide.

2-[2-((2R)-2-{[Formyl(hydroxy)amino]methyl}heptanoyl)hydrazino]-N-methyl-N-phenyl-4-(trifluoromethyl)-5-pyrimidinecarboxamide.

2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid morpholin-4-ylamide.

N-Hydroxy-N-((R)-2-{N'-[(N'-phenyl-hydrazinocarbonyl)-trifluoromethyl-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid piperidin-1-ylamide.

2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid pyrrol-1-ylamide.

N-{(R)-2-[N'-(Dimethylamino-fluoro-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-((R)-2-{N'-[(Ethyl-methyl-amino)-fluoro-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-Hydroxy-N-((2R)-2-(cyclopentylmethyl)-3-{N'-[7-(methyloxy)-1,2,4-benzotriazin-3-yl]-hydrazino}-3-oxopropyl)-formamide.

N-Hydroxy-N-{(R)-2-[N'-(1-methyl-1H-benzoimidazol-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-{(R)-2-[N'-(4-Azetidin-1-yl-5-fluoro-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(4-Cyclopropylamino-5-fluoro-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-[(R)-2-(N-Benzo[1,2,4]triazin-3-yl-hydrazinocarbonyl)-3-cyclopentyl-propyl]-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(morpholin-4-yl-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-[(R)-2-(N'-{[(2-hydroxy-ethyl)-methyl-amino]-trifluoromethyl-pyrimidin-2-yl}-hydrazinocarbonyl)-heptyl]-formamide.

N-Hydroxy-N-((R)-2-{N'-[(4-methyl-piperazin-1-yl)-trifluoromethyl-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-Hydroxy-N-((2R)-2-(cyclohexylmethyl)-3-{N'-[4-(cyclopropylamino)-5-fluoro-pyrimidin-2-yl]hydrazino}-3-oxopropyl)-formamide.

N-Hydroxy-N-((2R)-2-(cyclopentylmethyl)-3-{N'-[4-(cyclopropylamino)-5-fluoro-pyrimidin-2-yl]hydrazino}-3-oxopropyl)-formamide.

N-Hydroxy-N-[(2R)-3-{N'-[4-(azetidin-1-yl)-5-fluoro-pyrimidin-2-yl]-hydrazino}-2-(cyclopentylmethyl)-3-oxopropyl]-formamide.

N-Hydroxy-N-[(2R)-5-methyl-2-({N'-[4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-hexyl]-formamide.

N-[(R)-2-(N'-Benzo[1,2,4]triazin-3-yl-hydrazinocarbonyl)-5-methyl-hexyl]-N-hydroxy-formamide.

N-Hydroxy-N-[(2R)-5-methyl-2-({N'-[7-(methyloxy)-1,2,4-benzotriazin-3-yl]-hydrazino}-carbonyl)-hexyl]-formamide.

N-{(R)-2-[N'-(7-Chloro-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-((2R)-2-(cyclopentylmethyl)-3-{N'-[4-(morpholin-4-yl)-6-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-3-oxopropyl)-formamide.

N-Hydroxy-N-((2R)-2-(cyclopentylmethyl)-3-{N'-[4-[(2-hydroxyethyl)-(methyl)-amino]-6-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-3-oxopropyl)-formamide.

N-Hydroxy-N-[(2R)-6-methyl-2-({N'-[4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-heptyl]-formamide.

N-Hydroxy-N-((2R)-2-{[N'-(1,2,4-benzotriazin-3-yl)-hydrazino]-carbonyl}-6-methylheptyl)-formamide.

N-Hydroxy-N-{(R)-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-((R)-2-{N'-[(4-Ethyl-piperazin-1-yl)-trifluoromethyl-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(piperazin-1-yl-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-{(R)-2-[N'-(7-Fluoro-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-[(2R)-2-({N'-[4-(4-ethyl-1-piperazinyl)-6-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-6-methylheptyl]-formamide.

N-Hydroxy-N-[(2R)-6-methyl-2-({N'-[4-(piperazin-1-yl)-6-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-heptyl]-formamide.

N-Hydroxy-N-[(2R)-6-methyl-2-({N'-[4-(4-methyl-piperazin-1-yl)-6-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-heptyl]-formamide.

N-Hydroxy-N-((2R)-2-{[N'-(7-chloro-1,2,4-benzotriazin-3-yl)hydrazino]carbonyl}-6-methylheptyl)-formamide.

N-Hydroxy-N-((2R)-6-methyl-2-{[N'-(5-methyl-1,2,4-benzotriazin-3-yl)-hydrazino]-carbonyl}-heptyl)-formamide.

N-Hydroxy-N-((2R)-2-{[N'-(7-fluoro-1,2,4-benzotriazin-3-yl)-hydrazino]-carbonyl}-6-methylheptyl)-formamide.

N-Hydroxy-N-((R)-2-{N'-[(2-methoxy-ethylamino)-trifluoromethyl-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-Hydroxy-N-[(2R)-6-methyl-2-({N'-[7-(methyloxy)-1,2,4-benzotriazin-3-yl]-hydrazino}-carbonyl)-heptyl]-formamide.

N-Hydroxy-N-[(R)-2-(N'-{[4-(2-hydroxy-ethyl)-piperazin-1-yl]-trifluoromethyl-pyrimidin-2-yl}-hydrazinocarbonyl)-heptyl]-formamide.

N-Hydroxy-N-((R)-2-{N'-[(4-pyrimidin-2-yl-piperazin-1-yl)-trifluoromethyl-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-Hydroxy-N-((R)-2-{N'-[(2-hydroxy-ethylamino)-trifluoromethyl-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-Hydroxy-N-{(R)-2-[N'-(7-trifluoromethyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-formamide.

92

N-Hydroxy-N-{(R)-2-[N'-(6-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(2R)-2-(cyclopentylmethyl)-3-[N'-(5-methyl-1,2,4-benzotriazin-3-yl)hydrazino]-3-oxopropyl}-formamide.

N-Hydroxy-N-[(2R)-2-({N'-[4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-octyl]-formamide.

N-Hydroxy-N-((2R)-2-{[N'-(1,2,4-benzotriazin-3-yl)hydrazino]-carbonyl}-octyl)-formamide.

N-Hydroxy-N-[(2R)-2-({N'-[7-(methyloxy)-1,2,4-benzotriazin-3-yl]-hydrazino}-carbonyl)-octyl]-formamide.

N-Hydroxy-N-{(R)-2-[N'-(7-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-{(R)-2-[N'-(6-Chloro-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(5-methoxy-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(1-methyl-2-oxo-1,2-dihydro-pyridin-4-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-((R)-2-{N'-[(N'-pyridin-2-yl-hydrazino)-trifluoromethyl-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-Hydroxy-N-{(R)-2-[N'-(4-methyl-6-morpholin-4-yl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-((R)-2-{N'-[4-(4-Ethyl-piperazin-1-yl)-6-methyl-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-{(R)-2-[N'-(4,6-Dimethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(4-trifluoromethyl-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-[(R)-2-(N'-isoquinolin-1-yl-hydrazinocarbonyl)-heptyl]-formamide.

N-Hydroxy-N-[(R)-2-(N'-quinolin-2-yl-hydrazinocarbonyl)-heptyl]-formamide.

N-{(R)-2-[N'-(1-Benzyl-2-oxo-1,2-dihydro-pyridin-4-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(4-methyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-{(R)-2-[N'-(1-Butyl-2-oxo-1,2-dihydro-pyridin-4-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(9-methyl-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(6-oxo-4-trifluoromethyl-1,6-dihydro-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(methyl-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(5-trifluoromethyl-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-{(R)-2-[N'-(6-Ethoxy-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-[(R)-2-(N'-pyrido[2,3-e]-[1,2,4]triazin-3-yl-hydrazinocarbonyl)-heptyl]-formamide.

N-((R)-2-{N'-[1-(1-Ethyl-propyl)-2-oxo-1,2-dihydro-pyridin-4-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-Hydroxy-N-((R)-2-{N'-[2-oxo-1-(3-trifluoromethyl-benzyl)-1,2-dihydro-pyridin-4-yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-Hydroxy-N-{(R)-2-[N'-(4-methyl-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(6-methoxy-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(2-oxo-1-quinolin-8-yl-methyl-1,2-dihydro-pyridin-4-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-[(R)-2-(N'-{2-oxo-1-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethyl]-dihydro-pyridin-4-yl}-hydrazinocarbonyl)-heptyl]-formamide.

N-{(R)-2-[N'-(4,6-Bis-ethylamino-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(Bis-dimethylamino-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(4,6-Di-morpholin-4-yl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-((R)-2-{N'-[4-(4-methyl-piperazin-1-yl)-6-propylamino-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-{(R)-2-[N'-(Dimethylamino-morpholin-4-yl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(6-methyl-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-((R)-2-{N'-[5-(5-phenyl-[1,3,4]oxadiazol-2-yl)-pyridin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-{(R)-2-[N'-(7-tert-Butyl-1,4-dioxo-1,2,3,4-tetrahydro-pyrido[3,4-d]pyridazin-5-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-((R)-2-{N'-[4-Ethylamino-6-(4-methyl-[1,4]diazepan-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-((R)-2-{N'-[4-Ethylamino-6-(4-ethyl-piperazin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(6-trifluoromethyl-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(4-methyl-6-morpholin-4-yl-methyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(4-methyl-6-morpholin-4-yl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(2R)-2-(cyclopentylmethyl)-3-[N'-(4,6-dimethyl-2-pyrimidinyl)-hydrazino]-3-oxopropyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(4-methyl-6-pyrrolidin-1-yl-methyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-{(R)-2-[N'-(4-Dimethylaminomethyl-6-methyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-((R)-2-{N'-[4-methyl-6-(4-methyl-piperazin-1-yl-methyl)-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-Hydroxy-N-{(R)-2-[N'-(5-methyl-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-((R)-2-{N'-[Dimethylamino-(4-methyl-[1,4]diazepan-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(4-methyl-6-pyrrolidin-1-yl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-((R)-2-{N'-[4-methyl-6-)4-pyrrolidin-1-yl-piperidin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-((R)-2-{N'[(Ethyl-methyl-amino)-methyl-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-((R)-2-{N'-[(4-(4-Ethyl-piperazin-1-yl)-6-methyl-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-Hydroxy-N-[(2R)-7,7,7-trifluoro-2-({N'-[4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-heptyl]-formamide.

N-Hydroxy-N-((2R)-7,7,7-trifluoro-2-{[N'-(5-methyl-1,2,4-benzotriazin-3-yl)-hydrazino]-carbonyl}-heptyl)-formamide.

N-Hydroxy-N-((2R)-7,7,7-trifluoro-2-{[N'-(7-methyl-1,2,4-benzotriazin-3-yl)-hydrazino]-carbonyl}-heptyl)f-ormamide.

N-Hydroxy-N-{(R)-2-[N'-(4-methylamino-6-morpholin-4-yl-[1,3,5]-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-((R)-2-{N'-[4-(4-Ethyl-piperazin-1-yl)-6-methylamino-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-{(R)-2-[N'-(4-Ethylamino-6-morpholin-4-yl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(4,6,7-trimethyl-7,8-dihydro-pterin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(4,6,7-trimethyl-pteridin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(methoxymethoxymethyl-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-((R)-2-{N'-[4-methyl-6-(1-piperidin-1-yl-methanoyl)-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-6-methyl-pyrimidine-4-carboxylic acid cyclopropylamide.

2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-6-methyl-pyrimidine-4-carboxylic acid diisopropylamide.

N-{(R)-2-[N'-(5-Cyano-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(4,6-Diethyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-4-Cyclopentyl-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-butyl}-N-hydroxy-formamide.

N-{(R)-4-Cyclopentyl-2-[N'-(7-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-butyl}-N-hydroxy-formamide.

N-{(R)-4-Cyclopentyl-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-butyl}-N-hydroxy-formamide.

N-Hydroxy-N-((R)-2-{N'-[6-(4-methyl-piperazin-1-yl-methyl)-pyridin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-((R)-2-{N'-[5-(4,6-Dimethoxy-pyrimidin-2-yl)-pyridin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-{(R)-2-[N'-(Diethylamino-methyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-[(R)-2-(N'-{[(2-methoxy-ethyl)-methyl-amino]-methyl-[1,3,5]triazin-2-yl}-hydrazinocarbonyl)-heptyl]-formamide.

N-((R)-1-{N'-[4-(2,6-Dimethyl-morpholin-4-yl)-6-methyl-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-{(R)-2-[N'-(5-Fluoro-4-methyl-6-morpholin-4-yl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(4-Ethyl-6-morpholin-4-yl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(Ethyl-methyl-amino)-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-((R)-2-{N'-[4-Ethyl-6-(4-ethyl-piperazin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-((R)-2-{N'-[5-Fluoro-4-methyl-6-(4-methyl-piperazin-1-yl)-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-{(R)-2-[N'-(Dimethylamino-ethyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-((R)-2-{N'-[5-Fluoro-4-methyl-6-(4-methyl-[1,4]diazepan-1-yl)-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-{(R)-4-Cyclopentyl-2-[N'-(morpholin-4-yl-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-butyl}-N-hydroxy-formamide.

N-[(R)-2-(N'-{Ethyl-[(2-methoxy-ethyl)-methyl-amino]-[1,3,5]triazin-2-yl}-hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.

N-{(R)-2-[N'-(Dimethylamino-methyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(4-Cyclopropylamino-6-methyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-Cyclohexyl-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.

N-{(R)-2-Cyclohexyl-2-[N'-(7-methoxy-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.

N-{(R)-2-Cyclohexyl-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.

N-{(R)-4,4-Dimethyl-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-pentyl}-N-hydroxy-formamide.

N-{(R)-4,4-Dimethyl-2-[N'-(7-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-pentyl}-N-hydroxy-formamide.

N-{(R)-4,4-Dimethyl-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-pentyl}-N-hydroxy-formamide.

N-{(R)-4,4-Dimethyl-2-[N'-(morpholin-4-yl-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-pentyl}-N-hydroxy-formamide.

N-((R)-2-{N'-[Ethyl-(methyl-pyridin-2-yl-amino)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-{(R)-2-[N'-(4-Cyclopropylamino-6-ethyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-[(R)-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-3-(1-methyl-cyclopentyl)-propyl]-formamide.

N-Hydroxy-N-[(R)-2-[N'-(7-methoxy-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-3-(1-methyl-cyclopentyl)-propyl]-formamide.

N-Hydroxy-N-{(R)-3-(1-methyl-cyclopentyl)-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-propyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(4-isopropyl-6-morpholin-4-yl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(2R)-2-(cyclopentylmethyl)-3-[N'-(4-methyl-2-pyrimidinyl)-hydrazino]-3-oxopropyl}-formamide.

N-Hydroxy-N-[(2R)-6,6,6-trifluoro-2-({N'-[4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-hexyl]-formamide.

N-{(R)-2-[N'-(5,7-Dimethyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(3,6-Dimethyl-pyrazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-((R)-2-{N'-[4-(4-Ethyl-piperazine-1-yl)-6-isopropyl-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-{(R)-2-[N'-(4-Dimethylamino-6-isopropyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(methyl-trifluoromethyl-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-6,N,N-trimethyl-isonicotinamide.

N-Hydroxy-N[(2R)-2-({N'-[3-amino-6-(trifluoromethyl)-pyridin-2-yl]-hydrazino}-carbonyl)-heptyl]-formamide.

N-Hydroxy-N-[(R)-2-(N'-{4-isopropyl-6-[(2-methoxy-ethyl)-methyl-amino]-[1,3,5]triazin-2-yl}-hydrazinocarbonyl)-heptyl]-formamide.

N-{(R)-3-Cyclopentyl-2-[N'-(4-ethyl-6-morpholin-4-yl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-propyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(4-morpholin-4-yl-6-propyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-((R)-2-{N'-[4-(4-Ethyl-piperazin-1-yl)-6-propyl-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-{(R)-5,5-Dimethyl-2-[N'(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-hexyl}-N-hydroxy-formamide.

N-{(R)-5,5-Dimethyl-2-[N'-(7-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-hexyl}-N-hydroxy-formamide.

N-{(R)-5,5-Dimethyl-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-hexyl}-N-hydroxy-formamide.

N-{(R)-5,5-Dimethyl-2-[N'-(morpholin-4-yl-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-hexyl}-N-hydroxy-formamide.

N-{(R)-4-Ethyl-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazino carbonyl]-hexyl}-N-hydroxy-formamide.

N-{(R)-4-Ethyl-2-[N'-(7-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-hexyl}-N-hydroxy-formamide.

N-{(R)-4-Ethyl-2-[N'-(morpholin-4-yl-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-hexyl}-N-hydroxy-formamide.

N-((R)-3-Cyclopentyl-2-{N'-[4-ethyl-6-(4-ethyl-piperazin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-propyl)-N-hydroxy-formamide.

N-{(R)-3-Cyclopentyl-2-[N'-(4-cyclopropylamino-6-ethyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-propyl}-N-hydroxy-formamide.

N-{(R)-4-Ethyl-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-hexyl}-N-hydroxy-formamide.

N-Hydroxy-N-[(R)-2-(N'-{[(2-methoxy-ethyl)-methyl-amino]-propyl-[1,3,5]triazin-2-yl}-hydrazinocarbonyl)-heptyl]-formamide.

N-{(R)-2-[N'-(Dimethylamino-propyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(4-Ethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(4-isopropyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-{(R)-2-[N'-(4-Cyclopropyl-6-morpholin-4-yl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-[(2R)-2-({N'-[4-(pyridin-2-yl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-heptyl]-formamide.

N-((R)-2-{N'-[4-Cyclopropyl-6-(4-ethyl-piperazin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-{(R)-2-[N'-(Cyclopropyl-dimethylamino-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-((R)-2-{N'-[Cyclopropyl-(ethyl-methyl-amino)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-{(R)-2-[N'-(4-Cyclopropyl-6-pyrrolidin-1-yl[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(4,6-Dicyclopropyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-[(R)-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-3-(2-methyl-cyclopentyl)-propyl]-formamide.

N-[(R)-2-[N'-(Dimethylamino-ethyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-3-(2-methyl-cyclopentyl)-propyl]-N-hydroxy-formamide.

N-Hydroxy-N-[(R)-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-3-(2-methyl-cyclopentyl)-propyl]-formamide.

N-{(R)-2-[N'-(5-Ethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(2R)-2-(cyclopentylmethyl)-3-[N'-(7-methyl-1,2,4-benzotriazin-3-yl)-hydrazino]-3-oxopropyl}-formamide.

N-Hydroxy-N-[(2R)-2-(cyclopentylmethyl)-3-(N'-{4-ethyl-6-[ethyl(methyl)amino]-1,3,5-triazin-2-yl}-hydrazino)-3-oxopropyl]-formamide.

N-Hydroxy-N-((2R)-2-(cyclopentylmethyl)-3-{N'-[4-(dimethylamino)-6-ethyl-1,3,5-triazin-2-yl]-hydrazino}-3-oxopropyl)-formamide.

N-((R)-2-{N'-[4-Ethyl-6-(4-isopropyl-piperazin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-Hydroxy-N-[(2R)-3-[N'-(6-chloro-1,2,4-benzotriazin-3-yl)-hydrazino]-2-(cyclopentylmethyl)-3-oxopropyl]-formamide.

N-{(R)-4,4-Dimethyl-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-hexyl}-N-hydroxy-formamide.

N-{(R)-4,4-Dimethyl-2-[N'-(7-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-hexyl}-N-hydroxy-formamide.

N-{(R)-4,4-Dimethyl-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-hexyl}-N-hydroxy-formamide.

N-{(R)-4,4-Dimethyl-2-[N'-(morpholin-4-yl-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-hexyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(5-phenyl-[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-{(R)-2-[N'-(4-Ethyl-6-morpholin-4-yl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-((R)-2-{N'-[4-Ethyl-6-(4-methyl-piperazin-1-yl)-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-{(R)-2-[N'-(5-Ethyl-4-methyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-((R)-2-{N'-[4-Ethyl-6-(4-propyl-piperazin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-Hydroxy-N-((R)-2-{N'-[6-(4-pyrimidin-2-yl-piperazin-1-yl-methyl)-pyridin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-Hydroxy-N-((R)-2-{N'-[6-(3-[1,2,4]triazol-1-yl-methyl-[1,2,4]triazol-1-yl)-pyridin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-{(R)-3-Bicyclo[2.2.1]hept-7-yl-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-propyl}-N-hydroxy-formamide.

N-{(R)-3-Bicyclo[2.2.1]hept-7-yl-2-[N'-(morpholin-4-yl-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-propyl}-N-hydroxy-formamide.

N-hydroxy-N-[(R)-2-(N'-pyridin-3-yl-hydrazinocarbonyl)-heptyl]-formamide.

4-{4-Ethyl-6-[2-((2R)-2-{[formyl(hydroxy)amino]-methyl}-heptanoyl)-hydrazino]-1,3,5-triazin-2-yl}-1-methyl-1-propylpiperazin-1-ium iodide.

N-{(R)-3-Bicyclo[2.2.1]hept-7-yl-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-propyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(4-Azetidin-1-yl-6-ethyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-Cyclopentyl-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.

N-{(R)-2-Cyclopentyl-2-[N'-(morpholin-4-yl-4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.

N-{(R)-2-Cyclopentyl-2-[N'-(4-methyl-pyridin-2-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.

N-{(R)-2-Cyclopentyl-2-[N'-(dimethylamino-ethyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.

N-{(R)-2-Cyclopentyl-2-[N'-(7-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.

N-{(R)-2-Cyclopentyl-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-2-(4-methyl-cyclohexyl)-ethyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(7-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-2-(4-methyl-cyclohexyl)-ethyl}-formamide.

N-Hydroxy-N-{(R)-2-(4-methyl-cyclohexyl)-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-ethyl}-formamide.

N-Hydroxy-N-{(R)-2-(4-methyl-cyclohexyl)-2-[N'-(morpholin-4-yl-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-ethyl}-formamide.

N-Hydroxy-N-{(R)-2-(4-methyl-cyclohexyl)-2-[N'-(4-methyl-pyridin-2-yl)-hydrazinocarbonyl]-ethyl}-formamide.

N-{(R)-2-[N'-(Dimethylamino-ethyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-2-(4-methyl-cyclohexyl)-ethyl}-N-Hydroxy-formamide.

N-{(R)-2-[N'-(6,7-Dihydro-5 H-cyclopentapyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-((R)-2-[N'-[4-Ethyl-6-((S)-2-hydroxymethyl-pyrrolidin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl]-heptyl)-N-hydroxy-formamide.

N-{(R)-2-[N'-(Dimethylamino-pyridin-3-yl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(Dimethylamino-pyridin-4-yl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-N'-(5,6,7,8-tetrahydro-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-{(R)-2-[N'-(5,6-Diethyl-[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-[5-(4-hydroxy-phenyl)-[1,2,4]triazin-3-yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-[(R)-2-(N'-{[(2-Dimethylamino-ethyl)-methyl-amino]-ethyl-[1,3,5]triazin-2-yl}-hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.

N-{(R)-2-[N'-(2-Dimethylamino-quinazolin-4-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(3-methanesulfonyl-4,6-dimethyl-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-((R)-2-{N'-[4-Ethyl-6-(3-hydroxy-piperidin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-[(R)-2-(N'-[4,5']Bipyrimidinyl-2-yl-hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.

N-((R)-2-{N'-[(Cyclopropyl-methyl-amino)-ethyl-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-((R)-2-{N'-[4-Ethyl-6-((R)-3-hydroxy-pyrrolidin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-Hydroxy-N-[(R)-2-(N'-[3,3']Bipyridinyl-5-yl-hydrazinocarbonyl)-heptyl]-formamide.

N-Hydroxy-N-[(R)-2-(N'-(5-morpholin-4-yl-pyridin-3-yl)-hydrazinocarbonyl)-heptyl]-formamide.

N-Hydroxy-N-{(R)-2-[N'-(4-pyridin-3-yl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(5,6,7,8-tetrahydro-quinazolin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-[(R)-2-(N'-{[Cyclopropyl-1-(1-methyl-piperidin-4-yl)-amino]-ethyl-[1,3,5]triazin-2-yl}-hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.

N-((R)-2-{N'-[4-((R)-3-Dimethylamino-pyrrolidin-1-yl)-6-ethyl-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-Hydroxy-N-[(R)-2-(N'-[5-(1H-pyrrol-2-yl)-pyridin-3-yl]-hydrazinocarbonyl)-heptyl]-formamide.

N-Hydroxy-N-[(R)-2-(N'-[(4-methyl-piperazin-1-yl)-trifluoromethyl-pyrimidin-4-yl]-hydrazinocarbonyl)-heptyl]-formamide.

N-Hydroxy-N-[(R)-2-(N'-(5-Furan-3-yl-pyridin-3-yl)-hydrazinocarbonyl)-heptyl]-formamide.

N-{(R)-5,5-Dimethyl-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-5,5-Dimethyl-2-[N'-(7-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-5,5-Dimethyl-2-(4-methyl-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-Cycloheptyl-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.

N-{(R)-2-Cycloheptyl-2-[N'-(4-methyl-pyridin-2-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.

N-{(R)-2-Cycloheptyl-2-[N'-(dimethylamino-ethyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.

N-{(R)-2-Cycloheptyl-2-[N'-(7-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.

N-((R)-2-{N'-[4-Ethyl-6-(4-hydroxy-piperidin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-{(R)-5,5-Dimethyl-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(4-Dimethylamino-quinazolin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(4-pyridin-4-yl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-((R)-2-{N'-[4-(3-hydroxymethyl-phenyl)-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-Hydroxy-N-((R)-2-{N'-[4-(4-hydroxymethyl-phenyl)-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-((R)-2-{N'-[4-Ethyl-6-(3-methoxy-piperidin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(7-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-2-(4-methyl-cyclohexyl)-ethyl}-formamide.

N-[(R)-2-{N'-[Ethyl-(ethyl-methylamino)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-2-(4-methyl-cyclohexyl)-ethyl}-N-hydroxy-formamide.

N-[(R)-2-{N'-[Ethyl-(ethyl-methylamino)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-2-(4-methyl-cyclohexyl)-ethyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(7-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-2-(4-methyl-cyclohexyl)-ethyl}-formamide.

N-((R)-2-{N'-[4-(2,6-Dimethoxy-phenyl)-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-((R)-2-{N'-[4-Ethyl-6-((R)-3-methoxy-pyrrolidin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-((R)-2-{N'-[4-Ethyl-6-(4-methoxy-piperidin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-Hydroxy-N-[(R)-2-(N'-(6-pyrrolidin-1-yl-pyrimidin-4-yl)-hydrazinocarbonyl)-heptyl]-formamide.

N-Hydroxy-N-[(R)-2-(N'-[6-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl])-hydrazinocarbonyl)-heptyl]-formamide.

N-{(R)-2-[N'-(6-Dimethylamino-pyrimidin-4-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(Pyridin-4-yl-trifluoromethyl-pyrimidin-4-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(Pyridin-3-yl-trifluoromethyl-pyrimidin-4-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(2-Ethylamino-6-trifluoromethyl-pyrimidin-4-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-((R)-2-{N'-[5-(4-methoxy-phenyl)-[1,2,4]triazin-3-yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-Hydroxy-N-((R)-2-{N'-[4-(2,3,4-trimethoxy-phenyl)-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-{(R)-4,4-Dimethyl-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-4,4-Dimethyl-2-[N'-(7-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-4,4-Dimethyl-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-4,4-Dimethyl-2-[N'-(4-methyl-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(6-morpholin-4-yl-pyrimidin-4-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-[(R)-2-(N'-{5-[4-(2-hydroxy-ethoxy)-phenyl]-[1,2,4]triazin-3-yl}-hydrazinocarbonyl)-heptyl]-formamide.

N-{(R)-2-[N'-(4-Furan-2-yl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-((R)-2-{N'-[4-(3,5-Dimethyl-isoxazol-4-yl)-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(4-methyl-1-oxy-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-6-methyl-nicotinic acid.

N-Hydroxy-N-{(R)-2-[N'-(3-methoxy-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(2R)-2-[(N'-{4-[4-(methylsulfonyl)phenyl]-pyrimidin-2-yl}-hydrazino)-carbonyl]-heptyl}-formamide.

N-Hydroxy-N-[(2R)-2-({N'-[4-(furan-3-yl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-heptyl]-formamide.

N-[(2R)-2-({N'-[4-(2-aminophenyl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-heptyl]-N-hydroxy-formamide.

N-Hydroxy-N-[(2R)-2-({N'-[5-(5-methyl-1,3,4-oxadiazol-2-yl)-4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-heptyl]-formamide.

N-Hydroxy-N-((2*R*)-2-(cyclopentylmethyl)-3-{N'-[5-(5-methyl-1,3,4-oxadiazol-2-yl)-4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-3-oxopropyl)-formamide.

N-[(2R)-2-({N'-[6-(dimethylamino)-2-methyl-pyrimidin-4-yl]-hydrazino}-carbonyl)-heptyl]-N-hydroxy-formamide.

N-[(2R)-2-({N'-[2-Cyclopropyl-6-(dimethylamino)-pyrimidin-4-yl]-hydrazino}-carbonyl)-heptyl]-N-hydroxy-formamide.

N-Hydroxy-N-[(2R)-4-(2-thienyl)-2-({N'-[4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-butyl]-formamide.

N-Hydroxy-N-[(2R)-2-{[N'-(4-methyl-pyrimidin-2-yl)hydrazino]carbonyl}-4-(2-thienyl)-butyl]-formamide.

N-[(2R)-2-[(N'-{4-Ethyl-6-[ethyl(methyl)amino]-1,3,5-triazin-2-yl}-hydrazino)-carbonyl]-4-(2-thienyl)butyl]-N-hydroxy-formamide.

N-Hydroxy-N-((2R)-3-oxo-2-(2-thienylmethyl)-3-{N'-[4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-propyl)-formamide.

N-Hydroxy-N-[(2R)-3-[N'-(4-methyl-pyrimidin-2-yl)hydrazino]-3-oxo-2-(2-thienylmethyl)-propyl]-formamide.

N-[(2R)-3-(N'-{4-Ethyl-6-[ethyl(methyl)amino]-1,3,5-triazin-2-yl}hydrazino)-3-oxo-2-(2-thienylmethyl)-propyl]-N-hydroxy-formamide.

N-Hydroxy-N-[(2R)-2-({N'-[2-methyl-6-(pyridin-2-yl)-pyrimidin-4-yl]-hydrazino}-carbonyl)-heptyl]-formamide.

N-Hydroxy-N-[(2R)-2-({N'-[6-(pyridin-2-yl-methyl)-pyridazin-3-yl]-hydrazino}-carbonyl)-heptyl]-formamide.

N-Hydroxy-N-[(2R)-2-({N'-[2-methyl-6-(morpholin-4-yl)-pyrimidin-4-yl]-hydrazino}-carbonyl)-heptyl]-formamide.

N-Hydroxy-N-[(2R)-2-({N'-[6-(morpholin-4-yl)-2-(trifluoromethyl)-pyrimidin-4-yl]-hydrazino}-carbonyl)-heptyl]-formamide.

N-Hydroxy-N-{(2R)-2-[(N'-{4-[methyl-(pyridin-2-yl)-amino]-pyrimidin-2-yl}-hydrazino)-carbonyl]-heptyl}-formamide.

N-Hydroxy-N-((2R)-2-(cyclopentylmethyl)-3-{N'-[4-cyclopropyl-6-(dimethylamino)-1,3,5-triazin-2-yl]-hydrazino}-3-oxopropyl)-formamide.

*N*-Benzo[1,3]dioxol-5-yl-methyl-hydrazinecarboxylic acid tert-butyl ester.

N-[(R)-2-(N'-Benzo[1,3]dioxol-5-yl-methyl-hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.

N-{(R)-2-[N'-(2,3-Dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl-methyl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(4-Dimethylamino-benzyl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-((R)-2-{N'-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethyl]-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-[(R)-2-(N'-quinolin-2-yl-methyl-hydrazinocarbonyl)-heptyl]-formamide.

N-Hydroxy-N-{(R)-2-[N'-(1,2,3,4-tetrahydro-quinolin-2-yl-methyl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-[(R)-2-(N'-quinolin-6-yl-methyl-hydrazinocarbonyl)-heptyl]-formamide.

N-[(R)-2-(N'-Benzofuran-2-yl-methyl-hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.

N-[(R)-2-(N'-Cyclopropylmethyl-hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.

N-{(R)-2-[N'-(6-Fluoro-4H-benzo[1,3]dioxin-8-yl-methyl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(4-methoxy-benzyl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(2-methoxy-benzyl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(tetrahydro-furan-3-yl-methyl)-hydrazinocarbonyl]-heptyl}-formamide.

N-[(R)-2-(N'-Furan-3-yl-methyl-hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.

N-{(R)-2-[N'-(2,3-Dihydro-benzo[1,4]dioxin-6-yl-methyl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(2,3-Dihydro-benzo[1,4]dioxin-2-yl-methyl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(2-phenoxy-ethyl)-hydrazinocarbonyl]-heptyl}-formamide.

N-{(R)-2-[N'-((S)-2,3-Dihydroxy-propyl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(5-methyl-isoxazol-3-yl-methyl)-hydrazinocarbonyl]-heptyl}-formamide.

N-((R)-2-{N'-[1-(1-Benzo[1,3]dioxol-5-yl-methanoyl)-piperidin-4-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-((R)-2-{N'-[1-(1-Benzofuran-2-yl-methanoyl)-piperidin-4-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-Hydroxy-N-[(R)-2-(N'-{1-[1-(7-methoxy-benzofuran-2-yl)-methanoyl]-piperidin-4-yl}-hydrazinocarbonyl)-heptyl]-formamide.

N-{(R)-2-[N'-(1-Benzyl-piperidin-4-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-[(R)-2-(N'-{1-[1-(3,4-Dichloro-phenyl)-methanoyl]-piperidin-4-yl}-hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.

N-[(R)-2-(N'-{1-[1-(2,3-Dichloro-phenyl)-methanoyl]-piperidin-4-yl}-hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.


N-Hydroxy-N-[(R)-2-(N'-{1-[1-(4-methyl-piperazin-1-yl)-methanoyl]-pentyl}-hydrazinocarbonyl)-heptyl]-formamide.

N-[(R)-2-(N'-Benzyl-hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.


## GENERAL SYNTHETIC SEQUENCE

The compounds and processes of the present invention will be better understood in connection with the following synthetic schemes, which are merely illustrative of the methods by which the compounds of the invention may be prepared and are not intended to limit the scope of the invention as defined in the appended claims.

The present invention provides compounds of Formula (1) that can be prepared from the common racemic intermediate (8), or common chiral intermediates (17) and (25).




(1) Y = O, $CH_2$ or a bond




Scheme 1


As shown in Scheme 1, intermediate (8) can be prepared by reacting the mono-substituted dialkyl malonate (2) with a base, such as potassium hydroxide, in an appropriate solvent, such as ethanol/water, to afford the mono-acid (3). Coupling of (3) with O-benzylhydroxylamine or O-(tetrahydro-2H-pyran-2-yl)hydroxylamine in the presence of a coupling reagent, such as 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (EDCI), and a base, such as 4-dimethylaminopyridine (DMAP), in an appropriate solvent, such as dichloromethane, gives the amide (4), where P is benzyl or tetrahydro-2H-pyran-2-yl. Reduction of the ester functionality of compound (4) with a reducing agent, such as lithium borohydride, in an appropriate solvent, such as tetrahydrofuran, at room temperature provides the alcohol (5). Treatment of the alcohol (5) under Mitsunobu conditions affords the lactam (6). The same transformation may be achieved by treating (5) with triphenylphosphine, carbon tetrachloride and a base, such as triethylamine, to obtain (6). Hydrolysis of the lactam (6) using, for example, lithium hydroxide in an appropriate solvent mixture, such as THF-$H_2O$-MeOH, gives acid (7). Formylation of the amine group of (7) is achieved using formic acid and acetic anhydride in a solvent, such as dichloromethane, to provide the formylated compound (8).

Any racemates can be resolved at the level of any intermediate during the synthesis or at the level of the final product using, for example, a chiral chromatography method, to provide compound (8) in each of two enantiomeric forms.


Alternatively, an enantiomer of intermediate (8), such as (18) in Scheme 2 or (27) in Scheme 3, can be prepared by reacting an appropriate acid chloride (9) with a chiral agent, such as Evans' chiral oxazolidinone, in the presence of a base, such as n-butyl lithium, to afford the chiral intermediate (10) in Scheme 2 or (19) in Scheme 3. Treatment of the

compound (10) or (19) with a base, such as diisopropylethylamine, in the presence of a chelating agent, such as titanium tetrachloride, in a solvent, such as tetrahydrofuran, followed by addition of an electrophile, such as benzyloxymethylchloride, provides either of two chiral compounds (11) or (20), depending on the selection of chiral auxiliary. Conversion of compound (11) or (20) to the corresponding hydroxyacid (14) or (23) can be achieved by a sequence comprising oxidative cleavage of the chiral oxazolidinone, using, for example $H_2O_2$ and lithium hydroxide, to the respective intermediates (12) or (21), followed by hydrogenolysis, to afford intermediates (13) or (21), respectively. Compounds (10) or (19) can also be converted to intermediates (14) or (23), respectively, in a two-step procedure. For this transformation, (10) or (19) can be treated with a base, such as diisopropylethylamine, in the presence of a chelating agent, such as titanium tetrachloride, in a solvent, such as tetrahydrofuran, followed by addition of trioxane or any other formaldehyde equivalent to provide compounds (13) or (22), which are then submitted to oxidative cleavage of the chiral oxazolidinone, using, for example $H_2O_2$ and lithium hydroxide, to the respective acids (14) or (23), respectively.

Coupling of the acid (14) or (23) with benzyloxyamine or O-(tetrahydro-2H-pyran-2-yl)hydroxylamine in the presence of coupling agents, such as EDCI-DMAP, yields the amides (15) or (24), respectively. These can be cyclized to the azetidin-2-ones (16) or (25) using Mitsunobu conditions or a combination of triphenylphosphine-carbon tetrachloride-triethylamine. Hydrolysis of the azetidin-2-one (16) or (25), using for example lithium hydroxide, in an appropriate solvent, gives the corresponding acid (17) or (26), respectively. Conversion of compound (17) or (26) to the carboxylic acid (18) or (27) can be achieved using an appropriate formylating agent, such as formic acid/acetic anhydride or methyl formate, in neat reagents or in an appropriate solvent, such as dichloromethane.





Scheme 2





Scheme 3

As shown in Scheme 4, compound (8) can be coupled to $CBZNHNH_2$, using conditions such as DMAP-EDCI or EDCI-HOAt-NMM, and debenzylated to generate compound (28). Reaction of (28) with the halide or trifluoromethyl R1X affords (1) where R2 is H. Similarly, compounds (18) and (27) can be submitted to the same procedure to afford, respectively, (31) where R2 is H and (32) where R2 is H.



Scheme 4


Alternatively, as shown in Scheme 5, compound (28) is submitted to a reductive alkylation with the ketone R1C(O)R2 using as reductant, for example, sodium cyanoborohydride, to afford compound (1). If the aldehyde R1C(O)H is used in the reductive alkylation instead, compound (1) where R2 is H is formed. Similarly, compound (29) can be submitted to reductive alkylation with the ketone R1C(O)R2 to afford compound (31), or with the aldehyde R1C(O)H to afford compound (31) where R2 is H. Similarly, compound (30) can be submitted to reductive alkylation with the ketone R1C(O)R2 to afford compound (32), or with the aldehyde R1C(O)H to afford compound (32) where R2 is H.



Scheme 5

Alternatively, as shown in Scheme 6, the monoprotected hydrazine G1NHNH$_2$ (33), where G1 is benzyloxycarbonyl or tert-butoxycarbonyl, can be reacted with phthalic anhydride

to yield intermediate (34). (34) can be coupled to the alcohol R1OH under Mitsunobu conditions to yield (35), which upon hydrazinolysis originates hydrazine (36). Coupling of (36) to acid (8) using conditions such as DMAP/EDCI or EDCI/HOAt/NMM affords (37). (37) can be fully deprotected in one step using hydrogenolysis when G1 is benzyloxycarbonyl and P is benzyl, in one step using acidic conditions when G1 is tert-butoxycarbonyl and P is O-(tetrahydro-2H-pyran-2-yl), or in two steps (by acid treatment and hydrogenolysis) when G1 is benzyloxycarbonyl and P is O-(tetrahydro-2H-pyran-2-yl), or G1 is tert-butoxycarbonyl and P is benzyl. In all three cases, compound (1) where R2 is H is formed. Similarly, compounds (18) and (27) can be submitted to the same procedure to afford, respectively, (31) where R2 is H or (32) where R2 is H.





Scheme 6

As shown in Scheme 7, coupling of the acid (8) with the hydrazine $R1R2NNH_2$ (40), using conditions such as DMAP-EDCI or EDCI-HOAt-NMM, provides the hydrazide (41). Final deprotection (hydrogenolysis using a catalyst, such as 10% Pd/C, in an appropriate solvent, such as ethanol, in the case that P is Bn; treatment with 80% acetic acid-water at

53


room temperature or 40 °C in the case that P is THP) gives the desired compound (1). Similarly, coupling of the chiral acid (18) or (27) with the hydrazine (40) provides the corresponding hydrazide (42) or (43). Final deprotection gives the final desired compound (31) or (32).



Scheme 7

Hydrazines of general structure $R1R2NNH_2$ (40) may be purchased from available commercial sources or prepared according to literature methods by those skilled in the art. The following examples of specific structures of hydrazine (40) and the synthetic methods used to generate them are merely illustrative and are not to be construed as a limitation of the scope of the present invention.


Hydrazines (40) where R2 is alkyl or hydrogen, and R1 has the general structure (44) may be prepared from appropriate precursors shown in Scheme 8, 9 and 10.



(44)

As shown in Scheme 8, hydrazine (40) where R1 is (44) can be prepared from precursor (45) by treatment with an appropriate hydrazine, such as hydrazine monohydrate, in an appropriate solvent, such as methanol. Alternatively, as shown in Scheme 9, hydrazine (40)


where R1 is (44) can be prepared from precursor (46) by oxidation to the sulfone via treatment with an appropriate oxidant such as meta-chloroperbenzoic acid (m-CPBA) in an appropriate solvent such as methylene chloride. Further treatment with an appropriate hydrazine, such as hydrazine monohydrate, in an appropriate solvent, such as methanol, then provides the desired product (40) where R1 is (44). Alternatively, as shown in Scheme 10, hydrazine (40) where R1=(44) can be prepared from (47) via treatment with sodium nitrate in an appropriate solvent such as aqueous sulfuric acid to give (48). Compound (48) is then treated with an appropriate halogenating reagent such as phosphorus oxychloride at reflux followed by treatment with an appropriate hydrazine, such as hydrazine monohydrate, in an appropriate solvent, such as methanol, to provide intermediate (40) where R1 is (44). Compounds (45), (46), (47) and (48) are available from commercial sources, or can be prepared via literature methods by those skilled in the art (Pyrimidines. Brown, D.J. In "The Chemistry of Heterocyclic Compounds" vol. 52, Taylor, E.C., ed.; Wiley: New York, 1994).




(45) (40); R1=(44)

X = halogen; L1, L2, L3 = bond, N-G5, O, S;
G2, G3, G4, G5 = H, Alkyl, Acyl, Heterocyclic, Aryl, Heteroaryl.


Scheme 8




(46) (40); R1=(44)

L4, L5, L6 = bond, N-G10, O;
G6, G7, G8, G10 = H, Alkyl, Acyl, Heterocyclic, Aryl, Heteroaryl; G9 = Alkyl, Aryl.

Scheme 9





(47) (48) (40); R1=(44)

L7, L8, L9 = bond, O, S;
G11, G12, G13 = H, Alkyl, Acyl, Heterocyclic, Aryl, Heteroaryl.


Scheme 10

Hydrazines (40) where R2 is hydrogen, and R1 has the general structure (49) may be prepared from appropriate precursors shown in Schemes 11 and 12.




(49) G14, G15 = H, Alkyl, Aryl, Heteroaryl, Heterocyclic


As shown in Scheme 11, 4,6-dichloropyrimidine (50) may be reacted with tert-butylcarbazate in the presence of base, such as diisopropylethylamine, at 100 °C in an appropriate solvent such as ethanol to give compound (51). The amine G14G15NH may be reacted with (51) to afford compound (52), which may be deprotected under acidic conditions, such as trifluoroacetic acid in dichloromethane, to afford compound (40), where R2 is hydrogen and R1 is (49).




(50) (51) (52) (40); R1=(49) and R2=H

Scheme 11


Alternatively, as shown in Scheme 12, 4,6-dichloropyrimidine (50) may be reacted with one equivalent of amine G14G15NH in the presence of base, such as triethylamine or diisopropylethylamine, to afford compound (53), which may be treated with excess hydrazine to afford compound (40), where R2 is hydrogen and R1 is (49).





(50) (53) (40); R2=H and R1=(49)

Scheme 12

Hydrazines (40) where R2 is hydrogen, and R1 has the general structure (54) may be prepared from an appropriate precursor such as (55), by treatment with anhydrous hydrazine in an appropriate solvent such as ethanol, as shown in Scheme 13.





(54) G16, G17, G18 = H, Alkyl, Aryl




(55) (40); R2=H and R1=(54)


Scheme 13

Hydrazines (40) where R2 is hydrogen and R1 has the general structure (56) may be prepared from an appropriate precursor shown in Scheme 14.




(56) G19, G20 = H, Alkyl, Aryl

As shown in Scheme 14, 4-chloro-2-methylsulfanyl-6-trifluoromethyl-pyrimidine (57) may be treated with tert-butyl carbazate at 100 °C in an appropriate solvent, such as ethanol, to give intermediate (58). Treatment of (58) with an oxidant, such as meta-chloro perbenzoic acid, produces (59), which upon treatment with amine G19G20NH in a suitable solvent such as methanol or ethanol affords (60). Deprotection under acidic conditions, such as trifluroacetic acid in dichloromethane, affords (40), where R2 is hydrogen and R1 is (56).





Scheme 14

Hydrazines (40) where R2 is hydrogen and R1 has the general structure (61) may be prepared following procedures outlined in Scheme 15 (Pauldler, W. et al., J. Het. Chem. 767-771, 1970; Lieber, E. et al., J. Org. Chem. 17, 518-522, 1952; Chem. Abstr. 87, 68431, 1977; Taylor, E. C., J. Org. Chem. 52, 4287-4292, 1987).




(61) G21, G22 = H, alkyl, aryl, heteroaryl

As shown in Scheme 15, compound (62) may be reacted with (63) in the presence of a mild base, such as aqueous sodium bicarbonate, to yield (64). Treatment of (64) with hydrazine under microwave conditions affords (40) where R2 is H and R1 is (61). Alternatively, (62) may be reacted with (65) to afford (40) where R2 is H and R1 is (61). Alternatively, (62) may be condensed with (66) to yield (67), which upon treatment with phosphorous oxychloride forms (68). Treatment of (68) with hydrazine affords (40) where R2 is H and R1 is (61). Alternatively, the oxoacid (69) may be condensed with (63) to form (70), which may be converted to (71) by reaction with oxalyl chloride or phosphorous oxychloride. Coupling of (71) with a boronic acid $G22B(OH)_2$ under standard Suzuki conditions affords (72), which can be reacted with hydrazine to afford (40) where R2 is H and R1 is (61) and G22 is alkyl, heteroaryl only.




Scheme 15


Hydrazines (40) where R2 is hydrogen and R1 has the general structure (73) may be prepared following procedures outlined in Scheme 16.




(73) G23, G24, G25, G26 = H, alkyl, aryl, heteroaryl, heterocyclic

60


As shown in Scheme 16, cyanuric chloride (74) may be treated with one equivalent of amine (75) under mild conditions, such as 0 °C in acetone in the presence of aqueous potassium carbonate, to afford (76). Treatment of (76) with amine (77) under conditions such as 25 °C in acetone in the presence of potassium carbonate yields (78). Displacement of the remaining chloride in (78) with hydrazine affords (40) where R2 is H and R1 is (73).




(74) (75) (76) (77) (78) (40); R2=H and R1=(73)


Scheme 16

Hydrazines (40) where R2 is hydrogen and R1 has the general structure (79) may be prepared following procedures outlined in Scheme 17 (Menicagli, R. et al., Tetrahedron, 56, 9705-9711, 2000).





(79) G25, G26 = H, alkyl, aryl, heteroaryl, heterocyclic; G27 = alkyl, heterocyclic

As shown in Scheme 17, cyanuric chloride (74) may be reacted with the Grignard compound (80) to form (81), which upon treatment with amine (77) affords monochloride (82). Hydrazinolysis of (82) yields (40) where R2 is H and R1 is (73).





Scheme 17

Hydrazines (40) where R2 is hydrogen and R1 has the general structure (83) may be prepared following procedures outlined in Scheme 18 (Kobe, J. et al., Monatsh. Chem. 101, 724-735, 1970; Janietz, D. and Bauer, M., .Syntheais 33-34, 1993).




(83) G28 = aryl, heteroaryl; G29 = alkyl, aryl, heteroaryl, heterocyclic, NG30G31; G30, G31 = aryl, alkyl, heteroaryl, heterocyclic


As shown in Scheme 18, compound (84) may be coupled to boronic acid $G28B(OH)_2$ or equivalent under Suzuki coupling protocols to afford (85), which upon hydrazinolysis yields (40) where R2 is H and R1 is (83).




Scheme 18


62

Hydrazines (40) where R2 is hydrogen and R1 has the general structure (86) may be prepared following procedures outlined in Scheme 19.



(86) G30, G31 = alkyl, heterocyclic


As shown in Scheme 19, sequential reaction of cyanuric chloride (74) with Grignard compounds G30MgX and G31MgX in a solvent such as benzene affords monochloride (87), which can be treated with hydrazide to afford (40) where R2=H and R1=(86).




(74) (87) (40); R2=H and R1=(86)

Scheme 19

Hydrazines (40) where R2 is hydrogen and R1 has the general structure (88) may be prepared following procedures outlined in Scheme 20.




(88) G32 = alkyl, aryl, heteroaryl, heterocyclic;

G33 = hydrogen, alkyl, aryl, heteroaryl, heterocyclic; G34 = alkyl

As shown in Scheme 20, (89) can be reduced to (90) using reducing conditions such as iron and acetic acid. Sequential treatment of (90) with alkylating agents G32X and G33X (where X is halide or trifluoromethylsulfonate) affords (91). Alternatively, treatment of (90) with one equivalent of G32X affords (91) where G33 is H. Oxidation of (91) to the


corresponding sulfoxide or sulfone using as oxidant such as meta-chloro perbenzoic acid, and subsequent treatment with hydrazine affords (40) where R2 is H and R1 is (88).



(89) (90) (91) (40); R2=H and R1=(88)

Scheme 20


Hydrazines (40) where R2 is hydrogen and R1 has the general structure (92) may be prepared following procedures outlined in Scheme 21 (Wolf, F. J. et al., J. Am. Chem. Soc. 76, 3551-3553, 1954; Hay, M. et al., J. Med. Chem. 46, 169-182, 2003) and Scheme 22 (Ley, K. et al., Angew. Chem. Int. Ed. 11, 1009-1010, 1972).



= R1


(92) G35 = alkyl, aryl, heteroaryl, heterocyclic, alkoxy, halogen, amino; m,q = 0,1

As shown in Scheme 21, (93) may be reacted with cyanamide in the presence of a base such as aqueous sodium hydroxide to afford (95). Alternatively, treatment of (94) with guanidine and a base such as potassium tert-butoxide, followed by acidification, affords (95) as well. Reaction of (95) with sodium nitrite in acidic solution yields (96). Conversion of (96) to the respective chloride (97) may be achieved with phosphorous oxychloride, for example. Hydrazinolysis of (97) affords (40) where R2 is H and R1 is (92) and m=0 and q=1; the N-oxide in this molecule may be reduced by hydrogenolysis in the presence of Pd on carbon and the resulting hydrazine may then be coupled to acid (8), (18) or (27). Alternatively, the 1-N-oxide benzotriazine hydrazine may be coupled to the acids (8), (18) or (27), and the resulting compounds may then be submitted to hydrogenolysis in the presence of Pd on carbon in order to reduce the N-oxide group.




Scheme 21

Alternatively, as shown in Scheme 22, (98) may be reacted with disodium cyanamide in a solvent such as a mixture of methanol and water to afford (99), which tautomerizes to (100) in the presence of acid. Treatment of (100) with sodium nitrite in acidic media provides (101). Reaction of (101) with phosphorous oxychloride, followed by hydrazinolysis, affords (40), where R2 is H and R1 is (92) and m=q=1; the N-oxide groups in this molecule may be reduced by hydrogenolysis in the presence of Pd on carbon and the resulting hydrazine may then be coupled to acid (8), (18) or (27). Alternatively, the 1,4-bis-N-oxide benzotriazine hydrazine may be coupled to acid (8), (18) or (27), and the resulting compound may then be reduced by hydrogenolysis in the presence of Pd on carbon.




Scheme 22

## SYNTHETIC EXAMPLES

The invention will now be described by reference to the following examples which are merely illustrative and are not to be construed as a limitation of the scope of the present invention.

As used herein the symbols and conventions used in these processes, schemes and examples are consistent with those used in the contemporary scientific literature, for example, the *Journal of the American Chemical Society* or the *Journal of Biological Chemistry*. Standard single-letter or three-letter abbreviations are generally used to designate amino acid residues, which are assumed to be in the L-configuration unless otherwise noted. Unless otherwise noted, all starting materials were obtained from commercial suppliers and used without further purification.

| | |
|---|---|
| Hz (Hertz); | TLC (thin layer chromatography); |
| $T_r$ (retention time); | RP (reverse phase); |
| MeOH (methanol); | *i*-PrOH (isopropanol); |
| EtOH (ethanol); | TEA (triethylamine); |
| TFA (trifluoroacetic acid); | THF (tetrahydrofuran); |
| DMSO (dimethylsulfoxide); | AcOEt or EtOAc (ethyl acetate); |
| DCM (dichloromethane); | DMF (*N*,*N*-dimethylformamide); |
| CDI (1,1-carbonyldiimidazole); | HOAc (acetic acid); |
| HOSu (*N*-hydroxysuccinimide); | Ac (acetyl); |
| HOBT (1-hydroxybenzotriazole); | BOC (*tert*-butyloxycarbonyl); |

66

mCPBA (meta-chloroperbenzoic acid); FMOC (9-fluorenylmethoxycarbonyl);
DCC (dicyclohexylcarbodiimide); CBZ (benzyloxycarbonyl);
NMM (N-methyl morpholine); HOAt (1-hydroxy-7-azabenzotriazole);
DMAP (4-dimethylaminopyridine); Bn (benzyl);
TBAF (tetra-*n*-butylammonium fluoride); THP (tetrahydro-2H-pyran-2-yl)
HPLC (high pressure liquid chromatography);
BOP (bis(2-oxo-3-oxazolidinyl)phosphinic chloride);
EDCI (1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride);
HBTU (O-Benzotriazole-1-yl-N,N,N',N'- tetramethyluronium hexafluorophosphate).

All references to ether are to diethyl ether; brine refers to a saturated aqueous solution of NaCl. Unless otherwise indicated, all temperatures are expressed in °C (degrees Centigrade). All reactions are conducted under an inert atmosphere at room temperature unless otherwise noted, and all solvents are highest available purity unless otherwise indicated.

$^1$H NMR (hereinafter also "NMR") spectra were recorded on a Varian VXR-300, a Varian Unity-300, a Varian Unity-400 instrument, a Brucker AVANCE-400, a General Electric QE-300 or a Bruker AM 400 spectrometer. Chemical shifts are expressed in parts per million (ppm, δ units). Coupling constants are in units of hertz (Hz). Splitting patterns describe apparent multiplicities and are designated as s (singlet), d (doublet), t (triplet), q (quartet), quint (quintet), m (multiplet), br (broad).

Mass spectra were run on an open access LC-MS system using electrospray ionization. LC conditions: 4.5% to 90% $CH_3CN$ (0.02% TFA) in 3.2 min with a 0.4 min hold and 1.4 min re-equilibration; detection by MS, UV at 214 nm, and a light scattering detector (ELS). Column: 1 X 40 mm Aquasil (C18).

For preparative (prep) hplc; *ca* 50 mg of the final products were injected in 500 uL of DMSO onto a 50 X 20 mm I. D. YMC CombiPrep ODS-A column at 20 mL/min with a 10 min gradient from 10% $CH_3CN$ (0.1% TFA) to 90% $CH_3CN$ (0.1% TFA) in $H_2O$ (0.1% TFA) and a 2 min hold. Flash chromatography was run over Merck Silica gel 60 (230 - 400 mesh).

Infrared (IR) spectra were obtained on a Nicolet 510 FT-IR spectrometer using a 1-mm NaCl cell. Most of the reactions were monitored by thin-layer chromatography on 0.25

67

mm E. Merck silica gel plates (60F-254), visualized with UV light, 5% ethanolic phosphomolybdic acid or p-anisaldehyde solution.

The following synthetic schemes are merely illustrative of the methods by which the compounds of the invention may be prepared and are not intended to limit the scope of the invention as defined in the appended claims.

The compounds disclosed in Examples 2 to 353 were prepared following the general procedures described in Example 1. The compounds disclosed in Examples 355 to 379 were prepared following the general procedures described in Example 354.

**Preparation 1**

**(4S)-Benzyl-3-heptanoyl-oxazolidin-2-one.**

To a solution of (S)-(-)-4-benzyl-2-oxazolidinone (3.3 g, 18.6 mmol) in THF (50 mL) at -78 °C was added dropwise n-BuLi (7.4 mL, 2.5M solution in hexane, 18.6 mmol). After stirring for 30 min at the same temperature, the reaction mixture was treated with heptanoyl chloride (2.76 g, 18.6 mmol). The reaction mixture was stirred and allowed to warm to 10 °C over 5 h, and quenched with saturated aqueous $NH_4Cl$ solution (100 mL). The aqueous layer was extracted with EtOAc (100 mL x 2). The combined organic layers were washed with brine; and dried over $MgSO_4$. Removal of the solvent under reduced pressure yielded 4.63 g (86%) of the title compound. $^1H$ NMR (400 MHz, $CDCl_3$) δ 7.37-7.22 (m, 5H), 4.69 (m, 1H), 4.19 (m, 2H), 3.31 (dd, J = 13.4, 3.3 Hz, 1H), 2.95 (m, 2H), 2.79 (dd, J = 13.4, 9.7 Hz, 1H), 1.71 (m, 2H), 1.42-1.32 (m, 6H), 0.92 (t, J = 6.8 Hz, 3H). MH+ 290.

**Preparation 2**

**(4S)-Benzyl-3-[(2R)-benzyloxymethylheptanoyl]oxazolidin-2-one.**

To a solution of (S)-4-benzyl-3-heptanoyloxazolidin-2-one (4.63 g, 16.02 mmol) and titanium (IV) chloride (1.9 mL, 16.82 mmol) in dichloromethane (55 mL) at 0 °C was added dropwise diisopropylethylamine (3.1 mL, 17.62 mmol). After stirring at 0 °C for 1 hour, the resulting titanium enolate was reacted with benzylchloromethyl ether (TCI-America, 4.9 mL, 32.04 mmol) at 0 °C for 6 h. The reaction mixture was then quenched with water (100 mL). The aqueous layer was extracted with dichloromethane (100 mL x 2). The organic extracts were washed with brine, and dried over $MgSO_4$. After removing the solvent under reduced pressure,

purification by flash column chromatography using an eluting system of hexane/EtOAc (5:1) yielded 4.39 g (67%) of the title compound. $^1$H NMR (400 MHz, CDCl3) δ 7.38-7.21 (m, 10H), 4.74 (m, 1H), 4.57 (m, 2H), 4.28-4.13 (m, 3H), 3.82 (t, J = 8.7 Hz, 1H), 3.68 (dd, J = 9.0, 4.9 Hz, 1H), 3.25 (dd, J = 13.5, 3.1 Hz, 1H), 2.71 (dd, J = 13.5, 9.3 Hz, 1H), 1.74 (m, 1H), 1.54 (m, 1H), 1.31-1.28 (m, 6H), 0.89 (t, J = 6.7 Hz, 3H). MH+ 410.

**Preparation 3**

**(3R)-Benzyloxy-2-pentylpropionic acid.**

A 0.05 M solution of (S)-4-benzyl-3-[(R)-2-benzyloxymethylheptanoyl]oxazolidin-2-one (2.0 g, 4.89 mmol) in a 3:1 mixture of THF and $H_2O$ was treated with 30% $H_2O_2$ (4.5 mL, 39.12 mmol), followed by LiOH (0.48 g, 9.78 mmol) at 0 °C. The resulting mixture was stirred and allowed to warm to room temperature overnight. THF was then removed under vacuum. The residue was washed with dichloromethane (50 mL x 2) to remove (S)-4-benzyloxazolidin-2-one. The desired product was isolated by EtOAc extraction of the acidified (pH 1~2) aqueous phase. No further purification was required. Standing under high vacuum yielded 1.16 g (95%) of the title compound. $^1$H NMR (400 MHz, $CHCl_3$) δ 11.1 (br s, 1H), 7.36 (m, 5H), 4.57 (s, 2H), 3.69 (m, 1H), 3.58 (dd, J = 9.2, 5.2 Hz, 1H), 2.74 (m, 1H), 1.66 (m, 1H), 1.54 (m, 1H), 1.34-1.30 (m, 6H), 0.90 (t, J = 6.7 Hz, 3H). MH+ 251.

**Preparation 4**

**3-Hydroxy-(2R)-pentylpropionic acid.**

To a solution of (R)-3-benzyloxy-2-pentyl-propionic acid (1.54 g, 6.16 mmol) in EtOH (100 mL) was added 10% Pd/C (310 mg). The reaction mixture was subjected to hydrogenation overnight at room temperature. After the reaction was completed, the reaction mixture was filtered through a pad of Celite, and washed with EtOH (50 mL x 3). Removal of the solvent provided the title compound (0.92 g, 93%). No further purification was required. $^1$H NMR (400 MHz, $CHCl_3$) δ 6.30 (br s, 1H), 3.81 (d, J = 5.4 Hz, 2H), 2.64 (m, 1H), 1.69 (m, 1H), 1.56 (m, 1H), 1.41-1.27 (m, 6H), 0.91 (t, J = 7.7 Hz, 3H). MH+ 161.

**Preparation 5**

**N-Benzyloxy-3-hydroxy-(2R)-pentylpropionamide.**

To a mixture of (R)-3-hydroxy-2-pentylpropionic acid (0.92 g, 5.75 mmol), O-benzyl hydroxylamine hydrochloride (0.92 g, 5.75 mmol) and 4-(dimethylamino)pyridine (1.41 g, 11.50 mmol) in dichloromethane (25 mL) at 0 °C was added 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (1.11 g, 5.75 mmol). After stirring at room temperature overnight, the reaction was quenched with 1N aqueous HCl solution (25 mL) and extracted using dichloromethane (25 mL x 2). The organic extracts were washed with water, brine, and dried over $MgSO_4$. Removal of the solvent under reduced pressure yielded the title compound (1.43 g, 94%). $^1H$ NMR (400 MHz, $CHCl_3$) δ 9.22 (br s, 1H), 7.41-7.28 (m, 5H), 4.89 (q, J = 10.6 Hz, 2H), 3.70-3.37 (m, 3H), 2.17 (m, 1H), 1.54 (br s, 1H), 1.27 (m, 6H), 0.88 (t, J = 6.9 Hz, 3H). MH+ 266.

**Preparation 6**

**1-benzyloxy-(3R)-pentylazetidin-2-one.**

To a mixture of (R)-N-benzyloxy-3-hydroxy-2-pentylpropionamide (1.41 g, 5.32 mmol) and triphenylphosphine (1.68 g, 6.39 mmol) in THF (53 mL) was added dropwise diethyl azodicarboxylate (1.1 mL, 6.39 mmol) at 0 °C. The reaction mixture was stirred and allowed to warm to room temperature overnight. The reaction was then quenched with water (50 mL). The aqueous layer was extracted with EtOAc (50 mL x 2). The combined organic layers were washed with brine, and dried over $MgSO_4$. After removing the solvent under vacuum, the residue was purified by flash column chromatography (hex:EtOAc 5/1) to provide the title compound (1.17 g, 89%). $^1H$ NMR (400 MHz, $CHCl_3$) δ 7.35-7.25 (m, 5H), 4.87 (s, 2H), 3.28 (t, J = 4.85 Hx, 1H), 2.84 (q, J 2.35 Hz, 1H), 2.77 (m, 1H), 1.62 (m, 1H), 1.36 (m, 1H), 1.25-1.16 (m, 6H), 0.88 (t, J = 6.9 Hz, 3H). MH+ 248.

**Preparation 7**

**3-benzyloxyamino-(2R)-pentylpropionic acid.**

To a solution of (R)-1-benzyloxy-3-pentylazetidin-2-one (0.96 g, 3.89 mmol) in a mixture of THF-$H_2O$-MeOH (50 mL, 3:1:1 v/v) was added lithium hydroxide monohydrate (1.91 g, 38.9 mmol). After stirring at room temperature overnight, water (25 mL) was added to the mixture. The solution was acidified to pH 5~6 with 3N aqueous HCl solution. It was extracted with EtOAc (50 mL x 2). The combined organic layers were dried over $MgSO_4$. Removal of the

solvent under vacuum provided the title compound (0.98 g, 95%). $^1$H NMR (400 MHz, $CHCl_3$) δ 9.80 (br s, 1H), 7.37 (m, 5H), 4.75 (m, 2H), 3.14 (m, 2H), 2.74 (m, 1H), 1.70 (m, 1H), 1.53 (m, 1H), 1.38-1.25 (m, 6H), 0.91 (t, J = 6.8 Hz, 3H). MH+ 266.

**Preparation 8**

**(2R)-[(benzyloxyformylamino)methyl]heptanoic acid.**

To a cold solution of (R)-3-benzyloxyamino-2-pentylpropionic acid (1.03 g, 3.89 mmol) in $HCO_2H$ (19 mL) and dichloromethane (19 mL) at 0 °C was added acetic anhydride (3.9 mL, 41.2 mmol). The mixture was stirred at 0 °C for 3 hours. The volatiles were removed by evaporation under vacuum. Dichloromethane (50 mL) was added. The organic solution was washed with brine (50 mL x 2), and dried over $MgSO_4$. Filtration and evaporation under vacuum provided the title compound (1.08 g, 95%). $^1$H NMR (400 MHz, $CHCl_3$) δ 8.07 (br s, 1H), 7.29 (m, 5H), 4.91-4.71 (m, 2H), 3.76 (m, 2H), 2.67 (m, 1H), 1.54 (m, 1H), 1.41(m, 1H), 1.20 (m, 6H), 0.80 (t, J = 7.0 Hz, 3H). MH+ 294.

**Example 1**

**N-Hydroxy-N-[(R)-2-(N'-pyridin-2-yl-hydrazinocarbonyl)-heptyl]-formamide.**

(2R)-[(benzyloxyformylamino)methyl]heptanoic acid (1.2 mmoles), HOAt (1.3 mmoles), N'-pyridin-2-yl-hydrazine (1.2 mmoles) and NMM (5 mmoles) were dissolved in DMF and treated with EDCI (1.3 mmoles) at room temperature for 12 hours. The coupling product N-benzyloxy-N-[(R)-2-(N'-pyridin-2-yl-hydrazinocarbonyl)-heptyl]-formamide was isolated by prep hplc of the crude reaction mixture. This compound was submitted to atmospheric pressure hydrogenation over Pd/C in methanol for 1 hour, yielding the title compound. MH+ 295.

**Preparation 9**

**2-Hydrazino-5-ethylpyrimidine.**

To a solution of 2-chloro-5-ethylpyrimidine (0.31 g, 2.2 mmol) in MeOH (5 mL) was added hydrazine monohydrate (1.0 mL, 20.6 mmol). After stirring for 16 h at 50 °C, the solution was cooled to room temperature and purified by reverse phase HPLC to give 0.24 g (80%) of the title compound as a white solid. MH+ 139.

**Preparation 10**

**2-Hydrazino-4-methylpyrimidine.**

To a finely dispersed suspension of 2-chloropyrimidine (8.01 g, 69.9 mmol) in a 10:1 mixture of $Et_2O$-THF (500 mL) at –30°C was added dropwise MeLi (46 mL, 1.6M in $Et_2O$, 73.6 mmol). The reaction mixture was stirred at –30°C for 30 min, and was then warmed to 0°C and stirred for 30 min. To the reaction mixture was then added a 1:1:20 mixture of $H_2O$-HOAc-THF (100 mL), and the mixture was stirred at 0°C for 10 min. To the mixture was then added a solution of DDQ (16.7 g, 73.6 mmol) in THF (100 mL), and the mixture was stirred and warmed to room temperature for 30 min. The mixture was then diluted with $Et_2O$ (300 mL) and washed with 1N aq. NaOH (3x100 mL) followed by brine (300 mL). The organic phase was then dried over anhydrous $MgSO_4$, filtered, concentrated *in vacuo*, and purified by flash chromatography using EtOAc-hexanes (1:2) as eluent to afford 6.06 g of 2-chloro-4-methylpyrimidine (67%) as white crystalline plates.

To a solution of 2-chloro-4-methylpyrimidine (6.06 g, 47.1 mmol) in MeOH (40 mL) was added hydrazine monohydrate (10 mL, 206 mmol). The solution was stirred for 16 h at room temperature and then purified by reverse phase HPLC to provide 4.43 g of the title compound (76%) as a white solid. MH+ 125.

**Preparation 11**

**2-Hydrazino-4-morpholino-6-methylpyrimidine.**

To a solution of 2,4-dichloro-6-methylpyrimidine (0.41 g, 2.50 mmol) in MeOH (5 mL) was added morpholine (0.5 mL, 5.73 mmol). The solution was stirred for 30 min at room temperature, and then hydrazine monohydrate (1.0 mL, 20.6 mmol) was added. The solution was then heated at 60 °C and stirred for 16 h. The solution was then cooled to room temperature and purified by reverse phase HPLC to afford 0.31 g of the title compound (59%) as a waxy white solid. MH+ 210.

**Preparation 12**

**2-Hydrazino-4-(2,3,4-trimethoxyphenyl)pyrimidine.**

To a solution of 2-thiomethyl-4-chloropyrimidine (0.3410 g, 2.12 mmol) in 1,4-dioxane (21 mL) was added 2,3,4-trimethoxyphenylboronic acid (0.4950 g, 2.33 mmol) and aq. $Na_2CO_3$ (2.3 mL, 2.0M in water, 4.60 mmol). The mixture was sparged with dry nitrogen gas for 5 min, and then $Pd(Ph_3P)_4$ (123 mg, 0.106 mmol) was added. The mixture was protected from light and heated at 110°C for 16 h. The mixture was then cooled to room temperature, filtered, concentrated *in vacuo*, and purified by flash chromatography using EtOAc-hexanes (1:4) as eluent to give 0.5920 g of 2-thiomethyl-4-(2,3,4-trimethoxyphenyl)pyrimidine (95%) as a yellow solid.

To a solution of 2-thiomethyl-4-(2,3,4-trimethoxyphenyl)pyrimidine (0.5920 g, 2.02 mmol) in $CH_2Cl_2$ (10 mL) was added m-chloroperbenzoic acid (1.05 g, 6.08 mmol), and the solution was stirred for 3 h at which time it was observed to be a white suspension. The suspension was concentrated *in vacuo*, and MeOH (10 mL) was added followed by hydrazine monohydrate (2 mL, 41.2 mmol). The resulting solution was stirred for 16 h and then concentrated to about one-half volume *in vacuo*. The mixture was allowed to stand for 1 h, and the resulting solid was collected by vacuum filtration and was washed with water. Drying *in vacuo* afforded 0.3330 g of the title compound (60%) as a light brown solid. MH+ 277.

**Preparation 13**

**2-Hydrazino-4-morpholino-6-trifluoromethylpyrimidine.**

To a solution of 2-thiomethyl-4-chloro-6-trifluoromethylpyrimidine (1.9996 g, 8.75 mmol) in MeOH (50 mL) was added morpholine (1.5 mL, 17.2 mmol). The solution was stirred overnight, concentrated *in vacuo*, and the resulting white solid was collected by vacuum filtration and washed with water. To a solution of the solid in $CH_2Cl_2$ (50 mL) was added m-chloroperbenzoic acid (4.53 g, 26.3 mmol), and the resulting solution was stirred for 2 h at which time it was observed to be a white suspension. The solvent was removed *in vacuo*, and then MeOH (50 mL) was added followed by hydrazine monohydrate (3.0 mL, 61.8 mmol). The solution was stirred for 16 h, and was then concentrated to about one-half volume *in vacuo*. Water (100 mL) was then added to the resulting suspension, and the observed white solid was collected by vacuum filtration. This material was then washed with water and dried *in vacuo* to afford 1.7193 g of the title compound (75%) as a white solid. MH+ 264.

**Preparation 14**

**2-Hydrazino-5,6,7,8-tetrahydroquinazoline.**

To a mixture of ethyl 2-cyclohexanonecarboxylate (3.00 g, 17.6 mmol) and 2-methyl-2-thiopseudourea sulfate (3.68 g, 13.2 mmol) was added a solution of potassium carbonate (7.31 g, 52.9 mmol) in water (60 mL). The reaction solution was stirred at room temperature for 16 h, at which time it was observed to be a suspension. The white solid was collected by vacuum filtration, washed with water, and dried *in vacuo*. A mixture of the solid in phosphorus oxychloride (20 mL) was heated at 110°C in a sealed tube, at which time it was observed to be a solution. The solution was cooled to room temperature and was then poured over cracked ice and water (300 mL). The mixture was vigorously stirred at 0°C for 1 h, and the resulting precipitate was collected by vacuum filtration, washed with water, and dried *in vacuo* to afford 1.61 g of 2-thiomethyl-4-chloro-5,6,7,8-tetrahydroquinazoline (43%) as an off-white solid.

To a solution of 2-thiomethyl-4-chloro-5,6,7,8-tetrahydroquinazoline (0.5121 g, 2.39 mmol) in a 10:1 mixture of MeOH-HOAc (30 mL) was added activated zinc dust (500 mg, 7.65 mmol). The mixture was heated at 70°C for 1 h, and was then cooled to room temperature and filtered. The resulting solution was concentrated *in vacuo*, and azeotropically dried with toluene (50 mL). The residue was partitioned between EtOAc (150 mL) and 1 N aq. HCl (50 mL), and the organic phase was then washed with saturated aq. $NaHCO_3$ and brine. The organic phase was then dried over anhydrous $MgSO_4$ and concentrated *in vacuo* to provide 0.1461 g of 2-thiomethyl-5,6,7,8-tetrahydroquinazoline (34%) as a purple oil.

To a solution of 2-thiomethyl-5,6,7,8-tetrahydroquinazoline (0.1461 g, 0.81 mmol) in $CH_2Cl_2$ (5 mL) was added m-chloroperbenzoic acid (0.462 g, 2.68 mmol). The solution was stirred at room temperature for 3 h at which time it was observed to be a suspension. The solvent was then removed *in vacuo*, and MeOH (5 mL) was added followed by hydrazine monohydrate (1 mL, 20.6 mmol). The solution was then heated at 50°C and stirred for 16 h. The solution was cooled to room temperature and purified by reverse phase HPLC to give 0.1126 g of the title compound (85%) as a colorless oil. MH+ 165.

**Preparation 15**

**2-Hydrazino-4-(2-pyridyl)pyrimidine.**

To a solution of 2-amino-4-(2-pyridyl)pyrimidine (10.10 g, 58.66 mmol) in 5% aqueous sulfuric acid (200 mL) was added sodium nitrate (20.24 g, 293.3 mmol) portionwise over 10 min. The solution was stirred at room temperature for 2 h and was then adjusted to pH 10 by addition of 6N aq. NaOH. The resulting mixture was then extracted with 30% i-PrOH in $CHCl_3$ (10x300 mL), and the combined organic phase was dried over anhydrous $MgSO_4$ and concentrated *in vacuo*. The residue was triturated with hexanes and collected by vacuum filtration to afford 6.89 g of 4-(2-pyridyl)pyrimid-2-one (68%) as a beige solid.

A mixture of 4-(2-pyridyl)pyrimid-2-one (6.89 g, 39.8 mmol) in phosphorus oxychloride (30 mL) was heated at 110°C for 90 min in a sealed tube. The dark brown solution was then cooled to room temperature and poured over cracked ice and water (500 mL). The mixture was vigorously stirred at 0°C for 1 h, and was then adjusted to pH 14 with 6 N aq NaOH. The mixture was extracted with $CH_2Cl_2$ (2x300 mL), and the combined organic phase was dried over anhydrous $MgSO_4$ and concentrated *in vacuo*. To a solution of the residue in $CH_2Cl_2$ (10 mL) and MeOH (30 mL) was added hydrazine monohydrate (7.0 mL, 144.2 mmol), and the solution was stirred for 16 h at which time a white precipitate was observed. This solid was collected by vacuum filtration, washed with water, and dried *in vacuo* to provide 2.20 g of the title compound (30%) as an off-white solid. MH+ 188.

**Preparation 16**

**(6-Morpholin-4-yl-pyrimidin-4-yl)-hydrazine.**

A solution of 4,6 dichloropyrimidine (300 mg, 2 mmol), *tert*-butyl carbazate (280 mg, 2.1 mmol) and Hunig's base (453 µL, 2.6 mmol) in ethanol (3 ml)was stirred at 120 °C for 1 hour under microwave condition. After morpholine (700 µL, 8 mmol) was added, the mixture was then resubmitted to the same microwave condition for another hour. Evaporation of solvent under vacuum gave a white solid which was treated with TFA (3 ml) in DCM (3 ml) for 20 min. After evaporation of solvent, the residue was redissolved in methanol. Treatment with solid $NaHCO_3$ removed the traces of TFA that might have been left over. Filtration followed by evaporation of the solvent gave a residue which was submitted to reverse-phase HPLC purification to produce (6-morpholin-4-yl-pyrimidin-4-yl)-hydrazine (200 mg, 1 mmol, 50% in 3 steps) as a white solid. MH+ 196.

Alternatlively, the same compound may be generated by stirring a solution of 4,6 dichloropyrimidine (300 mg, 2 mmol), morpholine (280 mg, 2.1 mmol) and diisopropylethylamine (453 µL, 2.6 mmol) in ethanol (3 ml) for one hour. After addition of hydrazine (370 µL, 6 mmol), the mixture was stirred at 120 °C for 1 hour under microwave condition. After evaporation of the solvent, the compound was dissolved in DMSO before submitted to prep HPLC purificaton which then gave 6-morpholin-4-yl-pyrimidin-4-yl)-hydrazine. MH+ 196.

**Preparation 17**

**(2-Ethylamine-6-trifluoromethyl-pyrimidin-4-yl)-hydrazine.**

A solution of (4-chloro-6-trifluoromethyl-pyrimidin-2-yl)-ethyl-amine (100 mg, 0.38 mmol), hydrazine (87 µL, 3.8 mmol) in ethanol was heated at 70 °C over night. Evaporation of the solvent under vacuum gave a residue which was purified by prep HPLC to give (2-ethylamine-6-trifluoromethyl-pyrimidin-4-yl)-hydrazine (74 mg, 75%). MH+ 256.

**Preparation 18**

**[(4-Methyl-piperazin-1-yl)-trifluoromethyl-pyrimidin-4-yl]-hydrazine.**

A mixture of 4-chloro-2-methylthiol-6-(trifluomethyl)pyrimidine (228 mg, 1 mmol), tert-butyl carbazate (159 mg.6, 1.2 mmol) in ethanol was heated to 100 °C in the microwave reactor for 20 min. Evaporation of solvent gave a white solid. The solid was treated with MCPBA in DCM at rt overnight. Evaporation of the solvent gave a white solid which was treated with 1-methylpiperazine at 140 °C for 20 min. in ethanol under microwave conditions. Evaporation of solvents gave a solid which was treated TFA (3 ml) in DCM (3 ml) for 20 min. After the reaction was done,most of TFA and DCM was removed under vacuum. The residue was redissolved in methanol and treated with solid $NaHCO_3$ to remove TFA residue until no gas was generated. Filtration and vacuum evaporation of the filtrate gave a residue which was purified by prep. HPLC to give [(4-Methyl-piperazin-1-yl)-trifluoromethyl-pyrimidin-4-yl]-hydrazine (100 mg, 36%). MH+ 277.

**Example 2**

**N-Hydroxy-N-{(R)-2-[N'-(3-methoxy-phenyl)-hydrazinocarbonyl]-heptyl}-formamide.**

MH+ = 324.

**Example 3**

N-Hydroxy-N-{(R)-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

MH+ = 364.

**Example 4**

N-{(R)-2-[N'-(4-Cyano-phenyl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

MH+ = 319.

**Example 5**

N-{(R)-2-[N'-(2,6-Dimethyl-pyrimidin-4-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

MH+ = 324.

**Example 6**

N-Hydroxy-N-[(R)-2-(N'-quinoxalin-2-yl-hydrazinocarbonyl)-heptyl]-formamide.

MH+ = 346.

**Example 7**

N-Hydroxy-N-((2R)-2-[N'-(3,4-dihydro-quinoxalin-2-yl)-hydrazinocarbonyl]-heptyl)-formamide.

MH+ = 348.

**Example 8**

N-Hydroxy-N-{(R)-2-[N'-(1,3,4-trimethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)-hydrazinocarbonyl]-heptyl}-formamide.

MH+ = 377.

**Example 9**

4-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-benzenesulfonamide.

MH+ = 373.

**Example 10**

N-Hydroxy-N-[(2*R*)-2-(cyclohexylmethyl)-3-oxo-3-{N'-[4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-propyl]-formamide.
MH+ = 390.

**Example 11**

N-Hydroxy-N-[(2*R*)-2-(cyclopentylmethyl)-3-oxo-3-{N'-[4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-propyl]-formamide.
MH+ = 376.

**Example 12**

N-{(R)-2-[N'-(Dimethyl-trifluoromethyl-pyrimidin-4-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.
MH+ = 392.

**Example 13**

N-Hydroxy-N-{(R)-2-[N'-(6-trifluoromethyl-pyridazin-3-yl)-hydrazinocarbonyl]-heptyl}-formamide.
MH+ = 364.

**Example 14**

N-Hydroxy-N-{(R)-2-[N'-(6-trifluoromethyl-pyrimidin-4-yl)-hydrazinocarbonyl]-heptyl}-formamide.
MH+ = 364.

**Example 15**

N-Hydroxy-N-{(R)-2-[N'-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-hydrazinocarbonyl]-heptyl}-formamide.
MH+ = 350.

**Example 16**

N-Hydroxy-N-{(R)-2-[N'-(9H-purin-6-yl)-hydrazinocarbonyl]-heptyl}-formamide.
MH+ = 336.

**Example 17**

N-{(R)-2-[N'-(5-Cyano-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.
MH+ = 321.

**Example 18**

N-Hydroxy-N-((2*R*)-2-{[N'-(pyrimidin-2-yl)-hydrazino]carbonyl}-heptyl)-formamide.
MH+ = 296.

**Example 19**

N-Hydroxy-N-((2*R*)-2-(cyclobutylmethyl)-3-oxo-3-{N'-[4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-propyl)-formamide.
MH+ = 362.

**Example 20**

N-Hydroxy-N-{(R)-2-[N'-(6-imidazol-1-yl-pyrimidin-4-yl)-hydrazinocarbonyl]-heptyl}-formamide.
MH+ = 362.

**Example 21**

N-[(R)-2-(N'-Benzo[1,2,4]triazin-3-yl-hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.
MH+ = 347.

**Example 22**

N-Hydroxy-N-{(R)-2-[N'-(7-methoxy-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-formamide.
MH+ = 377.

**Example 23**

N-Hydroxy-N-{(R)-2-[N'-(1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-yl)-hydrazinocarbonyl]-heptyl}-formamide.
MH+ = 350.

**Example 24**

N-((R)-2-{N'-[6-(5-Chloro-pyridin-3-yl-oxy)-pyridazin-3-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.
MH+ = 423.

**Example 25**

N-Hydroxy-N-[(2*R*)-2-({N'-[6-(1*H*-pyrrol-1-yl)-3-pyridazinyl]-hydrazino}-carbonyl)-heptyl]-formamide.
MH+ = 361.

**Example 26**

N-Hydroxy-N-((2*R*)-2-{[*N'*-(9-methyl-9*H*-purin-6-yl)-hydrazino]-carbonyl}-heptyl)-formamide.
MH+ = 350.

**Example 27**

N-Hydroxy-N-{(R)-2-[N-({6-morpholin-4-yl}-9H-purin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.
MH+ = 421.

**Example 28**

N-{(R)-2-[N'-(6-Fluoro-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.
MH+ = 313.

**Example 29**

N-Hydroxy-N-((2*R*)-2-{[N'-(1-methyl-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-yl)-hydrazino]-carbonyl}-heptyl)-formamide.
MH+ = 350.

**Example 30**

N-{(R)-2-[N'-(4-Amino-6-isopropyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.
MH+ = 354.

**Example 31**

N-{(R)-2-[N'-(2,5-Dimethyl-4-nitro-2H-pyrazol-3-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.
MH+ = 357.

**Example 32**

N-{(R)-2-[N'-(3-Chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

MH+ = 384.

**Example 33**

N-{(R)-2-[N'-(6-Dimethylamino-9H-purin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

MH+ = 379.

**Example 34**

N-Hydroxy-N-[(2*R*)-4-cyclopropyl-2-({N'-[4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-butyl]-formamide.

MH+ = 362.

**Example 35**

N-Hydroxy-N-((2*R*)-2-(cyclopropylmethyl)-3-oxo-3-{N'-[4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-propyl)-formamide.

MH+ = 348.

**Example 36**

N-Hydroxy-N-{(R)-2-[N'-methyl-N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

MH+ = 378.

**Example 37**

2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid methyl ester.

MH+ = 422.

**Example 38**

2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid.

MH+ = 408.

**Example 39**

N-{(R)-2-[N'-(5-Fluoro-4-methoxy-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

MH+ = 344.

**Example 40**

**N-{(R)-2-[N'-(4-Dimethylamino-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.**

**MH+ = 339.**

**Example 41**

**N-Hydroxy-N-{(2*R*)-2-[(N'-{6-[(2-hydroxyethyl)amino]-1,3-dihydro-2*H*-purin-2-ylidene}-hydrazino)-carbonyl]-heptyl}-formamide.**

**MH+ = 395.**

**Example 42**

**N-{(R)-2-[N'-(5-Fluoro-4-morpholin-4-yl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.**

**MH+ = 399.**

**Example 43**

**N-{(R)-2-[N'-(5-Fluoro-4-methylamino-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.**

**MH+ = 343.**

**Example 44**

**2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid dimethylamide.**

**MH+ = 435.**

**Example 45**

**N-Hydroxy-N-{(R)-2-[N'-(3-oxo-3,4-dihydro-quinoxalin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.**

**MH+ = 362.**

**Example 46**

**N-{(R)-2-Butoxy-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.**

**MH+ = 366.**

**Example 47**

2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (2-fluoro-phenyl)-amide.
MH+ = 501.

Example 48

2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid tert-butylamide.
MH+ = 463.

Example 49

N-Hydroxy-N-((R)-2-{N'-[(1-piperidin-1-yl-methanoyl)-trifluoromethyl-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.
MH+ = 475.

Example 50

N-{(R)-2-[N'-(5-Cyano-4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.
MH+ = 389.

Example 51

N-Hydroxy-N-[(2*R*)-2-({N'-[9-(4,4,4-trifluorobutyl)-1,9-dihydro-2*H*-purin-2-ylidene]-hydrazino}-carbonyl)-heptyl]-formamide.
MH+ = 446.

Example 52

N-Hydroxy-N-((R)-2-{N'-[(1-morpholin-4-yl-methanoyl)-trifluoromethyl-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.
MH+ = 477.

Example 53

2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid benzylamide.
MH+ = 497.

Example 54

N-Hydroxy-N-[(2*R*)-3-[N'-(1,2,4-benzotriazin-3-yl)-hydrazino]-2-(cyclohexylmethyl)-3-oxopropyl]-formamide.

63.

MH+ = 373.

**Example 55**

**N-Hydroxy-N-((2*R*)-2-(cyclohexylmethyl)-3-{N'-[7-(methyloxy)-1,2,4-benzotriazin-3-yl]-hydrazino}-3-oxopropyl)-formamide.**

MH+ = 403.

**Example 56**

**2-[2-((2R)-2-{[Formyl(hydroxy)amino]methyl}heptanoyl)hydrazino]-N-methyl-N-2-pyridinyl-4-(trifluoromethyl)-5-pyrimidinecarboxamide.**

MH+ = 498.

**Example 57**

**2-[2-((2R)-2-{[Formyl(hydroxy)amino]methyl}heptanoyl)hydrazino]-N-methyl-N-phenyl-4-(trifluoromethyl)-5-pyrimidinecarboxamide.**

MH+ = 497.

**Example 58**

**2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid morpholin-4-ylamide.**

MH+ = 492.

**Example 59**

**N-Hydroxy-N-((R)-2-{N'-[(N'-phenyl-hydrazinocarbonyl)-trifluoromethyl-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.**

MH+ = 498.

**Example 60**

**2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid piperidin-1-ylamide.**

MH+ = 490.

**Example 61**

**2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid pyrrol-1-ylamide.**

MH+ = 472.

64

**Example 62**

**N-{(R)-2-[N'-(Dimethylamino-fluoro-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.**

MH+ = 357.

**Example 63**

**N-((R)-2-{N'-[(Ethyl-methyl-amino)-fluoro-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.**

MH+ = 371.

**Example 64**

**N-Hydroxy-N-((2R)-2-(cyclopentylmethyl)-3-{N'-[7-(methyloxy)-1,2,4-benzotriazin-3-yl]-hydrazino}-3-oxopropyl)-formamide.**

MH+ = 389.

**Example 65**

**N-Hydroxy-N-{(R)-2-[N'-(1-methyl-1H-benzoimidazol-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.**

MH+ = 348.

**Example 66**

**N-{(R)-2-[N'-(4-Azetidin-1-yl-5-fluoro-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.**

MH+ = 369.

**Example 67**

**N-{(R)-2-[N'-(4-Cyclopropylamino-5-fluoro-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.**

MH+ = 369.

**Example 68**

**N-[(R)-2-(N-Benzo[1,2,4]triazin-3-yl-hydrazinocarbonyl)-3-cyclopentyl-propyl]-N-hydroxy-formamide.**

MH+ = 359.

**Example 69**

N-Hydroxy-N-{(R)-2-[N'-(morpholin-4-yl-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.
MH+ = 449.

Example 70

N-Hydroxy-N-[(R)-2-(N'-{[(2-hydroxy-ethyl)-methyl-amino]-trifluoromethyl-pyrimidin-2-yl}-hydrazinocarbonyl)-heptyl]-formamide.
MH+ = 437.

Example 71

N-Hydroxy-N-((R)-2-{N'-[(4-methyl-piperazin-1-yl)-trifluoromethyl-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.
MH+ = 462.

Example 72

N-Hydroxy-N-((2R)-2-(cyclohexylmethyl)-3-{N'-[4-(cyclopropylamino)-5-fluoro-pyrimidin-2-yl]hydrazino}-3-oxopropyl)-formamide.
MH+ = 395.

Example 73

N-Hydroxy-N-((2R)-2-(cyclopentylmethyl)-3-{N'-[4-(cyclopropylamino)-5-fluoro-pyrimidin-2-yl]hydrazino}-3-oxopropyl)-formamide.
MH+ = 381.

Example 74

N-Hydroxy-N-[(2R)-3-{N'-[4-(azetidin-1-yl)-5-fluoro-pyrimidin-2-yl]-hydrazino}-2-(cyclopentylmethyl)-3-oxopropyl]-formamide.
MH+ = 381.

Example 75

N-Hydroxy-N-[(2R)-5-methyl-2-({N'-[4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-hexyl]-formamide.
MH+ = 364.

Example 76

N-[(R)-2-(N'-Benzo[1,2,4]triazin-3-yl-hydrazinocarbonyl)-5-methyl-hexyl]-N-hydroxy-formamide.

66

MH+ = 347.

**Example 77**

N-Hydroxy-N-[(2R)-5-methyl-2-({N'-[7-(methyloxy)-1,2,4-benzotriazin-3-yl]-hydrazino}-carbonyl)-hexyl]-formamide.

MH+ = 377.

**Example 78**

N-{(R)-2-[N'-(7-Chloro-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

MH+ = 381.

**Example 79**

N-Hydroxy-N-((2R)-2-(cyclopentylmethyl)-3-{N'-[4-(morpholin-4-yl)-6-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-3-oxopropyl)-formamide.

MH+ = 461.

**Example 80**

N-Hydroxy-N-((2R)-2-(cyclopentylmethyl)-3-{N'-[4-[(2-hydroxyethyl)-(methyl)-amino]-6-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-3-oxopropyl)-formamide.

MH+ = 449.

**Example 81**

N-Hydroxy-N-[(2R)-6-methyl-2-({N'-[4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-heptyl]-formamide.

MH+ = 378.

**Example 82**

N-Hydroxy-N-((2R)-2-{[N'-(1,2,4-benzotriazin-3-yl)-hydrazino]-carbonyl}-6-methylheptyl)-formamide.

MH+ = 361.

**Example 83**

N-Hydroxy-N-{(R)-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-formamide.

MH+ = 361.

97

**Example 84**

**N-((R)-2-{N'-[(4-Ethyl-piperazin-1-yl)-trifluoromethyl-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.**

**MH+ = 476.**

**Example 85**

**N-Hydroxy-N-{(R)-2-[N'-(piperazin-1-yl-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.**

**MH+ = 448.**

**Example 86**

**N-{(R)-2-[N'-(7-Fluoro-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.**

**MH+ = 365.**

**Example 87**

**N-Hydroxy-N-[(2R)-2-({N'-[4-(4-ethyl-1-piperazinyl)-6-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-6-methylheptyl]-formamide.**

**MH+ = 490.**

**Example 88**

**N-Hydroxy-N-[(2R)-6-methyl-2-({N'-[4-(piperazin-1-yl)-6-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-heptyl]-formamide.**

**MH+ = 462.**

**Example 89**

**N-Hydroxy-N-[(2R)-6-methyl-2-({N'-[4-(4-methyl-piperazin-1-yl)-6-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-heptyl]-formamide.**

**MH+ = 476.**

**Example 90**

**N-Hydroxy-N-((2R)-2-{[N'-(7-chloro-1,2,4-benzotriazin-3-yl)hydrazino]carbonyl}-6-methylheptyl)-formamide.**

**MH+ = 395.**

**Example 91**

N-Hydroxy-N-((2R)-6-methyl-2-{[N'-(5-methyl-1,2,4-benzotriazin-3-yl)-hydrazino]-carbonyl}-heptyl)-formamide.
MH+ = 375.

**Example 92**

N-Hydroxy-N-((2R)-2-{[N'-(7-fluoro-1,2,4-benzotriazin-3-yl)-hydrazino]-carbonyl}-6-methylheptyl)-formamide.
MH+ = 379.

**Example 93**

N-Hydroxy-N-((R)-2-{N'-[(2-methoxy-ethylamino)-trifluoromethyl-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.
MH+ = 437.

**Example 94**

N-Hydroxy-N-[(2R)-6-methyl-2-({N'-[7-(methyloxy)-1,2,4-benzotriazin-3-yl]-hydrazino)-carbonyl)-heptyl]-formamide.
MH+ = 391.

**Example 95**

N-Hydroxy-N-[(R)-2-(N'-{[4-(2-hydroxy-ethyl)-piperazin-1-yl]-trifluoromethyl-pyrimidin-2-yl}-hydrazinocarbonyl)-heptyl]-formamide.
MH+ = 492.

**Example 96**

N-Hydroxy-N-((R)-2-{N'-[(4-pyrimidin-2-yl-piperazin-1-yl)-trifluoromethyl-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.
MH+ = 526.

**Example 97**

N-Hydroxy-N-((R)-2-{N'-[(2-hydroxy-ethylamino)-trifluoromethyl-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.
MH+ = 423.

**Example 98**

N-Hydroxy-N-{(R)-2-[N'-(7-trifluoromethyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-formamide.

MH+ = 415.

**Example 99**

N-Hydroxy-N-{(R)-2-[N'-(6-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-formamide.

MH+ = 361.

**Example 100**

N-Hydroxy-N-{(2R)-2-(cyclopentylmethyl)-3-[N'-(5-methyl-1,2,4-benzotriazin-3-yl)hydrazino]-3-oxopropyl}-formamide.

MH+ = 373.

**Example 101**

N-Hydroxy-N-[(2R)-2-({N'-[4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-octyl]-formamide.

MH+ = 378.

**Example 102**

N-Hydroxy-N-((2R)-2-{[N'-(1,2,4-benzotriazin-3-yl)hydrazino]-carbonyl}-octyl)-formamide.

MH+ = 361.

**Example 103**

N-Hydroxy-N-[(2R)-2-({N'-[7-(methyloxy)-1,2,4-benzotriazin-3-yl]-hydrazino}-carbonyl)-octyl]-formamide.

MH+ = 391.

**Example 104**

N-Hydroxy-N-{(R)-2-[N'-(7-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-formamide.

MH+ = 361.

**Example 105**

N-{(R)-2-[N'-(6-Chloro-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

MH+ = 381.

**Example 106**

**N-Hydroxy-N-{(R)-2-[N'-(5-methoxy-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-formamide.**

**MH+ = 377.**

**Example 107**

**N-Hydroxy-N-{(R)-2-[N'-(1-methyl-2-oxo-1,2-dihydro-pyridin-4-yl)-hydrazinocarbonyl]-heptyl}-formamide.**

**MH+ = 325.**

**Example 108**

**N-Hydroxy-N-((R)-2-{N'-[(N'-pyridin-2-yl-hydrazino)-trifluoromethyl-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.**

**MH+ = 471.**

**Example 109**

**N-Hydroxy-N-{(R)-2-[N'-(4-methyl-6-morpholin-4-yl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.**

**MH+ = 395.**

**Example 110**

**N-((R)-2-{N'-[4-(4-Ethyl-piperazin-1-yl)-6-methyl-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.**

**MH+ = 422.**

**Example 111**

**N-{(R)-2-[N'-(4,6-Dimethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.**

**MH+ = 324.**

**Example 112**

**N-Hydroxy-N-{(R)-2-[N'-(4-trifluoromethyl-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.**

**MH+ = 363.**

**Example 113**

**N-Hydroxy-N-[(R)-2-(N'-isoquinolin-1-yl-hydrazinocarbonyl)-heptyl]-formamide.**

MH+ = 345.

**Example 114**

**N-Hydroxy-N-[(R)-2-(N'-quinolin-2-yl-hydrazinocarbonyl)-heptyl]-formamide.**

MH+ = 345.

**Example 115**

**N-{(R)-2-[N'-(1-Benzyl-2-oxo-1,2-dihydro-pyridin-4-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.**

MH+ = 401.

**Example 116**

**N-Hydroxy-N-{(R)-2-[N'-(4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.**

MH+ = 363.

**Example 117**

**N-Hydroxy-N-{(R)-2-[N'-(4-methyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.**

MH+ = 310.

**Example 118**

**N-{(R)-2-[N'-(1-Butyl-2-oxo-1,2-dihydro-pyridin-4-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.**

MH+ = 367.

**Example 119**

**N-Hydroxy-N-{(R)-2-[N'-(9-methyl-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.**

MH+ = 377.

**Example 120**

**N-Hydroxy-N-{(R)-2-[N'-(6-oxo-4-trifluoromethyl-1,6-dihydro-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.**

MH+ = 380.

**Example 121**

N-Hydroxy-N-{(R)-2-[N'-(methyl-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.
MH+ = 378.

Example 122

N-Hydroxy-N-{(R)-2-[N'-(5-trifluoromethyl-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.
MH+ = 363.

Example 123

N-{(R)-2-[N'-(6-Ethoxy-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.
MH+ = 339.

Example 124

N-Hydroxy-N-[(R)-2-(N'-pyrido[2,3-e]-[1,2,4]triazin-3-yl-hydrazinocarbonyl)-heptyl]-formamide.
MH+ = 348.

Example 125

N-((R)-2-{N'-[1-(1-Ethyl-propyl)-2-oxo-1,2-dihydro-pyridin-4-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.
MH+ = 381.

Example 126

N-Hydroxy-N-((R)-2-{N'-[2-oxo-1-(3-trifluoromethyl-benzyl)-1,2-dihydro-pyridin-4-yl]-hydrazinocarbonyl}-heptyl)-formamide.
MH+ = 469.

Example 127

N-Hydroxy-N-{(R)-2-[N'-(4-methyl-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.
MH+ = 309.

Example 128

N-Hydroxy-N-{(R)-2-[N'-(6-methoxy-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

MH+ = 325.

Example 129

N-Hydroxy-N-{(R)-2-[N'-(2-oxo-1-quinolin-8-yl-methyl-1,2-dihydro-pyridin-4-yl)-hydrazinocarbonyl]-heptyl}-formamide.

MH+ = 452.

Example 130

N-Hydroxy-N-[(R)-2-(N'-[2-oxo-1-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethyl]-dihydro-pyridin-4-yl]-hydrazinocarbonyl)-heptyl]-formamide.

MH+ = 471.

Example 131

N-{(R)-2-[N'-(4,6-Bis-ethylamino-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

MH+ = 383.

Example 132

N-{(R)-2-[N'-(Bis-dimethylamino-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

MH+ = 383

Example 133

N-{(R)-2-[N'-(4,6-Di-morpholin-4-yl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

MH+ = 467.

Example 134

N-Hydroxy-N-((R)-2-[N'-[4-(4-methyl-piperazin-1-yl)-6-propylamino-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

MH+ = 452.

Example 135

N-{(R)-2-[N'-(Dimethylamino-morpholin-4-yl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

MH+ = 425.

**Example 136**

**N-Hydroxy-N-{(R)-2-[N'-(6-methyl-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.**

**MH+ = 309.**

**Example 137**

**N-Hydroxy-N-((R)-2-{N'-[5-(5-phenyl-[1,3,4]oxadiazol-2-yl)-pyridin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.**

**MH+ = 439.**

**Example 138**

**N-{(R)-2-[N'-(7-tert-Butyl-1,4-dioxo-1,2,3,4-tetrahydro-pyrido[3,4-d]pyridazin-5-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.**

**MH+ = 435.**

**Example 139**

**N-((R)-2-{N'-[4-Ethylamino-6-(4-methyl-[1,4]diazepan-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.**

**MH+ = 452.**

**Example 140**

**N-((R)-2-{N'-[4-Ethylamino-6-(4-ethyl-piperazin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.**

**MH+ = 452.**

**Example 141**

**N-Hydroxy-N-{(R)-2-[N'-(6-trifluoromethyl-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.**

**MH+ = 363.**

**Example 142**

**N-Hydroxy-N-{(R)-2-[N'-(4-methyl-6-morpholin-4-yl-methyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.**

**MH+ = 409.**

**Example 143**

**N-Hydroxy-N-{(R)-2-[N'-(4-methyl-6-morpholin-4-yl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.**
**MH+ = 396.**

**Example 144**

**N-Hydroxy-N-{(2R)-2-(cyclopentylmethyl)-3-[N'-(4,6-dimethyl-2-pyrimidinyl)-hydrazino]-3-oxopropyl}-formamide.**
**MH+ = 336.**

**Example 145**

**N-Hydroxy-N-{(R)-2-[N'-(4-methyl-6-pyrrolidin-1-yl-methyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.**
**MH+ = 393.**

**Example 146**

**N-{(R)-2-[N'-(4-Dimethylaminomethyl-6-methyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.**
**MH+ = 367.**

**Example 147**

**N-Hydroxy-N-((R)-2-{N'-[4-methyl-6-(4-methyl-piperazin-1-yl-methyl)-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.**
**MH+ = 422.**

**Example 148**

**N-Hydroxy-N-{(R)-2-[N'-(5-methyl-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.**
**MH+ = 309.**

**Example 149**

**N-((R)-2-{N'-[Dimethylamino-(4-methyl-[1,4]diazepan-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.**
**MH+ = 452.**

**Example 150**

**N-Hydroxy-N-{(R)-2-[N'-(4-methyl-6-pyrrolidin-1-yl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.**

MH+ = 380.

Example 151

N-Hydroxy-N-((R)-2-{N'-[4-methyl-6-)4-pyrrolidin-1-yl-piperidin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

MH+ = 463.

Example 152

N-((R)-2-{N'[(Ethyl-methyl-amino)-methyl-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

MH+ = 368.

Example 153

N-((R)-2-{N'-[(4-(4-Ethyl-piperazin-1-yl)-6-methyl-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

MH+ = 423.

Example 154

N-Hydroxy-N-[(2R)-7,7,7-trifluoro-2-({N'-[4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-heptyl]-formamide.

MH+ = 418.

Example 155

N-Hydroxy-N-((2R)-7,7,7-trifluoro-2-{[N'-(5-methyl-1,2,4-benzotriazin-3-yl)-hydrazino]-carbonyl}-heptyl)-formamide.

MH+ = 415.

Example 156

N-Hydroxy-N-((2R)-7,7,7-trifluoro-2-{[N'-(7-methyl-1,2,4-benzotriazin-3-yl)-hydrazino]-carbonyl}-heptyl)f-ormamide.

MH+ = 415.

Example 157

N-Hydroxy-N-{(R)-2-[N'-(4-methylamino-6-morpholin-4-yl-[1,3,5]-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

MH+ = 411.

**Example 158**

N-((R)-2-{N'-[4-(4-Ethyl-piperazin-1-yl)-6-methylamino-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

MH+ = 438.

**Example 159**

N-{(R)-2-[N'-(4-Ethylamino-6-morpholin-4-yl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

MH+ = 425.

**Example 160**

N-Hydroxy-N-{(R)-2-[N'-(4,6,7-trimethyl-7,8-dihydro-pterin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

MH+ = 392.

**Example 161**

N-Hydroxy-N-{(R)-2-[N'-(4,6,7-trimethyl-pteridin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

MH+ = 390.

**Example 162**

N-Hydroxy-N-{(R)-2-[N'-(methoxymethoxymethyl-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

MH+ = 438.

**Example 163**

N-Hydroxy-N-((R)-2-{N'-[4-methyl-6-(1-piperidin-1-yl-methanoyl)-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

MH+ = 421.

**Example 164**

2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-6-methyl-pyrimidine-4-carboxylic acid cyclopropylamide.

MH+ = 393.

**Example 165**

2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-6-methyl-pyrimidine-4-carboxylic acid diisopropylamide.
MH+ = 437.

Example 166

N-{(R)-2-[N'-(5-Cyano-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.
MH+ = 320.

Example 167

N-{(R)-2-[N'-(4,6-Diethyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.
MH+ = 353.

Example 168

N-{(R)-4-Cyclopentyl-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-butyl}-N-hydroxy-formamide.
MH+ = 390.

Example 169

N-{(R)-4-Cyclopentyl-2-[N'-(7-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-butyl}-N-hydroxy-formamide.
MH+ = 387.

Example 170

N-{(R)-4-Cyclopentyl-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-butyl}-N-hydroxy-formamide.
MH+ = 387.

Example 171

N-Hydroxy-N-((R)-2-{N'-[6-(4-methyl-piperazin-1-yl-methyl)-pyridin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.
MH+ = 407.

Example 172

N-((R)-2-{N'-[5-(4,6-Dimethoxy-pyrimidin-2-yl)-pyridin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

MH+ = 433.

Example 173

N-{(R)-2-[N'-(Diethylamino-methyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

MH+ = 382.

Example 174

N-Hydroxy-N-[(R)-2-(N'-{[(2-methoxy-ethyl)-methyl-amino]-methyl-[1,3,5]triazin-2-yl}-hydrazinocarbonyl)-heptyl]-formamide.

MH+ = 397.

Example 175

N-((R)-1-{N'-[4-(2,6-Dimethyl-morpholin-4-yl)-6-methyl-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

MH+ = 424.

Example 176

N-{(R)-2-[N'-(5-Fluoro-4-methyl-6-morpholin-4-yl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

MH+ = 413.

Example 177

N-{(R)-2-[N'-(4-Ethyl-6-morpholin-4-yl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

MH+ = 410.

Example 178

N-{(R)-2-[N'-(Ethyl-methyl-amino)-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

MH+ = 382.

Example 179

N-((R)-2-{N'-[4-Ethyl-6-(4-ethyl-piperazin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

MH+ = 437.

100

**Example 180**

**N-((R)-2-{N'-[5-Fluoro-4-methyl-6-(4-methyl-piperazin-1-yl)-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.**

**MH+ = 426.**

**Example 181**

**N-{(R)-2-[N'-(Dimethylamino-ethyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.**

**MH+ = 368.**

**Example 182**

**N-((R)-2-{N'-[5-Fluoro-4-methyl-6-(4-methyl-[1,4]diazepan-1-yl)-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.**

**MH+ = 440.**

**Example 183**

**N-{(R)-4-Cyclopentyl-2-[N'-(morpholin-4-yl-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-butyl}-N-hydroxy-formamide.**

**MH+ = 475.**

**Example 184**

**N-[(R)-2-(N'-[Ethyl-[(2-methoxy-ethyl)-methyl-amino]-[1,3,5]triazin-2-yl}-hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.**

**MH+ = 412.**

**Example 185**

**N-{(R)-2-[N'-(Dimethylamino-methyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.**

**MH+ = 353.**

**Example 186**

**N-{(R)-2-[N'-(4-Cyclopropylamino-6-methyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.**

**MH+ = 365.**

**Example 187**

N-{(R)-2-Cyclohexyl-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.
MH+ = 376.

Example 188

N-{(R)-2-Cyclohexyl-2-[N'-(7-methoxy-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.
MH+ = 389.

Example 189

N-{(R)-2-Cyclohexyl-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.
MH+ = 373.

Example 190

N-{(R)-4,4-Dimethyl-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-pentyl}-N-hydroxy-formamide.
MH+ 364.

Example 191

N-{(R)-4,4-Dimethyl-2-[N'-(7-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-pentyl}-N-hydroxy-formamide.
MH+ = 361.

Example 192

N-{(R)-4,4-Dimethyl-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-pentyl}-N-hydroxy-formamide.
MH+ = 361.

Example 193

N-{(R)-4,4-Dimethyl-2-[N'-(morpholin-4-yl-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-pentyl}-N-hydroxy-formamide.
MH+ = 449.

Example 194

N-((R)-2-{N'-[Ethyl-(methyl-pyridin-2-yl-amino)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

MH+ = 431.

**Example 195**

N-{(R)-2-[N'-(4-Cyclopropylamino-6-ethyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

MH+ = 380.

**Example 196**

N-Hydroxy-N-[(R)-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-3-(1-methyl-cyclopentyl)-propyl]-formamide.

MH+ = 387.

**Example 197**

N-Hydroxy-N-[(R)-2-[N'-(7-methoxy-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-3-(1-methyl-cyclopentyl)-propyl]-formamide.

MH+ = 403

**Example 198**

N-Hydroxy-N-{(R)-3-(1-methyl-cyclopentyl)-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-propyl}-formamide.

MH+ = 390.

**Example 199**

N-Hydroxy-N-{(R)-2-[N'-(4-isopropyl-6-morpholin-4-yl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

MH+ = 424.

**Example 200**

N-Hydroxy-N-{(2R)-2-(cyclopentylmethyl)-3-[N'-(4-methyl-2-pyrimidinyl)-hydrazino]-3-oxopropyl}-formamide.

MH+ = 322.

**Example 201**

N-Hydroxy-N-[(2R)-6,6,6-trifluoro-2-({N'-[4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-hexyl]-formamide.

MH+ = 404.

103

**Example 202**

**N-{(R)-2-[N'-(5,7-Dimethyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.**

MH+ = 375.

**Example 203**

**N-{(R)-2-[N'-(3,6-Dimethyl-pyrazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.**

MH+ = 324.

**Example 204**

**N-((R)-2-{N'-[4-(4-Ethyl-piperazine-1-yl)-6-isopropyl-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.**

MH+ = 451.

**Example 205**

**N-{(R)-2-[N'-(4-Dimethylamino-6-isopropyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.**

MH+ = 382.

**Example 206**

**N-Hydroxy-N-{(R)-2-[N'-(methyl-trifluoromethyl-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.**

MH+ = 377.

**Example 207**

**2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-6,N,N-trimethyl-isonicotinamide.**

MH+ = 380.

**Example 208**

**N-Hydroxy-N[(2R)-2-({N'-[3-amino-6-(trifluoromethyl)-pyridin-2-yl]-hydrazino}-carbonyl)-heptyl]-formamide.**

MH+ = 378.

**Example 209**

N-Hydroxy-N-[(R)-2-(N'-[4-isopropyl-6-[(2-methoxy-ethyl)-methyl-amino]-[1,3,5]triazin-2-yl]-hydrazinocarbonyl)-heptyl]-formamide.
MH+ = 426.

Example 210

N-[(R)-3-Cyclopentyl-2-[N'-(4-ethyl-6-morpholin-4-yl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-propyl]-N-hydroxy-formamide.
MH+ = 422.

Example 211

N-Hydroxy-N-[(R)-2-[N'-(4-morpholin-4-yl-6-propyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl]-formamide.
MH+ = 424.

Example 212

N-((R)-2-[N'-[4-(4-Ethyl-piperazin-1-yl)-6-propyl-[1,3,5]triazin-2-yl]-hydrazinocarbonyl]-heptyl)-N-hydroxy-formamide.
MH+ = 451.

Example 213

N-[(R)-5,5-Dimethyl-2-[N'(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-hexyl]-N-hydroxy-formamide.
MH+ = 378.

Example 214

N-[(R)-5,5-Dimethyl-2-[N'-(7-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-hexyl]-N-hydroxy-formamide.
MH+ = 375.

Example 215

N-[(R)-5,5-Dimethyl-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-hexyl]-N-hydroxy-formamide.
MH+ = 375.

Example 216

N-[(R)-5,5-Dimethyl-2-[N'-(morpholin-4-yl-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-hexyl]-N-hydroxy-formamide.

MH+ = 463.

Example 217

N-{(R)-4-Ethyl-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazino carbonyl]-hexyl}-N-hydroxy-formamide.

MH+ = 378.

Example 218

N-{(R)-4-Ethyl-2-[N'-(7-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-hexyl}-N-hydroxy-formamide.

MH+ = 375.

Example 219

N-{(R)-4-Ethyl-2-[N'-(morpholin-4-yl-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-hexyl}-N-hydroxy-formamide.

MH+ = 463.

Example 220

N-((R)-3-Cyclopentyl-2-{N'-[4-ethyl-6-(4-ethyl-piperazin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-propyl)-N-hydroxy-formamide.

MH+ = 449.

Example 221

N-{(R)-3-Cyclopentyl-2-[N'-(4-cyclopropylamino-6-ethyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-propyl}-N-hydroxy-formamide.

MH+ = 392.

Example 222

N-{(R)-4-Ethyl-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-hexyl}-N-hydroxy-formamide.

MH+ = 375.

Example 223

N-Hydroxy-N-[(R)-2-(N'-{[(2-methoxy-ethyl)-methyl-amino]-propyl-[1,3,5]triazin-2-yl}-hydrazinocarbonyl)-heptyl]-formamide.

MH+ = 426.

106

**Example 224**

**N-{(R)-2-[N'-(Dimethylamino-propyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.**

**MH+ = 382.**

**Example 225**

**N-{(R)-2-[N'-(4-Ethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.**

**MH+ = 324.**

**Example 226**

**N-Hydroxy-N-{(R)-2-[N'-(4-isopropyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.**

**MH+ = 338.**

**Example 227**

**N-{(R)-2-[N'-(4-Cyclopropyl-6-morpholin-4-yl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.**

**MH+ = 422.**

**Example 228**

**N-Hydroxy-N-[(2R)-2-({N'-[4-(pyridin-2-yl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-heptyl]-formamide.**

**MH+ = 373.**

**Example 229**

**N-((R)-2-{N'-[4-Cyclopropyl-6-(4-ethyl-piperazin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.**

**MH+ = 449.**

**Example 230**

**N-{(R)-2-[N'-(Cyclopropyl-dimethylamino-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.**

**MH+ = 380.**

**Example 231**

N-((R)-2-{N'-[Cyclopropyl-(ethyl-methyl-amino)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.
MH+ = 394.

Example 232

N-{(R)-2-[N'-(4-Cyclopropyl-6-pyrrolidin-1-yl[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.
MH+ = 406.

Example 233

N-{(R)-2-[N'-(4,6-Dicyclopropyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.
MH+ = 377.

Example 234

N-Hydroxy-N-[(R)-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-3-(2-methyl-cyclopentyl)-propyl]-formamide.
MH+ = 387.

Example 235

N-[(R)-2-[N'-(Dimethylamino-ethyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-3-(2-methyl-cyclopentyl)-propyl]-N-hydroxy-formamide.
MH+ = 394.

Example 236

N-Hydroxy-N-[(R)-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-3-(2-methyl-cyclopentyl)-propyl]-formamide.
MH+ = 390.

Example 237

N-{(R)-2-[N'-(5-Ethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.
MH+ = 324.

Example 238

N-Hydroxy-N-{(2R)-2-(cyclopentylmethyl)-3-[N'-(7-methyl-1,2,4-benzotriazin-3-yl)-hydrazino]-3-oxopropyl}-formamide.

MH+ = 373.

**Example 239**

N-Hydroxy-N-[(2R)-2-(cyclopentylmethyl)-3-(N'-{4-ethyl-6-[ethyl(methyl)amino]-1,3,5-triazin-2-yl}-hydrazino)-3-oxopropyl]-formamide.

MH+ = 394.

**Example 240**

N-Hydroxy-N-((2R)-2-(cyclopentylmethyl)-3-{N'-[4-(dimethylamino)-6-ethyl-1,3,5-triazin-2-yl]-hydrazino}-3-oxopropyl)-formamide.

MH+ = 380.

**Example 241**

N-((R)-2-[N'-[4-Ethyl-6-(4-isopropyl-piperazin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

MH+ = 451.

**Example 242**

N-Hydroxy-N-[(2R)-3-[N'-(6-chloro-1,2,4-benzotriazin-3-yl)-hydrazino]-2-(cyclopentylmethyl)-3-oxopropyl]-formamide.

MH+ = 393.

**Example 243**

N-{(R)-4,4-Dimethyl-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-hexyl}-N-hydroxy-formamide.

MH+ = 378.

**Example 244**

N-{(R)-4,4-Dimethyl-2-[N'-(7-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-hexyl}-N-hydroxy-formamide.

MH+ = 375.

**Example 245**

N-{(R)-4,4-Dimethyl-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-hexyl}-N-hydroxy-formamide.

MH+ = 375.

109

**Example 246**

N-{(R)-4,4-Dimethyl-2-[N'-(morpholin-4-yl-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-hexyl}-N-hydroxy-formamide.

MH+ = 463.

**Example 247**

N-Hydroxy-N-{(R)-2-[N'-(5-phenyl-[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-formamide.

MH+ = 373.

**Example 248**

N-{(R)-2-[N'-(4-Ethyl-6-morpholin-4-yl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

MH+ = 409.

**Example 249**

N-((R)-2-{N'-[4-Ethyl-6-(4-methyl-piperazin-1-yl)-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

MH+ = 422.

**Example 250**

N-{(R)-2-[N'-(5-Ethyl-4-methyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

MH+ = 338.

**Example 251**

N-((R)-2-{N'-[4-Ethyl-6-(4-propyl-piperazin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

MH+ = 451.

**Example 252**

N-Hydroxy-N-((R)-2-{N'-[6-(4-pyrimidin-2-yl-piperazin-1-yl-methyl)-pyridin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

MH+ = 471.

**Example 253**

N-Hydroxy-N-((R)-2-[N'-[6-(3-[1,2,4]triazol-1-yl-methyl-[1,2,4]triazol-1-yl)-pyridin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.
MH+ = 443.

Example 254

N-{(R)-3-Bicyclo[2.2.1]hept-7-yl-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-propyl}-N-hydroxy-formamide.
MH+ = 402.

Example 255

N-{(R)-3-Bicyclo[2.2.1]hept-7-yl-2-[N'-(morpholin-4-yl-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-propyl}-N-hydroxy-formamide.
MH+ = 487.

Example 256

N-hydroxy-N-[(R)-2-(N'-pyridin-3-yl-hydrazinocarbonyl)-heptyl]-formamide.
MH+ = 295.

Example 257

4-{4-Ethyl-6-[2-((2R)-2-{[formyl(hydroxy)amino]-methyl}-heptanoyl)-hydrazino]-1,3,5-triazin-2-yl}-1-methyl-1-propylpiperazin-1-ium iodide.
MH+ = 465.

Example 258

N-{(R)-3-Bicyclo[2.2.1]hept-7-yl-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-propyl}-N-hydroxy-formamide.
MH+ = 399.

Example 259

N-{(R)-2-[N'-(4-Azetidin-1-yl-6-ethyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.
MH+ = 380.

Example 260

N-{(R)-2-Cyclopentyl-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.
MH+ = 362.

**Example 261**

**N-{(R)-2-Cyclopentyl-2-[N'-(morpholin-4-yl-4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.**

MH+ = 447.

**Example 262**

**N-{(R)-2-Cyclopentyl-2-[N'-(4-methyl-pyridin-2-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.**

MH+ = 307.

**Example 263**

**N-{(R)-2-Cyclopentyl-2-[N'-(dimethylamino-ethyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.**

MH+ = 366.

**Example 264**

**N-{(R)-2-Cyclopentyl-2-[N'-(7-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.**

MH+ = 359.

**Example 265**

**N-{(R)-2-Cyclopentyl-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.**

MH+ = 359.

**Example 266**

**N-Hydroxy-N-{(R)-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-2-(4-methyl-cyclohexyl)-ethyl}-formamide.**

MH+ = 387.

**Example 267**

**N-Hydroxy-N-{(R)-2-[N'-(7-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-2-(4-methyl-cyclohexyl)-ethyl}-formamide.**

MH+ = 387.

**Example 268**

N-Hydroxy-N-{(R)-2-(4-methyl-cyclohexyl)-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-ethyl}-formamide.
MH+ = 390.

Example 269

N-Hydroxy-N-{(R)-2-(4-methyl-cyclohexyl)-2-[N'-(morpholin-4-yl-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-ethyl}-formamide.
MH+ = 475.

Example 270

N-Hydroxy-N-{(R)-2-(4-methyl-cyclohexyl)-2-[N'-(4-methyl-pyridin-2-yl)-hydrazinocarbonyl]-ethyl}-formamide.
MH+ = 335.

Example 271

N-{(R)-2-[N'-(Dimethylamino-ethyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-2-(4-methyl-cyclohexyl)-ethyl}-N-Hydroxy-formamide.
MH+ = 394.

Example 272

N-{(R)-2-[N'-(6,7-Dihydro-5 H-cyclopentapyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.
MH+ = 336.

Example 273

N-((R)-2-[N'-[4-Ethyl-6-((S)-2-hydroxymethyl-pyrrolidin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl]-heptyl)-N-hydroxy-formamide.
MH+ = 424.

Example 274

N-{(R)-2-[N'-(Dimethylamino-pyridin-3-yl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.
MH+ = 416.

Example 275

N-{(R)-2-[N'-(Dimethylamino-pyridin-4-yl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

MH+ = 416.

**Example 276**

N-Hydroxy-N-{(R)-2-N'-(5,6,7,8-tetrahydro-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-formamide.

MH+ = 351.

**Example 277**

N-{(R)-2-[N'-(5,6-Diethyl-[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

MH+ = 353.

**Example 278**

N-Hydroxy-N-{(R)-2-[N'-[5-(4-hydroxy-phenyl)-[1,2,4]triazin-3-yl]-hydrazinocarbonyl}-heptyl)-formamide.

MH+ = 389.

**Example 279**

N-[(R)-2-(N'-{[(2-Dimethylamino-ethyl)-methyl-amino]-ethyl-[1,3,5]triazin-2-yl}-hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.

MH+ = 425.

**Example 280**

N-{(R)-2-[N'-(2-Dimethylamino-quinazolin-4-yl)-hydrazinocarbouyl]-heptyl}-N-hydroxy-formamide.

MH+ = 389.

**Example 281**

N-Hydroxy-N-{(R)-2-[N'-(3-methanesulfonyl-4,6-dimethyl-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

MH+ = 401.

**Example 282**

N-((R)-2-{N'-[4-Ethyl-6-(3-hydroxy-piperidin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

MH+ = 424.

**Example 283**

**N-[(R)-2-(N'-[4,5']Bipyrimidinyl-2-yl-hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.**

MH+ = 374.

**Example 284**

**N-((R)-2-{N'-[(Cyclopropyl-methyl-amino)-ethyl-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.**

MH+ = 394.

**Example 285**

**N-((R)-2-{N'-[4-Ethyl-6-((R)-3-hydroxy-pyrrolidin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.**

MH+ = 410.

**Example 286**

**N-Hydroxy-N-[(R)-2-(N'-[3,3']Bipyridinyl-5-yl-hydrazinocarbonyl)-heptyl]-formamide.**

MH+ = 372.

**Example 287**

**N-Hydroxy-N-[(R)-2-(N'-(5-morpholin-4-yl-pyridin-3-yl)-hydrazinocarbonyl)-heptyl]-formamide.**

MH+ = 380.

**Example 288**

**N-Hydroxy-N-{(R)-2-[N'-(4-pyridin-3-yl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.**

MH+ = 373.

**Example 289**

**N-Hydroxy-N-{(R)-2-[N'-(5,6,7,8-tetrahydro-quinazolin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.**

MH+ = 350.

**Example 290**

**N-[(R)-2-(N'-{[Cyclopropyl-1-(1-methyl-piperidin-4-yl)-amino]-ethyl-[1,3,5]triazin-2-yl}-hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.**

MH+ = 477.

Example 291

N-((R)-2-[N'-[4-((R)-3-Dimethylamino-pyrrolidin-1-yl)-6-ethyl-[1,3,5]triazin-2-yl]-hydrazinocarbonyl)-heptyl)-N-hydroxy-formamide.

MH+ = 437.

Example 292

N-Hydroxy-N-[(R)-2-(N'-[5-(1H-pyrrol-2-yl)-pyridin-3-yl]-hydrazinocarbonyl)-heptyl]-formamide.

MH+ = 360.

Example 293

N-Hydroxy-N-[(R)-2-(N'-[(4-methyl-piperazin-1-yl)-trifluoromethyl-pyrimidin-4-yl]-hydrazinocarbonyl)-heptyl]-formamide.

MH+ = 462.

Example 294

N-Hydroxy-N-[(R)-2-(N'-(5-Furan-3-yl-pyridin-3-yl)-hydrazinocarbonyl)-heptyl]-formamide.

MH+ = 361.

Example 295

N-{(R)-5,5-Dimethyl-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

MH+ = 392.

Example 296

N-{(R)-5,5-Dimethyl-2-[N'-(7-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

MH+ = 389.

Example 297

N-{(R)-5,5-Dimethyl-2-(4-methyl-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

MH+ = 337.

116

**Example 298**

N-{(R)-2-Cycloheptyl-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.

MH+ = 390.

**Example 299**

N-{(R)-2-Cycloheptyl-2-[N'-(4-methyl-pyridin-2-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.

MH+ = 335.

**Example 300**

N-{(R)-2-Cycloheptyl-2-[N'-(dimethylamino-ethyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.

MH+ = 394.

**Example 301**

N-{(R)-2-Cycloheptyl-2-[N'-(7-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.

MH+ = 387.

**Example 302**

N-((R)-2-{N'-[4-Ethyl-6-(4-hydroxy-piperidin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

MH+ = 424.

**Example 303**

N-{(R)-5,5-Dimethyl-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

MH+ = 389.

**Example 304**

N-{(R)-2-[N'-(4-Dimethylamino-quinazolin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

MH+ = 389.

**Example 305**

N-Hydroxy-N-{(R)-2-[N'-(4-pyridin-4-yl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.
MH+ = 373.

Example 306

N-Hydroxy-N-((R)-2-{N'-[4-(3-hydroxymethyl-phenyl)-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.
MH+ = 402.

Example 307

N-Hydroxy-N-((R)-2-{N'-[4-(4-hydroxymethyl-phenyl)-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.
MH+ = 402.

Example 308

N-((R)-2-{N'-[4-Ethyl-6-(3-methoxy-piperidin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.
MH+ = 438.

Example 309

N-Hydroxy-N-{(R)-2-[N'-(7-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-2-(4-methyl-cyclohexyl)-ethyl}-formamide.
MH+ = 387.

Example 310

N-[(R)-2-{N'-[Ethyl-(ethyl-methylamino)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-2-(4-methyl-cyclohexyl)-ethyl}-N-hydroxy-formamide.
MH+ = 408.

Example 311

N-[(R)-2-{N'-[Ethyl-(ethyl-methylamino)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-2-(4-methyl-cyclohexyl)-ethyl}-N-hydroxy-formamide.
MH+ = 408.

Example 312

N-Hydroxy-N-{(R)-2-[N'-(7-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-2-(4-methyl-cyclohexyl)-ethyl}-formamide.

118.

MH+ = 387.

Example 313

N-((R)-2-{N'-[4-(2,6-Dimethoxy-phenyl)-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

MH+ = 432.

Example 314

N-((R)-2-[N'-[4-Ethyl-6-((R)-3-methoxy-pyrrolidin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

MH+ = 424.

Example 315

N-((R)-2-{N'-[4-Ethyl-6-(4-methoxy-piperidin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

MH+ = 438.

Example 316

N-Hydroxy-N-[(R)-2-(N'-(6-pyrrolidin-1-yl-pyrimidin-4-yl)-hydrazinocarbonyl)-heptyl]-formamide.

MH+ = 365.

Example 317

N-Hydroxy-N-[(R)-2-(N'-[6-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-hydrazinocarbonyl)-heptyl]-formamide.

MH+ = 394.

Example 318

N-{(R)-2-[N'-(6-Dimethylamino-pyrimidin-4-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

MH+ = 339.

Example 319

N-{(R)-2-[N'-(Pyridin-4-yl-trifluoromethyl-pyrimidin-4-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

MH+ = 441.

**Example 320**

**N-{(R)-2-[N'-(Pyridin-3-yl-trifluoromethyl-pyrimidin-4-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.**

**MH+ = 441.**

**Example 321**

**N-{(R)-2-[N'-(2-Ethylamino-6-trifluoromethyl-pyrimidin-4-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.**

**MH+ = 407.**

**Example 322**

**N-Hydroxy-N-((R)-2-{N'-[5-(4-methoxy-phenyl)-[1,2,4]triazin-3-yl]-hydrazinocarbonyl}-heptyl)-formamide.**

**MH+ = 403.**

**Example 323**

**N-Hydroxy-N-((R)-2-{N'-[4-(2,3,4-trimethoxy-phenyl)-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.**

**MH+ = 462.**

**Example 324**

**N-{(R)-4,4-Dimethyl-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.**

**MH+ = 392.**

**Example 325**

**N-{(R)-4,4-Dimethyl-2-[N'-(7-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.**

**MH+ = 389.**

**Example 326**

**N-{(R)-4,4-Dimethyl-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.**

**MH+ = 389.**

**Example 327**

N-{(R)-4,4-Dimethyl-2-[N'-(4-methyl-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.
MH+ = 337.

Example 328

N-Hydroxy-N-{(R)-2-[N'-(6-morpholin-4-yl-pyrimidin-4-yl)-hydrazinocarbonyl]-heptyl}-formamide.
MH+ = 381.

Example 329

N-Hydroxy-N-[(R)-2-(N'-{5-[4-(2-hydroxy-ethoxy)-phenyl]-[1,2,4]triazin-3-yl}-hydrazinocarbonyl)-heptyl]-formamide.
MH+ = 433.

Example 330

N-{(R)-2-[N'-(4-Furan-2-yl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.
MH+ = 362.

Example 331

N-((R)-2-{N'-[4-(3,5-Dimethyl-isoxazol-4-yl)-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.
MH+ = 391.

Example 332

N-Hydroxy-N-{(R)-2-[N'-(4-methyl-1-oxy-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.
MH+ = 325.

Example 333

2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-6-methyl-nicotinic acid.
MH+ = 353.

Example 334

N-Hydroxy-N-{(R)-2-[N'-(3-methoxy-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

MH+ = 325.

Example 335

N-Hydroxy-N-{(2R)-2-[(N'-[4-[4-(methylsulfonyl)phenyl]-pyrimidin-2-yl}-hydrazino)-carbonyl]-heptyl}-formamide.

MH+ = 450.

Example 336

N-Hydroxy-N-[(2R)-2-({N'-[4-(furan-3-yl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-heptyl]-formamide.

MH+ = 362.

Example 337

N-[(2R)-2-({N'-[4-(2-aminophenyl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-heptyl]-N-hydroxy-formamide.

MH+ = 387.

Example 338

N-Hydroxy-N-[(2R)-2-({N'-[5-(5-methyl-1,3,4-oxadiazol-2-yl)-4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-heptyl]-formamide.

MH+ = 446.

Example 339

N-Hydroxy-N-((2*R*)-2-(cyclopentylmethyl)-3-{N'-[5-(5-methyl-1,3,4-oxadiazol-2-yl)-4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-3-oxopropyl)-formamide.

MH+ = 458.

Example 340

N-[(2R)-2-({N'-[6-(dimethylamino)-2-methyl-pyrimidin-4-yl]-hydrazino}-carbonyl)-heptyl]-N-hydroxy-formamide.

MH+ = 353.

Example 341

N-[(2R)-2-({N'-[2-Cyclopropyl-6-(dimethylamino)-pyrimidin-4-yl]-hydrazino}-carbonyl)-heptyl]-N-hydroxy-formamide.

MH+ = 379.

**Example 342**

N-Hydroxy-N-[(2R)-4-(2-thienyl)-2-({N'-[4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-butyl]-formamide.

MH+ = 404.

**Example 343**

N-Hydroxy-N-[(2R)-2-{[N'-(4-methyl-pyrimidin-2-yl)hydrazino]carbonyl}-4-(2-thienyl)-butyl]-formamide.

MH+ = 350.

**Example 344**

N-[(2R)-2-[(N'-{4-Ethyl-6-[ethyl(methyl)amino]-1,3,5-triazin-2-yl}-hydrazino)-carbonyl]-4-(2-thienyl)butyl]-N-hydroxy-formamide.

MH+ = 422.

**Example 345**

N-Hydroxy-N-((2R)-3-oxo-2-(2-thienylmethyl)-3-{N'-[4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-propyl)-formamide.

MH+ = 390.

**Example 346**

N-Hydroxy-N-[(2R)-3-[N'-(4-methyl-pyrimidin-2-yl)hydrazino]-3-oxo-2-(2-thienylmethyl)-propyl]-formamide.

MH+ = 336.

**Example 347**

N-[(2R)-3-(N'-{4-Ethyl-6-[ethyl(methyl)amino]-1,3,5-triazin-2-yl}hydrazino)-3-oxo-2-(2-thienylmethyl)-propyl]-N-hydroxy-formamide.

MH+ = 408.

**Example 348**

N-Hydroxy-N-[(2R)-2-({N'-[2-methyl-6-(pyridin-2-yl)-pyrimidin-4-yl]-hydrazino}-carbonyl)-heptyl]-formamide.

MH+ = 387.

**Example 349**

**N-Hydroxy-N-[(2R)-2-({N'-[6-(pyridin-2-yl-methyl)-pyridazin-3-yl]-hydrazino}-carbonyl)-heptyl]-formamide.**
**MH+ = 387.**

**Example 350**

**N-Hydroxy-N-[(2R)-2-({N'-[2-methyl-6-(morpholin-4-yl)-pyrimidin-4-yl]-hydrazino}-carbonyl)-heptyl]-formamide.**
**MH+ = 395.**

**Example 351**

**N-Hydroxy-N-[(2R)-2-({N'-[6-(morpholin-4-yl)-2-(trifluoromethyl)-pyrimidin-4-yl]-hydrazino}-carbonyl)-heptyl]-formamide.**
**MH+ = 449.**

**Example 352**

**N-Hydroxy-N-{(2R)-2-[(N'-{4-[methyl-(pyridin-2-yl)-amino]-pyrimidin-2-yl}-hydrazino)-carbonyl]-heptyl}-formamide.**
**MH+ = 402.**

**Example 353**

**N-Hydroxy-N-((2R)-2-(cyclopentylmethyl)-3-{N'-[4-cyclopropyl-6-(dimethylamino)-1,3,5-triazin-2-yl]-hydrazino}-3-oxopropyl)-formamide.**
**MH+ = 392.**

**Preparation 19**

**(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-carbamic acid tert-butyl ester.**

To a mixture of tert-butyl carbazate (5.15 g, 38.97 mmol) and phthalic anhydride (5.77 g, 38.97 mmol) was added $CHCl_3$ (70 mL). The reaction mixture was refluxed for 18 h. Removal of the solvent under reduced pressure yielded 8.20 g (80%) of the title compound as a white solid. MH+ 263.

**Preparation 20**

**Benzo[1,3]dioxol-5-yl-methyl-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-carbamic acid dimethyl-ethyl ester.**

To a solution of (1,3-dioxo-1,3-dihydro-isoindol-2-yl)-carbamic acid tert-butyl ester (0.31 g, 1.18 mmol), piperonyl alcohol (0.18 g, 1.18 mmol) and triphenylphosphine (0.40 g, 1.54 mmol) in THF (12 mL) at 0 °C was added dropwise diisopropyl azodicarboxylate (0.30 mL, 1.54 mmol). The reaction mixture was stirred and allowed to warm up to room temperature overnight. Removal of the solvent under reduced pressure, followed by purification by hplc yielded 0.28 g (60%) of the title compound. MH+ 397.

**Preparation 21**

***N*-Benzo[1,3]dioxol-5-yl-methyl-hydrazinecarboxylic acid tert-butyl ester.**

To N-benzo[1,3]dioxol-5-yl-methyl-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-carbamic acid dimethyl-ethyl ester (0.28 g, 0.71 mmol) in EtOH (3.6 mL) was added hydrazine monohydrate (0.14 mL, 2.84 mmol) in one portion at room temperature. The reaction mixture was stirred for 21 hrs. Toluene (5 mL) was added to the mixture, and the white solid was collected by filtration. The filtrate was evaporated *in vacuo*. Further standing under high vacuum yielded 0.17 g (89%) of the title compound. MH+ 267.

**Preparation 22**

**N-Benzo[1,3]dioxol-4-yl-methyl-N'-{(R)-2-[(benzyloxy-formyl-amino)-methyl]-heptanoyl}-hydrazinecarboxylic acid tert-butyl ester.**

To a mixture of *N*-benzo[1,3]dioxol-5-yl-methyl-hydrazinecarboxylic acid tert-butyl ester (168 mg, 0.632 mmol), (R)-2-[(benzyloxy-formyl-amino)-methyl]-heptanoic acid (185 mg, 0.632 mmol), 4-dimethylaminopyridine (100 mg, 0.822 mmol) in methylene chloride (7 mL) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (158 mg, 0.822 mmol) at room temperature. The reaction mixture was stirred for 19h at room temperature and then treated with aqueous 1N HCl solution. Separation of the organic layer, drying over anhydrous $MgSO_4$ and removal of the solvent provided the title compound No further purification was required. MH+ 542.

**Preparation 23**

**N-[(R)-2-(N'-Benzo[1,3]dioxol-5-yl-methyl-hydrazinocarbonyl)-heptyl]-N-benzyloxy-formamide.**

To the crude *N*-benzo[1,3]dioxol-4-ylmethyl-N'-{R-2-[(benzyloxy-formyl-amino)-methyl]-heptanoyl}-hydrazinecarboxylic acid *tert*-butyl ester obtained in Preparation 12 was added 5% TFA in methylene dichloride (20 mL) at room temperature. The resulting solution was stirred for 6 hours, and then washed with saturated aqueous $NaHCO_3$ solution (20 mL x 3). The organic layer was separated and dried ($MgSO_4$). Filtration and evaporation provided the title compound (0.221 g, 79% in two steps). MH+ 442.

**Example 354**

**N-[(R)-2-(N'-Benzo[1,3]dioxol-5-yl-methyl-hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.**

To a solution of N-[(R)-2-(*N'*-Benzo[1,3]dioxol-5-yl-methyl-hydrazinocarbonyl)-heptyl]-N-benzyloxy-formamide (0.221 g, 0.501 mmol) in EtOH (10 mL) was added 10% Pd/C (50 mg). The mixture was subjected to hydrogenation for 5 h at room temperature. The mixture was filtered through Celite. The filtrate was evaporated and purified by HPLC to afford the title compound (0.10 g, 57%) in a white solid. MH+ 352.

**Example 355**

**N-{(R)-2-[N'-(2,3-Dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl-methyl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.**

MH+ 366.

**Example 356**

**N-{(R)-2-[N'-(4-Dimethylamino-benzyl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.**

MH+ 351.

**Example 357**

**N-Hydroxy-N-((R)-2-{N'-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethyl]-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.**

MH+ 378.

126

**Example 358**

N-Hydroxy-N-[(R)-2-(N'-quinolin-2-yl-methyl-hydrazinocarbonyl)-heptyl]-formamide.
MH+ 359.

**Example 359**

N-Hydroxy-N-{(R)-2-[N'-(1,2,3,4-tetrahydro-quinolin-2-yl-methyl)-hydrazinocarbonyl]-heptyl}-formamide.
MH+ 363.

**Example 360**

N-Hydroxy-N-[(R)-2-(N'-quinolin-6-yl-methyl-hydrazinocarbonyl)-heptyl]-formamide.
MH+ 359.

**Example 361**

N-[(R)-2-(N'-Benzofuran-2-yl-methyl-hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.
MH+ 348.

**Example 362**

N-[(R)-2-(N'-Cyclopropylmethyl-hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.
MH+ 272.

**Example 363**

N-{(R)-2-[N'-(6-Fluoro-4H-benzo[1,3]dioxin-8-yl-methyl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.
MH+ 384

**Example 364**

N-Hydroxy-N-{(R)-2-[N'-(4-methoxy-benzyl)-hydrazinocarbonyl]-heptyl}-formamide.
MH+ = 338.

**Example 365**

N-Hydroxy-N-{(R)-2-[N'-(2-methoxy-benzyl)-hydrazinocarbonyl]-heptyl}-formamide.
MH+ = 338.

Example 366

N-Hydroxy-N-{(R)-2-[N'-(tetrahydro-furan-3-yl-methyl)-hydrazinocarbonyl]-heptyl}-formamide.

MH+ = 302.

Example 367

N-[(R)-2-(N'-Furan-3-yl-methyl-hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.

MH+ = 298.

Example 368

N-{(R)-2-[N'-(2,3-Dihydro-benzo[1,4]dioxin-6-yl-methyl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

MH+ = 366.

Example 369

N-{(R)-2-[N'-(2,3-Dihydro-benzo[1,4]dioxin-2-yl-methyl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

MH+ = 366.

Example 370

N-Hydroxy-N-{(R)-2-[N'-(2-phenoxy-ethyl)-hydrazinocarbonyl]-heptyl}-formamide.

MH+ = 338.

Example 371

N-{(R)-2-[N'-((S)-2,3-Dihydroxy-propyl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

MH+ = 292.

Example 372

N-Hydroxy-N-{(R)-2-[N'-(5-methyl-isoxazol-3-yl-methyl)-hydrazinocarbonyl]-heptyl}-formamide.

MH+ = 313.

Example 373

N-((R)-2-{N'-[1-(1-Benzo[1,3]dioxol-5-yl-methanoyl)-piperidin-4-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

MH+ = 449.

**Example 374**

**N-((R)-2-{N'-[1-(1-Benzofuran-2-yl-methanoyl)-piperidin-4-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.**

MH+ = 445.

**Example 375**

**N-Hydroxy-N-[(R)-2-(N'-{1-[1-(7-methoxy-benzofuran-2-yl)-methanoyl]-piperidin-4-yl}-hydrazinocarbonyl)-heptyl]-formamide.**

MH+ = 475.

**Example 376**

**N-{(R)-2-[N'-(1-Benzyl-piperidin-4-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.**

MH+ = 391.

**Example 377**

**N-[(R)-2-(N'-{1-[1-(3,4-Dichloro-phenyl)-methanoyl]-piperidin-4-yl}-hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.**

MH+ = 474.

**Example 378**

**N-[(R)-2-(N'-{1-[1-(2,3-Dichloro-phenyl)-methanoyl]-piperidin-4-yl}-hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.**

MH+ = 474.

**Example 379**

**N-Hydroxy-N-[(R)-2-(N'-{1-[1-(4-methyl-piperazin-1-yl)-methanoyl]-pentyl}-hydrazinocarbonyl)-heptyl]-formamide.**

MH+ = 414.

**Preparation 24**

**N-[(R)-2-(Hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.**

To a solution of N'-{(R)-2-[(Benzyloxyformylamino)methyl]heptanoyl}-hydrazinecarboxylic acid benzyl ester (1 mmol) in EtOH (10 mL) was added 10% Pd/C (50 mg). The mixture was

subjected to hydrogenation for 5 hours at room temperature and then filtered through Celite. The filtrate was evaporated and purified by hplc to afford N-[(R)-2-(Hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide as a glass. MH+ 218.

**Example 380**

**N-[(R)-2-(N'-Benzyl-hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.**

N-[(R)-2-(Hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide (50 mg, 0.23 mmoles) and benzaldehyde (24 mg, 0.23 mmoles) were dissolved in methanol (2mL) under argon in the presence of 4Å molecular sieves (50 mg), stirred for 1 hour and cooled to 0 °C. To the mixture was added one crystal of methyl orange indicator and enough methanolic HCl to keep the solution acidic (red color). Sodium cyanoborohydride (17 mg, 0.28 mmoles) was added, along with enough methanolic HCl to keep the solution acidic (red indicator). The system was warmed to room temperature, stirred for two days, neutralized with sodium bicarbonate solution, and extracted with ethyl acetate (3x). The organic layer was dried over anhydrous sodium sulfate, concentrated to dryness and purified by prep hplc to afford the title compound. MH+ 308.

## COMPOSITIONS, ADMINISTRATION AND BIOLOGICAL ASSAYS

Compounds of Formula (1) and their pharmaceutically acceptable salts may be administered in a standard manner for antibiotics, for example orally, parenterally, sub-lingually, dermally, transdermally, rectally, via inhalation or via buccal administration.

Compositions of Formula (1) and their pharmaceutically acceptable salts which are active when given orally can be formulated as syrups, tablets, capsules, creams and lozenges. A syrup formulation will generally consist of a suspension or solution of the compound or salt in a liquid carrier for example, ethanol, peanut oil, olive oil, glycerine or water with a flavoring or coloring agent. Where the composition is in the form of a tablet, any pharmaceutical carrier routinely used for preparing solid formulations may be used. Examples of such carriers include magnesium stearate, terra alba, talc, gelatin, acacia, stearic acid, starch, lactose and sucrose. Where the composition is in the form of a capsule, any routine encapsulation is suitable, for example, using the aforementioned carriers in a hard gelatin capsule shell. Where the composition is in the form of a soft gelatin shell capsule, any pharmaceutical carrier

routinely used for preparing dispersions or suspensions may be considered, for example, aqueous gums, celluloses, silicates or oils, and incorporated in a soft gelatin capsule shell.

Typical parenteral compositions consist of a solution or suspension of a compound or salt in a sterile aqueous or non-aqueous carrier optionally containing a parenterally acceptable oil, for example, polyethylene glycol, polyvinylpyrrolidone, lecithin, arachis oil or sesame oil.

Typical compositions for inhalation are in the form of a solution, suspension or emulsion that may be administered as a dry powder or in the form of an aerosol using a conventional propellant such as dichlorodifluoromethane or trichlorofluoromethane.

A typical suppository formulation comprises a compound of Formula (1) or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent, for example, polymeric glycols, gelatins, cocoa-butter or other low melting vegetable waxes or fats or their synthetic analogs.

Typical dermal and transdermal formulations comprise a conventional aqueous or non-aqueous vehicle, for example, a cream, ointment, lotion or paste or are in the form of a medicated plaster, patch or membrane.

Preferably the composition is in unit dosage form, for example a tablet, capsule or metered aerosol dose, so that the patient may administer a single dose.

Each dosage unit for oral administration contains suitably from 0.1 mg to 500 mg/Kg, and preferably from 1 mg to 100 mg/Kg, and each dosage unit for parenteral administration contains suitably from 0.1 mg to 100 mg/Kg, of a compound of Formula (1) or a pharmaceutically acceptable salt thereof calculated as the free acid. Each dosage unit for intranasal administration contains suitably 1-400 mg and preferably 10 to 200 mg per person. A topical formulation contains suitably 0.01 to 5.0% of a compound of Formula (1).

The daily dosage regimen for oral administration is suitably about 0.01 mg/Kg to 40 mg/Kg of a compound of Formula (1) or a pharmaceutically acceptable salt thereof calculated as the free acid. The daily dosage regimen for parenteral administration is suitably about 0.001 mg/Kg to 40 mg/Kg of a compound of Formula (1) or a pharmaceutically acceptable salt thereof calculated as the free acid. The daily dosage regimen for intranasal administration and oral inhalation is suitably about 10 to about 500 mg/person. The active ingredient may be administered from 1 to 6 times a day, sufficient to exhibit the desired activity.

No unacceptable toxicological effects are expected when compounds of the present invention are administered in accordance with the present invention.

The biological activity of the compounds of Formula (1) are demonstrated by the following test:

**Biological Assay.**

S. aureus or E. coli PDF activity is measured at 25°C, using a continuous enzyme-linked assay developed by Lazennec & Meinnel ("Formate dehydrogenase-coupled spectrophotometric assay of peptide deformylase", Anal. Biochem. 1997, 244, pp.180-182), with minor modifications. The reaction mixture is contained in 50 uL with 50 mM potassium phosphate buffer (pH 7.6), 15 mM NAD, 0.25 U formate dehydrogenase. The substrate peptide, f-Met-Ala-Ser, is included at the $K_M$ concentration. The reaction is triggered with the addition of 10 nM Def1 enzyme, and absorbance is monitored for 20 min at 340 nm.

**Antimicrobial Activity Assay.**

Whole-cell antimicrobial activity was determined by broth microdilution using the National Committee for Clinical Laboratory Standards (NCCLS) recommended procedure, Document M7-A4, "Methods for Dilution Susceptibility Tests for Bacteria that Grow Aerobically" (incorporated by reference herein). The compound was tested in serial two-fold dilutions ranging from 0.06 to 64 mcg/ml. A panel of 12 strains were evaluated in the assay. This panel consisted of the following laboratory strains: Staphylococcus aureus Oxford, Staphylococcus aureus WCUH29, Enterococcus faecalis I, Enterococcus faecalis 7, Haemophilus influenzae Q1, Haemophilus influenzae NEMC1, Moraxella catarrhalis 1502, Streptococcus pneumoniae 1629, Streptococcus pneumoniae N1387, Streptococcus pneumoniae N1387, E. coli 7623 (AcrABEFD+) and E. coli 120 (AcrAB-). The minimum inhibitory concentration (MIC) was determined as the lowest concentration of compound that inhibited visible growth. A mirror reader was used to assist in determining the MIC endpoint.

All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication


were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

The above description fully discloses the invention including preferred embodiments thereof. Modifications and improvements of the embodiments specifically disclosed herein are within the scope of the following claims. Without further elaboration, it is believed that one skilled in the area can, using the preceding description, utilize the present invention to its fullest extent. Therefore the Examples herein are to be construed as merely illustrative and not a limitation of the scope of the present invention in any way. The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows.

What is claimed is:

1. A compound according to Formula (1):

In one aspect of the present invention, there is provided a compound of formula (1):



(1)

wherein:

R is selected from the group consisting of:

$C_{2-6}$ alkyl (optionally substituted by alkoxy, halogen, or $C_{1-3}$ alkylsulfanyl); $C_{2-6}$ alkenyl (optionally substituted by alkoxy, halogen, or $C_{1-3}$ alkylsulfanyl); $C_{2-6}$ alkynyl (optionally substituted by alkoxy, halogen, or $C_{1-3}$ alkylsulfanyl); $(CH_2)_n$—$C_{3-6}$ carbocycle (optionally substituted by alkoxy, halogen, or $C_{1-3}$ alkylsulfanyl); and $(CH_2)_n$—R4, wherein R4 is selected from the group consisting of phenyl, furan, benzofuran, thiophene, benzothiophene, tetrahydrofuran, tetrahydropyran, dioxane, 1,4-benzodioxane or benzo[1,3]dioxole; R4 is optionally substituted by one or more substituent selected from Cl, Br, I, $C_{1-3}$ alkyl (optionally substituted by one to three F) and $C_{1-2}$ alkoxy (optionally substituted by one to three F)};

R1 and R2 are independently selected from the group consisting of:

hydrogen, $C_{1-3}$ substituted alkyl, $C_{2-3}$ substituted alkenyl, $C_{2-3}$ substituted alkynyl, $(CH_2)_n$—$C_{3-6}$ substituted carbocycle, aryl, heteroaryl, and heterocyclic;


Y represents O, $CH_2$ or a covalent bond; and

n is an integer from 0 to 2;

or a salt, solvate, or physiologically functional derivative thereof.

2. A compound according to claim 1, wherein R2 represents hydrogen;

3. A compound according to claim 2, with the following absolute configuration:



or a salt, solvate or physiologically functional derivative thereof.

4. A compound according to claim 3 selected from the group consisting of:

N-Hydroxy-N-[(R)-2-(N'-pyridin-2-yl-hydrazinocarbonyl)-heptyl]-formamide.
N-Hydroxy-N-{(R)-2-[N'-(3-methoxy-phenyl)-hydrazinocarbonyl]-heptyl}-formamide.
N-Hydroxy-N-{(R)-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.
N-{(R)-2-[N'-(4-Cyano-phenyl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.
N-{(R)-2-[N'-(2,6-Dimethyl-pyrimidin-4-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.
N-Hydroxy-N-[(R)-2-(N'-quinoxalin-2-yl-hydrazinocarbonyl)-heptyl]-formamide.
N-Hydroxy-N-((2*R*)-2-{N'-(3,4-dihydro-quinoxalin-2-yl)-hydrazinocarbonyl}-heptyl)-formamide.
N-Hydroxy-N-{(R)-2-[N'-(1,3,4-trimethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)-hydrazinocarbonyl]-heptyl}-formamide.
4-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-benzenesulfonamide.
N-Hydroxy-N-[(2*R*)-2-(cyclohexylmethyl)-3-oxo-3-{N'-[4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-propyl]-formamide.
N-Hydroxy-N-[(2*R*)-2-(cyclopentylmethyl)-3-oxo-3-{N'-[4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-propyl]-formamide.
N-{(R)-2-[N'-(Dimethyl-trifluoromethyl-pyrimidin-4-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.
N-Hydroxy-N-{(R)-2-[N'-(6-trifluoromethyl-pyridazin-3-yl)-hydrazinocarbonyl]-heptyl}-formamide.
N-Hydroxy-N-{(R)-2-[N'-(6-trifluoromethyl-pyrimidin-4-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(9H-purin-6-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-{(R)-2-[N'-(5-Cyano-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-((2*R*)-2-{[N'-(pyrimidin-2-yl)-hydrazino]carbonyl}-heptyl)-formamide.

N-Hydroxy-N-((2*R*)-2-(cyclobutylmethyl)-3-oxo-3-{N'-[4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-propyl)-formamide.

N-Hydroxy-N-{(R)-2-[N'-(6-imidazol-1-yl-pyrimidin-4-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-[(R)-2-(N'-Benzo[1,2,4]triazin-3-yl-hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(7-methoxy-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-((R)-2-{N'-[6-(5-Chloro-pyridin-3-yl-oxy)-pyridazin-3-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-Hydroxy-N-[(2*R*)-2-({N'-[6-(1*H*-pyrrol-1-yl)-3-pyridazinyl]-hydrazino}-carbonyl)-heptyl]-formamide.

N-Hydroxy-N-((2*R*)-2-{[N'-(9-methyl-9*H*-purin-6-yl)-hydrazino]-carbonyl}-heptyl)-formamide.

N-Hydroxy-N-{(R)-2-[N-({6-morpholin-4-yl}-9H-purin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-{(R)-2-[N'-(6-Fluoro-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-N'-hydroxy-formamide.

N-Hydroxy-N-((2*R*)-2-{[N'-(1-methyl-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-yl)-hydrazino]-carbonyl}-heptyl)-formamide.

N-{(R)-2-[N'-(4-Amino-6-isopropyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(2,5-Dimethyl-4-nitro-2H-pyrazol-3-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(3-Chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(6-Dimethylamino-9H-purin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-[(2*R*)-4-cyclopropyl-2-({N'-[4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-butyl]-formamide.

N-Hydroxy-N-((2*R*)-2-(cyclopropylmethyl)-3-oxo-3-{N'-[4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-propyl)-formamide.

N-Hydroxy-N-{(R)-2-[N'-methyl-N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid methyl ester.

2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid.

N-{(R)-2-[N'-(5-Fluoro-4-methoxy-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(4-Dimethylamino-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(2*R*)-2-[(N'-{6-[(2-hydroxyethyl)amino]-1,3-dihydro-2*H*-purin-2-ylidene}-hydrazino)-carbonyl]-heptyl}-formamide.

N-{(R)-2-[N'-(5-Fluoro-4-morpholin-4-yl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(5-Fluoro-4-methylamino-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid dimethylamide.

N-Hydroxy-N-{(R)-2-[N'-(3-oxo-3,4-dihydro-quinoxalin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-{(R)-2-Butoxy-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.

2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (2-fluoro-phenyl)-amide.

2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid tert-butylamide.

N-Hydroxy-N-((R)-2-{N'-[(1-piperidin-1-yl-methanoyl)-trifluoromethyl-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-{(R)-2-[N'-(5-Cyano-4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-[(2*R*)-2-({N'-[9-(4,4,4-trifluorobutyl)-1,9-dihydro-2*H*-purin-2-ylidene]-hydrazino}-carbonyl)-heptyl]-formamide.

N-Hydroxy-N-((R)-2-{N'-[(1-morpholin-4-yl-methanoyl)-trifluoromethyl-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid benzylamide.

N-Hydroxy-N-[(2*R*)-3-[N'-(1,2,4-benzotriazin-3-yl)-hydrazino]-2-(cyclohexylmethyl)-3-oxopropyl]-formamide.

N-Hydroxy-N-((2*R*)-2-(cyclohexylmethyl)-3-{N'-[7-(methyloxy)-1,2,4-benzotriazin-3-yl]-hydrazino}-3-oxopropyl)-formamide.

2-[2-((2R)-2-{[Formyl(hydroxy)amino]methyl}heptanoyl)hydrazino]-N-methyl-N-2-pyridinyl-4-(trifluoromethyl)-5-pyrimidinecarboxamide.

2-[2-((2R)-2-{[Formyl(hydroxy)amino]methyl}heptanoyl)hydrazino]-N-methyl-N-phenyl-4-(trifluoromethyl)-5-pyrimidinecarboxamide.

2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid morpholin-4-ylamide.

N-Hydroxy-N-((R)-2-{N'-[(N'-phenyl-hydrazinocarbonyl)-trifluoromethyl-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid piperidin-1-ylamide.

2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid pyrrol-1-ylamide.

N-{(R)-2-[N'-(Dimethylamino-fluoro-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-((R)-2-{N'-[(Ethyl-methyl-amino)-fluoro-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-Hydroxy-N-((2R)-2-(cyclopentylmethyl)-3-{N'-[7-(methyloxy)-1,2,4-benzotriazin-3-yl]-hydrazino}-3-oxopropyl)-formamide.

N-Hydroxy-N-{(R)-2-[N'-(1-methyl-1H-benzoimidazol-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-{(R)-2-[N'-(4-Azetidin-1-yl-5-fluoro-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(4-Cyclopropylamino-5-fluoro-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-[(R)-2-(N-Benzo[1,2,4]triazin-3-yl-hydrazinocarbonyl)-3-cyclopentyl-propyl]-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(morpholin-4-yl-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-[(R)-2-(N'-{[(2-hydroxy-ethyl)-methyl-amino]-trifluoromethyl-pyrimidin-2-yl}-hydrazinocarbonyl)-heptyl]-formamide.

N-Hydroxy-N-((R)-2-{N'-[(4-methyl-piperazin-1-yl)-trifluoromethyl-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-Hydroxy-N-((2R)-2-(cyclohexylmethyl)-3-{N'-[4-(cyclopropylamino)-5-fluoro-pyrimidin-2-yl]hydrazino}-3-oxopropyl)-formamide.

N-Hydroxy-N-((2R)-2-(cyclopentylmethyl)-3-{N'-[4-(cyclopropylamino)-5-fluoro-pyrimidin-2-yl]hydrazino}-3-oxopropyl)-formamide.

N-Hydroxy-N-[(2R)-3-{N'-[4-(azetidin-1-yl)-5-fluoro-pyrimidin-2-yl]-hydrazino}-2-(cyclopentylmethyl)-3-oxopropyl]-formamide.

N-Hydroxy-N-[(2R)-5-methyl-2-({N'-[4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-hexyl]-formamide.

N-[(R)-2-(N'-Benzo[1,2,4]triazin-3-yl-hydrazinocarbonyl)-5-methyl-hexyl]-N-hydroxy-formamide.

N-Hydroxy-N-[(2R)-5-methyl-2-({N'-[7-(methyloxy)-1,2,4-benzotriazin-3-yl]-hydrazino}-carbonyl)-hexyl]-formamide.

N-{(R)-2-[N'-(7-Chloro-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-((2R)-2-(cyclopentylmethyl)-3-{N'-[4-(morpholin-4-yl)-6-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-3-oxopropyl)-formamide.

N-Hydroxy-N-((2R)-2-(cyclopentylmethyl)-3-{N'-[4-[(2-hydroxyethyl)-(methyl)-amino]-6-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-3-oxopropyl)-formamide.

N-Hydroxy-N-[(2R)-6-methyl-2-({N'-[4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-heptyl]-formamide.

N-Hydroxy-N-((2R)-2-{[N'-(1,2,4-benzotriazin-3-yl)-hydrazino]-carbonyl}-6-methylheptyl)-formamide.

N-Hydroxy-N-{(R)-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-((R)-2-{N'-[(4-Ethyl-piperazin-1-yl)-trifluoromethyl-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(piperazin-1-yl-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-{(R)-2-[N'-(7-Fluoro-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-[(2R)-2-({N'-[4-(4-ethyl-1-piperazinyl)-6-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-6-methylheptyl]-formamide.

N-Hydroxy-N-[(2R)-6-methyl-2-({N'-[4-(piperazin-1-yl)-6-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-heptyl]-formamide.

N-Hydroxy-N-[(2R)-6-methyl-2-({N'-[4-(4-methyl-piperazin-1-yl)-6-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-heptyl]-formamide.

N-Hydroxy-N-((2R)-2-{[N'-(7-chloro-1,2,4-benzotriazin-3-yl)hydrazino]carbonyl}-6-methylheptyl)-formamide.

N-Hydroxy-N-((2R)-6-methyl-2-{[N'-(5-methyl-1,2,4-benzotriazin-3-yl)-hydrazino]-carbonyl}-heptyl)-formamide.

N-Hydroxy-N-((2R)-2-{[N'-(7-fluoro-1,2,4-benzotriazin-3-yl)-hydrazino]-carbonyl}-6-methylheptyl)-formamide.

N-Hydroxy-N-((R)-2-{N'-[(2-methoxy-ethylamino)-trifluoromethyl-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-Hydroxy-N-[(2R)-6-methyl-2-({N'-[7-(methyloxy)-1,2,4-benzotriazin-3-yl]-hydrazino}-carbonyl)-heptyl]-formamide.

N-Hydroxy-N-[(R)-2-(N'-{[4-(2-hydroxy-ethyl)-piperazin-1-yl]-trifluoromethyl-pyrimidin-2-yl}-hydrazinocarbonyl)-heptyl]-formamide.

N-Hydroxy-N-((R)-2-{N'-[(4-pyrimidin-2-yl-piperazin-1-yl)-trifluoromethyl-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-Hydroxy-N-((R)-2-{N'-[(2-hydroxy-ethylamino)-trifluoromethyl-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-Hydroxy-N-{(R)-2-[N'-(7-trifluoromethyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(6-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(2R)-2-(cyclopentylmethyl)-3-[N'-(5-methyl-1,2,4-benzotriazin-3-yl)hydrazino]-3-oxopropyl}-formamide.

N-Hydroxy-N-[(2R)-2-({N'-[4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-octyl]-formamide.

N-Hydroxy-N-((2R)-2-{[N'-(1,2,4-benzotriazin-3-yl)hydrazino]-carbonyl}-octyl)-formamide.

N-Hydroxy-N-[(2R)-2-({N'-[7-(methyloxy)-1,2,4-benzotriazin-3-yl]-hydrazino}-carbonyl)-octyl]-formamide.

N-Hydroxy-N-{(R)-2-[N'-(7-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-{(R)-2-[N'-(6-Chloro-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(5-methoxy-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(1-methyl-2-oxo-1,2-dihydro-pyridin-4-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-((R)-2-{N'-[(N'-pyridin-2-yl-hydrazino)-trifluoromethyl-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-Hydroxy-N-{(R)-2-[N'-(4-methyl-6-morpholin-4-yl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-((R)-2-{N'-[4-(4-Ethyl-piperazin-1-yl)-6-methyl-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-{(R)-2-[N'-(4,6-Dimethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(4-trifluoromethyl-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-[(R)-2-(N'-isoquinolin-1-yl-hydrazinocarbonyl)-heptyl]-formamide.

N-Hydroxy-N-[(R)-2-(N'-quinolin-2-yl-hydrazinocarbonyl)-heptyl]-formamide.

N-{(R)-2-[N'-(1-Benzyl-2-oxo-1,2-dihydro-pyridin-4-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(4-methyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-{(R)-2-[N'-(1-Butyl-2-oxo-1,2-dihydro-pyridin-4-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(9-methyl-4-oxo-4H-pyrido[1,2-a][1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(6-oxo-4-trifluoromethyl-1,6-dihydro-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(methyl-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(5-trifluoromethyl-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-{(R)-2-[N'-(6-Ethoxy-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-[(R)-2-(N'-pyrido[2,3-e]-[1,2,4]triazin-3-yl-hydrazinocarbonyl)-heptyl]-formamide.

N-((R)-2-{N'-[1-(1-Ethyl-propyl)-2-oxo-1,2-dihydro-pyridin-4-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-Hydroxy-N-((R)-2-{N'-[2-oxo-1-(3-trifluoromethyl-benzyl)-1,2-dihydro-pyridin-4-yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-Hydroxy-N-{(R)-2-[N'-(4-methyl-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(6-methoxy-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(2-oxo-1-quinolin-8-yl-methyl-1,2-dihydro-pyridin-4-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-[(R)-2-(N'-{2-oxo-1-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethyl]-dihydro-pyridin-4-yl}-hydrazinocarbonyl)-heptyl]-formamide.

N-{(R)-2-[N'-(4,6-Bis-ethylamino-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(Bis-dimethylamino-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(4,6-Di-morpholin-4-yl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-((R)-2-{N'-[4-(4-methyl-piperazin-1-yl)-6-propylamino-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-{(R)-2-[N'-(Dimethylamino-morpholin-4-yl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(6-methyl-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-((R)-2-{N'-[5-(5-phenyl-[1,3,4]oxadiazol-2-yl)-pyridin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-{(R)-2-[N'-(7-tert-Butyl-1,4-dioxo-1,2,3,4-tetrahydro-pyrido[3,4-d]pyridazin-5-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-((R)-2-{N'-[4-Ethylamino-6-(4-methyl-[1,4]diazepan-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-((R)-2-{N'-[4-Ethylamino-6-(4-ethyl-piperazin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(6-trifluoromethyl-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(4-methyl-6-morpholin-4-yl-methyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(4-methyl-6-morpholin-4-yl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(2R)-2-(cyclopentylmethyl)-3-[N'-(4,6-dimethyl-2-pyrimidinyl)-hydrazino]-3-oxopropyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(4-methyl-6-pyrrolidin-1-yl-methyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-{(R)-2-[N'-(4-Dimethylaminomethyl-6-methyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-((R)-2-{N'-[4-methyl-6-(4-methyl-piperazin-1-yl-methyl)-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-Hydroxy-N-{(R)-2-[N'-(5-methyl-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-((R)-2-{N'-[Dimethylamino-(4-methyl-[1,4]diazepan-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(4-methyl-6-pyrrolidin-1-yl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-((R)-2-{N'-[4-methyl-6-)4-pyrrolidin-1-yl-piperidin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-((R)-2-{N'[(Ethyl-methyl-amino)-methyl-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-((R)-2-{N'-[(4-(4-Ethyl-piperazin-1-yl)-6-methyl-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-Hydroxy-N-[(2R)-7,7,7-trifluoro-2-({N'-[4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-heptyl]-formamide.

N-Hydroxy-N-((2R)-7,7,7-trifluoro-2-{[N'-(5-methyl-1,2,4-benzotriazin-3-yl)-hydrazino]-carbonyl}-heptyl)-formamide.

N-Hydroxy-N-((2R)-7,7,7-trifluoro-2-{[N'-(7-methyl-1,2,4-benzotriazin-3-yl)-hydrazino]-carbonyl}-heptyl)f-ormamide.

N-Hydroxy-N-{(R)-2-[N'-(4-methylamino-6-morpholin-4-yl-[1,3,5]-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-((R)-2-{N'-[4-(4-Ethyl-piperazin-1-yl)-6-methylamino-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-{(R)-2-[N'-(4-Ethylamino-6-morpholin-4-yl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(4,6,7-trimethyl-7,8-dihydro-pterin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(4,6,7-trimethyl-pteridin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(methoxymethoxymethyl-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-((R)-2-{N'-[4-methyl-6-(1-piperidin-1-yl-methanoyl)-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-6-methyl-pyrimidine-4-carboxylic acid cyclopropylamide.

2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-6-methyl-pyrimidine-4-carboxylic acid diisopropylamide.

N-{(R)-2-[N'-(5-Cyano-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(4,6-Diethyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-4-Cyclopentyl-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-butyl}-N-hydroxy-formamide.

N-{(R)-4-Cyclopentyl-2-[N'-(7-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-butyl}-N-hydroxy-formamide.

N-{(R)-4-Cyclopentyl-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-butyl}-N-hydroxy-formamide.

N-Hydroxy-N-((R)-2-{N'-[6-(4-methyl-piperazin-1-yl-methyl)-pyridin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-((R)-2-{N'-[5-(4,6-Dimethoxy-pyrimidin-2-yl)-pyridin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-{(R)-2-[N'-(Diethylamino-methyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-[(R)-2-(N'-{[(2-methoxy-ethyl)-methyl-amino]-methyl-[1,3,5]triazin-2-yl}-hydrazinocarbonyl)-heptyl]-formamide.

N-((R)-1-{N'-[4-(2,6-Dimethyl-morpholin-4-yl)-6-methyl-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-{(R)-2-[N'-(5-Fluoro-4-methyl-6-morpholin-4-yl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(4-Ethyl-6-morpholin-4-yl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(Ethyl-methyl-amino)-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-((R)-2-{N'-[4-Ethyl-6-(4-ethyl-piperazin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-((R)-2-{N'-[5-Fluoro-4-methyl-6-(4-methyl-piperazin-1-yl)-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-{(R)-2-[N'-(Dimethylamino-ethyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-((R)-2-{N'-[5-Fluoro-4-methyl-6-(4-methyl-[1,4]diazepan-1-yl)-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-{(R)-4-Cyclopentyl-2-[N'-(morpholin-4-yl-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-butyl}-N-hydroxy-formamide.

N-[(R)-2-(N'-{Ethyl-[(2-methoxy-ethyl)-methyl-amino]-[1,3,5]triazin-2-yl}-hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.

N-{(R)-2-[N'-(Dimethylamino-methyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(4-Cyclopropylamino-6-methyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-Cyclohexyl-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.

N-{(R)-2-Cyclohexyl-2-[N'-(7-methoxy-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.

N-{(R)-2-Cyclohexyl-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.

N-{(R)-4,4-Dimethyl-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-pentyl}-N-hydroxy-formamide.

N-{(R)-4,4-Dimethyl-2-[N'-(7-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-pentyl}-N-hydroxy-formamide.

N-{(R)-4,4-Dimethyl-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-pentyl}-N-hydroxy-formamide.

N-{(R)-4,4-Dimethyl-2-[N'-(morpholin-4-yl-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-pentyl}-N-hydroxy-formamide.

N-((R)-2-{N'-[Ethyl-(methyl-pyridin-2-yl-amino)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-{(R)-2-[N'-(4-Cyclopropylamino-6-ethyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-[(R)-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-3-(1-methyl-cyclopentyl)-propyl]-formamide.

N-Hydroxy-N-[(R)-2-[N'-(7-methoxy-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-3-(1-methyl-cyclopentyl)-propyl]-formamide.

N-Hydroxy-N-{(R)-3-(1-methyl-cyclopentyl)-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-propyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(4-isopropyl-6-morpholin-4-yl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(2R)-2-(cyclopentylmethyl)-3-[N'-(4-methyl-2-pyrimidinyl)-hydrazino]-3-oxopropyl}-formamide.

N-Hydroxy-N-[(2R)-6,6,6-trifluoro-2-({N'-[4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-hexyl]-formamide.

N-{(R)-2-[N'-(5,7-Dimethyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(3,6-Dimethyl-pyrazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-((R)-2-{N'-[4-(4-Ethyl-piperazine-1-yl)-6-isopropyl-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-{(R)-2-[N'-(4-Dimethylamino-6-isopropyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(methyl-trifluoromethyl-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-6,N,N-trimethyl-isonicotinamide.

N-Hydroxy-N[(2R)-2-({N'-[3-amino-6-(trifluoromethyl)-pyridin-2-yl]-hydrazino}-carbonyl)-heptyl]-formamide.

N-Hydroxy-N-[(R)-2-(N'-{4-isopropyl-6-[(2-methoxy-ethyl)-methyl-amino]-[1,3,5]triazin-2-yl}-hydrazinocarbonyl)-heptyl]-formamide.

N-{(R)-3-Cyclopentyl-2-[N'-(4-ethyl-6-morpholin-4-yl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-propyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(4-morpholin-4-yl-6-propyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-((R)-2-{N'-[4-(4-Ethyl-piperazin-1-yl)-6-propyl-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-{(R)-5,5-Dimethyl-2-[N'(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-hexyl}-N-hydroxy-formamide.

N-{(R)-5,5-Dimethyl-2-[N'-(7-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-hexyl}-N-hydroxy-formamide.

N-{(R)-5,5-Dimethyl-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-hexyl}-N-hydroxy-formamide.

N-{(R)-5,5-Dimethyl-2-[N'-(morpholin-4-yl-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-hexyl}-N-hydroxy-formamide.

N-{(R)-4-Ethyl-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazino carbonyl]-hexyl}-N-hydroxy-formamide.

N-{(R)-4-Ethyl-2-[N'-(7-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-hexyl}-N-hydroxy-formamide.

N-{(R)-4-Ethyl-2-[N'-(morpholin-4-yl-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-hexyl}-N-hydroxy-formamide.

N-((R)-3-Cyclopentyl-2-{N'-[4-ethyl-6-(4-ethyl-piperazin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-propyl)-N-hydroxy-formamide.

N-{(R)-3-Cyclopentyl-2-[N'-(4-cyclopropylamino-6-ethyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-propyl}-N-hydroxy-formamide.

N-{(R)-4-Ethyl-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-hexyl}-N-hydroxy-formamide.

N-Hydroxy-N-[(R)-2-(N'-{[(2-methoxy-ethyl)-methyl-amino]-propyl-[1,3,5]triazin-2-yl}-hydrazinocarbonyl)-heptyl]-formamide.

N-{(R)-2-[N'-(Dimethylamino-propyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(4-Ethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(4-isopropyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-{(R)-2-[N'-(4-Cyclopropyl-6-morpholin-4-yl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-[(2R)-2-({N'-[4-(pyridin-2-yl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-heptyl]-formamide.

N-((R)-2-{N'-[4-Cyclopropyl-6-(4-ethyl-piperazin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-{(R)-2-[N'-(Cyclopropyl-dimethylamino-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-((R)-2-{N'-[Cyclopropyl-(ethyl-methyl-amino)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-{(R)-2-[N'-(4-Cyclopropyl-6-pyrrolidin-1-yl[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(4,6-Dicyclopropyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-[(R)-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-3-(2-methyl-cyclopentyl)-propyl]-formamide.

N-[(R)-2-[N'-(Dimethylamino-ethyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-3-(2-methyl-cyclopentyl)-propyl]-N-hydroxy-formamide.

N-Hydroxy-N-[(R)-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-3-(2-methyl-cyclopentyl)-propyl]-formamide.

N-{(R)-2-[N'-(5-Ethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(2R)-2-(cyclopentylmethyl)-3-[N'-(7-methyl-1,2,4-benzotriazin-3-yl)-hydrazino]-3-oxopropyl}-formamide.

N-Hydroxy-N-[(2R)-2-(cyclopentylmethyl)-3-(N'-{4-ethyl-6-[ethyl(methyl)amino]-1,3,5-triazin-2-yl}-hydrazino)-3-oxopropyl]-formamide.

N-Hydroxy-N-((2R)-2-(cyclopentylmethyl)-3-{N'-[4-(dimethylamino)-6-ethyl-1,3,5-triazin-2-yl]-hydrazino}-3-oxopropyl)-formamide.

N-((R)-2-{N'-[4-Ethyl-6-(4-isopropyl-piperazin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-Hydroxy-N-[(2R)-3-[N'-(6-chloro-1,2,4-benzotriazin-3-yl)-hydrazino]-2-(cyclopentylmethyl)-3-oxopropyl]-formamide.

N-{(R)-4,4-Dimethyl-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-hexyl}-N-hydroxy-formamide.

N-{(R)-4,4-Dimethyl-2-[N'-(7-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-hexyl}-N-hydroxy-formamide.

N-{(R)-4,4-Dimethyl-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-hexyl}-N-hydroxy-formamide.

N-{(R)-4,4-Dimethyl-2-[N'-(morpholin-4-yl-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-hexyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(5-phenyl-[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-{(R)-2-[N'-(4-Ethyl-6-morpholin-4-yl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-((R)-2-{N'-[4-Ethyl-6-(4-methyl-piperazin-1-yl)-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-{(R)-2-[N'-(5-Ethyl-4-methyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-((R)-2-{N'-[4-Ethyl-6-(4-propyl-piperazin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-Hydroxy-N-((R)-2-{N'-[6-(4-pyrimidin-2-yl-piperazin-1-yl-methyl)-pyridin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-Hydroxy-N-((R)-2-{N'-[6-(3-[1,2,4]triazol-1-yl-methyl-[1,2,4]triazol-1-yl)-pyridin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-{(R)-3-Bicyclo[2.2.1]hept-7-yl-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-propyl}-N-hydroxy-formamide.

N-{(R)-3-Bicyclo[2.2.1]hept-7-yl-2-[N'-(morpholin-4-yl-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-propyl}-N-hydroxy-formamide.

N-hydroxy-N-[(R)-2-(N'-pyridin-3-yl-hydrazinocarbonyl)-heptyl]-formamide.

4-{4-Ethyl-6-[2-((2R)-2-{[formyl(hydroxy)amino]-methyl}-heptanoyl)-hydrazino]-1,3,5-triazin-2-yl}-1-methyl-1-propylpiperazin-1-ium iodide.

N-{(R)-3-Bicyclo[2.2.1]hept-7-yl-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-propyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(4-Azetidin-1-yl-6-ethyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-Cyclopentyl-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.

N-{(R)-2-Cyclopentyl-2-[N'-(morpholin-4-yl-4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.

N-{(R)-2-Cyclopentyl-2-[N'-(4-methyl-pyridin-2-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.

N-{(R)-2-Cyclopentyl-2-[N'-(dimethylamino-ethyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.

N-{(R)-2-Cyclopentyl-2-[N'-(7-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.

N-{(R)-2-Cyclopentyl-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-2-(4-methyl-cyclohexyl)-ethyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(7-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-2-(4-methyl-cyclohexyl)-ethyl}-formamide.

N-Hydroxy-N-{(R)-2-(4-methyl-cyclohexyl)-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-ethyl}-formamide.

N-Hydroxy-N-{(R)-2-(4-methyl-cyclohexyl)-2-[N'-(morpholin-4-yl-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-ethyl}-formamide.

N-Hydroxy-N-{(R)-2-(4-methyl-cyclohexyl)-2-[N'-(4-methyl-pyridin-2-yl)-hydrazinocarbonyl]-ethyl}-formamide.

N-{(R)-2-[N'-(Dimethylamino-ethyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-2-(4-methyl-cyclohexyl)-ethyl}-N-Hydroxy-formamide.

N-{(R)-2-[N'-(6,7-Dihydro-5 H-cyclopentapyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-((R)-2-[N'-[4-Ethyl-6-((S)-2-hydroxymethyl-pyrrolidin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl]-heptyl)-N-hydroxy-formamide.

N-{(R)-2-[N'-(Dimethylamino-pyridin-3-yl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(Dimethylamino-pyridin-4-yl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-N'-(5,6,7,8-tetrahydro-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-{(R)-2-[N'-(5,6-Diethyl-[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-[5-(4-hydroxy-phenyl)-[1,2,4]triazin-3-yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-[(R)-2-(N'-{[(2-Dimethylamino-ethyl)-methyl-amino]-ethyl-[1,3,5]triazin-2-yl}-hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.

N-{(R)-2-[N'-(2-Dimethylamino-quinazolin-4-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(3-methanesulfonyl-4,6-dimethyl-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-((R)-2-{N'-[4-Ethyl-6-(3-hydroxy-piperidin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-[(R)-2-(N'-[4,5']Bipyrimidinyl-2-yl-hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.

N-((R)-2-{N'-[(Cyclopropyl-methyl-amino)-ethyl-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-((R)-2-{N'-[4-Ethyl-6-((R)-3-hydroxy-pyrrolidin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-Hydroxy-N-[(R)-2-(N'-[3,3']Bipyridinyl-5-yl-hydrazinocarbonyl)-heptyl]-formamide.

N-Hydroxy-N-[(R)-2-(N'-(5-morpholin-4-yl-pyridin-3-yl)-hydrazinocarbonyl)-heptyl]-formamide.

N-Hydroxy-N-{(R)-2-[N'-(4-pyridin-3-yl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(5,6,7,8-tetrahydro-quinazolin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-[(R)-2-(N'-{[Cyclopropyl-1-(1-methyl-piperidin-4-yl)-amino]-ethyl-[1,3,5]triazin-2-yl}-hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.

N-((R)-2-{N'-[4-((R)-3-Dimethylamino-pyrrolidin-1-yl)-6-ethyl-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-Hydroxy-N-[(R)-2-(N'-[5-(1H-pyrrol-2-yl)-pyridin-3-yl]-hydrazinocarbonyl)-heptyl]-formamide.

N-Hydroxy-N-[(R)-2-(N'-[(4-methyl-piperazin-1-yl)-trifluoromethyl-pyrimidin-4-yl]-hydrazinocarbonyl)-heptyl]-formamide.

N-Hydroxy-N-[(R)-2-(N'-(5-Furan-3-yl-pyridin-3-yl)-hydrazinocarbonyl)-heptyl]-formamide.

N-{(R)-5,5-Dimethyl-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-5,5-Dimethyl-2-[N'-(7-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-5,5-Dimethyl-2-(4-methyl-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-Cycloheptyl-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.

N-{(R)-2-Cycloheptyl-2-[N'-(4-methyl-pyridin-2-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.

N-{(R)-2-Cycloheptyl-2-[N'-(dimethylamino-ethyl-[1,3,5]triazin-2-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.

N-{(R)-2-Cycloheptyl-2-[N'-(7-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.

N-((R)-2-{N'-[4-Ethyl-6-(4-hydroxy-piperidin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-{(R)-5,5-Dimethyl-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(4-Dimethylamino-quinazolin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(4-pyridin-4-yl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

151

N-Hydroxy-N-((R)-2-{N'-[4-(3-hydroxymethyl-phenyl)-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-Hydroxy-N-((R)-2-{N'-[4-(4-hydroxymethyl-phenyl)-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-((R)-2-{N'-[4-Ethyl-6-(3-methoxy-piperidin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(7-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-2-(4-methyl-cyclohexyl)-ethyl}-formamide.

N-[(R)-2-{N'-[Ethyl-(ethyl-methylamino)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-2-(4-methyl-cyclohexyl)-ethyl}-N-hydroxy-formamide.

N-[(R)-2-{N'-[Ethyl-(ethyl-methylamino)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-2-(4-methyl-cyclohexyl)-ethyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(7-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-2-(4-methyl-cyclohexyl)-ethyl}-formamide.

N-((R)-2-{N'-[4-(2,6-Dimethoxy-phenyl)-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-((R)-2-{N'-[4-Ethyl-6-((R)-3-methoxy-pyrrolidin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-((R)-2-{N'-[4-Ethyl-6-(4-methoxy-piperidin-1-yl)-[1,3,5]triazin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-Hydroxy-N-[(R)-2-(N'-(6-pyrrolidin-1-yl-pyrimidin-4-yl)-hydrazinocarbonyl)-heptyl]-formamide.

N-Hydroxy-N-[(R)-2-(N'-[6-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl])-hydrazinocarbonyl)-heptyl]-formamide.

N-{(R)-2-[N'-(6-Dimethylamino-pyrimidin-4-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(Pyridin-4-yl-trifluoromethyl-pyrimidin-4-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(Pyridin-3-yl-trifluoromethyl-pyrimidin-4-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(2-Ethylamino-6-trifluoromethyl-pyrimidin-4-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-((R)-2-{N'-[5-(4-methoxy-phenyl)-[1,2,4]triazin-3-yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-Hydroxy-N-((R)-2-{N'-[4-(2,3,4-trimethoxy-phenyl)-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-{(R)-4,4-Dimethyl-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-4,4-Dimethyl-2-[N'-(7-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-4,4-Dimethyl-2-[N'-(5-methyl-benzo[1,2,4]triazin-3-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-4,4-Dimethyl-2-[N'-(4-methyl-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(6-morpholin-4-yl-pyrimidin-4-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-[(R)-2-(N'-{5-[4-(2-hydroxy-ethoxy)-phenyl]-[1,2,4]triazin-3-yl}-hydrazinocarbonyl)-heptyl]-formamide.

N-{(R)-2-[N'-(4-Furan-2-yl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-((R)-2-{N'-[4-(3,5-Dimethyl-isoxazol-4-yl)-pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(4-methyl-1-oxy-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-6-methyl-nicotinic acid.

N-Hydroxy-N-{(R)-2-[N'-(3-methoxy-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(2R)-2-[(N'-{4-[4-(methylsulfonyl)phenyl]-pyrimidin-2-yl}-hydrazino)-carbonyl]-heptyl}-formamide.

N-Hydroxy-N-[(2R)-2-({N'-[4-(furan-3-yl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-heptyl]-formamide.

N-[(2R)-2-({N'-[4-(2-aminophenyl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-heptyl]-N-hydroxy-formamide.

N-Hydroxy-N-[(2R)-2-({N'-[5-(5-methyl-1,3,4-oxadiazol-2-yl)-4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-heptyl]-formamide.

N-Hydroxy-N-((2R)-2-(cyclopentylmethyl)-3-{N'-[5-(5-methyl-1,3,4-oxadiazol-2-yl)-4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-3-oxopropyl)-formamide.

N-[(2R)-2-({N'-[6-(dimethylamino)-2-methyl-pyrimidin-4-yl]-hydrazino}-carbonyl)-heptyl]-N-hydroxy-formamide.

N-[(2R)-2-({N'-[2-Cyclopropyl-6-(dimethylamino)-pyrimidin-4-yl]-hydrazino}-carbonyl)-heptyl]-N-hydroxy-formamide.

N-Hydroxy-N-[(2R)-4-(2-thienyl)-2-({N'-[4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-butyl]-formamide.

N-Hydroxy-N-[(2R)-2-{[N'-(4-methyl-pyrimidin-2-yl)hydrazino]carbonyl}-4-(2-thienyl)-butyl]-formamide.

N-[(2R)-2-[(N'-{4-Ethyl-6-[ethyl(methyl)amino]-1,3,5-triazin-2-yl}-hydrazino)-carbonyl]-4-(2-thienyl)butyl]-N-hydroxy-formamide.

N-Hydroxy-N-((2R)-3-oxo-2-(2-thienylmethyl)-3-{N'-[4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-propyl)-formamide.

N-Hydroxy-N-[(2R)-3-[N'-(4-methyl-pyrimidin-2-yl)hydrazino]-3-oxo-2-(2-thienylmethyl)-propyl]-formamide.

N-[(2R)-3-(N'-{4-Ethyl-6-[ethyl(methyl)amino]-1,3,5-triazin-2-yl}hydrazino)-3-oxo-2-(2-thienylmethyl)-propyl]-N-hydroxy-formamide.

N-Hydroxy-N-[(2R)-2-({N'-[2-methyl-6-(pyridin-2-yl)-pyrimidin-4-yl]-hydrazino}-carbonyl)-heptyl]-formamide.

N-Hydroxy-N-[(2R)-2-({N'-[6-(pyridin-2-yl-methyl)-pyridazin-3-yl]-hydrazino}-carbonyl)-heptyl]-formamide.

N-Hydroxy-N-[(2R)-2-({N'-[2-methyl-6-(morpholin-4-yl)-pyrimidin-4-yl]-hydrazino}-carbonyl)-heptyl]-formamide.

N-Hydroxy-N-[(2R)-2-({N'-[6-(morpholin-4-yl)-2-(trifluoromethyl)-pyrimidin-4-yl]-hydrazino}-carbonyl)-heptyl]-formamide.

N-Hydroxy-N-{(2R)-2-[(N'-{4-[methyl-(pyridin-2-yl)-amino]-pyrimidin-2-yl}-hydrazino)-carbonyl]-heptyl}-formamide.

N-Hydroxy-N-((2R)-2-(cyclopentylmethyl)-3-{N'-[4-cyclopropyl-6-(dimethylamino)-1,3,5-triazin-2-yl]-hydrazino}-3-oxopropyl)-formamide.

*N*-Benzo[1,3]dioxol-5-yl-methyl-hydrazinecarboxylic acid tert-butyl ester.

N-[(R)-2-(N'-Benzo[1,3]dioxol-5-yl-methyl-hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.

N-{(R)-2-[N'-(2,3-Dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl-methyl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(4-Dimethylamino-benzyl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-((R)-2-{N'-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethyl]-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-[(R)-2-(N'-quinolin-2-yl-methyl-hydrazinocarbonyl)-heptyl]-formamide.

N-Hydroxy-N-{(R)-2-[N'-(1,2,3,4-tetrahydro-quinolin-2-yl-methyl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-[(R)-2-(N'-quinolin-6-yl-methyl-hydrazinocarbonyl)-heptyl]-formamide.

N-[(R)-2-(N'-Benzofuran-2-yl-methyl-hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.

N-[(R)-2-(N'-Cyclopropylmethyl-hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.

N-{(R)-2-[N'-(6-Fluoro-4H-benzo[1,3]dioxin-8-yl-methyl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(4-methoxy-benzyl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(2-methoxy-benzyl)-hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(tetrahydro-furan-3-yl-methyl)-hydrazinocarbonyl]-heptyl}-formamide.

N-[(R)-2-(N'-Furan-3-yl-methyl-hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.

N-{(R)-2-[N'-(2,3-Dihydro-benzo[1,4]dioxin-6-yl-methyl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(2,3-Dihydro-benzo[1,4]dioxin-2-yl-methyl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(2-phenoxy-ethyl)-hydrazinocarbonyl]-heptyl}-formamide.

N-{(R)-2-[N'-((S)-2,3-Dihydroxy-propyl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(5-methyl-isoxazol-3-yl-methyl)-hydrazinocarbonyl]-heptyl}-formamide.

N-((R)-2-{N'-[1-(1-Benzo[1,3]dioxol-5-yl-methanoyl)-piperidin-4-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-((R)-2-{N'-[1-(1-Benzofuran-2-yl-methanoyl)-piperidin-4-yl]-hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-Hydroxy-N-[(R)-2-(N'-{1-[1-(7-methoxy-benzofuran-2-yl)-methanoyl]-piperidin-4-yl}-hydrazinocarbonyl)-heptyl]-formamide.

N-{(R)-2-[N'-(1-Benzyl-piperidin-4-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-[(R)-2-(N'-{1-[1-(3,4-Dichloro-phenyl)-methanoyl]-piperidin-4-yl}-hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.

N-[(R)-2-(N'-{1-[1-(2,3-Dichloro-phenyl)-methanoyl]-piperidin-4-yl}-hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.

N-Hydroxy-N-[(R)-2-(N'-{1-[1-(4-methyl-piperazin-1-yl)-methanoyl]-pentyl}-hydrazinocarbonyl)-heptyl]-formamide.

N-[(R)-2-(N'-Benzyl-hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.

5. A method of treating a bacterial infection by administering to a subject in need of treatment a compound according to claim 1.

156

# INHIBIDORES DE LA PÉPTIDO-DESFORMILASA

## CAMPO DE LA INVENCIÓN

La presente invención se refiere al empleo de nuevos compuestos antibacterianos y a composiciones farmacéuticas que contienen estos compuestos como inhibidores de la péptido-desformilasa.

## ANTECEDENTES DE LA INVENCIÓN

El iniciador bacteriano metionil-tRNA se modifica mediante metionil-tRNA-formiltransferasa (FMT) para producir formil-metionil-tRNA. Después se incorpora formil metionina (f-met) en el extremo N-terminal de polipéptidos recién sintetizados. Después la polipéptido-desformilasa (PDF ó Def) desformila los productos de traducción primaria para producir N-metionil polipéptidos. La mayoría de las proteínas intracelulares son procesadas adicionalmente por la metionina-amino-peptidasa (MAP) para producir el péptido maduro y metionina libre, que se recicla. PDF y MAP son ambos esenciales para el crecimiento bacteriano y se requiere PDF para la actividad de MAP. Esta serie de reacciones se denomina ciclo de la metionina (Figura 1).





Figura 1. Ciclo de la metionina.

Hasta la fecha, genes homólogos de la polipéptido-desformilasa se han encontrado en bacterias, en plantas que contienen cloroplastos, en ratones y en seres humanos. Las proteínas vegetales tienen el núcleo codificado pero parecen llevar una señal para la localización del cloroplasto. Esto es concordante con la observación de que el RNA de los cloroplastos y los procesos de síntesis proteica son muy similares a los de las eubacterias. Mientras que la información que existe sobre la expresión proteica de los homólogos del gen PDF en mamíferos es limitada (Bayer Aktiengesellschaft, Patente WO2001/42431), no se ha demostrado hasta la fecha ningún cometido funcional para tales proteínas (Meinnel, T., Parasitology Today 16(4), 165-168, 2000).

La polipéptido-desformilasa se encuentra en todas las eubacterias para las que está disponible una amplia información sobre la secuencia genómica. La diversidad de secuencias entre los homólogos de PDF es grande, con tan sólo 20% de identidad entre secuencias relacionadas distantes. Sin embargo, la conservación alrededor del sitio activo es muy alta, con varios residuos que se conservan completamente, incluyendo una cisteína y dos histidinas que se requieren para coordinar el metal del sitio activo (Meinnel, T. et al., J. Mol. Biol.. 267, 749-761, 1997).


Se reconoce que PDF es una diana antibacteriana atractiva, ya que se ha demostrado que esta enzima es esencial para el crecimiento bacteriano *in vitro* (Mazel, D. et al., EMBO J. 13 (4) 914-923, 1994), no se cree que esté implicada en la síntesis proteica eucariota (Rajagopalan et al., J. Am. Chem. Soc. 119, 12418-12419, 1997), y se conserva universalmente en procariotas (Kozak, M. Microbiol. Rev. 47, 1-45, 1983). Por lo tanto, los inhibidores de PDF pueden servir potencialmente como agentes antibacterianos de amplio espectro.

## RESUMEN DE LA INVENCIÓN

La presente invención implica nuevos compuestos antibacterianos representados por la Fórmula (1) más adelante y su uso como inhibidores de PDF.

## DESCRIPCIÓN DETALLADA DE LA INVENCIÓN

En un aspecto de la presente invención, se proporciona un compuesto de fórmula (1):




(1)

en la que:

R se selecciona del grupo que consiste en:

alquilo $C_{2-6}$ (opcionalmente sustituido con alcoxi, halógeno, o alquilsulfanilo $C_{1-3}$); alquenilo $C_{2-6}$ (opcionalmente sustituido con alcoxi, halógeno, o alquilsulfanilo $C_{1-3}$); alquinilo $C_{2-6}$ (opcionalmente sustituido con alcoxi, halógeno, o alquilsulfanilo $C_{1-3}$); carbociclo $(CH_2)_n$—$C_{3-6}$ (opcionalmente sustituido con alcoxi, halógeno, o alquilsulfanilo $C_{1-3}$); y $(CH_2)_n$—R4, donde R4 se selecciona del grupo que consiste en fenilo, furano, benzofurano, tiofeno, benzotiofeno, tetrahidrofurano, tetrahidropirano, dioxano, 1,4-benzodioxano o benzo[1,3]dioxol; R4 opcionalmente está sustituido con uno o más

sustituyentes seleccionados de Cl, Br, I, alquilo $C_{1-3}$ (opcionalmente sustituido con uno a tres F) y alcoxi $C_{1-2}$ (opcionalmente sustituido con uno a tres F);

R1 y R2 se seleccionan independientemente del grupo que consiste en:


hidrógeno, alquilo $C_{1-3}$ sustituido, alquenilo $C_{2-3}$ sustituido, alquinilo $C_{2-3}$ sustituido, carbociclo $(CH_2)_n$—$C_{3-6}$ sustituido, arilo, heteroarilo, y heterocíclico;

Y representa O, $CH_2$ o un enlace covalente; y

n es un numero entero de 0 a 2;

o una sal, solvato, o uno de sus derivados fisiológicamente funcional.

En esta invención el grupo R2 más preferido es hidrógeno. En esta invención la configuración absoluta más preferida de los compuestos de fórmula (1) se indica más abajo:




Como se emplea en este documento, el término "alquilo" se refiere a radicales hidrocarbonados saturados de cadena lineal o ramificada. Ejemplos de "alquilo" como se usa en este documento incluye, pero no está limitado a, metilo, etilo, n-propilo, isopropilo, n-butilo, isobutilo, t-butilo, n-pentilo, isopentilo, hexilo y similares.

Como se emplea en este documento, el término "alquilo sustituido" se refiere a un radical hidrocarbonado saturado de cadena lineal o ramificada, opcionalmente sustituido con sustituyente seleccionados del grupo que incluye alquilo $C_{1-3}$ (sustituido opcionalmente con uno a tres flúor), alquenilo $C_{2-3}$, alquinilo $C_{2-3}$, alcoxi $C_{1-2}$ (opcionalmente sustituido con uno a tres flúor), sulfanilo, sulfinilo, sulfonilo, oxo, hidroxi, mercapto, amino, guanidino, carboxi, aminocarbonilo, arilo, ariloxi, heteroarilo, heteroariloxi, heterociclo, aminosulfonilo, sulfonilamino, carboxiamida, ureido, nitro, ciano y halógeno, estando permitidos múltiples grados de sustitución.

Como se emplea en este documento, el término "alquenilo" se refiere a un radical hidrocarbonado de cadena lineal o ramificada que tiene al menos un doble enlace carbono-

carbono. Ejemplos de "alquenilo" como se emplea en este documento incluyen, pero no están limitados a, etenilo y propenilo.

Como se emplea en este documento, el término "alquenilo sustituido" se refiere a un radical hidrocarbonado de cadena lineal o ramificada que tiene al menos un doble enlace carbono-carbono, opcionalmente sustituido con sustituyentes seleccionados del grupo que incluye alquilo $C_{1-3}$ (opcionalmente sustituido con uno a tres F), amino, arilo, ciano y halógeno, estando permitidos múltiples grados de sustitución.

Como se emplea en este documento, el término "alquinilo" se refiere a un radical hidrocarbonado de cadena lineal o ramificada que tiene al menos un triple enlace carbono-carbono. Ejemplos de "alquinilo" como se usa en este documento incluyen, pero no están limitados a, acetilenilo y 1-propinilo.

Como se emplea en este documento, el término "alquinilo sustituido" se refiere a un radical hidrocarbonado de cadena lineal o ramificada que tiene al menos un triple enlace carbono-carbono, opcionalmente sustituido con sustituyentes seleccionados del grupo que incluye alquilo $C_{1-3}$ (opcionalmente sustituido con uno a tres F), amino, arilo y halógeno, estando permitidos múltiples grados de sustitución.

Como se emplea en este documento, el término "halógeno" se refiere a flúor (F), cloro (Cl), bromo (Br), o yodo (I), y "halo" se refiere a los radicales halógeno fluoro, cloro, bromo y iodo.

Como se emplea en este documento, el término "carbociclo" se refiere a un radical hidrocarbonado cíclico no-aromático que tiene de tres a siete átomos de carbono. Para los carbociclos con anillos de cinco a siete miembros, se permite un doble enlace en el anillo. A modo de ejemplo los grupos "carbociclo" incluyen, pero no están limitados a, ciclopropilo, ciclobutilo, ciclopentilo, cicopentenilo, ciclohexilo y cicloheptilo.

Como se emplea en este documento, el término "carbociclo sustituido" se refiere a un radical hidrocarbonado cíclico no-aromático que tiene de tres a siete átomos de carbono, y que opcionalmente está sustituido con sustituyentes seleccionados del grupo que incluye alquilo $C_{1-3}$ (opcionalmente sustituido con uno a tres F), alquenilo $C_{2-3}$, alquinilo $C_{2-3}$, alcoxi $C_{1-2}$ (opcionalmente sustituido con uno a tres F), sulfanilo, sulfinilo, sulfonilo, oxo, hidroxi, mercapto, amino, guanidino, carboxi, aminocarbonilo, arilo, ariloxi, heteroarilo, heterociclo,

aminosulfonilo, sulfonilamino, carboxiamida, nitro, ureido, ciano y halógeno, siendo permitidos múltiples grados de sustitución. Para los carbociclos con anillos de cinco a siete miembros, se permite un doble enlace en el anillo.

Como se emplea en este documento, el término "arilo" se refiere a un anillo benceno opcionamente sustituido o a un anillo benceno opcionalmente sustituido condensado con uno o más anillos benceno opcionalmente sustituidos para formar un sistema de anillos. A modo de ejemplo los sustituyentes opcionales incluyen alquilo $C_{1-3}$ sustituido, alquenilo $C_{2-3}$ sustituido, alquinilo $C_{2-3}$ sustituido, heteroarilo, heterociclo, arilo, alcoxi $C_{1-3}$ (opcionalmente sustituido con uno a tres F), ariloxi, aralcoxi, acilo, aroílo, heteroaroílo, aciloxi, aroiloxi, heteroaroiloxi, sulfanilo, sulfinilo, sulfonilo, aminosulfonilo, sulfonilamino, carboxiamida, aminocarbonilo, carboxi, oxo, hidroxi, mercapto, amino, nitro, ciano, halógeno o ureído, estando permitidos múltiples grados de sustitución. Tal anillo o sistema de anillos puede estar opcionalmente condensado con uno o más anillos arilo opcionalmente sustituidos (incluyendo anillos benceno), anillos carbociclos o anillos heterocíclicos. Ejemplos de grupos "arilo" incluyen, pero no están limitados a, fenilo, naftilo, tetrahidronaftilo, bifenilo, indanilo, antracilo o fenantrilo, así como sus derivados sustituidos.

Como se emplea en este documento, el término "heteroarilo" se refiere a un anillo aromático de cinco a seis miembros monocíclico opcionalmente sustituido que contiene una o más sustituciones heteroatómicas seleccionadas entre S, SO, $SO_2$, O, N, o N-óxido, o a tales anillos aromáticos condensadoscon uno o más anillos opcionalmente sustituidos, tales como anillos heteroarilo, anillos arilo, anillos heterocíclicos o anillos carbociclo (por ejemplo, un sistema de anillos bicíclico o tricíclico). Ejemplos de sustituyentes opcionales se seleccionan del grupo que incluye alquilo $C_{1-3}$ sustituido, alquenilo $C_{2-3}$ sustituido, alquinilo $C_{2-3}$ sustituido, heteroarilo, heterociclo, arilo, alcoxi $C_{1-3}$ (opcionalmente sustituido con uno a tres F), ariloxi, aralcoxi, acilo, aroílo, heteroaroílo, aciloxi, aroiloxi, heteroaroiloxi, sulfanilo, sulfinilo, sulfonilo, aminosulfonilo, sulfonilamino, carboxiamida, aminocarbonilo, carboxi, oxo, hidroxi, mercapto, amino, nitro, ciano, halógeno o ureído, estando permitidos múltiples grados de sustitución. Ejemplos de grupos "heteroarilo" empleados aquí incluyen, pero no están limitados a, benzoimidazolilo, benzotiazolilo, benzoisotiazolilo, benzotiofenilo, benzopirazinilo, benzotriazolilo, benzotriazinilo, benzo[1,4]dioxanilo, benzofuranilo, 9*H*-*a*-carbolinilo,

cinnolinilo, 2,3-dihidro-[1,4]dioxino[2,3-b]-piridinilo, furanilo, furo[2,3-b]piridinilo, imidazolilo, imidazolidinilo, imidazopiridinilo, isoxazolilo, isotiazolilo, isoquinolinilo, indolilo, indazolilo, indolizinilo, naftiridinilo, oxazolilo, oxotiadiazolilo, oxadiazolilo, ftalazinilo, piridilo, pirrolilo, purinilo, pteridinilo, fenazinilo, pirazolilo, piridilo, pirazolopirimidinilo, pirazolopiridinilo, pirrolizinilo, piridazilo, pirazinilo, pirimidilo, 4-oxo-1,2-dihidro-4H-pirrolo[3,2,1-ij]-quinolin-4-ilo, quinoxalinilo, quinazolinilo, quinolinilo, quinolizinilo, tiofenilo, triazolilo, triazinilo, tetrazolopirimidinilo, triazolopirimidinilo, tetrazolilo, tiazolilo, tiazolidinilo sus versiones sustituidas.

Como se emplea en este documento, el término "heterocíclico" se refiere a un anillo de tres a siete miembros que contiene uno o más restos heteroatómicos seleccionados entre S, SO, $SO_2$, O, N, o N-óxido, opcionalmente sustituidos con sustituyentes seleccionados del grupo que incluye alquilo $C_{1-3}$ sustituido, alquenilo $C_{2-3}$ sustituido, alquinilo $C_{2-3}$ sustituido, heteroarilo, heterociclo, arilo, alcoxi $C_{1-3}$ (opcionalmente sustituido con uno a tres F), ariloxi, aralcoxi, acilo, aroílo, heteroaroílo, aciloxi, aroiloxi, heteroaroiloxi, sulfanilo, sulfinilo, sulfonilo, aminosulfonilo, sulfonilamino, carboxiamida, aminocarbonilo, carboxi, oxo, hidroxi, mercapto, amino, nitro, ciano, halógeno, o ureído, estando permitidos múltiples grados de sustitución. Tal anillo puede ser saturado o tener uno o más grados de instauración. Tal anillo puede estar opcionalmente condensado con uno o más anillos opcionalmente sustituidos, anillo(s) "heterociclos", anillo(s) arilo, anillo(s) heteroarilo o anillo(s) carbociclo. Ejemplos de restos "heterocíclicos" incluyen, pero no están limitados a, 1,4-dioxanilo, 1,3-dioxanilo, pirrolidinilo, pirrolidin-2-onilo, piperidinilo, imidazolidina-2,4-dionepiperidinilo, piperazinilo, piperazina-2,5-dionilo, morfolinilo, dihidropiranilo, dihidrocinnolinilo, 2,3-dihidrobenzo[1,4]dioxinilo, 3,4-dihidro-2H-benzo[b][1,4]-dioxepinilo, tetrahidropiranilo, 2,3-dihidrofuranilo, 2,3-dihidrobenzofuranilo, dihidroisoxazolilo, tetrahidrobenzodiazepinilo, tetrahidroquinolinilo, tetrahidrofuranilo, tetrahidronaftiridinilo, tetrahidropurinilo, tetrahidrotiopiranilo, tetrahidrotiofenilo, dihidroquinoxalinilo, tetrahidroquinoxalinilo, tetrahidropiridinilo, tetrahidrocarbolinilo, 4H-benzo[1,3]-dioxinilo, benzo[1,3]dioxonilo, 2,2-difluorobenzo-[1,3]-dioxonilo, 2,3-dihidro-ftalazina-1,4-dionilo, isoindol-1,3-dionilo, y similares.

Como se usa en este documento, el término "alcoxi" se refiere al grupo $-OR_a$, donde $R_a$ es alquilo como se define anteriormente. A modo de ejemplo grupos alcoxi útiles en la presente

invención incluyen, pero no están limitados a, metoxi, difluorometoxi, trifluorometoxi, etoxi, n-propoxi, isopropoxi, n-butoxi y t-butoxi.

Como se usa en este documento el término "aralcoxi" se refiere al grupo $-OR_aR_b$, donde $R_a$ es alquilo y $R_b$ es arilo como se define anteriormente.

Como se usa en este documento el término "ariloxi" se refiere al grupo $-OR_a$, donde $R_a$ is arilo como se define anteriormente.

Como se usa en este documento, el término "mercapto" se refiere al grupo -SH.

Como se usa en este documento, el término "sulfanilo" se refiere al grupo $-SR_a$, donde $R_a$ es alquilo sustituido, carbociclo sustituido, arilo, heteroarilo o heterociclo, como se define anteriormente.

Como se usa en este documento, el término "sulfinilo" se refiere al grupo $-S(O)R_a$, donde $R_a$ es alquilo sustituido, carbociclo sustituido, arilo, heteroarilo o heterociclo, como se define anteriormente.

Como se usa en este documento, el término "sulfonilo" se refiere al grupo $-S(O)_2R_a$, donde $R_a$ es alquilo sustituido, carbociclo sustituido, arilo, heteroarilo o heterociclo, como se define anteriormente.

Como se usa en este documento, el término "oxo" se refiere al grupo =O.

Como se usa en este documento, el término "hidroxi" se refiere al grupo -OH.

Como se usa en este documento, el término "amino" se refiere al grupo $-NH_2$. El grupo amino opcionalmente está sustituido con alquilo, carbociclo sustituido, arilo, heteroarilo o heterociclo, como se define anteriormente.

Como se usa en este documento, el término "ciano" se refiere al grupo -CN.

Como se usa en este documento, el término "aminosulfonilo" se refiere al grupo $-S(O)_2NH_2$. El grupo aminosulfonilo opcionalmente está sustituido con alquilo sustituido, carbociclo sustituido, arilo, heteroarilo o heterociclo, como se define anteriormente.

Como se usa en este documento, el término "sulfonilamino" se refiere al grupo $-NHS(O)_2R_a$ donde $R_a$ es alquilo sustituido, carbociclo sustituido, arilo, heteroarilo o heterociclo, como se define anteriormente.

Como se usa en este documento, el término "carboxiamida" se refiere al grupo $-NHC(O)R_a$ donde $R_a$ es alquilo sustituido, carbociclo sustituido, arilo, heteroarilo o heterociclo, como se define anteriormente.

Como se usa en este documento, el término "carboxi" se refiere al grupo -C(O)OH. El grupo carboxi opcionalmente está sustituido con alquilo sustituido, carbociclo sustituido, arilo, heteroarilo o heterociclo, como se define anteriormente.

Como se usa en este documento, el término "aminocarbonilo" se refiere al grupo -$C(O)NH_2$. El grupo aminocarbonilo opcionalmente está sustituido con alquilo sustituido, carbociclo sustituido, arilo, heteroarilo o heterociclo, como se define anteriormente.

Como se usa en este documento, el término "ureído" se refiere al grupo $-NHC(O)NHR_a$ en donde $R_a$ es hidrógeno, alquilo, carbociclo o arilo como se define anteriormente.

Como se usa en este documento, el término "guanidino" se refiere al grupo -$NHC(=NH)NH_2$.

Como se usa en este documento, el término "acilo" se refiere al grupo $-C(O)R_a$, donde $R_a$ es alquilo, carbociclo, o heterociclo como se define en este documento.

Como se usa en este documento, el término "aroílo" se refiere al grupo $-C(O)R_a$, donde $R_a$ es arilo como se define en este documento.

Como se usa en este documento, el término "heteroaroílo" se refiere al grupo $-C(O)R_a$, donde $R_a$ es heteroarilo como se define en este documento.

Como se usa en este documento, el término "aciloxi" se refiere al grupo $-OC(O)R_a$, donde $R_a$ es alquilo, carbociclo, o heterociclo como se define en este documento.

Como se usa en este documento, el término "aroiloxi" se refiere al grupo $-OC(O)R_a$, donde $R_a$ es arilo como se define en este documento.

Como se usa en este documento, el término "heteroaroiloxi" se refiere al grupo $-OC(O)R_a$, donde $R_a$ es heteroarilo como se define en este documento.

También están incluidos en la presente invención las sales y complejos farmacéuticamente aceptables, tales como las sales de hidrocloruro, hidrobromuro y trifluoroacetato y las sales de sodio, potasio y magnesio. Los compuestos de la presente invención pueden contener uno o más átomos de carbono asimétrico y pueden existir en forma racémica y ópticamente activa. Dentro del alcance de la presente invención se contemplan todos estos compuestos y diastereoisómeros.

Compuestos preferidos útiles en la presente invención se seleccionan del grupo que consiste en:

N-hidroxi-N-[(R)-2-(N'-piridin-2-il-hidrazinocarbonil)-heptil]-formamida.

N-hidroxi-N-{(R)-2-[N'-(3-metoxi-fenil)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-{(R)-2-[N'-(4-ciano-fenil)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(2,6-dimetil-pirimidin-4-il)- hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-[(R)-2-(N'-quinoxalin-2-il-hidrazinocarbonil)-heptil]-formamida.

N-hidroxi-N-((2*R*)-2-{N'-(3,4-dihidro-quinoxalin-2-il)- hidrazinocarbonil)-heptil]-formamida.

N-hidroxi-N-{(R)-2-[N'-(1,3,4-trimetil-1H-pirazolo[3,4-b]piridin-6-il)- hidrazinocarbonil)-heptil]-formamida.

4-(N'-{(R)-2-[(Formil-hidroxi-amino)-metil]-heptanoil}-hidrazino)-benzenosulfonamida.

N-hidroxi-N-((2*R*)-2-(ciclohexilmetil)-3-oxo-3-{N'-[4-(trifluorometil)-pirimidin-2-il}-hidrazino}-propil]-formamida.

N-hidroxi-N-((2*R*)-2-(ciclopentilmetil)-3-oxo-3-{N'-[4-(trifluorometil)-pirimidin-2-il}-hidrazino}-propil]-formamida.

N-{(R)-2-[N'-(Dimetil-trifluorometil-pirimidin-4-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(6-trifluorometil-piridazin-3-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(6-trifluorometil-pirimidin-4-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(5-metil-[1,2,4]triazolo[1,5-a]pirimidin-7-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(9H-purin-6-il)-hidrazinocarbonil]-heptil}-formamida.

N-{(R)-2-[N'-(5-ciano-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-((2*R*)-2-{[N'-(pirimidin-2-il)-hidrazino]carbonil}-heptil)-formamida.

N-hidroxi-N-((2*R*)-2-(ciclobutilmetil)-3-oxo-3-{N'-[4-(trifluorometil)-pirimidin-2-il]-hidrazino}-propil)-formamida.

N-hidroxi-N-{(R)-2-[N'-(6-imidazol-1-il-pirimidin-4-il)- hidrazinocarbonil]-heptil}-formamida.

N-[(R)-2-(N'-Benzo[1,2,4]triazin-3-il-hidrazinocarbonil)-heptil]-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(7-metoxi-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(1-metil-1H-pirazolo[3,4-d]pirimidin-6-il)-hidrazinocarbonil]-heptil}-formamida.

N-((R)-2-{N'-[6-(5-Cloro-piridin-3-il-oxi)-piridazin-3-il]-hidrazinocarbonil}heptil)-N-hidroxi-formamida.

N-hidroxi-N-[(2*R*)-2-({N'-[6-(1*H*-pirrol-1-il)-3-piridazinil]-hidrazino}-carbonil)-heptil]-formamide.

N-hidroxi-N-[(2*R*)-2-({N'-(9-metil-9*H*-purin-6-il)-hidrazino]-carbonil}-heptil)-formamida.

N-hidroxi-N-{(R)-2-[N-({6-morfolin-4-il}-9H-purin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-{(R)-2-[N'-(6-Fluoro-piridin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-((2*R*)-2-{[N'-(1-metil-1*H*-pirazolo[3,4-*d*]pirimidin-4-il)-hidrazino]-carbonil}-heptil)-formamida.

N-{(R)-2-[N'-(4-Amino-6-isopropil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(2,5-Dimetil-4-nitro-2H-pirazol-3-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(3-Cloro-1-metil-1H-pirazolo[3,4-d]pirimidin-6-il)-hidrazinocarbonil]-heptil}-n-hidroxi-formamida.

N-{(R)-2-[N'-(6-Dimetilamino-9H-purin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-[(2*R*)-4-cicloropropil-2-({N'-[4-(trifluorometil)-pirimidin-2-il]-hidrazino}-carbonil)-butil]-formamida.

N-hidroxi-N-((2*R*)-2-(ciclopropilmetil)-3-oxo-3-{N'-[4-(trifluorometil)-pirimidin-2-il]-hidrazino}-propil)-formamida.

N-hidroxi-N-{(R)-2-[N'-metil-N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-formamida.

éster metílico del ácido 2-(N'-{(R)-2-[(Formil-hidroxi-amino)-metil]-heptanoil}-hidrazino)-4-trifluorometil-pirimidina-5-carboxílico.

ácido 2-(N'-{(R)-2-[(Formil-hidroxi-amino)-metil]-heptanoil}-hidrazino)-4-trifluorometil-pirimidina-5-carboxílico.

N-{(R)-2-[N'-(5-fluoro-4-metoxi-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(4-Dimetilamino-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N- hidroxi-formamida.

N-hidroxi-N-{(2*R*)-2-[(N'-{6-[(2-hidroxietil)amino]-1,3-dihidro-2*H*-purin-2-ilideno}-hidrazino)-carbonil]-heptil}-formamida.

N-{(R)-2-[N'-(5-Fluoro-4-morfolin-4-il-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(5-Fluoro-4-metilamino-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

dimetilamida del ácido 2-(N'-{(R)-2-[(Formil-hidroxi-amino)-metil]-heptanoil}-hidrazino)-4-trifluorometil-pirimidina-5-carboxílico.

N-hidroxi-N-{(R)-2-[N'-(3-oxo-3,4-dihidro-quinoxalin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-{(R)-2-Butoxi-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-etil}-N-hidroxi-formamida.

(2-fluoro-fenil)-amida del ácido 2-(N'-{(R)-2-[(Formil-hidroxi-amino)-metil]-heptanoil}-hidrazino)-4-trifluorometil-pirimidina-5-carboxílico.

ter-butilamida del ácido 2-(N'-{(R)-2-[(Formil-hidroxi-amino)-metil]-heptanoil}-hidrazino)-4-trifluorometil-pirimidina-5-carboxílico.

N-hidroxi-N-((R)-2-{N'-[(1-piperidin-1-il-metanoil)-trifluorometil-pirimidin-2-il]-hidrazinocarbonil}-heptil)-formamida.

N-{(R)-2-[N'-(5-ciano-4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-[(2*R*)-2-({N'-[9-(4,4,4-trifluorobutil)-1,9-dihidro-2*H*-purin-2-ilideno]-hidrazino}-carbonil)-heptil]-formamida.

N-hidroxi-N-((R)-2-{N'-[(1-morfolin-4-il-metanoil)-trifluorometil-pirimidin-2-il]-hidrazinocarbonil}-heptil)-formamida.

benzilamida del ácido 2-(N'-{(R)-2-[(Formil-hidroxi-amino)-metil]-heptanoil}-hidrazino)-4-trifluorometil-pirimidina-5-carboxílico.

N-hidroxi-N-[(2*R*)-3-[N'-(1,2,4-benzotriazin-3-il)-hidrazino]-2-(ciclohexilmetil)-3-oxopropil]-formamida.

N-hidroxi-N-((2*R*)-2-(ciclohexilmetil)-3-{N'-[7-(metiloxi)-1,2,4-benzotriazin-3-il)-hidrazino}-3-oxopropil)-formamida.

2-[2-((2R)-2-{[Formil(hidroxi)amino]metil}heptanoil)hidrazino]-N-metil-N-2-piridinil-4-(trifluorometil)-5-pirimidinecarboxamida.

2-[2-((2R)-2-{[Formil(hidroxi)amino]metil}heptanoil)hidrazino]-N-metil-N-fenil-4-(trifluorometil)-5-pirimidinecarboxamida.

morfolin-4-ilamida del ácido 2-[2-((2R)-2-{[Formil(hidroxi)amino]metil}heptanoil)hidrazino)-4-trifluorometil-pirimidina-5-carboxílico.

N-hidroxi-N-((R)-2-{N-[(N-fenil-hidrazinocarbonil)-trifluorometil-pirimidin-2-il]-hidrazinocarbonil}-heptil)-formamida.

piperidin-1-ilamida del ácido 2-(N-{(R)-2-[(Formil-hidroxi-amino)-metil]-heptanoil}-hidrazino)-4-trifluorometil-pirimidina-5-carboxílico.

pirrol-1-ilamida del ácido 2-(N-{(R)-2-[(Formil-hidroxi-amino)-metil]-heptanoil}-hidrazino)-4-trifluorometil-pirimidina-5-carboxílico.

N-{(R)-2-[N-(Dimetilamino-fluoro-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-((R)-2-{N-[(Etil-metil-amino)-fluoro-pirimidin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-hidroxi-N-((2R)-2-(ciclopentilmetil)-3-{N-[7-(metiloxi)-1,2,4-benzotriazin-3-il]-hidrazino}-3-oxopropil)-formamida.

N-hidroxi-N-{(R)-2-[N-(1-metil-1H-benzoimidazol-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-{(R)-2-[N-(4-Azetidin-1-il-5-fluoro-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-[N-(4-Ciclopropilamino-5-fluoro-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-[(R)-2-(N-Benzo[1,2,4]triazin-3-il-hidrazinocarbonil)-3-ciclopentil-propil]-N- hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N-(morfolin-4-il-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-[(R)-2-(N-{[2-hidroxi-etil)-metil-amino]-trifluorometil-pirimidin-2-il}-hidrazinocarbonil)-heptil]-formamida.

N-hidroxi-N-((R)-2-(N-[(4-metil-piperazin-1-il)-trifluorometil-pirimidin-2-il]-hidrazinocarbonil)-heptil]-formamida.

N-hidroxi-N-((2R)-2-(ciclohexilmetil)-3-{N'-[4-(ciclopropilamino)-5-fluoro-pirimidin-2-il]hidrazino}-3-oxopropil)-formamida.

N-hidroxi-N-((2R)-2-(ciclopentilmetil)-3-{N'-[4-(ciclopropilamino)-5-fluoro-pirimidin-2-il]hidrazino}-3-oxopropil)-formamida.

N-hidroxi-N-[(2R)-3-{N'-[4-(azetidin-1-il)-5-fluoro-pirimidin-2-il]-hidrazino}-2-(ciclopentilmetil)-3-oxopropil]-formamida.

N-hidroxi-N-[(2R)-5-metil-2-({N'-[4-(trifluorometil)-pirimidin-2-il]-hidrazino}-carbonil)-hexil]-formamida.

N-[(R)-2-(N'-Benzo[1,2,4]triazin-3-il-hidrazinocarbonil)-5-metil-hexil]-N-hidroxi-formamida.

N-hidroxi-N-[(2R)-5-metil-2-({N'-[7-(metiloxi)-1,2,4-benzotriazin-3-il]-hidrazino}-carbonil)-hexil]-formamida.

N-{(R)-2-[N'-(7-Cloro-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-((2R)-2-(ciclopentilmetil)-3-{N'-[4-(morfolin-4-il)-6-(trifluorometil)-pirimidin-2-il]-hidrazino}-3-oxopropil)-formamida.

N-hidroxi-N-((2R)-2-(ciclopentilmetil)-3-{N'-[4-[(2-hidroxietil)-(metil)-amino]-6-(trifluorometil)-pirimidin-2-il]-hidrazino}-3-oxopropil)-formamida.

N-hidroxi-N-[(2R)-6-metil-2-({N'-[4-(trifluorometil)-pirimidin-2-il]-hidrazino}-carbonil)-heptil]-formamida.

N-hidroxi-N-((2R)-2-{[N'-(1,2,4-benzotriazin-3-il)-hidrazino]-carbonil-6-metilheptil-formamida.

N-hidroxi-N-{(R)-2-[N'-(5-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-formamida.

N-((R)-2-{N'-[(4-Etil-piperazin-1-il)-trifluorometil-pirimidin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(piperazin-1-il-trifluorometil-pirimidin-2-il)- hidrazinocarbonil]-heptil}-formamida.

N-{(R)-2-[N'-(7-Fluoro-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-[(2R)-2-({N'-[4-(4-etil-1-piperazinil)-6-(trifluorometil)-pirimidin-2-il]-hidrazino}-carbonil)-6-metilheptil]-formamida.

N-hidroxi-N-[(2R)-6-metil-2-({N'-[4-(piperazin-1-il)-6-(trifluorometil)-pirimidin-2-il]-hidrazino}-carbonil)-heptil]-formamida.

N-hidroxi-N-[(2R)-6-metil-2-({N'[4-(4-metil-piperazin-1-il)-6-(trifluorometil)-pirimidin-2-il]-hidrazino}-carbonil)-heptil]-formamida.

N-hidroxi-N-((2R)-2-{[N'[7-cloro-1,2,4-benzotriazin-3-il)hidrazino]carbonil}-6-metilheptil)-formamida.

N-hidroxi-N-((2R)-6-metil-2-{[N'(5-metil-1,2,4-benzotriazin-3-el)-hidrazino]-carbonil}-heptil)-formamida.

N-hidroxi-N-((2R)-6-{[N'(7-fluoro-1,2,4-benzotriazin-3-il)-hidrazino]-carbonil}-6-metilheptil-formamida.

N-hidroxi-N-((R)-2-{N'[(2-metoxi-etilamino)-trifluorometil-pirimidin-2-il]-hidrazinocarbonil}-heptil)-formamida.

N-hidroxi-N-[(2R)-6-metil-2-({N'[7-(metiloxi)-1,2,4-benzotriazin-3-il]-hidrazino}-carbonil)-heptil]-formamida.

N-hidroxi-N-[(R)-2-(N'{[4-(2-hidroxi-etil)-piperazin-1-il]-trifluorometil-pirimidin-2-il}-hidrazinocarbonil)-heptil]-formamida.

N-hidroxi-N-((R)-2-(N'[(4-pirimidin-2-il-piperazin-1-il)-trifluorometil-pirimidin-2-il]hidrazinocarbonil}-heptil)-formamida.

N-hidroxi-N-((R)-2-(N'[(2-hidroxi-etilamino)-trifluorometil-pirimidin-2-il]-hidrazinocarbonil}-heptil)-formamida.

N-hidroxi-N-{(R)-2-[N'(7-trifluorometil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(R)-2-[N'(6-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(2R)-2-(ciclopentilmetil)-3-[N'(5-metil-1,2,4-benzotriazin-3-il)hidrazino]-3-oxopropil}-formamida.

N-hidroxi-N-[(2R)-2-({N'[4-(trifluorometil)-pirimidin-2-il]-hidrazino}-carbonil)-octil]-formamida.

N-hidroxi-N-((2R)-2-{[N'(1,2,4-benzotriazin-3-il)hidrazino]-carbonil}-octil)-formamida.

N-hidroxi-N-[(2R)-2-({N'[7-(metiloxi)-1,2,4-benzotriazin-3-il)-hidrazino}carbonil]-octil}-formamida.

N-hidroxi-N-{(R)-2-[N'(7-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-formamida.

N-{(R)-2-[N'(6-Cloro-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(5-metoxi-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(1-metil-2-oxo-1,2-dihidro-piridin-4-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-((R)-2-{N'-[(N'-piridin-2-il-hidrazino)-trifluorometil-pirimidin-2-il]-hidrazinocarbonil}-heptil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(4-metil-6-morfolin-4-il-pirimidin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-((R)-2-{N'-[4-(4-Etil-piperazin-1-il)-6-metil-pirimidin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-{(R)-2-[N'-(4,6-Dimetil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(4-trifluorometil-piridin-2-il)-hidrazinocarbonil]-heptil}-formamide.

N-hidroxi-N-[(R)-2-(N'-isoquinolin-1-il-hidrazinocarbonil)-heptil]-formamida.

N-hidroxi-N-[(R)-2-(N'-quinolin-2-il-hidrazinocarbonil)-heptil]-formamida.

N-{(R)-2-[N'-(1-Benzil-2-oxo-1,2-dihidro-piridin-4-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(4-oxo-4H-pirido[1,2-a][1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(4-metil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-{(R)-2-[N'-(1-Butil-2-oxo-1,2-dihidro-piridin-4-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(9-metil-4-oxo-4H-pirido[1,2-a][1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(6-oxo-4-trifluorometil-1,6-dihidro-pirimidin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(metil-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(5-trifluorometil-piridin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-{(R)-2-[N'-(6-Etoxi-piridin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-[(R)-2-[N'-pirido[2,3-e]-[1,2,4]triazin-3-il-hidrazinocarbonil)-heptil]-formamida.

N-((R)-2-[N'-[1-(1-Etil-propil)-2-oxo-1,2-dihidro-piridin-4-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-hidroxi-N-((R)-2-{N'-[2-oxo-1-(3-trifluorometil-benzil)-1,2-dihidro-piridin-4-il]-hidrazinocarbonil}-heptil-formamida.

N-hidroxi-N-{(R)-2-[N'-(4-metil-piridin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(6-metoxi-piridin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(2-oxo-1-quinolin-8-il-metil-1,2-dihidro-piridin-4-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-[(R)-2-(N'-{2-oxo-1-[2-(5,6,7,8-tetrahidro-[1,8]naftiridin-2-il)-etil]-dihidro-piridin-4-il}-hidrazinocarbonil)-heptil]-formamida.

N-{(R)-2-[N'-(4,6-Bis-etilamino-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(Bis-dimetilamino-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(4,6-Di-morfolin-4-il-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-((R)-2-{N'-[4-(4-metil-piperazin-1-il)-6-propilamino-[1,3,5]triazin-2-il]-hidrazinocarbonil]-heptil)-formamida.

N-{(R)-2-[N'-(Dimetilamino-morfolin-4-il-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(6-metil-piridin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-((R)-2-{N'-[5-(5-fenil-[1,3,4]oxadiazol-2-il)-piridin-2-il]-hidrazinocarbonil}-heptil)-formamida.

N-{(R)-2-[N'-(7-ter-Butil-1,4-dioxo-1,2,3,4-tetrahidro-pirido[3,4-d]piridazin-5-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-((R)-2-{N'-[4-Etilamino-6-(4-metil-[1,4]diazepan-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-((R)-2-{N'-[4-Etilamino-6-(4-etil-piperazin-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(6-trifluorometil-piridin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(4-metil-6-morfolin-4-il-metil-pirimidin-2-il)- hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(4-metil-6-morfolin-4-il[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(2R)-2-(ciclopentilmetil)-3-[N'-(4,6-dimetil-2-pirimidinil)-hidrazino]-3-oxopropil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(4-metil-6-pirrolidin-1-il-metil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(4-Dimetilaminometil-6-metil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-((R)-2-{N'-[4-metil-6-(4-metil-piperazin-1-il-metil)-pirimidin-2-il]-hidrazinocarbonil}-heptil)-formamida.

N-hidroxi-N-{(R)-2-[N'-(5-metil-piridin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-((R)-2-{N'-[Dimetilamino-(4-metil-[1,4]diazepan-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(4-metil-6-pirrolidin-1-il-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-((R)-2-{N'-[4-metil-6-)4-pirrolidin-1-il-piperidin-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-formamida.

N-((R)-2-{N[(Etil-metil-amino)-metil-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-((R)-2-{N'-[(4-(4-Etil-piperazin-1-il)-6-metil-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-hidroxi-N-[(2R)-7,7,7-trifluoro-2-({N'-[4-(trifluorometil)-pirimidin-2-il]-hidrazino}-carbonil)-heptil]-formamida.

N-hidroxi-N-[(2R)-7,7,7-trifluoro-2-({N'-(5-metil-1,2,4-benzotriazin-3-il)-hidrazino]-carbonil}-heptil)-formamida.

N-hidroxi-N-[(2R)-7,7,7-trifluoro-2-({N'-(7-metil-1,2,4-benzotriazin-3-il)-hidrazino]-carbonil}-heptil)-formamida.

N-hidroxi-N-{(R)-2-[N'-(4-metilamino-6-morfolin-4-il-[1,3,5]-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-((R)-2-{N'-[4-(4-Etil-piperazin-1-il)-6-metilamino-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-{(R)-2-[N'-(4-Etilamino-6-morfolin-4-il-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(4,6,7-trimetil-7,8-dihidro-pterin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(4,6,7-trimetil-pteridin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(metoximetoximetil-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-((R)-2-{N'-[4-metil-6-(1-piperidin-1-il-metanoil)-pirimidin-2-il]-hidrazinocarbonil]-heptil)-formamida.

ciclopropilamida del ácido 2-(N'-{(R)-2-[(Formil-hidroxi-amino)-metil]-heptanoil}-hidrazino)-6-metil-pirimidine-4-carboxílico.

diisopropilamida del ácido 2-(N'-{(R)-2-[(Formil-hidroxi-amino)-metil]-heptanoil}-hidrazino)-6-metil-pirimidine-4-carboxílico.

N-{(R)-2-[N'-(5-ciano-piridin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(4,6-Dietil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-4-Ciclopentil-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-butil}-N-hidroxi-formamida.

N-{(R)-4-Ciclopentil-2-[N'-(7-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-butil}-N-hidroxi-formamida.

N-{(R)-4-Ciclopentil-2-[N'-(5-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-butil}-N-hidroxi-formamida.

N-hidroxi-N-((R)-2-{N'[6-(4-metil-piperazin-1-ilmetil)-piridin-2-il]-hidrazinocarbonil}-heptil)-formamida.

N-((R)-2-{N'-[5-(4,6-Dimetoxi-pirimidin-2-il)-piridin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-{(R)-2-[N'-(Dietilamino-metil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}- N-hidroxi-formamida.

N-hidroxi-N-[(R)-2-(N'-{[(2-metoxi-etil)-metil-amino]-metil-[1,3,5]triazin-2-il}-hidrazinocarbonil)-heptil]-formamida.

N-((R)-2-{N'-[4-(2,6-Dimetil-morfolin-4-il)-6-metil-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-{(R)-2-[N'-(5-Fluoro-4-metil-6-morfolin-4-il-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(4-Etil-6-morfolin-4-il-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(Etil-metil-amino)-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-((R)-2-{N'-[4-Etil-6-(4-etil-piperazin-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-((R)-2-{N'-[5-Fluoro-4-metil-6-(4-metil-piperazin-1-il)-pirimidin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-{(R)-2-[N'-(Dimetilamino-etil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-((R)-2-{N'-[5-Fluoro-4-metil-6-(4-metil-[1,4]diazepan-1-il)-pirimidin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-{(R)-4-Ciclopentil-2-[N'-(morfolin-4-il-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-butil}-N-hidroxi-formamida.

N-[(R)-2-(N'-{Etil-[(2-metoxi-etil)-metil-amino]-[1,3,4]triazin-2-il}-hidrazinocarbonil)-heptil]-N-hidroxi-formamida.

N-{(R)-2-[N'-(Dimetilamino-metil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(Ciclopropilamino-6-metil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-Ciclohexil-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-etil}-N-hidroxi-formamida.

N-{(R)-2-Ciclohexil-2-[N'-(7-metoxi-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-etil}-N-hidroxi-formamida.

N-{(R)-2-Ciclohexil-2-[N'-(5-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-etil}-N-hidroxi-formamida.

N-{(R)-4,4-Dimetil-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-pentil}-N-hidroxi-formamida.

N-{(R)-4,4-Dimetil-2-[N'-(7-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-pentil}-N-hidroxi-formamida.

N-{(R)-4,4-Dimetil-2-[N'-(5-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-pentil}-N-hidroxi-formamida.

N-{(R)-4,4-Dimetil-2-[N'-(morfolin-4-il-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-pentil}-N-hidroxi-formamida.

N-((R)-2-{N'-[Etil-(metil-piridin-2-il-amino)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-{(R)-2-[N'-(4-Ciclopropilamino-6-etil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-[(R)-2-[N'-(5-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-3-(1-metil-ciclopentil)-propil]-formamida.

N-hidroxi-N-[(R)-2-[N'-(7-metoxi-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-3-(1-metil-ciclopentil)-propil]-formamida.

N-hidroxi-N-{(R)-3-(1-metil-ciclopentil)-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-propil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(4-isopropil-6-morfolin-4-il-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(2R)-2-(ciclopentilmetil)-3-[N'-(4-metil-2-pirimidinil)-hidrazino]-3-oxopropil}-formamida.

N-hidroxi-N-[(2R)-6,6,6-trifluoro-2-({N'-[4-(trifluorometil)-pirimidin-2-il]-hidrazino}-carbonil)-hexil]-formamida.

N-{(R)-2-[N'-(5,7-Dimetil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(3,6-Dimetil-pirazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-((R)-2-{N'-[4-(4-Etil-piperazine-1-il)-6-isopropil-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-{(R)-2-[N'-(4-Dimetilamino-6-isopropil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(metil-trifluorometil-piridin-2-il)-hidrazinocarbonil]-heptil}-formamida.

2N'-{(R)-2-[(Formil-hidroxi-amino)-metil]-heptanoil}-hidrazino)-6,N,N-trimetil-isonicotinamida.

N-hidroxi-N[(2R)-2-({N'-[3-amino-6-(trifluorometil)-piridin-2-il]-hidrazino}-carbonil)-heptil]-formamida.

N-hidroxi-N-[(R)-2-(N'-{4-isopropil-6-[(2-metoxi-etil)-metil-amino]-[1,2,4]triazin-2-il}-hidrazinocarbonil)-heptil]-formamida.

N-{(R)-3-Ciclopentil-2-[N'-(4-etil-6-morfolin-4-il-6-propil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-propil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(4-morfolin-4-il-6-propil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-((R)-2-{N'-[4-(4-Etil-piperazin-1-il)-6-propil-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-{(R)-5,5-Dimetil-2-[N'(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.

N-{(R)-5,5-Dimetil-2-[N'-(7-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.

N-{(R)-5,5-Dimetil-2-[N'-(5-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.

N-{(R)-5,5-Dimetil-2-[N'-(morfolin-4-il-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.

N-{(R)-4-Etil-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.

N-{(R)-4-Etil-2-[N'-(7-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.

N-{(R)-4-Etil-2-[N'-(morfolin-4-il-trifluorometil-pirimidin-2-il-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.

N-((R)-3-Ciclopentil-2-{N'-[4-etil-6-(4-etil-piperazin-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-propil)-N-hidroxi-formamida.

N-((R)-3-Ciclopentil-2-{N'-[4-ciclopropilamino-6-etil-[1,3,5]triazin-2-il]-hidrazinocarbonil]-propil}-N-hidroxi-formamida.

N-{(R)-4-Etil-2-[N'-(5-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.

N-hidroxi-N-[(R)-2-(N'-{[(2-metoxi-etil)-metil-amino]-propil-[1,3,5]triazin-2-il}-hidrazinocarbonil-heptil]-formamida.

N-{(R)-2-[N'-(Dimetilamino-propil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(4-Etil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(4-isopropil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-{(R)-2-[N'-(4-Ciclopropil-6-morfolin-4-il[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-[(2R)-2-({N'-[4-(piridin-2-il)-pirimidin-2-il]-hidrazino}-carbonil)-heptil]-formamida.

N-((R)-2-{N'-[4-Ciclopropil-6-(4-etil-piperazin-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-{(R)-2-[N'-(Ciclopropil-dimetilamino-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-((R)-2-{N'-[Ciclopropil-(etil-metil-amino)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-{(R)-2-[N'-(4-Ciclopropil-6-pirrolidin-1-il[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(4,6-Diciclopropil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-[(R)-2-[N'-(5-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-3-(2-metil-ciclopentil)-propil]-formamida.

N-[(R)-2-[N'-(Dimetilamino-etil-[1,3,5]triazin-2-il)-hidrazinocarbnil]-3-(2-metil-ciclopentil)-propil]-formamida.

N-hidroxi-N-[(R)-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-3-(2-metil-ciclopentil)-propil]-formamida.

N-{(R)-2-[N'-(5-Etil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-{(2R)-2-(ciclopentilmetil)-3-[N'-(7-metil-1,2,4-benzotriazin-3-il)-hidrazino]-3-oxopropil}-formamida.

N-hidroxi-N-[(2R)-2-(ciclopentilmetil)-3-(N'-{4-etil-6-[etil(metil)amino]-1,3,5-triazin-2-il}-hidrazino)-3-oxopropil]-formamida.

N-hidroxi-N-((2R)-2-(ciclopentilmetil)-3-{N'[4-(dimetilamino)-6-etil-1,3,5-triazin-2-il]-hidrazino}-3-oxopropil)-formamida.

N-((R)-2-{N'-[4-Etil-6-(4-isopropil-piperazin-1-il)-[1,3,5]triazin-2.il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-hidroxi-N-[(2R)-3-[N'-(6-cloro-1,2,4-benzotriazin-3-il)-hidrazino]-2-(ciclopentilmetil)-3-oxopropil]-formamida.

N-{(R)-4,4-Dimetil-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.

N-{(R)-4,4-Dimetil-2-[N'-(7-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.

N-{(R)-4,4-Dimetil-2-[N'-(5-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.

N-{(R)-4,4-Dimetil-2-[N'-(morfolin-4-il-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(5-fenil-[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-formamida.

N-{(R)-2-[N'-(4-Etil-6-morfolin-4-il-pirimidin-2-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.

N-((R)-2-{N'-[4-Etil-6-(4-metil-piperazin-1-il)-pirimidin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-{(R)-2-[N'-(5-Etil-4-metil-pirimidin-2-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.

N-((R)-2-{N'-[4-Etil-6-(4-propil-piperazin-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-hidroxi-N-((R)-2-{N'-[6-(4-pirimidin-2-il-piperazin-1-il-metil)-piridin-2-il]-hidrazinocarbonil{-heptil)-formamida.

N-hidroxi-N-((R)-2-{N'-[6-(3-[1,2,4]triazol-1-il-metil-[1,2,4]triazol-1-il)-piridin-2-il]-hidrazinocarbonil{-heptil)-formamida.

N-{(R)-3-Biciclo[2.2.1]Pet-7-il-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.

N-{(R)-3-Biciclo[2.2.1]Pet-7-il-2-[N'-(morfolin-4-il-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.

N-hidroxi-N-[(R)-2-(N'-piridin-3-il-hidrazinocarbonil)-heptil]-formamida.

Yoduro de 4-{4-Etil-6-[2((2R)-2-{[formil(hidroxi)amino[-metil}-heptanoil)-hidrazino]-1,3,5-triazin-2-il}-1-metil-1-propilpiperazin-1-io.

N-{(R)-3-Biciclo[2.2.1]hept-7-il-2-[N'-(5-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(4-Azetidin-1-il-6-etil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-Ciclopentil-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-etil}-N-hidroxi-formamida.

N-{(R)-2-Ciclopentil-2-[N'-(morfolin-4-il-4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-etil}-N-hidroxi-formamida.

N-{(R)-2-Ciclopentil-2-[N'-(4-metil-piridin-2-il)-hidrazinocarbonil]-etil}-N-hidroxi-formamida.

N-{(R)-2-Ciclopentil-2-[N'-(dimetilamino-etil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-etil}-N-hidroxi-formamida.

N-{(R)-2-Ciclopentil-2-[N'-(7-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-etil}-N-hidroxi-formamida.

N-{(R)-2-Ciclopentil-2-[N'-(5-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-etil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(5-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-2-(4-metil-ciclohexil)-etil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(7-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-2-(4-metil-ciclohexil)-etil}-formamida.

N-hidroxi-N-{(R)-2-(4-metil-ciclohexil)-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-etil}-formamida.

N-hidroxi-N-{(R)-2-(4-metil-ciclohexil)-2-[N'-(morfolin-4-il-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-etil}-formamida.

N-hidroxi-N-{(R)-2-(4-metil-ciclohexil)-2-[N'-(4-metil-piridin-2-il)-hidrazinocarbonil]-etil}-formamida.

N-{(R)-2-[N'-(Dimetilamino-etil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-2-(4-metil-ciclohexil)-etil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(6,7-Dihidro-5H-ciclopentapirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-((R)-2-[N'-[4-Etil-6-((S)-2-hidroximetil-pirrolidin-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil]-hetil)-N-hidroxi-formamida.

N-{(R)-2-[N'-(Dimetilamino-piridin-3-il-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(Dimetilamino-piridin-4-il-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-N'-(5,6,7,8-tetrahidro-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-formamida.

N-{(R)-2-[N'-(5,6-Dietil-[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-[5-(4-hidroxi-fenil)-[1,2,4]triazin-3-il]-hidrazinocarbonil}-heptil)-formamida.

N-[(R)-2-(N'-{[(2-Dimetilamino-etil)-metil-amino]-etil-[1,3,5]triazin-2-il}-hidrazinocarbonil)-heptil]-N-hidroxi-formamida.

N-{(R)-2-[N'-(2-Dimetilamino-quinazolin-4-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-[5-(3-metanosulfonil-4,6-dimetil-piridin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-((R)-2-{N'-[4-Etil-6-(3-hidroxi-piperidin-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-[(R)-2-(N'-[4,5]Bipirimidinil-2-il-hidrazinocarbonil)-heptil]-N-hidroxi-formamida.

N-((R)-2-{N'-[(Ciclopropil-metil-amino)-etil-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-((R)-2-{N'-[4-Etil-6-((R)-3-hidroxi-pirrolidin-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-hidroxi-N-[(R)-2-(N'-[3,3]Bipiridinil-5-il-hidrazinocarbonil)-heptil]-formamida.

N-hidroxi-N-[(R)-2-(N'-[5-morfolin-4-il-piridin-3-il)-hidrazinocarbonil)-heptil]-formamida.

N-hidroxi-N-{(R)-2-[N'-(4-piridin-3-il-pirimidin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(5,6,7,8-tetrahidro-quinazolin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-[(R)-2-(N'-{[Ciclopropil-1-(1-metil-piperidin-4-il)-amino]-etil-]1,3,5]triazin-2-il}-hidrazinocarbonil)-heptil]-N-hidroxi-formamida.

N-((R)-2-{N'-[4-((R)-3-Dimetilamino-pirrolidin-1-il)-6-etil-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-hidroxi-N-[(R)-2-(N'-[5-(1H-pirrol-2-il)-piridin-3-il]-hidrazinocarbonil)-heptil]-formamida.

N-hidroxi-N-[(R)-2-(N'-[(4-metil-piperazin-1-il)-trifluorometil-pirimidin-4-il]-hidrazinocarbonil)-heptil]-formamida.

N-hidroxi-N-[(R)-2-(N'-(5-Furan-3-il-piridin-3-il)-hidrazinocarbonil)-heptil]-formamida.

N-{(R)-5,5-Dimetil-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-5,5-Dimetil-2-[N'-(7-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-5,5-Dimetil-2-[N'-(4-metil-piridin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-Cicloheptil-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-etil}-N-hidroxi-formamida.

N-{(R)-2-Cicloheptil-2-[N'-(4-metil-piridin-2-il)-hidrazinocarbonil]-etil}-N-hidroxi-formamida.

N-{(R)-2-Cicloheptil-2-[N'-(dimetilamino-etil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-etil}-N-hidroxi-formamida.

N-{(R)-2-Cicloheptil-2-[N'-(7-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-etil}-N-hidroxi-formamida.

N-((R)-2-{N'-[4-Etil-6-(4-hidroxi-piperidin-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-{(R)-5,5-Dimetil-2-[N'-(5-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(4-Dimetilamino-quinazolin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(4-piridin-4-il-pirimidin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-((R)-2-{N'-[4-(3-hidroximetil-fenil)-pirimidin-2-il]-hidrazinocarbonil}-heptil)-formamida.

N-hidroxi-N-((R)-2-{N'-[4-(4-hidroximetil-fenil)-pirimidin-2-il]-hidrazinocarbonil}-heptil)-formamida.

N-((R)-2-{N'-[4-Etil-6-(3-metoxi-piperidin-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(7-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-2-(4-metil-ciclohexil)-etil}-formamida.

N-[(R)-2-{N'-[Etil-(etil-metilamino)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-2-)-metil-ciclohexil)-etil}-N-hidroxi-formamida.

N-[(R)-2-{N'-[Etil-(etil-metilamino)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-2-)-metil-ciclohexil)-etil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(7-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-2-(4-metil-ciclohexil)-etil}-formamida.

N-((R)-2-{N'-[4-(2,6-Dimetoxi-fenil)-pirimidin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-((R)-2-{N'-[4-Etil-6-((R)-3-metoxi-pirrolidin-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-((R)-2-{N'-[4-Etil-6-(4-metoxi-piperidin-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-hidroxi-N-[(R)-2-(N'-(6-pirrolidin-1-il-pirimidin-4-il)-hidrazinocarbonil)-heptil]-formamida.

N-hidroxi-N-[(R)-2-(N'-[6-(4-metil-piperazin-1-il)-pirimidin-4-il])-hidrazinocarbonil)-heptil]-formamida.

N-{(R)-2-[N'-(6-Dimetilamino-pirimidin-4-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(Piridin-4-il-trifluorometil-pirimidin-4-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(Piridin-3-il-trifluorometil-pirimidin-4-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(2-Etilamino-6-trifluorometil-pirimidin-4-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-((R)-2-{N'-[5-(4-metoxi-fenil)-[1,2,4]triazin-3-il]-hidrazinocarbonil}-heptil)-formamida.

N-hidroxi-N-((R)-2-{N'-[4-(2,3,4-trimetoxi-fenil)-pirimidin-2-il]-hidrazinocarbonil}-heptil)-formamida.

N-{(R)-4,4-Dimetil-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-4,4-Dimetil-2-[N'-(7-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-4,4-Dimetil-2-[N'-(5-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-4,4-Dimetil-2-[N'-(4-metil-piridin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(6-morfolin-4-il-pirimidin-4-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-[(R)-2-(N'-{5-[4-(2-hidroxi-etoxi)-fenil]-[1,2,4]triazin-3-il}-hidrazinocarbonil)-heptil]-formamida.

N-{(R)-2-[N'-(4-Furan-2-il-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-((R)-2-{N'-[4-(3,5-Dimetil-isoxazol-4-il)-pirimidin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(4-metil-1-oxi-piridin-2-il)-hidrazinocarbonil]-heptil}-formamida.

Ácido 2-(N'-{(R)-2-[(Formil-hidroxi-amino)-metil]-heptanoil}-hidrazino)-6-metil-nicotínico.

N-hidroxi-N-{(R)-2-[N'-(3-metoxi-piridin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(2R)-2-[(N'-{4-[4-(metilsulfonil)fenil]-pirimidin-2-il}-hidrazino)-carbonil]-heptil}-formamida.

N-hidroxi-N-[(2R)-2-({N'-[4-(furan-3-il)-pirimidin-2-il]-hidrazino}-carbonil)-heptil]-formamida.

N-[(2R)-2-({N'-[4-(2-aminofenil)-pirimidin-2-il]-hidrazino}-carbonil)-heptil]-N-hidroxi-formamida.

N-hidroxi-N-[(2R)-2-({N'-[5-(5-metil-1,3,4-oxadiazol-2-il)-4-(trifluorometil)-pirimidin-2-il]-hidrazino}-carbonil)-heptil]-formamida.

N-hidroxi-N-[(2R)-2-(ciclopentilmetil)-3-{N'-[5-(5-metil-1,3,4-oxadiazol-2-il)-4-(trifluorometil(-pirimidin-2-il]-hidrazino}-3-oxopropil)-formamida.

N-[(2R)-2-({N'-[6-(dimetilamino)-2-metil-pirimidin-4-il]-hidrazino}-carbonil)-heptil]-N-hidroxi-formamida.

N-[(2R)-2-({N'-[2-Ciclopropil-6-(dimetilamino)-pirimidin-4-il]-hidrazino}-carbonil)-heptil]-N-hidroxi-formamida.

N-hidroxi-N-[(2R)-4-(2-tienil)-2-({N'-[4-(trifluorometil)-pirimidin-2-il]-hidrazino}-carbonil)-butil]-formamida.

N-hidroxi-N-[(2R)-2-{[N'-(4-metil-pirimidin-2-il)hidrazino]carbonil}-4-(2-tienil)-butil]-formamida.

N-[(2R)-2-[(N'-{4-Etil-6-[etil(metil)amino]-1,3,5-triazin-2-il}-hidrazino)-carbonil]-4-(2-tienil)butil]-N-hidroxi-formamida.

N-hidroxi-N-((2R)-3-oxo-2-(2-tienilmetil)-3-{N'-[4-(trifluorometil)-pirimidin-2-il]-hidrazino}-propil)-formamida.

N-hidroxi-N-[(2R)-3-[N'-(4-metil-pirimidin-2-il)hidrazino]-3-oxo-2-(2-tienilmetil)-propil]-formamida.

N-[(2R)-3-(N'-{4-Etil-6-[etil(metil)amino]-1,3,5-triazin-2-il}hidrazino)-3-oxo-2-(2-tienilmetil)-propil]-N-hidroxi-formamida.

N-hidroxi-N-[(2R)-2-({N'-[2-metil-6-(piridin-2-il)-pirimidin-4-il]-hidrazino}-carbonil)-heptil]-formamida.

N-hidroxi-N-[(2R)-2-({N'-[6-(piridin-2-il-metil)-piridazin-3-il]-hidrazino}-carbonil)-heptil]-formamida.

N-hidroxi-N-[(2R)-2-({N'-[2-metil-6-(morfolin-4-il)-pirimidin-4-il]-hidrazino}-carbonil)-heptil]-formamida.

N-hidroxi-N-[(2R)-2-({N'-[6-(morfolin-4-il)-2-(trifluorometil)-pirimidin-4-il]-hidrazino}-carbonil)-heptil]-formamida.

N-hidroxi-N-{(2R)-2-[(N'-{4-[metil-(piridin-2-il)-amino]-pirimidin-2-il}-hidrazino)-carbonil]-heptil}-formamida.

N-hidroxi-N-((2R)-2-(ciclopentilmetil)-3-{N'-[4-ciclopropil-6-(dimetilamino)-1,3,5-triazin-2-il]-hidrazino}-3-oxopropil)-formamida.

éster *ter*-butílico del ácido *N*-Benzo[1,3]dioxol-5-il-metil-hidrazinacarboxílico.

N-[(2R)-2-(N'-Benzo[1,3]dioxol-5-il-metil-hidrazinocarbonil)-heptil]-N-hidroxi-formamida.

N-{(2R)-2-[N'-(2,3-Dihidro-[1,4]dioxino[1,2-b]piridin-7-il-metil)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(2R)-2-[N'-(4-Dimetilamino-benzil)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-((R)-2-{N'-[2-(5,6,7,8-tetrahidro-[1,8]naftiridin-2-il)-etil]-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-[(R)-2-(N'-quinolin-2-il-metil-hidrazinocarbonil)-heptil]-formamida.

N-hidroxi-N-{(R)-2-[N'-(1,2,3,4-tetrahidro-quinolin-2-il-metil)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-[(R)-2-(N'-quinolin-6-il-metil-hidrazinocarbonil)-heptil]-formamida.

N-[(2R)-2-(N'-Benzofuran-2-il-metil-hidrazinocarbonil)-heptil]-N-hidroxi-formamida.

N-[(2R)-2-(N'-Ciclopropilmetil-hidrazinocarbonil)-heptil]-N-hidroxi-formamida.

N-{(2R)-2-[N'-(6-Fluoro-4H-benzo[1,3]dioxin-8-il-metil)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(4-metoxi-benzil)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(2-metoxi-benzil)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(tetrahidro-furan-3-il-metil)-hidrazinocarbonil]-heptil}-formamida.

N-[(2R)-2-(N'-Furan-3-il-metil-hidrazinocarbonil)-heptil]-N-hidroxi-formamida.

N-{(2R)-2-[N'-(2,3-Dihidro-benzo[1,4]dioxin-6-il-metil)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(2R)-2-[N'-(2,3-Dihidro-benzo[1,4]dioxin-2-il-metil)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(2-fenoxi-etil)-hidrazinocarbonil]-heptil}-formamida.

N-{(2R)-2-[N'-((S)-2,3-Dihidroxi-propil)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(5-metil-isoxazol-3-il-metil)-hidrazinocarbonil]-heptil}-formamida.

N-((R)-2-{N'-[1-(1-Benzo[1,3]dioxol-5-il-metanoil)-piperidin-4-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-((R)-2-{N'-[1-(1-Benzofuran-2-il-metanoil)-piperidin-4-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-hidroxi-N-[(R)-2-(N'-{1-[1-(7-metoxi-benzofuran-2-il)-metanoil]-piperidin-4-il}-hidrazinocarbonil)-heptil]-formamida.

N-{(R)-2-[N'-(1-Benzil-piperidin-4-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-[(R)-2-(N'-{1-[1-(3,4-Dicloro-fenil)-metanoil]-piperidin-4-il}-hidrazinocarbonil)-heptil]-N-hidroxi-formamida.

N-[(R)-2-(N'-{1-[1-(2,3-Dicloro-fenil)-metanoil]-piperidin-4-il}-hidrazinocarbonil)-heptil]-N-hidroxi-formamida.


N-hidroxi-N-[(R)-2-(N'-{1-[1-(4-metil-piperazin-1-il)-metanoil]-pentil}-hidrazinocarbonil)-heptil]-formamida.

N-[(R)-2-(N'-Benzil-hidrazinocarbonil)-heptil]-N-hidroxi-formamida.


## SECUENCIA SINTÉTICA GENERAL

Los compuestos y procedimientos de la presente invención se entenderán mejor en conexión con los siguientes esquemas sintéticos, que son meramente ilustrativos de los métodos mediante los cuales se pueden preparar los compuestos de la invención y no pretenden limitar el alcance de la invención como se define en las reivindicaciones anexas.

La presente invención proporciona compuestos de Fórmula (1) que se pueden preparar a partir del intermedio racémico común (8), o de los intermedios quirales comunes (17) y (25).




(1) Y = O, $CH_2$ o un enlace



Esquema 1

Como se muestra en el Esquema 1, el intermedio (8) se puede preparar haciendo reaccionar malonato de dialquilo monosustituido (2) con una base, tal como hidróxido potásico, en un solvente apropiado, tal como etanol/agua, para proporcionar el mono-ácido (3). El acoplamiento de (3) con O-bencilhidroxilamina o O-(tetrahidro-2H-piran-2-il)hidroxilamina en presencia de un reactivo de acoplamiento, tal como hidrocloruro de 1-[3-(dimetilamino)propil]-3-etilcarbodiimida (EDCI), y una base, tal como 4-dimetilaminopiridina (DMAP), en un solvente apropiado, tal como diclorometano, proporciona la amida (4), donde P es bencilo o tetrahidro-2H-piran-2-ilo. La reducción de la función éster del compuesto (4) con un agente reductor, tal como borohidruro de litio, en un solvente apropiado, tal como tetrahidrofurano, a temperatura ambiente suministra el alcohol (5). El tratamiento del alcohol (5) en condiciones de Mitsunobu proporciona la lactama (6). Se puede conseguir la misma transformación tratando (5) con trifenilfosfina, tetracloruro de carbono y una base, tal como trietilamina, para obtener (6). La hidrólisis de la lactama (6) empleando, por ejemplo, hidróxido de litio en una mezcla de solventes apropiada, tal como THF-$H_2O$-MeOH, da el ácido (7). La formilación del grupo amina de (7) se consigue empleando ácido fórmico y anhídrido acético en un solvente, tal como diclorometano, para proporcionar el compuesto formilado (8).


Cualquier racemato se puede resolver en el nivel de cualquier intermedio durante la síntesis o en el nivel del producto final empleando, por ejemplo, un método de cromatografía quiral, para proporcionar el compuesto (8) en cualquiera de sus dos formas enantiómeras.

De manera alternativa, un enantiómero del intermedio (8), tal como (18) en el Esquema 2 ó (27) en el Esquema 3, se puede preparar haciendo reaccionar un cloruro de ácido apropiado (9) con un agente quiral, tal como la oxazolidinona quiral de Evans, en presencia de una base, tal como n-butil-litio, para proporcionar el intermedio quiral (10) del Esquema 2 ó (19) del Esquema

3. El tratamiento del compuesto (10) o (19) con una base, tal como diisopropiletilamina, en presencia de un agente quelante, tal como tetracloruro de titanio, en un solvente, tal como tetrahidrofurano, seguido por la adición de un electrófilo, tal como cloruro de benciloximetilo, proporciona cualquiera de los dos compuestos quirales (11) o (20), dependiendo de la selección del auxiliar quiral. La conversión del compuesto (11) o (20) en el correspondiente hidroxiácido (14) o (23) se puede lograr mediante una secuencia que comprende la escisión oxidativa de la oxazolidinona quiral, empleando, por ejemplo $H_2O_2$ e hidróxido de litio, a los respectivos intermedios (12) o (21), seguida por hidrogenolisis, para proporcionar los intermedios (13) o (21), respectivamente. Los compuestos (10) o (19) también se pueden convertir a intermedios (14) o (23), respectivamente, en un procedimiento de dos pasos. Para esta transformación, (19 o (19) se pueden tratar con una base, tal como diisopropiletilamina, en presencia de un agente quelante, tal como tetracloruro de titanio, en un solvente tal como tetrahidrofurano, seguido por la adición de trioxano o cualquier otro formaldehído equivalente para proporcionar los compuestos (13) o (22), los cuales después son sometidos a escisión oxidativa de la oxazolidinona quiral, utilizando, por ejemplo H2O2 e hidroxido de litio, a los respectivos ácidos (14) o (23), respectivamente.


El acoplamiento del ácido (14) o (23) con benziloxiamina o O-(tetrahidro-2H-piran-2-il)hidroxilamina en presencia de agentes acopladores, tal como EDCI-DMAP, proporciona las amidas (15) o (24), respectivamente. Estas pueden ser ciclizadas a las azetidin-2-onas (16) o (25) utilizando las condiciones de Mitsunobu o una combinación de trifenilfosfina-carbono tetracloruro-trietilamina. La hidrólisis de la acetidin-2-ona (16) o (25), utilizando por ejemplo hidroxido de litio, en un solvente apropiado, proporciona el correspondiente ácido (17) o (26), respectivamente. La conversión del compuesto (17) o (26) al ácido carboxílico (18) o (27) se puede lograr utilizando un agente de formilación apropiado, tal como ácido fórmico/anhídrido acético o formato de metilo, en reactivos puros o en un solvente apropiado, tal como diclorometano.

Esquema 2







Esquema 3





Como se muestra en el Esquema 4, el compuesto (8) se puede acoplar a CBZNHNH2 utilizando condiciones tales como DMAP-EDCI o EDCI-HOAt-NMM, y debencilar para generar el compuesto (28). La reacción de (28) con el haluro o trifluorometil R1X proporciona (1) donde R2 es H. De manera similar, los compuestos (18) y (27) se pueden someter al mismo procedimiento para proporcionar, respectivamente, (31) donde R2 es H y (32) donde R2 es H.

Esquema 4




Alternativamente, como se muestra en el esquema 5, el compuesto (28) se puede someter a una alquilación reductiva con la cetona R1C(O)R2 utilizando como reductor, cianoborohidruro sódico, para proporcionar el compuesto (1). Si en cambio se utiliza el aldehido R1C(O)H en la alquilación reductiva, se forma el compuesto (1) donde R2 es H. De manera similar, el compuesto (29) se puede someter a alquilación reductiva con la cetona R1C(O)R2 para proporcionar el compuesto (31), o con el aldehido R1C(O)H para proporcionar el compuesto (31) donde R2 es H. De manera similar, el compuesto (30) se puede someter a alquilación reductiva con la cetona R1C(O)R2 para proporcionar el compuesto (32), o con el aldehido R1C(O)H para proporcionar el compuesto (32) donde R2 es H.

Esquema 5




Alternativamente, como se muestra en el esquema 6, la hidracina monoprotegida G1NHNH2 (33), donde G1 es benziloxicarbonilo o tert-butoxicarbonilo, se puede hacer reaccionar con anhídrido ftálico para proporcionar el intermedio (34). El intermedio (34) se puede acoplar al alcohol R1OH bajo las condiciones de Mitsunobu para proporcionar (35), el cual ante hidrazinolisis origina hidrazina (36). El acoplamiento de (36) al ácido (8) utilizando condiciones tales como DMAP/EDCI o EDCI/HOAt/NMM proporciona (37). (37) se puede desproteger completamente en un paso utilizando hidrogenolisis cuando G1 es benciloxicarbonilo y P es bencilo, en un paso que utiliza condiciones acidas cuando G1 es tert-butoxicarbonilo y P es O-(tetrahidro-2H-piran-2-ilo), o en dos pasos (mediante tratamiento ácido e hidrogenolisis) cuando G1 es benciloxicarbonilo y P es O-(tetrahidro-2H-piran-2-ilo), o G1 es tert-butoxicarbonilo y P es bencilo. En todos los tres casos, se forma el compuesto (1) donde R2 es H. De manera similar, los compuestos (18) y (27) se pueden someter al mismo procedimiento, respectivamente, (31) donde R2 es H o (32) donde R2 es H.

Esquema 6





Como se muestra en el Esquema 7, el acoplamiento del ácido (8) con la hidrazina R1R2NNH2 (4=), utilizando condiciones tales como DMAP-EDCI o EDCI-HOAt-NMM, proporciona la hidrazida (41). La desprotección final (hidrogenolisis que utiliza un catalizador, tal como Pd/C al 10%, en un solvente apropiado, tal como etanol, en el caso que P es Bn; tratamiento con agua-ácido acético al 80% a temperatura ambiente o a 40 °C en el caso que P es THP) proporciona el compuesto deseado (1). De manera similar, el acoplamiento del ácido quiral (18) o (27) con la hidracina (40) proporciona la correspondiente hidrazida (42) o (43). La desprotección final proporciona el compuesto final deseado (31) o (32).

Esquema 7



Las hidrazinas con estructura general R1R2NNH2 (40) se pueden adquirir en fuentes comerciales disponibles o se pueden preparar según los métodos en la literatura por aquellos con experiencia en el estado de la técnica. Los siguientes ejemplos de estructuras específicas de la hidrazina (40) y los métodos sintéticos utilizados para generarlas son meramente ilustrativos y no se deben interpretar como una limitación al alcance de la presente invención.

Las hidrazinas (40) donde R2 es alquilo o hidrógeno, y R1 tiene la estructura general (44) se pueden preparar a partir de precursores apropiados como se muestra en el Esquema 8, 9 y 10.



= R1


(44)

(44)

Como se muestra en el Esquema 8, la hidracina (40) donde R1 es (44) se puede preparar a partir del precursor (45) mediante tratamiento con una hidrazina apropiada, tal como monohidrato de hidrazina, en un solvente apropiado, tal como metanol. Alternativamente, como se muestra en el Esquema 9, la hidrazina (40) donde R1 es (44) se puede preparar a partir del precursor (46) mediante la oxidación a la sulfona via tratamiento con un oxidante apropiado tal como ácido meta-cloroperbenzoico (m-CPBA) en un solvente apropiado tal como cloruro de metileno. El tratamiento adicional con una hidrazina apropiada, tal como monohidrato de hidrazina, en un solvente apropiado, tal como metanol, luego proporciona el producto deseado (40) donde R1 es (44). Alternativamente, como se muestra en el esquema 10, la hidrazina (40) donde R1=(44) se puede preparar a partir de (47) a través de tratamiento con nitrato sódico en un solvente apropiado tal como ácido sulfúrico acuoso para proporcionar (48). Luego el compuesto (48) es tratado con un reactivo de halogenación tal como oxicloruro de fósforo a reflujo seguido por tratamiento con una hidrazina apropiada, tal como monohidrato de hidrazina, en un solvente apropiado, tal como metanol, para proporcionar el intermedio (40) donde R1 es (44). Los compuestos (45), (46), (47) y (48) están disponibles en fuentes comerciales, o se pueden preparar mediante métodos en la literatura por aquellos con experiencia en el estado de la técnica


(Pirimidinas, Brown, D.J. en "La Química de los Compuestos Heterocíclicos" vol. 52, Taylor, e.C., ed.; Wiley; New York, 1994).

Esquema 8





(45) (40); R1=(44)

Esquema 9





(46) (40); R1=(44)

Esquema 10





(47) (48) (40); R1=(44)

Las hidracinas (40) donde R2 es hidrógeno, y R1 tiene la estructura general (49), se pueden preparar a partir de los precursores apropiados mostrados en los Esquemas 11 y 12.



(49) G14, G15 = H, Alquilo, Arilo, Heteroarilo, Heterociclico


Como se muestra en el Esquema 11, la 4,6-dicloropirimidina (50) se puede hacer reaccionar con tert-butilcarbazato en presencia de una base, tal como diisopropiletilamina, a 100°C en un solvente apropiado tal como etanol para proporcionar el compuesto (51). La amina G14G15NH se puede hacer reaccionar con (51) para proporcionar el compuesto (52), el cual se puede desproteger bajo condiciones acidas, tal como ácido trifluoroacético en diclorometano, para proporcionar el compuesto (40), donde R2 es hidrógeno y R1 es (49).




Esquema 11


Alternativamente, como se muestra en el Esquema 12, la 4,6-dicloropirimidina (50) se puede hacer reaccionar con un equivalente de amina G14G15NH en presencia de una base, tal como trietilamina o diisopropiletilamina, para proporconar el compuesto (53), el cual se puede

tratar con hidrazina en exceso para proporcionar el compuesto (40), donde R2 es hidrógeno y R1 es (49).





Esquema 12

Las hidracinas (40) donde R2 es hidrógeno, y R1 tiene la estructura general (54) se puede preparar a partir de un precursor apropiado tal como (55), mediante el tratamiento con hidrazina anhidra en un solvente apropiado tal como etanol, como se muestra en el Esquema 13.





(54)G16, G17, G18 = H, Alquilo, Arilo





Esquema 13

Las hidracinas (40) donde R2 es hidrógeno y R1 tiene la estructura general (56) se pueden preparar a partir de un precursor apropiado mostrado en el Esquema 14.




(56) G19, G20 = H, Alquilo, Arilo

Como se muestra en el Esquema 14, 4-cloro-2-metilsulfanil-6-trifluorometil-pirimidina (57) se puede tratar con carbazato de tert-butilo a 100°C en un solvente apropiado, tal como etanol, para proporcionar el intermedio (58). El tratamiento de (58) con un oxidante, tal como ácido meta-cloro perbenzoico, produce (59), el cual al tratar con la amina G19G20NH en un solvente apropiado tal como metanol o etanol proporciona (60). La desprotección bajo condiciones acidas, tal como ácido trifluoroacético en diclorometano, proporciona (40), donde R2 es hidrógeno y R1 es (56).





Esquema 14

Las hidracinas (40 donde R2 es hidrógeno y R1 tiene la estructura general (61) se pueden preparar siguiendo los procedimientos presentados en el Esquema 15 (Pauldler, W. J. Het. Chem. 767-771, 1970; Lieber, E., J. Org. Chem. 17, 518-522, 1952; Chem. Abstr. 87, 68431, 1977; Taylor, e. C., J. Org. Chem. 52, 4287-42992, 1987).




(61) G21, G22 = H, alquilo, arilo, heteroarilo

Como se muestra en el Esquema 15, el compuesto (62) puede reaccionar con (63) en presencia de una base suave, tal como bicarbonato de sodio acuoso, para proporcionar (64). El tratamiento de (64) con hidrazina bajo condiciones de microondas proporciona (40) donde R2 es H y R1 es (61). Alternativamente, (62) se puede hacer reaccionar con (65) para proporcionar (67), el cual al tratar con oxicloruro fosforoso forma (68). El tratamiento de (68) con hidrazina proporciona (40) donde R2 es H y R1 es (61). Alternativamente, el oxoácido (69) se puede condensar con (63) para formar (70), el cual se puede convertir en (71) mediante reacción con cloruro de oxalilo o oxicloruro fosforoso. El acoplamiento de (71) con ácido borónico G22B(OH)2 bajo condiciones estándares de Suzuki proporciona (72), el cual se puede hacer reaccionar con hidrazina para proporcionar (40) donde R2 es H y R1 es (61) y G22 es alquilo, heteroarilo solamente.




Las hidracinas (40) donde R2 es hidrógeno y R1 tiene la estructura general (73) se pueden preparar siguiendo los procedimientos descritos en el Esquema 16.



= R1

(73) G23, G24, G25, G26 = H, alquilo, arilo, heteroarilo,heterociclico


Como se muestra en el Esquema 16, el cloruro cianúrico (74) se puede tratar con un equivalente de amina (75) bajo condiciones suaves, tales como 0°C en acetona en presencia de carbonato potásico acuoso, para proporcionar (76). El tratamiento de (76) con amina (77) bajo condiciones tales como 25°C en acetona en presencia de carbonato potásico proporciona (78). El desplazamiento del cloruro restante en (78) con hidrazina proporciona (40) donde R2 es H y R1 es (73).



(74) (75) (76) (77) (78) (40); R2=H and R1=(73)


Esquema 16

Las hidrazinas (40) donde R2 es hidrógeno y R1 tiene la estructura general (79) se pueden preparar siguiendo los procedimientos descritos en el Esquema 17 (Menicagli, R., Tetrahedron, 56, 9705-9711; 2000).




(79) G25, G26 = H, alquilo, arilo, heteroarilo, heterociclico; G27 = alquilo, heterociclico

Como se muestra en el Esquema 17, el cloruro cianúrico (74) se puede hacer reaccionar con el compuesto de Grignard (80) para formar (81), el cual al tratar con la amina (77) proporciona el monocloruro (82). La hidrazinolisis de (82) proporciona (40) donde R2 es H y R1 es (73).



Esquema 17


Las hidracinas (40) donde R2 es hidrógeno y R1 tiene la estructura general (83) se pueden preparar siguiendo los procedimientos descritos en el Esquema 18 (Kobe, J., Monatsh. Chem. 101, 724-35, 1970; Janietz, D. y Bauer, M., Sintesis 33-34, 1993).



(83) G28 = arilo, heteroarilo; G29= alquilo, arilo, heteroarilo, heteroarilo, heterociclico, NG30G31;


G30, G31 = arilo, heteroarilo, heterociclico

Como se muestra en el Esquema 18, el compuesto (84) se puede acoplar a ácido borónico G28B(OH)2 o equivalente bajo los protocolos de acoplamiento de Suzuki para proporcionar (85), el cual ante hidrazinolisis produce (40) donde R2 es H y R1 es (83).





Esquema 18

Las hidracinas (40) donde R2 es hidrógeno y R1 tiene la estructura general (86) se pueden preparar siguiendo los procedimientos descritos en el Esquema 19.





(86) G30, G31 = alquilo, heterociclico

Como se muestra en el Esquema 19, la reacción secuencial de cloruro cianúrico (74) con compuestos Grignard G30MgX y G31MgX en un solvente tal como benceno proporciona monocloruro (87), el cual se puede tratar con hidrazina para proporcionar (40) donde R2=H y R1=(86).




Esquema 19


Las hidracinas (40) donde R2 es hidrogen y R1 tiene la estructura general (88) se pueden preparar siguiendo los procedimientos descritos en el Esquema 20.



(88) G32= alquilo, arilo, heteroarilo, heterociclico;

G33 = hidrógeno, alquilo, arilo, heteroarilo, heterociclico; G34 = alquilo


Como se muestra en el Esquema 20, (89) se puede reducir a (90) utilizando las condiciones de reducción tales como hierro y ácido acético. El tratamiento secuencial de (90) con agentes de alquilación G32X y G33X (donde X es haluro o trifluorometilsulfonato) proporciona (91). Alternativamente, el tratamiento de (90) con un equivalente de G32X proporciona )1) donde G33 es H. La oxidación de (91) al correspondiente sulfoxido o sulfona utilizando un oxidante tal como ácido meta-cloro perbenzoico, y tratamiento subsecuente con hidrazina proporciona (40) donde R2 es H y R1 es (88).



(89) (90) (91) (40); R2=H and R1=(88)


Esquema 20

Las hidrazinas (40) donde R2 es hidrógeno y R1 tiene la estructura general (92) se pueden preparar siguiendo los procedimientos descritos en el Esquema 21 (Wolf, f. J. J. Am. Chem. Soc. 76, 3551-3553, 1954; Hay, M, J. Med. Chem. 46, 169-182- 2003) y el Esquema 22 (Ley, K. Angew. Int. Ed. 11, 1009-1010, 1972).



(92) G35 = alquilo, arilo, heteroarilo, heterociclico, alcoxilo, halogeno, amino; m,q = 0.1


Como se muestra en el Esquema 21, (93) se puede hacer reaccionar con cianamida en presencia de una base tal como hidroxido sódico acuoso para proporcionar (95). Alternativamente, el tratamiento de (94) con guanidina y una base tal como ter-butoxido potásico, seguido por acidificación, proporciona (95) también. La reacción de (95) con nitrito sódico en solución acida proporciona (96). La conversión de (96) al cloruro respectivo (97) se puede lograr por ejemplo con oxicloruro fosforoso. La hidrazinolisis de (97) proporciona (40) donde r2 es H y R1 es (92) y M=0 y q=1; el N-oxido en esta molécula se puede reducir mediante midrogenolisis en la presencia de Pd sobre carbono y la hidrazina resultante luego puede ser acoplada a ácido (8), (18) o (27). Alternativamente, la hidrazina 1-N-oxido de benzotriazina se puede acoplar a los ácidos (8), (18) o (27), y los compuestos resultantes luego se pueden someter a hidrogenolisis en presencia de Pd sobre carbono con el objeto de reducir el grupo N-oxido.




Esquema 21

Alternativamente, como se muestra en el Esquema 22, (98) se puede hacer reaccionar con cianamida de disodio en un solvente tal como una mezcla de metanol y agua para proporcionar (99), el cual tautomeriza a (100) en presencia de ácido. El tratamiento de (100) con nitrito sódico

en medios acídicos proporciona (101). La reacción de (101) con oxicloruro fosforoso, seguido por hidrazinolisis, proporciona (40), donde R2 es H y R1 es (92) y m=q=1; los grupos N-oxido en esta molécula se pueden reducir mediante hidrogenolisis en presencia de Pd sobre carbono y la hidrazina resultante luego se puede acoplar a ácido (8), (18) o (27). Alternativamente, la hidrazina 1,4-bis-N-oxido-de benzotriazina se puede acoplar a ácido (8), (18) o (27), y el compuesto resultante se puede reducir mediante hidrogenolisis en presencia de Pd sobre carbono.




Esquema 22

**EJEMPLOS SINTÉTICOS**

La invención se describirá ahora haciendo referencia a los siguientes ejemplos que son meramente ilustrativos y no han de interpretarse como una limitación del alcance de la presente invención.

Tal y como se emplean en este documento los símbolos y convenciones empleados en estos procedimientos, esquemas y ejemplos son consistentes con los empleados en la bibliografía científica contemporánea, por ejemplo, el *Journal of the American Chemical Society* o el *Journal of Biological Chemistry*. Para designar los residuos de aminoácidos se emplean generalmente las abreviaturas estándar de una o tres letras, que se asume que están en configuración L a no ser que

se indique lo contrario. A menos que se indique lo contrario, todos los materiales de inicio se obtuvieron de proveedores comerciales y se emplearon sin purificación adicional.

| | |
|---|---|
| Hz (hertz); | TLC (cromatografía de capa fina); |
| $T_r$ (tiempo de retención); | RP (fase inversa); |
| MeOH (metanol); | *i*-PrOH (isopropanol); |
| EtOH (etanol); | TEA (trietilamina); |
| TFA (ácido trifluoroacético); | THF (tetrahidrofurano); |
| DMSO (dimetilsulfóxido); | AcOEt ó EtOAc (acetato de etilo); |
| DCM (diclorometano); | DMF (*N*,*N*-dimetilformamida); |
| CDI (1,1-carbonildiimidazol); | HOAc (ácido acético); |
| HOSu (*N*-hidroxisuccinimida); | Ac (acetilo); |
| HOBT (1-hidroxibenzotriazol); | BOC (*tert*-butiloxicarbonilo); |
| mCPBA (ácido meta-cloroperbenzoico); | FMOC (9-fluorenilmetoxicarbonil); |
| DCC (diciclohexilcarbodiimida); | CBZ (benciloxicarbonilo); |
| NMM (N-metil morfolina); | HOAt (1-hidroxi-7-azabenzotriazol); |
| DMAP (4-dimetilaminopiridina); | Bn (bencilo); |
| TBAF (fluoruro de tetra-*n*-butilamonio); | THB (tetrahidro-2H |
| HPLC (cromatografía líquida de alta presión); | |
| BOP (cloruro bis(2-oxo-3-oxazolidinil)fosfínico); | |
| EDCI (hidrocloruro de 1-etil-3-[3-dimetilaminopropil]carbodiimida); | |
| HBTU (hexafluorofosfato de O-Benzotriazol-1-il-N,N,N',N'- tetrametiluronio). | |

Todas las referencias que se hacen a éter quieren decir éter dietílico; salmuera se refiere a una solución acuosa saturada de NaCl. A menos que se indique lo contrario, todas las temperaturas se expresan en °C (grados centígrados). Todas las reacciones se llevan a cabo en atmósfera inerte a temperatura ambiente a menos que se indique lo contrario, y todos los solventes son de la mayor pureza disponible a menos que se indique lo contrario.

Los espectros de RMN $^1$H (más adelante también "RMN") se registraron en un Varian VXR-300, un Varian Unity-300, un instrumento Varian Unity-400, un Brucker AVANCE-400, un General Electric QE-300 o un espectrómetro Bruker AM 400. Los desplazamientos químicos se

expresan en partes por millón (ppm, unidades δ). Las unidades de las constantes de acoplamiento son hertz (Hz). Los patrones de desdoblamiento describen multiplicidades aparentes que se designan como s (singlete), d (doblete), t (triplete), q (cuartete), quint (quintete), m (multiplete), br (ancho).

Los espectros de masas se hicieron en un sistema de acceso libre LC-MS empleando ionización por electropulverización. Condiciones LC: 4,5% a 90% de $CH_3CN$ (0,02% TFA) en 3,2 min con 0,4 min de retención y 1,4 min de re-equilibración; detección mediante MS, UV a 214 nm, y un detector de dispersión de luz (ELS). Columna: Aquasil (C18) de 1 X 40 mm.

Para hplc preparativa (prep); *ca* 50 mg de los productos finales se inyectaron en 500 µL de DMSO en una columna de 50 X 20 mm I. D. YMC CombiPrep ODS-A a 20 ml/min con un gradiente 10 min de 10% de $CH_3CN$ (0.1% TFA) a 90% de $CH_3CN$ (0.1% TFA) en $H_2O$ (0.1% TFA) y una retención de 2 min. La cromatografía de desarrollo rápido se desarrolló sobre Merck Silica gel 60 (malla 230 - 400).

Los espectros de infrarrojo (IR) se obtuvieron en un espectrómetro Nicolet 510 FT-IR empleando una célula de NaCl de 1-mm. La mayoría de las reacciones se vigilaron mediante cromatografía de capa fina en placas de gel de sílice de E. Merck de 0,25 mm (60F-254), visualizadas con luz UV, en ácido etanólico fosfomolíbdico al 5% o solución de p-anisaldehído.

Los siguientes esquemas sintéticos son meramente ilustrativos de los métodos mediante los que se pueden preparar los compuestos de la invención y no pretenden limitar el alcance de la invención como se define en las reivindicaciones anexas.

Los compuestos descritos en los ejemplos 2 a 353 se prepararon siguiendo los procedimientos generales descritos en el ejemplo 1. Los compuestos descritos en los ejemplos 355 a se prepararon siguiendo los procedimientos generales descritos en el ejemplo 354.

**Preparación 1**

**(4S)-Bencil-3-heptanoil-oxazolidin-2-ona.**

A una solución de (S)-(-)-4-bencil-2-oxazolidinona (3,3 g, 18,6 mmol) en THF (50 ml) a -78 °C se agregó por goteo n-BuLi (7,4 ml, solución en hexano 2,5M, 18.6 mmol). Después de agitar durante 30 min a la misma temperatura, la mezcla de reacción se trató con cloruro de heptanoílo (2,76 g, 18,6 mmol). La mezcla de reacción se agitó y se dejó calentar hasta 10 °C durante 5 h, y se

detuvo la reacción con solución acuosa saturada de $NH_4Cl$ (100 ml). La capa acuosa se extrajo con EtOAc (100 ml x 2). Las capas orgánicas combinadas se lavaron con salmuera, y se secaron sobre $MgSO_4$. La eliminación del solvente a presión reducida proporcionó 4,63 g (86%) del compuesto del titulo. RMN $^1H$ (400 MHz, $CDCl_3$) δ 7,37-7,22 (m, 5H), 4,69 (m, 1H), 4,19 (m, 2H), 3,31 (dd, J = 13,4; 3,3 Hz, 1H), 2,95 (m, 2H), 2,79 (dd, J = 13,4; 9,7 Hz, 1H), 1,71 (m, 2H), 1,42-1,32 (m, 6H), 0,92 (t, J = 6,8 Hz, 3H). MH+ 290.

**Preparación 2**

**(4S)-Bencil-3-[(2R)-benciloximetilheptanoil]oxazolidin-2-ona.**

A una solución de (S)-4-bencil-3-heptanoiloxazolidin-2-ona (4,63 g, 16,02 mmol) y cloruro de titanio (IV) (1,9 ml, 16,82 mmol) en diclorometano (55 ml) a 0 °C se agregó por goteo diisopropiletilamina (3,1 ml, 17,62 mmol). Después de agitar a 0 °C durante 1 hora, el enolato de titanio resultante se hizo reaccionar con éter bencilclorometílico (TCI-America, 4,9 ml, 32,04 mmol) a 0 °C durante 6 h. La mezcla de reacción se inactivó con agua (100 ml). La capa orgánica se extrajo con diclorometano (100 ml x 2). Los extractos orgánicos se lavaron con salmuera, y se secaron sobre $MgSO_4$. Después de eliminar el solvente a presión reducida, la purificación mediante cromatografía de columna de desarrollo rápido empleando un sistema de elución hexano/EtOAc (5:1), proporcionó 4,39 g (67%) del compuesto del titulo. RMN $^1H$ (400 MHz, $CDCl_3$) δ 7,38-7,21 (m, 10H), 4,74 (m, 1H), 4,57 (m, 2H), 4,28-4,13 (m, 3H), 3,82 (t, J = 8,7 Hz, 1H), 3,68 (dd, J = 9,0; 4,9 Hz, 1H), 3,25 (dd, J = 13,5; 3,1 Hz, 1H), 2,71 (dd, J = 13,5; 9,3 Hz, 1H), 1,74 (m, 1H), 1,54 (m, 1H), 1,31-1,28 (m, 6H), 0,89 (t, J = 6,7 Hz, 3H). MH+ 410.

**Preparación 3**

**Ácido (3R)-benciloxi-2-pentilpropiónico.**

Una solución 0,05 M de (S)-4-bencil-3-[(R)-2-benciloximetilheptanoil]oxazolidin-2-ona (2,0 g, 4,89 mmol) en una mezcla 3:1 de THF y $H_2O$ se trató con $H_2O_2$ al 30% (4,5 ml, 39,12 mmol), y seguidamente con LiOH (0,48 g, 9,78 mmol) a 0 °C. La mezcla resultante se agitó y se dejó calentar hasta temperatura ambiente durante la noche. Después se eliminó el THF a vacío. El residuo se lavó con diclorometano (50 ml x 2) para eliminar (S)-4-benciloxazolidin-2-ona. El producto deseado se aisló mediante extracción con EtOAc de la fase acuosa acidificada (pH 1~2).

No fue necesaria ninguna purificación adicional. Al dejarse a alto vacío se consiguieron 1,16 g (95%) del compuesto del titulo. RMN $^1H$ (400 MHz, $CHCl_3$) δ 11,1 (br s, 1H), 7,36 (m, 5H), 4,57 (s, 2H), 3,69 (m, 1H), 3,58 (dd, J = 9,2; 5,2 Hz, 1H), 2,74 (m, 1H), 1,66 (m, 1H), 1,54 (m, 1H), 1,34-1,30 (m, 6H), 0,90 (t, J = 6,7 Hz, 3H). MH+ 251.

**Preparación 4**

**Ácido 3-hidroxi-(2R)-pentilpropiónico.**

A una solución de ácido (R)-3-benciloxi-2-pentil-propiónico (1,54 g, 6,16 mmol) en EtOH (100 ml) se agregó Pd/C 10% (310 mg). La mezcla de reacción se sometió a hidrogenación durante la noche a temperatura ambiente. Después de que se completara la reacción, la mezcla de reacción se filtró a través de un lecho de Celite, y se lavó con EtOH (50 ml x 3). La eliminación del solvente proporcionó el compuesto del titulo (0,92 g, 93%). No fue necesaria ninguna purificación adicional. RMN $^1H$ (400 MHz, $CHCl_3$) δ 6,30 (br s, 1H), 3,81 (d, J = 5,4 Hz, 2H), 2,64 (m, 1H), 1,69 (m, 1H), 1,56 (m, 1H), 1,41-1.27 (m, 6H), 0,91 (t, J = 7,7 Hz, 3H). MH+ 161.

**Preparación 5**

**N-Benciloxi-3-hidroxi-(2R)-pentilpropionamida.**

A una mezcla de ácido (R)-3-hidroxi-2-pentilpropiónico (0,92 g, 5,75 mmol), hidrocloruro de O-bencil hidroxilamina (0,92 g, 5,75 mmol) y 4-(dimetilamino)piridina (1,41 g, 11,50 mmol) en diclorometano (25 ml) a 0 °C se agregó hidrocloruro de 1-[3-(dimetilamino)propil]-3-etilcarbodiimida (1,11 g, 5,75 mmol). Después de agitar a temperatura ambiente durante la noche, la reacción se detuvo con solución acuosa de HCl 1N (25 ml) y se extrajo empleando diclorometano (25 ml x 2). Los extractos orgánicos se lavaron con agua, salmuera, y se secaron sobre $MgSO_4$. La eliminación del solvente a presión reducida proporcionó el compuesto del titulo (1,43 g, 94%). RMN $^1H$ (400 MHz, $CHCl_3$) δ 9,22 (br s, 1H), 7,41-7,28 (m, 5H), 4,89 (q, J = 10,6 Hz, 2H), 3,70-3,37 (m, 3H), 2,17 (m, 1H), 1,54 (br s, 1H), 1,27 (m, 6H), 0,88 (t, J = 6,9 Hz, 3H). MH+ 266.

**Preparación 6**

**1-Benciloxi-(3R)-pentilazetidin-2-ona.**

A una mezcla de (R)-N-benciloxi-3-hidroxi-2-pentilpropionamida (1,41 g, 5,32 mmol) y trifenilfosfina (1,68 g, 6,39 mmol) en THF (53 ml) se agregó por goteo dietil azodicarboxilato (1,1 ml, 6,39 mmol) a 0 °C. La mezcla de reacción se agitó y se dejó calentar hasta temperatura ambiente durante la noche. Después la reacción se detuvo con agua (50 ml). La capa acuosa se extrajo con EtOAc (50 ml x 2). Las capas orgánicas combinadas se lavaron con salmuera, y se secaron sobre $MgSO_4$. Después de eliminar el solvente a vacío, el residuo se purificó mediante cromatografía de columna de desarrollo rápido (hex:EtOAc 5/1) para proporcionar el compuesto del titulo (1,17 g, 89%). RMN $^1H$ (400 MHz, $CHCl_3$) δ 7,35-7,25 (m, 5H), 4,87 (s, 2H), 3,28 (t, J = 4,85 Hx, 1H), 2,84 (q, J 2,35 Hz, 1H), 2,77 (m, 1H), 1,62 (m, 1H), 1,36 (m, 1H), 1,25-1,16 (m, 6H), 0,88 (t, J = 6,9 Hz, 3H). MH+ 248.

**Preparación 7**

**Ácido 3-benciloxiamino-(2R)-pentilpropiónico.**

A una solución de (R)-1-benciloxi-3-pentilazetidin-2-ona (0,96 g, 3,89 mmol) en una mezcla de THF-$H_2O$-MeOH (50 ml, 3:1:1 v/v) se agregó hidróxido de litio monohidratado (1,91 g, 38,9 mmol). Después de agitar a temperatura ambiente durante la noche, se agregó agua (25 ml) a la mezcla. La solución se acidificó hasta pH 5~6 con solución acuosa de HCl 3N. Se extrajo con EtOAc (50 ml x 2). Las capas orgánicas combinadas se secaron sobre $MgSO_4$. La eliminación del solvente a vacío proporcionó el compuesto del titulo (0,98 g, 95%). RMN $^1H$ (400 MHz, $CHCl_3$) δ 9,80 (br s, 1H), 7,37 (m, 5H), 4,75 (m, 2H), 3,14 (m, 2H), 2,74 (m, 1H), 1,70 (m, 1H), 1,53 (m, 1H), 1,38-1,25 (m, 6H), 0,91 (t, J = 6,8 Hz, 3H). MH+ 266.

**Preparación 8**

**Ácido (2R)-[(benciloxiformilamino)metil]heptanoico.**

A una solución fría de ácido (R)-3-benciloxiamino-2-pentilpropiónico (1,03 g, 3,89 mmol) en $HCO_2H$ (19 ml) y diclorometano (19 ml) a 0 °C se agregó anhídrido acético (3,9 ml, 41,2 mmol). La mezcla se agitó a 0 °C durante 3 horas. Los volátiles se eliminaron por evaporación a vacío. Se agregó diclorometano (50 ml). La solución orgánica se lavó con salmuera (50 ml x 2), y se secó sobre $MgSO_4$. La filtración y evaporación a vacío proporcionó el compuesto del titulo (1,08 g,

95%). RMN $^1H$ (400 MHz, $CHCl_3$) δ 8,07 (br s, 1H), 7,29 (m, 5H), 4,91-4,71 (m, 2H), 3,76 (m, 2H), 2,67 (m, 1H), 1,54 (m, 1H), 1,41(m, 1H), 1,20 (m, 6H), 0,80 (t, $J$ = 7,0 Hz, 3H). MH+ 294.

**Ejemplo 1**

**N-Hidroxi-N-[(R)-2-(N'-piridin-2-il-hidrazinocarbonil)-heptil]-formamida.**

Se disolvieron ácido (2R)-[(benciloxiformilamino)metil]heptanoico (1,2 mmoles), HOAt (1,3 mmoles), N'-piridin-2-il-hidrazina (1,2 mmoles) y NMM (5 mmoles) en DMF y se trataron con EDCI (1,3 mmoles) a temperatura ambiente durante 12 horas. Se aisló el producto de acoplamiento N-benciloxi-N-[(R)-2-(N'-piridin-2-il-hidrazinocarbonil)-heptil]-formamida mediante hplc prep de la mezcla de reacción cruda. Este compuesto se sometió a hidrogenación a presión atmosférica sobre Pd/C en metanol durante 1 hora, lo que proporcionó el compuesto del titulo. MH+ 295.

**Preparación 9**

**2-hidrazino-5-etilpirimidina.**

A una solución de 2-cloro-5-etilpirimidina (0.31 g, 2.2 mmol) en MeOH (5 mL) se agregó monohidrato de hidrazina (1.0 mL, 20.6 mmol). Después de agitar durante 16 h a 50°C, la solución se enfrio a temperatura ambiente y se purificó mediante HPLC de fase inversa para proporcionar 0.24 g (80%) del compuesto del titulo como un sólido blanco. MH+ 139.

**Preparación 10**

**2-hidrazino-4-metilpirimidina.**

A una suspersión finamente dispersa de 2-cloropirimidina (8.01 g, 69.9 mmol) en una mezcla 10:1 de Et2O-THF (500 mL) a –30°C se agregó por goteo MeLi (46 mL, 1.6M en Et2O, 73.6 mmol). La mezcla de reacción se agitó a –30°C durante 30 minutos, y luego se calentó a 0°C y se agitó durante 30 min. A la mezcla de reacción luego se agregó una mezcla 1:1::20 de H2O-HOAc-THF (100 mL), y la mezcla se agitó a 0°C durante 10 minutos. Luego se agregó a la mezcla una solución de DDQ (16.7 g, 73.6 mmol) en THF (100 mL), y la mezcla se agitó y se calentó a temperatura ambiente durante 30 minutos. Luego la mezcla se diluyó con Et2O (300 mL) y se lavó con NaOH acuoso 1N (3x100 mL) seguido por salmuera (300 mL). Luego la fase

orgánica fue secada sobre MgSO4 anhidro, filtrada, concentrada *al vacío*, y purificada mediante cromatografía flash utilizando EtOAc-hexanos (1:2) como eluyente para proporcionar 6.06 g de 2-cloro-4-metilpirimidina (67%) como placas cristalinas blancas. A una solución de 2-cloro-4-metilpirimidina (6.06 g, 47.1 mmol) en MeOH (40 mL) se agregó monohidrato de hidrazina (10 mL, 206 mmol). La solución fue agitada durante 16 h a temperatura ambiente y luego se purificó mediante HPLC de fase inversa para proporcionar 4.43 g del compuesto del titulo (76%) como un sólido blanco. MH+ 125.

**Preparación 11**

**2-Hidrazina-4-morfolino-6-metilpiridina.**

A una solución de 2,4-dicloro-6-metilpirimidina (0.41 g, 2.50 mmol) en MeOH (5 mL) se agregó morfolina (0.5 mL, 5.73 mmol). La solución fue agitada durante 30 minutos a temperatura ambiente, y luego se agregó monohidrato de hidrazina (1.0 mL, 20.6 mmol). Luego la solución fue calentada a 60°C y agitada durante 16 h. Luego la solución fue enfriada a temperatura ambiente y se purificó mediante HPLC de fase inversa para proporcionar 0.31 g del compuesto del titulo (59%) como un sólido blanco ceroso. MH+ 210.

**Preparación 12**

**2-Hidrazino-4-(2,3,4-trimetoxifenil)pirimidina.**

A una solución de 2-tiometil-4-cloropirimidina (0.3410 g, 2.12 mmol) en 1,4-dioxano (21 mL) se agregó ácido 2,3,4-trimetoxifenilborónico (0.4950 g, 2.33 mmol) y Na2CO3 acuoso (2.3 mL, 2.0M en agua, 4.60 mmol). La mezcla fue rociada con gas de nitrogeno seco durante 5 minutos, y luego se agregó Pd(Ph3P)4 (123 mg, 0.106 mmol). La mezcla se protegió de la luz y se calentó a 110°C durante 16 horas. Luego la mezcla se enfrió a temperatura ambiente, se filtró, se concentró al vacio, y se purificó mediante cromatografía flash utilizando EtOAc-hexanos (1:4) como eluyente para proporcionar 0.5920 g de 2-tiometil-4-(2,3,4-trimetoxifenil)pirimidina (95%) como un sólido amarillo.

A una solución de 2-tiometil-4-(2,3,4-trimetoxifenil)pirimidina (0.5920 g, 2.02 mmol) en CG2CL2 (10 mL) se agregó ácido m-cloroperbenzoico (1.05 g, 6.08 mmol), y la solución se agitó durante 3 horas tiempo en el cual se observó como una suspensión blanca. La suspensión se concentró *al vacío*, y se agregó MeOH (10 mL) seguido por monohidrato de hidrazina (2 mL,

41.2 mmol). La solución resultante fue agitada durante 16 horas y luego se concentró a medio volumen aproximadamente *al vacío*. La mezcla se dejo reposar durante 1h, y el sólido resultante fue recolectado mediante filtración al vacío y se lavó con agua. El secado al vacío proporcionó 0.3330 g del compuesto del titulo (60%) como un sólido castaño brillante. MH+ 277.

**Preparación 13**

**2-Hidrazino-4-morfolino-6-trifluorometilpirimidina.**

A una solución de 2-tiometil-4-cloro-6-trifluorometilpirimidina (1.9996 g, 8.75 mmol) en MeOH (50 mL) se agregó morfolina (1.5 mL, 17.2 mmol). La solución fue agitada durante la noche, concentrada al vacío, y el sólido blanco resultante fue recolectado mediante filtración al vacío y lavado con agua. A una solución del sólido en CH2Cl2 (50 mL) se agregó ácido mcloroperbenzóico (4.53 g, 26.3 mmol), y la solución resultante se agitó durante 2h tiempo en el cual se observó como una suspensión blanca. El solvente se removió al vacío, y luego se agregó MeOH (%0 mL) seguido por monohidrato de hidrazina (3.0 mL, 61.8 mmol). La solución fue agitada durante 16 h, y luego se concentró a medio volumen aproximadamente *al vacío.* Luego se agregó agua (100 mL) a la suspensión resultante, y el sólido blanco observado fue recolectado mediante filtración al vacío. Luego este material fue lavado con agua y secado al vacío para proporcionar 1.7193 g del compuesto del titulo (75%) como un sólido blanco. MH+ 264.

**Preparación 14**

**2-Hidrazino-5,6,7,8-tetrahidroquinazolina**

A una mezcla de 2-ciclohexanonecarboxilato de etilo (3.00 g, 17.6 mmol) y sulfato de 2-metil-2-tiopseudourea (3.68 g, 13.2 mmol) se agregó una solución de carbonato potásico (7.31 g, 52.9 mmol) en agua (60 mL). La solución de reacción se agitó a temperatura ambiente durante 16 h, tiempo en el cual ésta se observó como una suspensión. El sólido blanco se recolectó mediante filtración al vacío, se lavó con agua, y se secó al vacío. Una mezcla del sólido en oxicloruro de fósforo (20 mL) se calentó a 110°C en un tubo sellado, tiempo en el cual ésta se observó como una solución. La solución se enfrió a temperatura ambiente y luego se vertió sobre hielo picado y agua (300 mL). La mezcla fue vigorosamente agitada a 0°C durante 1h, y el precipitado resultante fue recolectado mediante filtración al vacío, lavado con agua, y secado al vacío para proporcionar 1.61 g de 2-tiometil-4-cloro-5,6,7,8-tetrahidroquinazolina (43%) como un sólido blancuzco.

A una solución de 2-tiometil-4-cloro-5,6,7,8-tetrahidroquinazolina (0.5121 g, 2.39 mmol) en una mezcla 1:1 de MeOH-HOAc (30 mL) se agregó polvo de zinc activado (500 mg, 7.65 mmol). La mezcla se calentó a 70°C durante 1h, y luego se enfrió a temperatura ambiente y se filtró. La solución resultante fue concentrada al vacío, y luego se seco azeotropicamente con tolueno (50 mL). El residuo fue particionado entre EtOAc (150 mL) y HCl acuoso 1N (50 mL), y luego la fase orgánica fue lavada con NaHCO3 acuoso saturado y salmuera. Luego la fase orgánica fue secada sobre MgSO4 anhidro y concentrada al vacío para proporcionar 0.1461 g de 2-tiometil-5,6,7,8-tetrahidroquinazolina (34%) como un aceite de color púrpura.

A una solución de 2-tiometil-5,6,7,8-tetrahidroquinazolina (0.1461 g, 0.81 mmol) en CH2Cl2 (5 mL) se agregó ácido m-cloroperbenzóico (0.462 g, 2.68 mmol). La solución fue agitada a temperatura ambiente durante 3h, tiempo en el cual ésta fue observada como una suspensión. Luego el solvente fue removido al vacío, y se agregó MeOH (5 mL) seguido por monohidrato de hidrazina (1 mL, 20.6 mmol). Luego la solución fue calentada a 50°C y agitada durante 16 h. La solución fue enfriada a temperatura ambiente y purificada mediante HPLC de fase inversa para proporcionar 0.1126 g del compuesto del titulo (85%) como un aceite incoloro. MH+ 165.

**Preparación 15**

**2-Hidrazino-4-(2-piridil)pirimidina.**

A una solución de 2-amino-4-(2-piridil)pirimidina (10.10 g, 58.66 mmol) en ácido sulfúrico acuoso al 5% (200 mL) se agregó por porciones nitrato sódico (20.24 g, 293.3 mmol) durante 10 minutos. La solución se agitó a temperatura ambiente durante 2 h y luego se ajustó a pH 10 mediante la adición de NaOH acuoso 6N. Luego la mezcla resultante se extrajo con i-PrOH al 30% en CHCl3 (10x300 mL), y la fase orgánica combinada fue secada sobre MgSO4 anhidro y concentrada al vacío. El residuo fue triturado con hexanos y recolectado mediante filtración al vacío para proporcionar 6.89 g de 4-(2-piridil)pirimid-2-ona (68%) como un sólido de color beige.

Una mezcla de 4-(2-piridil)pirimid-2-ona (6.89 g, 39.8 mmol) en oxicloruro de fósforo (30 mL) se calentó a 110°C durante 90 minutos en un tubo sellado. Luego la solución de color castaño oscuro fue enfriada a temperatura ambiente y vertida sobre hielo cuerteado y agua (500 mL). La mezcla fue vigorosamente agitada a 0°C durante 1 h, y luego se ajustó a pH 14 con NaOH 6N acuoso. La mezcla fue extraida con CH2Cl2 (2x300 mL), y la fase orgánica combinada fue

secada sobre MgSO4 anhidro y concentrada al vacío. A una solución del residuo en CH2Cl2 (10 mL) y MeOH (30 mL) se agregó monohidrato de hidrazina (7.0 mL, 144.2 mmol), y la solución se agitó durante 16 h tiempo en el cual se observo un precipitado blanco. Este sólido fue recolectado mediante filtración al vacio, lavado con agua, y secado al vacío para proporcionar 2.20 g del compuesto del titulo (30%) como un sólido de color blancuzco. MH+ 188.

**Preparación 16**

**(6-Morfolin-4-il-pirimidin-4-il)-hidrazina.**

Una solución de 4,6-dicloropirimidina (300 mg, 2 mmol), carbazato de tert-butilo (280 mg, 2.1 mmol) y base de Hunig (453 µL, 2.6 mmol) en etanol (3 ml) se agitó a 120°C durante 1 hora bajo condición de microondas. Después de agregar la morfolina (700 µL, 8 mmol), la mezcla fue luego sometida nuevamente a la misma condición de microondas durante otra hora. La evaporación del solvente al vacío proporcionó un solido blanco el cual fue tratado con TFA (3 ml) en DCM (3 ml) durante 20 min. Después de la evaporación del solvente, el residuo fue disuelto nuevamente en metanol. El tratamiento con NaHCO3 sólido retiró los rastrosa de TFA que pueden haber quedado. La filtración seguida por evaporación del solvente proporcionó un residuo el cual fue sometido a purificación de HPLC de fase inversa para producir (6-morfolin-4-il-pirimidin-4-il)-hidrazina (200 mg, 1 mmol, 50% en 3 pasos) como un sólido blanco. MH+ 196.

Alternativamente, el mismo compuesto puede ser generado mediante agitación de una solución de 4,6-diclopirimidina (300 mg, 2 mmol), morfolina (280 mg, 2.1 mmol) y diisopropiletilamina (453 µL, 2.6 mmol) en etanol (3 ml) durante 1 hora. Después de la adición de hidrazina (370 µL, 2.6 mmol) en etanol (3 ml) durante 1 hora. Después de la adición de hidrazina (370 µL, 6 mmol), la mezcla fue agitada a 120°C durante 1 hora bajo condición de microondas. Después de la evaporación del solvente, el compuesto fue disuelto en DMSO antes de ser sometido a purificación de HPLC preparativa, la cual luego proporcionó 6-morfolin-4-il-pirimidin-4-il)hidrazina. MH+ 196.

**Preparación 17**

**(2-Etilamina-6-trifluorometil-pirimidin-4-il)-hidrazina**

Una solución de (4-cloro-6-trifluorometil-pirimidin-2-il)-etil-amina (100 mg, 0.38 mmol), hidrazina (87 µL, 3.8 mmol) en etanol se calentó a 70°C durante la noche. La evaporación del solvente al vacío proporcionó un residuo el cual fue purificado mediante HPLC preparativa para proporcionar (2-etilamina-6-trifluorometil-pirimidin-4-il)-hidrazina (74 mg, 75%). MH+256.

**Preparación 18**

**[(4-Metil-piperazin-1-il)-trifluorometil-pirimidin-4-il]-hidrazina.**

Una mezcla de 4-cloro-2-metiltiol-6(trifluometil)pirimidina (228 mg, 1 mmol), carbazato de tert-butilo (159 mg, 6, 1.2 mmol) en etanol fue calentada a 100°C en el reactor de microondas durante 20 minutos. La evaporación del solvente proporcionó un sólido blanco. El sólido fue tratado con MCPBA en DCM a temperatura ambiente durante la noche. La evaporación del solvente proporcionó un sólido blanco el cual fue tratado con 1-metilpiperazina a 140°C durante 20 min. en etanol bajo condiciones de microondas. La evaporación de los solventes proporcionó un sólido el cual fue tratado con TFA (3 ml) en DCM (3 ml) durante 20 min. Después de realizar la reacción, la mayoria de TFA y DCM fue retirada al vacío. El residuo fue disuelto nuevamente en metanol y tratado con NaHCO3 sólido para remover el residuo de TFA hasta que no se generó gas. La filtración y evaporación al vacío del filtrado proporcionaron un residuo el cual fue purificado mediante HPLC preparativa para proporcionar [(4-metil-piperazin-1-il)-trifluorometil-pirimidin-4-il]-hidrazina (100 mg, 36%). MH+ 277.

Ejemplo 2

N-Hidroxi-N-{(R)-2-[N'-(3-metoxi-fenil)-hidrazinocarbonil]-heptil}-formamida.
MH+ = 324

Ejemplo 3

N-Hidroxi-N-{(R)-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-formamida.
MH+ = 364

Ejemplo 4

N-{(R)-2-[N'-(4-ciano-fenil)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.
MH+ = 319

Ejemplo 5

N-{(R)-2-[N'-(2,6-dimetil-pirimidin-4-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.
MH+ = 324

Ejemplo 6

N-Hidroxi-N-{(R)-2-(N'-quinoxalin-2-il-hidrazinocarbonil]-heptil}-formamida.
MH+ = 346

Ejemplo 7

N-Hidroxi-N-((2R)-2-{N'-(3,4-dihidro-quinoxalin-2-il)-hidrazinocarbonil}-heptil)-formamida.
MH+ = 348

Ejemplo 8

N-Hidroxi-N-{(R)-2-[N'-(1,3,4-trimetil-1H-pirazolo[3,4-b]piridin)-6-il)-hidrazinocarbonil]-heptil}-formamida.
MH+ = 377

Ejemplo 9

4-(N'-{(R)-2-[(formal-hidroxi-amino)-metil]-heptanoil}-hidrazino)bencenosulfonamida.
MH+ = 373

Ejemplo 10

N-Hidroxi-N-[(2R)-2-(ciclohexilmetil)-3-oxo-3-{N'(triflourometil)-pirimidin-2-il]-hidrazino}-propil]-formamida.

MH+ = 390

Ejemplo 11

N-Hidroxi-N-[(2R)-2-(ciclopentilmetil)-3-oxo-3-{N'(triflourometil)-pirimidin-2-il]-hidrazino}-propil]-formamida.

MH+ = 376.

Ejemplo 12

N-{(R)-2-[N'-(dimetil-triflourometil-pirimidin-4-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

MH+ = 392

Ejemplo 13

N-hidroxi-N-{(R)-2-[N'-(6-triflourometil-piridazin-3-il)-hidrazinocarbonil]-heptil}-formamida.

MH+ = 364

Ejemplo 14

N-hidroxi-N-{(R)-2-[N'-(6-triflourometil-pirimidin-4-il)-hidrazinocarbonil]-heptil}-formamida.

MH+ = 364

Ejemplo 15

N-hidroxi-N-{(R)-2-[N'-(5-metil-[1,2,4]triazolo[1,5,a]-3-il)-pirimidin-7-il)-hidrazinocarbonil]-heptil}-formamida.

MH+ = 350

Ejemplo 16

N-hidroxi-N-{(R)-2-[N'-(9H-purin-6-il)-hidrazinocarbonil]-heptil}-formamida.
MH+ = 336

Ejemplo 17

N-{(R)-2-[N'-(5-ciano-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida. MH+ = 321

Ejemplo 18

N-hidroxi-N-((2R)-2-{[N'-(pirimidin-2-il)-hidrazino]-carbonil}reptil)-formamida.
MH+ = 296

Ejemplo 19

N-Hidroxi-N-((R)-2-(ciclobutilmetil-3-oxo-3-{N'[4-(triflourometil)-pirimidin-2-il]-hidrazino}-propil]-formamida.
MH+ = 362

Ejemplo 20

N-Hidroxi-N-{(R)-2-[N'-(6-imidazol-1-il-pirimidin-4-il)hidrazinocarbonil]-heptil}-formamida.
MH+ = 362.

Ejemplo 21

N-[(R)-2-(N'benzo[1,2,4]triazin-3-il-hidrazinocarbonil)-heptil]-N-hidroxi-formamida. MH+ = 347

Ejemplo 22

N-Hidroxi-N-{(R)-2-[N'-(7-metoxi-benzo[1,2,4]triazin-il)-hidrazinocarbonil]-heptil}-formamida.
MH+ = 377

Ejemplo 23

N-Hidroxi-N-{(R)-2-[N'-(1-metil-1H-il-pirazolo-[3,4,d]pirimidin-6-il)-hidrazinocarbonil]-heptil}-formamida.
MH+ = 350.

Ejemplo 24

N-((R)-2-{N'[6-(5-coloro-piridin-3-il-oxi)-piridazin-3-il]-hidrazinocarbonil}-heptil]-N-hidroxi-formamida.
MH+ = 423

Ejemplo 25

N-Hidroxi-N-[(2R)-2-({[N'-[6-(1H-pirrol-1-il)-3-piridazinil]-hidrazino}-carbonil)-heptil]-formamida.
MH+ = 361.

Ejemplo 26

N-Hidroxi-N-((2R)-2-{[N'-[9-metil-9H-purin-6-il)hidrazino]-carbonil}-heptil)-formamida.
MH+ = 350

Ejemplo 27

N-Hidroxi-N-{(R)-2-[N-({6-morfolin-4-il}-9H-purin-2-il)-hidrazinocarbonil]-heptil}-formamida.

MH+ = 421

Ejemplo 28

N-{(R)-2-{N'(6-fluoro-piridin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida. MH+ = 313

Ejemplo 29

N-Hidroxi-N-((2R)-2-{[N'-(1-metil-1H-pirazolo[3,4-d]pirimidin-4-il)-hidrazino]-carbonil}-heptil}-formamida.

MH+ = 350

Ejemplo 30

N-{(R)-2-{N'(4-amino-6-isopropil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

MH+ = 354.

Ejemplo 31

N-{(R)-2-[N'-(2,5-dimetil-4-nitro-2H-pirazol-3-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

MH+ = 357

Ejemplo 32

N-{(R)-2-{N'(3-cloro-1-metil-1H-pirazolo[3,4-d]pirimidin-6-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

MH+ = 379

Ejemplo 33

N-{(R)-2-[N'(6-dimetilamino-9H-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

MH+ = 379

Ejemplo 34

N-Hidroxi-N-[(2R)-4-ciclopropil-2-({N'-[4-(trifluorometil)-pirimidin-2-il]-hidrazino}-carbonil)-butil]-formamida.

MH+ = 362

Ejemplo 35

N-Hidroxi-N-((2R)-2-ciclopropilmetil)-3-oxo-3-{N'-[4-(trifluorometil)-pirimidin-2-il]-hidrazino}-propil)-formamida.

MH+ = 348

Ejemplo 36

N-Hidroxi-N-{(R)-2-[N'-metil-N'-(4-(trifluorometil-pirimidin-2-il]-hidrazinocarbonil]-heptil}-formamida.

MH+ = 378.

Ejemplo 37

Ester metilico del acido 2-(N'-{(R)-2-[(formal-hidroxi-amino)-metil]-heptanoil}-hydrazino)-4-trifluorometil-pirimidina-5-carboxilico.

MH+ = 422

Ejemplo 38

Acido 2-(N'-{(R)-2-[(formil-hidroxi-amino)-metil]-heptanoil}-hydrazino)-4-trifluorometil-pirimidina-
5-carboxilico.
MH+ = 362

Ejemplo 39

N-{(R)-2-[N'(5-fluoro-4-metoxi-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.
MH+ = 344

Ejemplo 40

N-hidroxi-N-{(2R)-2-[N'(4-dimetilamino-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.
MH+ = 339

Ejemplo 41

N-hidroxi-N-{(2R)-2-[(N'{6-[(2-hidroxietil)amino]-1,3-dihidro-2H-purin-2-ilideno}-hidrazino)-carbonil]-heptil}-formamida.
MH+ = 395.

Ejemplo 42

N-{(R)-2-[N'(5-morfolin-4-il-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.
MH+ = 399

Ejemplo 43

N-{(R)-2-[N'-(5-fluoro-4-metilamino-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

MH+ = 343

Ejemplo 44

Dimetilamida del acido 2-(N'-{(R)-2-[(formal-hidroxi-amino)-metil]-heptanoil}-hidrazino)-4-trifluorometil-pirimidina-5-carboxilico.

MH+ = 435

Ejemplo 45

N-hidroxi-N-{(R)-2-[N'-(N'-(3-oxo-3,4-dihidro-quinoxalin-2-il)- hidrazinocarbonil]-heptil}-formamide.

MH+ = 435

Ejemplo 46

N-{(R)-2-butoxi-2-[N'-(4-trifluorometil-pirimidin-2-il)- hidrazinocarbonil]-etil}-N-hidroxi-formamide.

MH+ = 366

Ejemplo 47

(2-fluoro-fenil)-amida del acido 2-(N'{(R)-2-[N'-[(formil-hidroxi-amino)-metil]-heptanoil}-hidrazino)-4-trifluorometil-pirimidina-5-carboxilico

MH+ = 501

Ejemplo 48

tert-butilamida del acido 2-(N'{(R)-2-[(formil-hidroxi-amino)-metil]-heptanoil}-hidrazino)-4-trifluorometil-pirimidina-5-carboxilico

MH+ = 463

Ejemplo 49

N-hidroxi-((R)-2-{N'[(1-piperidin-1-il-metanoil)-trifluorometil-pirimidin-2-il]hidrazinocarbonil}-heptil)-formamide

MH+ = 463

Ejemplo 50

N-{(R)-2-{N'[(5-ciano-4-trifluorometil-pirimidin-2-il)hidrazinocarbonil]-heptil}-N-hidroxi-formamide

MH+ = 389

Ejemplo 51

N-hidroxi-N-[(2R)-2-{N'[9-(4,4,4-trifluorobutil)1,9-dihidro-2H-purin-2-ilideno]-hidrazino}-carbonil)-heptil]-formamide

MH+ = 446

Ejemplo 52

N-hidroxi-N-((R)-2-{N'[(1-morfolin-4-il-metanoil)-trifluorometil-pirimidin-2-il]-hidrazinocarbonil}-heptil)-formamide

MH+ = 477

Ejemplo 53

Bencilamida del acido 2-(N'{(R)-2-[(formal-hidroxi-amino)-metil]heptanoil}]-

hidrazino)-4-trifluorometil-pirimidina-5-carboxilico.
MH+ = 497.

Ejemplo 54

N-hidroxi-N-[(2R)-3-{N'[(1,2,4-benzotriazin-3-il)-hidrazino]-2-(-ciclohexilmetil-3-oxopropil]-formamida
MH+ = 373.

Ejemplo 55

N-hidroxi-N-((2R)-2-(ciclohexilmetil)-3-{N'[7-(metiloxi)-1,2,4-benzotriazin-3-il]-hidrazino}-3-oxopropil)-formamida
MH+ = 403

Ejemplo 56

2-[2-((2R)-2-{[{formal(hidroxi)amino]metil}heptanoil)-hidrazino]-N-metil-N-2-piridinil)-4-(trifluorometil)-5-pirimidinacarboxamida
MH+ = 498

Ejemplo 57

2-[2-((2R)-2-{[{formal(hidroxi)amino]metil}heptanoil)-hidrazino]-N-metil-N-fenil-4-(trifluorometil)-5-pirimidinacarboxamida
MH+ = 497

Ejemplo 58

Morfolin-4-ilamida del acido 2-(N;-{(R)-2-(formal-hidroxi-amino)-metil]-heptanoil}]-hidrazino}-4-trifluorometil-pirimidina-5-carboxilco.
MH+ = 492

Ejemplo 59

N-hidroxi-N-((R)-2-{N'fenil-hidrazinocarbonil)-trifluorometil-pirimidin-2-il]-hidrazinocarbonil}-heptil)-formamida
MH+ = 498

Ejemplo 60

Piperidin-1-ilamida del acido 2-(N'-{(R)-2-[(formal-hidroxi-amino)-metil]-heptanoil}-hidrazino)-4-trifluorometil-pirimidina-5-carboxilico.
MH+ = 492

Ejemplo 61

Pirrol-1-ilamida del acido 2-(N'-{(R)-2-[(formal-hidroxi-amino)-metil]-heptanoil}-hidrazino)-4-trifluorometil-pirimidina-5-carboxilico.
MH+ = 357

Ejemplo 62

N-{(R)-2-[N'-(dimetilamino-fluoro-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida
MH+ = 357.

Ejemplo 63

N-((R)-2-{N'-(etil-metil-amino)-fluoro-pirimidin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida

MH+ = 371.

Ejemplo 64

N-hidroxi-N-((2R)-2-(ciclopentilmetil)-3-{N'-[7-(metiloxi)-1,2,4-benzotriazin-3-il]-hidrazino}-3-oxopropil)-formamida.

MH+ = 389

Ejemplo 65

N-hidroxi-N-{(R)-2-[N'-(1-metil-1H-benzoimidazol-2-il)-hidrazinocarbonil]-heptil}-formamida .

MH+ = 348

Ejemplo 66

N-{(R)-2-[N'-(4-azetidin-1-il-5-fluoro-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

MH+ = 369

Ejemplo 67

N-{(R)-2-[N'-(4-ciclopropilamino-5-fluoro-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

MH+ = 369

Ejemplo 68

N-[(R)-2-[N'-benzo[1,2,4]triazin-3-il-hidrazinocarbonil)-3-N-ciclopentil-propil]-N-hidroxi-formamida.

MH+ = 359

Ejemplo 69

N-hidroxi-N-{(R)-2-[N'-(morfolin-4-il-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-formamida.

MH+ = 449

Ejemplo 70

N-hidroxi-N-[(R)-2-(N'-{[(2-hidroxi-etil)-metil-amino]-trifluorometil-pirimidin-2-il}-hidrazinocarbonil)-heptil]-formamida.

MH+ = 437

Ejemplo 71

N-hidroxi-N-((R)-2-{N'-[(4-metil-piperazin-1-il)-trifluorometil-pirimidin-2-il]-hidrazinocarbonil}-heptil)-formamida.

MH+ = 462

Ejemplo 72

N-hidroxi-N-((2R)-2-(ciclohexilmetil)-3-{N'-[4-ciclopropilamino)-5-fluoro-pirimidin-2-il]hidrazino}-3-oxopropil)-formamida.

MH+ = 395

Ejemplo 73

N-hidroxi-N-((2R)-2-(ciclopentilmetil)-3-{N'-[4-ciclopropilamino)-5-fluoro-pirimidin-2-il]hidrazino}-3-oxopropil)-formamida.

MH+ = 381

Ejemplo 74

N-hidroxi-N-[(2R)-3-{-[4-(azetidin-1-il)-5-fluoro-pirimidin-2-il]-hidrazino}-2-(ciclopentilmetil-3-oxopropil]-formamida.

MH+ = 381

Ejemplo 75

N-hidroxi-N-[(2R)-5-metil-2-({N'-[4-(trifluorometil)-pirimidin-2-il]-hidrazino}-carbonil)-hexil]-formamida.

MH+ = 364

Ejemplo 76

N-[(R)-2-(N'benzo[1,2,4]triazin-3-il-hidrazinocarbonil)-5-metil-hexil]-N-hidroxy-formamida.

MH+ = 364

Ejemplo 77

N-hidroxi-N-[(2R)-5-metil-2-({N'-[7-(metiloxil)-1,2,4-benzotriazin-3-il]-hidrazino}-carbonil)-hexil]-formamida.

MH+ = 377

Ejemplo 78

N-{(R)-2-(N'-(7-cloro-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-N-hidroxy-formamida

.

MH+ = 381

Ejemplo 79

N-hidroxi-N-((2R)-2-(ciclopentilmetil)-3-{N'-[4-(morfolin-4-il)-6-(trifluorometil)-pirimidin-2-il]-hidrazino}-3-oxopropil)-formamida.

MH+ = 461

Ejemplo 80

N-hidroxi-N-((2R)-2-(ciclopentilmetil)-3-{N'-[4-[(2-hidroxietil)-(metil)-amino]-6-(trifluorometil)-pirimidin-2-il]-hidrazino}-3-oxopropil)-formamida.

MH+ = 449

Ejemplo 81

N-hidroxi-N-[(2R)-6-metil-2-({N'-[4-(trifluorometil)-pirimidin-2-il]-hidrazino}-carbonil)-heptil]-formamida.

MH+ = 378

Ejemplo 82

N-hidroxi-N-((2R)-2-{[N'-(1,2,4-benzotriazin-3-il)-hidrazino]-carbonil}-6metilheptil)-formamida.

MH+ = 361

Ejemplo 84

N-((R)-2-{[N'-[(4-etil-piperazin-1-il)-trifluorometil-pirimidin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

MH+ = 476

Ejemplo 85

N-hidroxi-N-{(R)-2-[N'-(piperazin-1-il-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-formamida.

MH+ = 448

Ejemplo 86

N-{(R)-2-[N'-(7-il-fluoro-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

MH+ = 365

Ejemplo 87

N-hidroxi-N-[(2R)-2-({N'-[4-(4-etil-1-piperazinil)-6-(trifluorometil)-pirimidin-2-il]-hidrazino}-carbonil)-6-metilheptil]-formamida.

MH+ = 490

Ejemplo 88

N-hidroxi-N-[(2R)-6-metil-2-({N'-[4-(piperazin-1-il)-6-(trifluorometil)-pirimidin-2-il]-hidrazino}-carbonil)-heptil]-formamida.

MH+ = 462

Ejemplo 89

N-hidroxi-N-[(2R)-6-metil-2-({N'-[4-(4-metil-piperazin-1-il)-6-(trifluorometil)-pirimidin-2-il]-hidrazino}-carbonil)-heptil]-formamida.

MH+ = 476

Ejemplo 90

N-hidroxi-N-((2R)-2-{[N'-(7-cloro-1,2,4-benzotriazin-3-il)-hidrazino]-carbonil}-6-metilheptil]-formamida.

MH+ = 395

Ejemplo 91

N-hidroxi-N-((2R)-6-metil-2-{[N'-(5-metil-1,2,4-benzotriazin-3-il)-hidrazino]-carbonil}-heptil)-formamida.

MH+ = 375

Ejemplo 92

N-hidroxi-N-((2R)-2-{[N'-(7-fluoro-1,2,4-benzotriazin-3-il)-hidrazino]-carbonil}-6-metilheptil)-formamida.

MH+ = 379

Ejemplo 93

N-hidroxi-N-((2R)-2-{N'-[(2-metoxi-etilamino)-trifluorometil-pirimidin-2-il]-hidrazinocarbonil}-heptil)-formamida.

MH+ = 437

Ejemplo 94

N-hidroxi-N-[(2R)-6-metil-2-({N'-[7-(metiloxi)-1,2,4-benzotriazin-3-il]-hidrazino}-carbonil)-heptil]-formamida.

MH+ = 391

Ejemplo 95

N-hidroxi-N-[(R)-2-(N'-{[4-(2-hidroxi-etil)-piperazin-1-il]-trifluorometil-pirimidin-2-il}-hidrazinocarbonil)-heptil]-formamida.
MH+ = 492

Ejemplo 96

N-hidroxi-N-((R)-2-{N'-[(4-pirimidin-2-il-piperazin-1-il)-trifluorometil-pirimidin-2-il]-hidrazinocarbonil}-heptil)-formamida.
MH+ = 526

Ejemplo 97

N-hidroxi-N-((R)-2-{N'-[(2-hidroxi-etilamino)-trifluorometil-pirimidin-2-il]-hidrazinocarbonil}-heptil)-formamida.
MH+ = 423.

Ejemplo 98

N-hidroxi-N-{(R)-2-{N'-(7-trifluorometil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-formamida.
MH+ = 415.

Ejemplo 99

N-hidroxi-N-{(R)-2-[N'-(6-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-formamida.
MH+ = 361.

Ejemplo 100

N-hidroxi-N-{(2R)-2-(ciclopentilmetil)-3-[N'-(5-metil-1,2,4-benzotriazin-3-il)-hidrazino]-3-oxopropil}-formamida.

MH+ = 373.

Ejemplo 101

N-hidroxi-N-[(2R)-2-({N'-[4-(trifluorometil)-pirimidin-2-il]-hidrazino}-carbonil)-octil]-formamida.

MH+ = 378.

Ejemplo 102

N-hidroxi-N-((2R)-2-{[N'-(1,2,4-benzotriazin-3-il)hidrazino]-carbonil}-octil)-formamida.

MH+ = 361.

Ejemplo 103

N-hidroxi-N-[(2R)-2-({N'-[7-(metiloxi)-1,2,4-benzotriazin-3-il]-hidrazino}-carbonil)-octil]-formamida.

MH+ = 391.

Ejemplo 104

N-hidroxi-N-{(R)-2-[N'-(7-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-formamida.

MH+ = 361.

Ejemplo 105

N-{(R)-2-[N'-(6-cloro-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida .

MH+ = 381.

Ejemplo 106

N-hidroxi-N-{(R)-2-[N'-(5-metoxi-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-formamida.
MH+ = 377

Ejemplo 107

N-hidroxi-N-{(R)-2-[N'-(1-metil-2-oxo-1,2-dihidro-piridin-4-il)-hidrazinocarbonil]-heptil}-formamida.
MH+ = 325

Ejemplo 108

N-hidroxi-N-((R)-2-{N'-[(N'-piridin-2-il-hidrazino)-trifluorometil-pirimidin-2-il]-hidrazinocarbonil}-heptil)-formamida.
MH+ = 471

Ejemplo 109

N-hidroxi-N-{(R)-2-[N'-(4-metil-6-mofolin-4-il-pirimidin-2-il)-hidrazinocarbonil]-heptil}-formamida.
MH+ = 395

Ejemplo 110

N-((R)-2-{N'-[4-(4-etil-piperazin-1-il)-6-metil-pirimidin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

MH+ = 422.

Ejemplo 111

N-{(R)-2-[N'-(4,6-dimetil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.
MH+ = 324

Ejemplo 112

N-hidroxi-N-{(R)-2-[N'-(4-trifluorometil-piridin-2-il)-hidrazinocarbonil]-heptil}-formamida.
MH+ = 363

Ejemplo 113

N-hidroxi-N-[(R)-2-(N'-isoquinolin-1-il)-hidrazinocarbonil)-heptil]-formamida.
MH+ = 345

Ejemplo 114

N-hidroxi-N-[(R)-2-(N'-quinolin-2-il-hidrazinocarbonil)-heptil]-formamida.
MH+ = 345

Ejemplo 115

N-{(R)-2-[N'-(1-benzil-2-oxo-1,2-dihidro-piridin-4-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.
MH+ = 401

Ejemplo 116

N-hidroxi-N-{(R)-2-[N'-(4-oxo-4H-pirido[1,2-a][1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-formamida.
MH+ = 363

Ejemplo 117

N-hidroxi-N-{(R)-2-[N'-(4-metil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-formamida. MH+ = 310

Ejemplo 118

N-{(R)-2-[N'-(1-butil-2-oxo-1,2-dihidro-piridin-4-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.
MH+ = 367

Ejemplo 119

N-hidroxi-N-{(R)-2-[N'-(9-metil-4-oxo-4H-pirido[1,2-a][1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-formamida.
MH+ = 377

Ejemplo 120

N-hidroxi-N-{(R)-2-[N'-(6-oxo-4-trifluorometil-1,6-dihidro-pirimidin-2-il)-hidrazinocarbonil]-heptil}-formamida.
MH+ = 380.

Ejemplo 121

N-hidroxi-N-{(R)-2-[N'-(metil-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-formamida.

MH+ = 378

Ejemplo 122

N-hidroxi-N-{(R)-2-[N'-(5-trifluorometil-piridin-2-il)-hidrazinocarbonil]-heptil}-formamida.
MH+ = 363

Ejemplo 123

N-{(R)-2-[N'-(6-etoxi-piridin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.
MH+ = 339

Ejemplo 124

N-hidroxi-N-[(R)-2-(N'-pirido[2,3-e]-[1,2,4]triazin-3-il-hidrazinocarbonil)-heptil]-formamida.
MH+ = 348

Ejemplo 125

N-((R)-2-{N'-[1-(1-etil-propil)-2-oxo-1,2-dihidro-piridin-4-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.
MH+ = 381

Ejemplo 126

N-hidroxi-N-((R)-2-{N'[2-oxo-1-(3-trifluorometil-bencil)-1,2-dihidro-piridin-4-il]-hidrazinocarbonil}-heptil)-formamida.
MH+ = 469

Ejemplo 127

N-hidroxi-N-{(R)-2-[N'-(4-metil-piridin-2-il)-hidrazinocarbonil]-heptil}-formamida.
MH+ = 309

Ejemplo 128

N-hidroxi-N-{(R)-2-[N'-(6-metoxi-piridin-2-il)-hidrazinocarbonil]-heptil}-formamida.
MH+ = 309

Ejemplo 129

N-hidroxi-N-{(R)-2-[N'-(2-oxo-1-quinolin-8-il-metil-1,2-dihidro-piridin-4-il)-hidrazinocarbonil]-heptil}-formamida.
MH+ = 452

Ejemplo 130

N-hidroxi-N-[(R)-2-(N'-{2-oxo-1-[2-(5,6,7,8-tetrahidro-[1,8]naftiridin-2-il)-etil]-dihidro-piridin-4-il}-hidrazinocarbonil)-heptil]-formamida.
MH+ = 471

Ejemplo 131

N-{(R)-2-[N'-(4,6-bis-etilamino-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.
MH+ = 383

Ejemplo 132

N-{(R)-2-[N'-(bis-dimetilamino-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.
MH+ = 383

Ejemplo 133

N-{(R)-2-[N'-(4,6-di-morfolin-4-il-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.
MH+ = 467

Ejemplo 134

N-hidroxi-N-((R)-2-{N'-[4-(4-metil-piperazin-1-il)-6-propilamino[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-formamida.
MH+ = 452.

Ejemplo 135

N-{(R)-2-[N'-(dimetilamino-morfolin-4-il-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.
MH+ = 425

Ejemplo 136

N-hidroxi-N-{(R)-2-[N'-(6-metil-piridin-2-il)-hidrazinocarbonil]-heptil}-formamida.
MH+ = 309

Ejemplo 137

N-hidroxi-N-((R)-2-{N'-[5-(5-fenill-[1,3,4]oxadiazol-2-il)-piridin-2-il]-hidrazinocarbonil}-heptil)-formamida.

MH+ = 439.

Ejemplo 138

N-{(R)-2-[N'-(7-tertbutil-1,4-dioxo-1,2,3,4-tetrahidro-pirido-[,3,4]piridazin-5-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.
MH+ = 435

Ejemplo 139

N-((R)-2-{N'-[4-etilamino-6-(4-metil-[1,4]-diazepan-1-il)-[1,3,5]-triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.
MH+ = 425

Ejemplo 140

N-((R)-2-{N'-[4-etilamino-6-(4-etil-piperazin-1-il)-[1,3,5]-triazin-2-il]-[1,3,5]-triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.
MH+ = 452

Ejemplo 141

N-hidroxi-N-{(R)-2-[N'-(6-trifluorometil-piridin-2-il)-hidrazinocarbonil]-heptil}-formamida.
MH+ = 363

Ejemplo 142

N-hidroxi-N-{(R)-2-[N'-(4-metil-6-morfolin-4-ilmetil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-formamida.
MH+ = 409

Ejemplo 143

N-hidroxi-N-{(R)-2-[N'-(4-metil-6-morfolin-4-il-[1,2,5]triazin-2-il)-hidrazinocarbonil]-heptil}-formamida.

MH+ = 396

Ejemplo 144

N-hidroxi-N-{(2R)-2-(ciclopentilmetil-3-[N'1,(4,6-dimetil-2-pirimidinil)-hidrazino]-3-oxopropil}-formamida.

MH+ = 336

Ejemplo 145

N-hidroxi-N-{(R)-2-[N'-(4-metil-6-pirrolidin-1-il-metil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-formamida.

MH+ = 393

Ejemplo 146

N-{(R)-2-[N'-(4-dimetilaminometil-6-metil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

MH+ = 367

Ejemplo 147

N-hidroxi-N-((R)-2-{N'-[4-metil-6-(4-metil-piperazin-1-il-metil)-pirimidin-2-il]-hidrazinocarbonil}-heptil)-formamida.

MH+ = 422

Ejemplo 148

N-hidroxi-N-{(R)-2-[N'-(5-metil-piridin-2-il)-hidrazinocarbonil]-heptil}-formamida. MH+ = 309

Ejemplo 149

N-((R)-2-{N'-[dimetilamino(4-metil-[1,4]diazepan-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil}heptil)-N-hidroxi-formamida.

MH+ = 452.

Ejemplo 150

N-hidroxi-N-{(R)-2-[N'-(4-metil-6-pirrolidin-1-il-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-formamida.

MH+ = 380

Ejemplo 151

N-hidroxi-N-((R)-2-{N'-[4-metil-6-)4-pirrolidin-1-il-piperidin-1-il[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-formamida.

MH+ = 463

Ejemplo 152

N-((R)-2-{N'-[etil-amino)-metil-[1,3,5]triazin-2-il]-hidrazinocarbonil}heptil)-N-hidroxi-formamida.

MH+ = 368.

Ejemplo 153

N-((R)-2-{N'-[(4-etil-piperazin-1-il)-6-metil-[1,3,5]triazin-2-il]-hidrazinocarbonil}heptil)-N-hidroxi-formamida.

MH+ = 423

Ejemplo 154

N-hidroxi-N-[(2R)-7,7,7-trifluoro-2-({N'-[4-(trifluorometil)4-pirimidin-2-il]-hidrazino}-carbonil)-heptil]-formamida.

MH+ = 418

Ejemplo 155

N-hidroxi-N-((2R)-7,7,7-trifluoro-2-{[N'-(5-metil-1,2,4-benzotriazin-3-il)-hidrazino}-carbonil}-heptil)-formamida.

MH+ = 415

Ejemplo 156

N-hidroxi-N-((2R)-7,7,7-trifluoro-2-{[N'-(7-metil-1,2,4-benzotriazin-3-il)-hidrazino]-carbonil}-heptil)-formamida.

MH+ = 415

Ejemplo 157

N-hidroxi-N-{(R)-2-[N'-(4-metilamino-6-morfolin-4-il-[1,3,5]-2-il)-hidrazinocarbonil]-heptil}-formamida.

MH+ = 411

Ejemplo 158

**N-((R)-2-{N'-[4-(4-etil-piperazin-1-il)-6-metilamino-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.**

MH+ = 438.

**Ejemplo 159**

**N-{(R)-2-[N'-(4-etilamino-6-morfolin-4-il-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 425.

**Ejemplo 160**

**N-hidroxi-N-{(R)-2-[N'-(4,6,7-trimetil-7,8-dihidro-pterin-2-il)-hidrazinocarbonil]-heptil}-formamida.**

MH+ = 392.

**Ejemplo 161**

**N-hidroxi-N-{(R)-2-[N'-(4,6,7-trimetil-pteridin-2-il)-hidrazinocarbonil]-heptil}-formamida.**

MH+ = 390.

**Ejemplo 162**

**N-hidroxi-N-{(R)-2-[N'-(metoximetoximetil-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-formamida.**

MH+ = 438.

**Ejemplo 163**

**N-hidroxi-N-((R)-2-{N'-[4-metil-6-1-piperidin-1-il-metanoil)-pirimidin-2-il]-hidrazinocarbonil}-heptil)-formamida.**

MH+ = 421.

**Ejemplo 164**

**Ciclopropilamida del ácido 2-(N'-{(R)-2-[(formil-hidroxi-amino)-metil]-heptanoil}-hidrazino)-6-mtil-pirimidina-4-carboxílico.**

MH+ = 393.

**Ejemplo 165**

**Diisopropilamida del ácido 2-(N'-{(R)-2-[(formil-hidroxi-amino)-metil]-heptanoil}-hidrazino)-6-metil-pirimidina-4-carboxílico.**

MH+ = 437.

**Ejemplo 166**

**N-{(R)-2-[N'-(5-ciano-piridin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 320.

**Ejemplo 167**

**N-{(R)-2-[N'-(4,6-dietil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 353.

**Ejemplo 168**

**N-{(R)-4-ciclopentil-2-[N'-(4-trifluorometil-piridimin-2-il)-hidrazinocarbonil]-butil}-N-hidroxi-formamida.**

MH+ = 390.

**Ejemplo 169**

**N-{(R)-4-ciclopentil-2-[N'-(7-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-butil}-N-hidroxi-formamida.**

MH+ = 387.

**Ejemplo 170**

**N-{(R)-4-ciclopentil-2-[N'-(5-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-butil}-N-hidroxi-formamida.**

MH+ = 387.

**Ejemplo 171**

**N-hidroxi-N-((R)-2-{N'-[6-(4-metil-piperazin-1-il-metil)-piridin-2-il]-hidrazinocarbonil}-heptil)-formamida.**

MH+ = 407.

**Ejemplo 172**

**N((R)-2-{N'-[5-(4,6-dimetoxi-pirimidin-2-il)-piridin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.**

**Ejemplo 173**

**N-{(R)-2-[N'-(dietilamino-metil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 382.

**Ejemplo 174**

**N-hidroxi-N-[(R)-2-(N'-{[(2-metoxi-etil)-metil-amino]-metil-[1,3,5]-triazin-2-il}-hidrazinocarbonil)-heptil]-formamida.**

MH+ = 397.

**Ejemplo 175**

**N((R)-1-{N'-[4-(2,6-dimetil-mofolin-4-il)-6-metil-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.**

MH+ = 424.

**Ejemplo 176**

**N-{(R)-2-[N'-(5-fluoro-4-metil-6-morfolin-4-il-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 413.

**Ejemplo 177**

**N-{(R)-2-[N'-(4-etil-6-morfolin-4-il-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 410.

**Ejemplo 178**

**N-{(R)-2-[N'-(etil-metil-amino)-[1,3,5]-triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 382.

**Ejemplo 179**

**N((R)-2-{N'-[4-etil-6-(4-etil-piperazin-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.**

MH+ = 437.

**Ejemplo 180**

**N-((R)-2-{N'-[5-fluoro-4-metil-6-(4-metil-piperazin-1-il)-pirimidin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.**

MH+ = 426.

**Ejemplo 181**

**N-{(R)-2-[N'-(dimetilamino-etil-[1,3,5]-triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 368.

**Ejemplo 182**

**N-((R)-2-{N'-[5-fluoro-4-metil-6-(4-metil-[1,4]-diazepan-1-il)-pirimidin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.**

MH+ = 440.

**Ejemplo 183**

**N-{(R)-4-ciclopentil-2-[N'-(morfolin-4-il-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-butil}-N-hidroxi-formamida.**

MH+ = 475.

250

**Ejemplo 184**

**N-[(R)-2-(N'-{etil-[(2-metoxi-etil)-metil-amino]-[1,3,5]triazin-2-il}-hidrazinocarbonil]-heptil]-N-hidroxi-formamida.**

MH+ = 412.

**Ejemplo 185**

**N-{(R)-2-[N'-(dimetilamino-metil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 353.

**Ejemplo 186**

**N-{(R)-2-[N'-(4-ciclopropilamino-6-metil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 365.

**Ejemplo 187**

**N-{(R)-2-ciclohexil-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-etil}-N-hidroxi-formamida.**

MH+ = 376.

**Ejemplo 188**

**N-{(R)-2-ciclohexil-2-[N'-(7-metoxi-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-etil}-N-hidroxi-formamida.**

MH+ = 389.

**Ejemplo 189**

**N-{(R)-2-ciclohexil-2-[N'-(5-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-etil}-N-hidroxi-formamida.**

MH+ = 373.

**Ejemplo 190**

**N-{(R)-4,4-dimetil-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-pentil}-N-hidroxi-formamida.**

MH+ 364.

**Ejemplo 191**

**N-{(R)-4,4-dimetil-2-[N'-(7-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-pentil}-N-hidroxi-formamida.**

MH+ = 361.

**Ejemplo 192**

**N-{(R)-4,4-dimetil-2-[N'-(5-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-pentil}-N-hidroxi-formamida.**

MH+ = 361.

**Ejemplo 193**

**N-{(R)-4,4-dimetil-2-[N'-(morfolin-4-il-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-pentil}-N-hidroxi-formamida.**

MH+ = 449.

**Ejemplo 194**

**N-(R)-2-{N'-[etil-(metil-piridin-2-il-amino)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.**

MH+ = 431.

**Ejemplo 195**

**N-{(R)-2-[N'-(4-ciclopropilamino-6-etil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 380.

**Ejemplo 196**

**N-hidroxi-N-[(R)-2-[N'-(5-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-3-(1-metil-ciclopentil)-propil]-formamida.**

MH+ = 387.

**Ejemplo 197**

**N-hidroxi-N-[(R)-2-[N'-(7-metoxi-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-3-(1-metil-ciclopentil)-propil]-formamida.**

MH+ = 403

**Ejemplo 198**

**N-hidroxi-N-{(R)-3-(1-metil-ciclopentil)-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-propil}-formamida.**

MH+ = 390.

**Ejemplo 199**

**N-hidroxi-N-{(R)-2-[N'-(4-isopropil-6-morfolin-4-il-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-formamida.**

MH+ = 424.

**Ejemplo 200**

**N-hidroxi-N-{(2R)-2(R)-2—(ciclopentilmetil)-3-[N'-(4-metil-2-pirimidinil)-hidrazino]-3-oxopropil}-formamida.**

MH+ = 322.

**Ejemplo 201**

**N-hidroxi-N-[(2R)-6,6,6-trifluoro-2-({N'-[4-(trifluorometil)-pirimidin-2-il]-hidrazino}-carbonil)-hexil}]-formamida.**

MH+ = 404.

**Ejemplo 202**

**N-{(R)-2-[N'-(5,7-dimetil-benzo[1,2,,4]triazin-3-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 375.

**Ejemplo 203**

**N-{(R)-2-[N'-(3,6-dimetil-pirazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 324.

**Ejemplo 204**

**N-((R)-2-{N'-[4-(4-etil-piperazina-1-il)-6-isopropil-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.**

MH+ = 451

**Ejemplo 205**

**N-{(R)-2-{N'-(4-dimetilamino-6-isopropil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

**MH+ = 382**

**Ejemplo 206**

**N-hidroxi-N-{(R)-2-[N'-[4-(metil-trifluorometil-piridin-2-il)-hidrazinocarbonil]-heptil}-formamida.**

MH+ = 377

**Ejemplo 207**

**2-(N-{(R)-2-[(4-formil-hidroxi-amino)-metil]-heptanoil}-hidrazino)-6,N,N-trimetil-isonicotinamida.**

**MH+ = 380**

**Ejemplo 208**

**N-hidroxi-N[(2R)-2-({N'-[3-amino-6-(trifluorometil)-piridin-2-il]-hidrazino}-carbonil)-heptil]-formamida.**

MH+ = 378

**Ejemplo 209**

**N-hidroxi-N-[(R)-2-(N'-{4-isopropil-6-[(2-metoxi-etil)-metil-amino]-[1,3,5]triazin-2-il}-hidrazinocarbonil)-heptil]-formamida.**

MH+ = 426

**Ejemplo 210**

**N-{(R)-3-ciclopentil-2-[N'-(4-etil-6-morfolin-4-il-[1,3,5]triazin-2-il)-hidrazinocarbonil]-propil}-N-hidroxi-formamida.**

MH+ = 422

**Ejemplo 211**

**N-hidroxi-N-{(R)-2-[N'-(4-morfolin-4-il-6-propil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-formamida.**

MH+ = 424.

**Ejemplo 212**

**N-((R)-2-{N'-[4-(4-etil-piperazin-1-il-6-propil-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.**

MH+ = 451.

**Ejemplo 213**

**N-{(R)-5,5-dimetil-2-[N'(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.**

MH+ = 378.

**Ejemplo 214**

**N-{(R)-5,5-dimetil-2-[N'-(7-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.**

MH+ = 375.

**Ejemplo 215**

**N-{(R)-5,5-dimetil-2-[N'-(5-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.**

MH+ = 375.

**Ejemplo 216**

**N-{(R)-5,5-dimetil-2-[N'-(morfolin-4-il-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.**

MH+ = 463.

**Ejemplo 217**

**N-{(R)-4-etil-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.**

MH+ = 378.

**Ejemplo 218**

**N-{(R)-4-etil-2-[N'-(7-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.**

MH+ = 375.

**Ejemplo 219**

**N-{(R)-4-Etil-2-[N'-(morfolin-4-il-trifluorometil-pirimidin-2-il)hidrazinocarbonil]-hexil}-N-hidroxi-formamida.**

MH+ = 463.

**Ejemplo 220**

**N-((R)-3-ciclopentil-2-{N'-[4-etil-6-(4-etil-piperazin-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-propil)-N-hidroxi-formamida.**

MH+ = 449.

**Ejemplo 221**

**N-{(R)-3-ciclopentil-2-[N'-(4-ciclopropilamino-6-etil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-propil}-N-hidroxi-formamida.**

MH+ = 392.

**Ejemplo 222**

**N-{(R)-4-etil-2-[N'-(5-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.**

MH+ = 375

**Ejemplo 223**

**N-hidroxi-N-[(R)-2-(N'-{[(2-metoxi-etil)-metil-amino]-propil-[1,3,5]triazin-2-il}-hidrazinocarbonil)-heptil]-formamida.**

MH+ = 426.

**Ejemplo 224**

**N-{(R)-2-[N'-(dimetilamino-propil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 382.

**Ejemplo 225**

**N-{(R)-2-[N'-(4-etil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 324.

**Ejemplo 226**

**N-hidroxi-N-{(R)-2-[N'-(4-isopropil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-formamida.**

MH+ = 338.

**Ejemplo 227**

**N-{(R)-2-[N'-(4-ciclopropil-6-morfolin-4-il-[1,3,5-]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 422.

**Ejemplo 228**

**N-hidroxi-N-[(2R)-2-({N'-[4-(piridin-2-il)-pirimidin-2-il]-hidrazino}-carbonil)-heptil]-formamida.**

**MH+ = 373.**

**Ejemplo 229**

**N-(R)-2-{N'-[4-ciclopropil-6-(4-etil-piperazin-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil}heptil)-N-hidroxi-formamida.**

MH+ = 449.

**Ejemplo 230**

**N-{(R)-2-[N'-(ciclopropil-dimetilamino-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 380.

**Ejemplo 231**

**N-{(R)-2-[N'-(ciclopropil-(etil-metil-amino)-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 380.

**Ejemplo 232**

**N-{(R)-2-[N'-(ciclopropil-6-pirrolidin-1-il[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 406.

**Ejemplo 233**

**N-{(R)-2-[N'-(4,6-diciclopropil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 377.

**Ejemplo 234**

**N-hidroxi-N-[(R)-2[N'-(5-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-3-(2-metil-ciclopentil)-propil]-formamida.**

MH+ = 387.

**Ejemplo 235**

**N-{(R)-2-[N'(dimetilamino-etil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-3-(2-metil-ciclopentil)-propil]-N-hidroxi-formamida.**

MH+ = 394.

**Ejemplo 236**

**N-hidroxi-N-[(R)-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-3-(2-metil-ciclopentil)-propil]-formamida.**

MH+ = 390.

**Ejemplo 237**

**N-{(R)-2-[N'-(5-etil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 324.

**Ejemplo 238**

**N-hidroxi-N-{(2R)-2-(ciclopentilmetil)-3-[N'-(7-metil-1,2,4-benzotriazin-3-il)-hidrazino]-3-oxopropil}-formamida.**

MH+ = 373.

**Ejemplo 239**

**N-hidroxi-N-[(2R)-2-(ciclopentilmetil)-3-(N'-{4-etil-6-[etil(metil)amino]-1,3,5-triazin-2-il}-hidrazino)-3-oxopropil]-formamida.**

MH+ = 394.

**Ejemplo 240**

**N-hidroxi-N-((2R)-2-(ciclopentilmetil)-3-(N'-[4-(dimetilamino)-6-etil-1,3,5-triazin-2-il]-hidrazino}-3-oxopropil)-formamida.**

MH+ = 380.

**Ejemplo 241**

**N-((R)-2-{N'-[4-etil-6-(4-isopropil-piperazin-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.**

MH+ = 451.

**Ejemplo 242**

**N-hidroxi-N-[(2R)-3-[N'-(6-cloro-1,2,4-benzotriazin-3-il)-hidrazino]-2-(ciclopentilmetil)-3-oxopropil]-formamida.**

MH+ = 393.

**Ejemplo 243**

**N-{(R)-4,4-dimetil-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.**

MH+ = 378.

**Ejemplo 244**

**N-{(R)-4,4-dimetil-2-[N'-(7-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.**

MH+ = 375.

**Ejemplo 245**

**N-{(R)-4,4-dimetil-2[N'-(5-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.**

MH+ = 375.

**Ejemplo 246**

**N-{(R)-4,4-dimetil-2-[N'-(morfolin-4-il-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.**

MH+ = 463.

**Ejemplo 247**

**N-hidroxi-N-{(R)-2-[N'-(5-fenil-[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-formamida.**

MH+ = 373.

**Ejemplo 248**

**N-{(R)-2-[N'-(4-etil-6-morfolin-4-il-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 409.

**Ejemplo 249**

**N-((R)-2-[N'-[4-etil-6-(4-metil-piperazin-1-il)-pirimidin-2-il]-hidrazinocarbonil}heptil)-N-hidroxi-formamida.**

MH+ = 422.

**Ejemplo 250**

**N-{(R)-2-[N'-(5-etil-4-metil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 338.

**Ejemplo 251**

**N-((R)-2-{N'-[4-etil-6-(4-propil-piperazin-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.**

MH+ = 451.

261

**Ejemplo 252**

**N-hidroxi-N-((R)-2-{N'-[6-(4-pirimidin-2-il-piperazin-1-il-metil)-piridin-2-il]-hidrazinocarbonil}-heptil)-formamida.**

MH+ = 471.

**Ejemplo 253**

**N-hidroxi-N-((R)-2-{N'-[6-(3-[1,2,4]triazol-1-il-metil-[1,2,4]-triazol-1-il)-piridin-2-il]-hidrazinocarbonil}-heptil)-formamida.**

MH+ = 443.

**Ejemplo 254**

**N-{(R)-3-biciclo[2.2.1]hept-7-il-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-propil}-N-hidroxi-formamida.**

MH+ = 402.

**Ejemplo 255**

**N-{(R)-3-biciclo[2.2.1]hept-7-il-2-[N'-(morfolin-4-il-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-propil}-N-hidroxi-formamida.**

MH+ = 487

**Ejemplo 256**

**N-hidroxi-N-[(R)-2-(N'-piridin-3-il-hidrazinocarbonil)-heptil]-formamida.**

MH+ = 295.

**Ejemplo 257**

**Yoduro de 4-{4-etil-6-[2-((2R)-2-{[formil(hidroxi)amino]-metil}-heptanoil)-hidrazino]-1,3,5-triazin-2-il}-1-metil-1-propilpiperazin-1-io.**

MH+ = 465.

**Ejemplo 258**

**N-{(R)-3-biciclo[2.2.1]hept-7-il-2-[N'-(5-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-propil}-N-hidroxi-formamida.**

MH+ = 399.

**Ejemplo 259**

**N-{(R)-2-[N'-(4-azetidin-1-il-6-etil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 380.

**Ejemplo 260**

**N-{(R)-2-ciclopentil-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-etil}-N-hidroxi-formamida.**

MH+ = 362.

**Ejemplo 261**

**N-{(R)-2-ciclopentil-2-[N'-(morfolin-4-il-4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-etil}-N-hidroxi-formamida.**

MH+ = 447.

**Ejemplo 262**

**N-{(R)-2-ciclopentil-2-[N'-(4-metil-piridin-2-il)-hidrazinocarbonil]-etil}-N-hidroxi-formamida.**

MH+ = 307.

**Ejemplo 263**

**N-{(R)-2-ciclopentil-2-[N'-(dimetilamino-etil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-etil}-N-hidroxi-formamida.**

MH+ = 366.

**Ejemplo 264**

**N-{(R)-2-ciclopentil-2-[N'-(7-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-etil}-N-hidroxi-formamida.**

MH+ = 359.

**Ejemplo 265**

**N-{(R)-2-ciclopentil-2-[N'-(5-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-etil}-N-hidroxi-formamida.**

MH+ = 359.

**Ejemplo 266**

**N-hidroxi-N-{(R)-2-[N'-(5-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-2-(4-metil-ciclohexil)-etil}-formamida.**

MH+ = 387.

**Ejemplo 267**

**N-hidroxi-N-{(R)-2-[N'-(7-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarboni]-2-(4-metil-ciclohexil)-etil}-formamida.**

MH+ = 387.

**Ejemplo 268**

**N-hidroxi-N-{(R)-2-(4-metil-ciclohexil)-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-etil}-formamida.**

MH+ = 390.

**Ejemplo 269**

**N-hidroxi-N-{(R)-2-(4-metil-ciclohexil)-2-[N'-(morfolin-4-il-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-etil}-formamida.**

**Ejemplo 270**

**N-hidroxi-N-{(R)-2-(4-metil-ciclohexil)-2-[N'-(4-metil-piridin-2-il)-hidrazinocarbonil]-etil}-formamida.**

MH+ = 335.

**Ejemplo 271**

**N-{(R)-2-[N'-(dimetilamino-etil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-2-(4-metil-ciclohexil)-etil}-N-hidroxi-formamida.**

MH+ = 394.

**Ejemplo 272**

**N-{(R)-2-[N'-(6,7-dihidro-5-H-ciclopentapirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 336.

**Ejemplo 273**

**N-((R)-2-[N'-[4-etil-6-((S)-2-hidroximetil-pirrolidin-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil]-heptil)-N-hidroxi-formamida.**

MH+ = 424.

**Ejemplo 274**

**N-{(R)-2-[N'-(dimetilamino-piridin-3-il-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 416.

**Ejemplo 275**

**N-{(R)-2-[N'-(dimetilamino-piridin-4-il-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 416.

**Ejemplo 276**

**N-hidroxi-N-{(R)-2-N'-(5,6,7,8-tetrahidro-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-formamida.**

MH+ = 351

**Ejemplo 277**

**N-{(R)-2-[N'-(5,6-dietil-[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 353.

**Ejemplo 278**

**N-hidroxi-N-{(R)-2-[N'-[5-(4-hidroxi-fenil)-[1,2,4]triazin-3-il]-hidrazinocarbonil)}-heptil)-formamida.**

MH+ = 389.

**Ejemplo 279**

**N-[(R)-2-(N'-{[2-dimetilamino-etil)-etil)-metil-amino]-etil-[1,3,5]triazin-2-il}-hidrazinocarbonil)-heptil]-N-hidroxi-formamida.**

MH+ = 425.

**Ejemplo 280**

**N-{(R)-2-[N'-(2-dimetilamino-quinazolin-4-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 389.

**Ejemplo 281**

**N-hidroxi-N-{(R)-2-[N'-(3-metanosulfonil-4,6-dimetil-piridin-2-il)-hidrazinocarbonil]-heptil}-formamida.**

MH+ = 401.

**Ejemplo 282**

**N-((R)-2-{N'-[4-etil-6-(3-hidroxi-piperidin-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.**

MH+ = 424.

**Ejemplo 283**

**N[(R)-2-(N'-[4,5']bipirimidinil-2-il-hidrazinocarbonil)-heptil]-N-hidroxi-formamida.**

MH+ = 384.

**Ejemplo 284**

**N(-((R)-2-{N'-[ciclopropil.metil-amino)-etil-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.**

MH+ = 394.

**Ejemplo 285**

**N-((R)-2-{(N'-[4-etil-6-((R)-3-hidroxi-pirrolidin-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.**

MH+ = 410.

**Ejemplo 286**

**N-hidroxi-N-[(R)-2-(N'-[3,3']bipiridinil-5-il-hidrazinocarbonil)-heptil]-formamida.**

MH+= 372.

**Ejemplo 287**

**N-hidroxi-N-[(R)-2-(N'-(5-morfolin-4-il-piridin-3-il)-hidrazinocarbonil)-heptil]-formamida.**

MH+ = 380

**Ejemplo 288**

**N-hidroxi-N-{(R)-2-[N'-(4-piridin-3-il-pirimidin-2-il)-hidrazinocarbonil]-heptil}-formamida.**

MH+ = 373.

**Ejemplo 289**

**N-hidroxi-N-{(R)-2-[N'-(5,6,7,8-tetrahidro-quinazolin-2-il)-hidrazinocarbonil]-heptil}-formamida.**

MH+ = 350.

**Ejemplo 290**

**N-[(R)-2-(N'-{[ciclopropil-1-(1-meil-piperidin-4-il)-amino]-etil-[1,3,5]triazin-2-il}-hidrazinocarbonil)-heptil]-N-hidroxi-formamida.**

MH+ = 477

**Ejemplo 291**

**N-((R)-2-[N'-[4-((R)-3-dimetilamino-pirrolidin-1-il)-6-etil-[1,3,5]triazin-2-il]-hidrazinocarbonil]-heptil)-N-hidroxi-formamida.**

MH+ = 437.

**Ejemplo 292**

**N-hidroxi-N-[(R)-2-(N'-[5-(1H-pirrol-2-il)-piridin-3-il]-hidrazinocarbonil)-heptil]-formamida.**

MH+ = 360.

**Ejemplo 293**

**N-hidroxi-N-[(R)-2-(N'-[4-metil-piperazin-1-il-)-trifluorometil-pirimidin-4-il]-hidrazinocarbonil)-heptil]-formamida.**

MH+ = 462.

**Ejemplo 294**

**N-hidroxi-N-[(R)-2-(N'-(5-Furan-3-il-piridin-3-il)-hidrazinocarbonil)-heptil]formamida.**

MH+ = 361.

**Ejemplo 295**

**N-{(R)-5,5-dimetil-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 392.

**Ejemplo 296**

**N-{(R)-5,5-dimetil-2-[N'-(7-,etil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 389.

**Ejemplo 297**

**N-{(R)-5,5-dimetil-2-(4-metil-piridin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 337.

**Ejemplo 298**

**N-{(R)-2-cicloheptil-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-etil}-N-hidroxi-formamida.**

MH+ = 390.

**Ejemplo 299**

**N-{(R)-2-cicloheptil-2-[N'-(4-metil-piridin-2-il)-hidrazinocarbonil]-etil}-N-hidroxi-formamida.**

MH+ = 335.

**Ejemplo 300**

**N-{(R)-2-cicloheptil-2-[N'-(dimetilamino-etil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-etil}-N-hidroxi-formamida.**

MH+ = 394.

**Ejemplo 301**

**N-{(R)-2-cicloheptil-2-[N'-(7-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-etil}-N-hidroxi-formamida.**

MH+ = 387.

**Ejemplo 302**

**N-((R)-2{N'-[4-etil-6-(4-hidroxi-piperidin-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.**

MH+ = 424.

**Ejemplo 303**

**N-{(R)-5,5-dimetil-2-[N'-(5-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 389.

**Ejemplo 304**

**N-{(R)-2-[N'-(4-dimetilamino-quinazolin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 389.

**Ejemplo 305**

**N-hidroxi-N-{(R)-2-[N'-(4-piridin-4-il-pirimidin-2-il)-hidrazinocarbonil]-heptil}-formamida.**

MH+ = 373.

**Ejemplo 306**

**N-hidroxi-N-((R)-2-{N'-[4-(3-hidroximetil-fenil)-pirimidin-2-il]-hidrazinocarbonil}-heptil)-formamida.**

MH+ = 402.

**Ejemplo 307**

**N-hidroxi-N-((R)-2-{N'-[4-(4-hidroximetil-fenil)-pirimidin-2-il]-hidrazinocarbonil}-heptil)-formamida.**

MH+ = 402.

**Ejemplo 308**

**N-((R)-2-{N'-[4-etil-6-(3-metoxi-piperidin-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.**

MH+ = 438.

**Ejemplo 309**

**N-hidroxi-N-{(R)-2-[N'-(7-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-2-(4-metil-ciclohexil)-etil}-formamida.**

MH+ = 387.

**Ejemplo 310**

**N-[(R)-2-{N'-[etil-(etil-metilamino)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-2-(4-metil-ciclohexil)-etil}-N-hidroxi-formamida.**

MH+ = 408.

**Ejemplo 311**

**N-[(R)-2-{N'-[etil-(etil-metilamino)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-2-(4-metil-ciclohexil)-etil}-N-hidroxi-formamida.**

MH+ = 408.

**Ejemplo 312**

**N-hidroxi-N-{(R)-2-[N'-(7-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-2-(4-metil-ciclohexil)-etil}-formamida.**

MH+ = 387.

**Ejemplo 313**

**N-((R)-2-{N'-[4-(2,6-dimetoxi-fenil)-pirimidin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.**

MH+ = 432.

**Ejemplo 314**

**N-((R)-2-{N'-[4-etil-6-((R)-3-metoxi-pirrolidin-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.**

MH+ = 424.

**Ejemplo 315**

**N-((R)-2-{N'-[4-etil-6-(4-metoxi-piperidin-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.**

MH+ = 438.

**Ejemplo 316**

**N-hidroxi-N-[(R)-2-(N'-(6-pirrolidin-1-il-pirimidin-4-il)-hidrazinocarbonil)-heptil]-formamida.**

MH+ = 365.

**Ejemplo 317**

**N-hidroxi-N-[(R)-2-(N'-[6-(4-metil-piperazin-1-il)-pirimidin-4-il])-hidrazinocarbonil)-heptil]-formamida.**

MH+ = 394.

**Ejemplo 318**

**N-{(R)-2-[N'-(6-dimetilamino-pirimidin-4-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 339.

**Ejemplo 319**

**N-{(R)-2-[N'-(piridin-4-il-trifluorometil-pirimidin-4-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 441.

**Ejemplo 320**

**N-{(R)-2-[N'-(piridin-3-il-trifluorometil-pirimidin-4-il)-hidrazinocarbonil]-heptil}N-hidroxi-formamida.**

MH+ = 441.

**Ejemplo 321**

**N-{(R)-2-[N'-(2-etilamino-6-trifluorometil-pirimidin-4-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 407.

**Ejemplo 322**

**N-hidroxi-N-((R)-2-{N'-[5-(4-metoxi-fenil)-[1,2,4]triazin-3-il]-hidrazinocarbonil}-heptil)-formamida.**

MH+ = 403.

**Ejemplo 323**

**N-hidroxi-N-((R)-2-{N'-[4-(2,3,4-trimetoxi-fenil)-pirimidin-2-il]-hidrazinocarbonil}-heptil)-formamida.**

MH+ = 462.

**Ejemplo 324**

**N-{(R)-4,4-dimetil-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 392.

**Ejemplo 325**

**N-{(R)-4,4-dimetil-2-[N'-(7-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 389.

**Ejemplo 326**

**N-{(R)-4,4-dimetil-2-[N'-(5-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 389.

**Ejemplo 327**

**N-{(R)-4,4-dimetil-2-[N'-(4-metil-piridin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 337.

**Ejemplo 328**

**N-hidroxi-N-{(R)-2-[N'-(6.morfolin-4-il-pirimidin-4-il)-hidrazinocarbonil]-heptil}formamida.**

MH+ = 381.

**Ejemplo 329**

**N-hidroxi-N-[(R)-2-(N'-{5-[4-(2-hidroxi-etoxi)-fenil]-[1,2,4]triazin-3-il}-hidrazinocarbonil)-heptil]-formamida.**

MH+ = 433.

**Ejemplo 330**

**N-{(R)-2-[N'-(4-furan-2-il-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 362.

**Ejemplo 331**

**N-((R)-2-{N'-[4-(3,5-dimetil-isoxazol-4-il)-pirimidin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.**

MH+ = 391.

**Ejemplo 332**

**N-hidroxi-N-{(R)-2-[N'-(4-metil-1-oxi-piridin-2-il)-hidrazinocarbonil]-heptil}-formamida.**

MH+ = 325.

**Ejemplo 333**

**Acido 2-(N'-{(R)-2-[(formil-hidroxi-amino)-metil]-heptanoil}-hidrazino)-6-metil-nicotínico.**

MH+ = 353.

**Ejemplo 334**

**N-hidroxi-N-{(R)-2-[N'-(3-metoxi-piridin-2-il)-hidrazinocarbonil]-heptil}-formamida.**

MH+ = 325.

**Ejemplo 335**

**N-hidroxi-N-{(2R)-2-[(N'-{4-[4-(metilsulfonil)fenil]-pirimidin-2-il}-hidrazino)-carbonil]-heptil}-formamida.**

MH+ = 450.

**Ejemplo 336**

**N-hidroxi-N-[(2R)-2-({N'-[4-(furan-3-il)-pirimidin-2-il]-hidrazino}-carbonil)-heptil]-formamida.**

MH+ = 362.

**Ejemplo 337**

**N[(2R)-2-({N'-[4-(2-aminofenil)-pirimidin-2-il]-hidrazino}-carbonil)-heptil]-N-hidroxi-formamida.**

MH+ = 387.

**Ejemplo 338**

**N-hidroxi-N-[(2R)-({N'-[5-(5-metil-1,3,4-oxadiazol-2-il)-4-(trifluorometil)-pirimidin-2-il]-hidrazino}-carbonil)-heptil]-formamida.**

MH+ = 446.

**Ejemplo 339**

**N-hidroxi-N-((2R)-2-(ciclopentilmetil)-3-{N'-[5-(5-metil-1,3,4-oxadiazol-2-il)-4-(trifluorometil)-pirimidin-2-il]-hidrazino}-3-oxopropil)-formamida.**

MH+ = 458.

**Ejemplo 340**

**N-[(2R)-2-({N'-[6-(dimetilamino)-2-metil-pirimidin-4-il]-hidrazino}-carbonil)-heptil]-N-hidroxi-formamida.**

MH+ = 353.

**Ejemplo 341**

**N-[(2R)-2-({N'-[2-ciclopropil-6-(dimetilamino)-pirimidin-4-il]-hidrazino}-carbonil)-heptil]-N-hidroxi-formamida.**

MH+ = 379.

**Ejemplo 342**

**N-hidroxi-N-[(2R)-4-(2-tienil)-2-({N'-[4-(trifluorometil)-pirimidin-2-il]-hidrazino}-carbonil)-butil]-formamida.**

MH+ = 404.

**Ejemplo 343**

**N-hidroxi-N-[(2R)-2-{[N'-(4-metil-pirimidin-2-il)hidrazino]carbonil}-4-(2-tienil)-butil]-formamida.**

MH+ = 350.

**Ejemplo 344**

**N-[(2R)-2-[(N'-{4-etil-6-[etil(metil)amino]-1,3,5-triazin-2-il}-hidrazino)-carbonil]-4-(2-tienil)butil]-N-hidroxi-formamida.**

MH+ = 422.

**Ejemplo 345**

**N-hidroxi-N-((2R)-3-oxo-2-(2-tienilmetil)-3-{N'-[4-(trifluorometil)-pirimidin-2-il]-hidrazino}-propil)-formamida.**

Mh+ = 390.

**Ejemplo 346**

**N-hidroxi-N-[(2R)-3-[N'-(4-metil-pirimidin-2-il)hidrazino]-3-oxo-2-(2-tienilmetil)-propil]-formamida.**

MH+ = 336.

**Ejemplo 347**

**N-[(2R)-3-(N'-{4-etil-6-[etil(metil)amino]-1,3,5-triazin-2-il}hidrazino)-3-oxo-2-(2-tienilmetil)-propil]-N-hidroxi-formamida.**

MH+ = 408.

**Ejemplo 348**

**N-Hidroxi-N-[(2R)-2-({N'-[2-metil-6-(piridin-2-il)-pirimidin-4-il]-hidrazino}-carbonil)-heptil]-formamida.**

MH+ = 387.

**Ejemplo 349**

**N-hidroxi-N-[(2R)-2-({N'-[6-(piridin-2-il-metil)-piridazin-3-il]-hidrazino}-carbonil)-heptil]-formamida.**

MH+ = 387.

**Ejemplo 350**

**N-hidroxi-N-[(2R)-2-({N'-[2-metil-6-(morfolin-4-il)-pirimidin-4-il]-hidrazino}-carbonil)-heptil]-formamida.**

MH+ = 395.

**Ejemplo 351**

**N-hidroxi-N-[(2R)-2-({N'-[6-(morfolin-4-il)-2-(trifluorometil)-pirimidin-4-il]-hidrazino}-carbonil)-heptil]-formamida.**

MH+ = 449.

**Ejemplo 352**

**N-hidroxi-N-{(2R)-2-[(N'-{4-[metil-(piridin-2-il)-amino]-pirimidin-2-il}-hidrazino)-carbonil]-heptil}-formamida.**

MH+ = 402.

**Ejemplo 353**

**N-hidroxi-N-((2R)-2-(ciclopentilmetil)-3-{N'-[4-ciclopropil-6-(dimetilamino)-1,3,5-triazin-2-il]-hidrazino}-3-oxopropil)-formamida.**

MH+ = 392.

**Preparación 19**

**Éster tert-butílico del ácido (1,3-dioxo-1,3-dihidro-isoindol-2-il)carbámico.**

A una mezcla de carbazato tert-butílico (5.15 g, 38.97 mmol) y anhídrido ftálico (5.77 g, 38.97 mmol) se agregó CHCl3 (70 mL). La mezcla de reacción fue sometida a reflujo durante 18 h. La remoción del solvente bajo presión reducida proporcionó 8.20 g (80%) del compuesto del título como un sólido blanco. MG+ 263.

**Preparación 20**

**Éster dimetil-etílico del ácido benzo[1,3]dioxol-5-il-metil-(1,3-dioxo-1,3-dihidro-isoindol-2-il)-carbámico.**

A una solución de éster tert-butílico del ácido (1,3-dioxo-1,3-dihidro-isoindol-2-il)-carbámico (0.31 g, 1.18 mmol), alcohol piperonílico (0.18 g, 1.18 mmol) y trifenilfosfina (0.40 g, 1.54 mmol) en THF (12 mL) a 0°C se agregó por goteo azodicarboxilato de diisopropilo (0.30 mL, 1.54 mmol). La mezcla de reacción se agitó y se dejo calentar hasta temperatura ambiente durante la noche. La remoción del solvente bajo presión reducida, seguido por purificación mediante hplc proporcionó 0.28 g (60%) del compuesto del titulo. MH+ 397.

**Preparación 21**

**Éster tert-butílico del ácido N-benzo[1,3]dioxol-5-il-metil-hidrazinacarboxílico.**

A éster dimetil-etílico del ácido N-benzo[1,3]dioxol-5-il-metil-(1,3-dioxo-1,3-dihidro-isoindol-2-il)-carbámico (0.28 g, 0.71 mmol) en EtOH (3.6 mL) se agregó monohidrato de hidrazina (0.14 mL, 2.84 mmol) en una porción a temperatura ambiente. La mezcla de reacción se agitó durante

21 horas. Se agrego tolueno a la mezcla, y el sólido blanco fue recolectado mediante filtración. El filtrado fue evaporado *al vacío*. Un reposamiento adicional al vacío proporcionó 0.17 g (89%) del compuesto del titulo. MH+ 267.

Preparación 22

**Éster tert-butílico del ácido N-benzo[1,3]dioxol-4-il-metil-N'-{(R)-2-[(benziloxi-formil-amino)-metil]heptanoil}hidrazinacarboxílico.**

A una mezcla de éster tert-butílico del ácido N-benzo[1,3]dioxol-5-il-metil-hidrazinacarboxílico (168 mg, 0.632 mmol), ácido (R)-2-[(benciloxi-formil-amino)-metil]-heptanoico (185 mg, 0.632 mmol), 4-dimetilaminopiridina (100 mg, 0.822 mmol) en cloruro de metileno (7 mL) se agregó hidrocloruro de 1-(3-dimetilaminopropil)-3-etilcarbodiimida (158 mg, 0.822 mmol9) a temperatura ambiente. La mezcla de reacción se agitó durante 19 h a temperatura ambiente y luego se trató con solución HCl acuosa 1N. La separación de la capa orgánica, secado sobre MgSO4 anhidro y remoción del solvente proporcionó el compuesto del titulo. No se requirió purificación adicional- MH+ 542.

**Preparación 23**

**N-[(R)-2-(N'-benzo[1,3]dioxol-5-il-metil-hidrazinocarbonil)-heptil]-N-benciloxi-formamida.**

Al éster tert-butílico del ácido N-benzo[1,3]dioxil-4-ilmetil-N'-{R-[benziloxi-formil-amino)-metil]-heptanoil}-hidrazinacarboxílico obtenido en la preparación 12 se agregó TFA al 5% en dicloruro de metileno (20 mL) a temperatura ambiente. La solución resultante fue agitada durante 6 horas, y luego se lavó con solución de $NaHCO_3$ acuoso saturado (20 mL x 3). La capa orgánica fue separada y secada ($MgSO_4$). La filtración y evaporación proporcionó el compuesto del titulo (0.221 g, 79% en dos pasos). MH+ 442.

**Ejemplo 354**

**N-[(R)-2-(N'-benzo[1,3]dioxol-5-il-metil-hidrazinocarbonil)-heptil]-N-hidroxi-formamida.**

A una solución de N-[(R)-2-(N'-benzo[1,3]dioxol-5-il-metil-hidrazinocarbonil)-heptil]-N-benciloxi-formamida. (0.221 g, 0.501 mmol) en EtOH (10 mL) se agregó Pd/C al 10% (50 mg). La mezcla se sometió a hidrogenación durante 5 h a temperatura ambiente. La mezcla fue filtrada

a través de Celite. El filtrado fue evaporado y purificado mediante HPLC para proporcionar el compuesto del titulo (0.10 g, 57%) en un sólido blanco. MH+ 352.

**Ejemplo 355**

**N-{(R)-2-[N'-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-7-il-metil)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ 366.

**Ejemplo 356**

**N-{(R)-2-[N'-(4-dimetilamino-bencil)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 351.

**Ejemplo 357**

**N-hidroxi-N-((R)-2-{N'-[2-(5,6,7,8,-tetrahidro-[1,8]naftiridin-2-il)-etil]-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ 378.

**Ejemplo 358**

**N-hidroxi-N-[(R)-2-(N'-quinolin-2-il-metil-hidrazinocarbonil)-heptil]-formamida.**

MH+ = 359.

**Ejemplo 359**

**N-hidroxi-N-{(R)-2-[N'-(1,2,3,4-tetrahidro-quinolin-2-il-metil)-hidrazinocarbonil]-heptil}-formamida.**

MH+ 363.

**Ejemplo 360**

**N-hidroxi-N-[(R)-2-(N'-quinolin-6-il-metil-hidrazinocarbonil)-heptil]-formamida.**

MH+ 359.

**Ejemplo 361**

**N-[(R)-2-(N'-benzofuran-2-il-metil-hidrazinocarbonil)-heptil]-N-hidroxi-formamida.**
MH+ 348.

**Ejemplo 362**

**N-[(R)-2-(N'-ciclopropilmetil-hidrazinocarbonil)-heptil]-N-hidroxi-formamida.**
MH+ 272.

**Ejemplo 363**

**N-{(R)-2-[N'-(6-fluoro-4H-benzo[1,3]dioxin-8-il-metil)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**
MH+ 384.

**Ejemplo 364**

**N-hidroxi-N-{(R)-2-[N'-(4-metoxi-bencil)-hidrazinocarbonil]-heptil}-formamida.**
MH+ = 338.

**Ejemplo 365**

**N-hidroxi-N-{(R)-2-[N'-(2-metoxi-bencil)-hidrazinocarbonil]-heptil}-formamida.**
MH+ = 338.

**Ejemplo 366**

**N-hidroxi-N-{(R)-2-[N'-(tetrahidro-furan-3-il-metil)-hidrazinocarbonil]-heptil}-formamida.**
MH+ = 302.

**Ejemplo 367**

**N-[(R)-2-(N'-furan-3-il-metil-hidrazinocarbonil)-heptil]-N-hidroxi-formamida.**
MH+ = 298.

**Ejemplo 368**

**N-{(R)-2-[N'-(2,3-dihidro-benzo[1,4]dioxin-6-il-metil)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 366.

**Ejemplo 369**

**N-{(R)-2-[N'-(2,3-dihidro-benzo[1,4]dioxin-2-il-metil)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 366.

**Ejemplo 370**

**N-hidroxi-N-{(R)-2-[N'-(2-fenoxi-etil)-hidrazinocarbonil]-heptil}-formamida.**

MH+ = 338.

**Ejemplo 371**

**N-{(R)-2-[N'-((S)-2,3-dihidroxi-propil)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+m = 292.

**Ejemplo 372**

**N-hidroxi-N-{(R)-2-[N'-(-metil-isoxazol-3-il-metil)-hidrazinocarbonil]-heptil}formamida.**

MH+ = 313.

**Ejemplo 373**

**N-((R)-2-{N'-[1-(1-benzo[1,3]dioxol-5-il-metanoil)-piperidin-4-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.**

**Ejemplo 374**

**N-((R)-2-{N'-[1-(1-benzofuran-2-il-metanoil)-piperidin-4-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.**

MH+ = 445.

**Ejemplo 375**

**N-hidroxi-N-[(R)-2-(N'-{1-[1-(7-metoxi-benzofuran-2-il)-metanoil]-piperidin-4-il}-hidrazinocarbonil)-heptil]-formamida.**

MH+ = 475.

**Ejemplo 376**

**N-{(R)-2-[N'-(1-bencil-piperidin-4-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.**

MH+ = 391.

**Ejemplo 377**

**N-[(R)-2-(N'-{1-[1-(3,4-dicloro-fenil)-metanoil]-piperidin-4-il}-hidrazinocarbonil)-heptil]-N-hidroxi-formamida.**

MH+ = 474.

**Ejemplo 378**

**N-[(R)-2-(N'-{1-[1-(2,3-dicloro-enil)-metanoil]-piperidin-4-il}hidrazinocarbonil)-heptil]-N-hidroxi-formamida.**

MH+ = 474.

**Ejemplo 379**

**N-hidroxi-N-[(R)-2-(N'-{1-[1-(4-metil-piperazin-1-il)-metanoil]-pentil}-hidrazinocarbonil)-heptil]-formamida.**

MH+ = 414.

**Preparación 24**

**N-[(R)-2-(hidrazinocarbonil)-heptil]-N-hidroxi-formamida.**

A una solución de éster bencílico del ácido N'-{(R)-2-[(benciloxiformilamino)metil]heptanoil}-hidrazinacarboxílico ( 1 mmol) en EtOH (10 mL) se agregó Pd/C al 10% (50 mg). La mezcla fue sometida a hidrogenación durante 5 horas a temperatura ambiente y luego se filtró a través de Celite. El filtrado se evaporó y purificó mediante hplc para proporcionar N-[(R)-2-(hidrazinocarbonil)-heptil]-N-hidroxi-formamida como un vidrio. MH+ 218.

**Ejemplo 380**

**N-[(R)-2-(N'-bencil-hidrazinocarbonil)-heptil]-N-hidroxi-formamida.**

N-[(R)-2-(hidrazinocarbonil)-heptil]-N-hidroxi-formamida (50 mg, 0.23 mmoles) y benzaldehído (24 mg, 0.23 mmoles) fueron disueltos en metanol (2 mL) bajo argon en presencia de tamices molecular de 4Å (50 mg), se agitó durante 1 hora y se enfrió a 0°C. A la mezcla se agregó un cristal de un indicador de naranja de metilo y suficiente HCl metanólico para mantener la solución ácida (color rojo). Se agregó cianoborohidruro sódico (17 mg, 0.28 mmoles), junto con suficiente HCl metanólico para mantener la solución ácida (indicador rojo). El sistema fue calentado a temperatura ambiente, agitado durante 2 días, neutralizado con solución de bicarbonato de sodio, y extraido con acetato de etilo (3x). La capa organica fue secada sobre sulfato sódico anhidro, concentrada hasta sequedad y purificada mediante hplc preparativa para proporcionar el compuesto del titulo. MH+ 308.

## COMPOSICIONES, ADMINISTRACIÓN YANÁLISIS BIOLÓGICOS

Los compuestos de fórmula (1) y sus sales farmacéuticamente aceptables se pueden administrar de la manera estándar para antibióticos, por ejemplo oralmente, parenteralmente, sublingualmente, dérmicamente, transdérmicamente, rectalmente, vía inhalación o vía administración bucal.

Las composiciones de fórmula (1) y sus sales farmacéuticamente aceptables que son activas cuando se suministran oralmente se pueden formular como jarabes, comprimidos, cápsulas, cremas y pastillas. Una formulación de jarabe consistirá generalmente en una suspensión o solución del compuesto o una sal en un vehículo líquido por ejemplo, etanol, aceite de cacahuete, aceite de oliva, glicerina o agua con un agente saborizante o colorante. Cuando la composición está en forma de comprimido, se puede emplear cualquier vehículo farmacéutico empleado habitualmente para preparar formulaciones sólidas. Ejemplos de tales vehículos incluyen estearato magnésico, terra alba, talco, gelatina, goma arábiga, ácido esteárico, almidón, lactosa y sacarosa. Cuando la composición está en forma de cápsula, es adecuada cualquier encapsulación habitual, por ejemplo, empleando los vehículos antes mencionados dentro de una cubierta para cápsula rígida de gelatina. Cuando la composición está en forma de cápsula de cubierta de gelatina blanda, se puede considerar cualquier vehículo farmacéutico empleado habitualmente para preparar dispersiones o suspensiones, por ejemplo, gomas acuosas, celulosas, silicatos o aceites, y se puede incorporar en una cubierta para cápsula de gelatina blanda.

Composiciones parenterales típicas consisten en una solución o suspensión de un compuesto o su sal en un vehículo estéril acuoso o no acuoso que opcionalmente contiene un aceite parenteralmente aceptable, por ejemplo, polietilenglicol, polivinilpirrolidona, lecitina, aceite de cacahuete o aceite de sésamo.

Composiciones típicas para inhalación están en forma de solución, suspensión o emulsión que se puede administrar como un polvo seco o en forma de aerosol empleando un propelente convencional tal como diclorodifluorometano o triclorofluorometano.

Una composición para supositorio típica comprende un compuesto de fórmula (1) o una de sus sales farmacéuticamente aceptables que es activa cuando se administra por esta vía, con un agente aglutinante y/o un agente lubricante, por ejemplo, glicoles poliméricos, gelatinas, manteca de cacao u otras ceras o grasas vegetales de bajo punto de fusión o sus análogas sintéticas.

Formulaciones dérmicas y transdérmicas típicas comprenden un vehículo convencional acuoso o no acuoso, por ejemplo, una crema, ungüento, loción o pasta o están en forma de un apósito, parche o membrana que contiene una medicina.

Preferiblemente la composición está en forma de dosis unitaria, por ejemplo un comprimido, cápsula o dosis de aerosol medida, de manera que el paciente se puede administrar una única dosis.

Cada unidad de dosificación para administración oral contiene convenientemente de 0,1 mg a 500 mg/kg, y preferiblemente de 1 mg a 100 mg/kg, y cada unidad de dosificación para administración parenteral contiene convenientemente de 0,1 mg a 100 mg/kg, de un compuesto de fórmula (1) o una de sus sales farmacéuticamente aceptables calculada como el ácido libre. Cada unidad de dosificación para la administración intranasal contiene convenientemente 1-400 mg y preferiblemente 10 a 200 mg por persona. Una formulación tópica contiene convenientemente 0,01 a 5,0% de un compuesto de fórmula (1).

El régimen de dosificación diario para la administración oral es convenientemente alrededor de 0,01 mg/kg a 40 mg/kg de un compuesto de fórmula (1) o una de sus sales farmacéuticamente aceptables calculada como el ácido libre. El régimen de dosificación diario para la administración parenteral es convenientemente alrededor de 0,001 mg/kg a 40 mg/kg de un compuesto de fórmula (1) o una de sus sales farmacéuticamente aceptable calculada como el ácido libre. El régimen de dosificación diario para la administración intranasal y la inhalación oral es

convenientemente alrededor de 10 a alrededor de 500 mg/persona. El ingrediente activo se puede administrar de 1 a 6 veces al día, lo que es suficiente para mostrar la actividad deseada.

No se esperan efectos toxicológicos inaceptables al administrar los compuestos de la presente invención de acuerdo con la presente invención.

La actividad biológica de los compuestos de fórmula (I) se demuestra mediante el siguiente ensayo:

**Análisis biológico**

Se mide la actividad de PDF de S. aureus o E. coli a 25°C, empleando un análisis continuo de enzima unida desarrollado por Lazennec&Meinnel ("Formate dehydrogenase-coupled spectrophotometric assay of peptide deformylase", Anal. Biochem. 1997, 244, pág.180-182), con modificaciones menores. La mezcla de reacción está contenida en 50 µl con tampón de fosfato potásico 50 mM (pH 7,6), NAD 15 mM, 0,25 U de formiato deshidrogenasa. El péptido sustrato, f-Met-Ala-Ser, se incluye en la concentración $K_M$. Se da comienzo a la reacción con la adición de 10 nM de la enzima Def1 y la absorbancia se vigila durante 20 minutos a 340 nm.

**Análisis de la actividad antimicrobiana**

La actividad antimicrobiana de toda la célula se determinó mediante microdilución del caldo empleando el procedimiento recomendado por el National Committee for Clinical Laboratory Standards (NCCLS), Documento M7-A4, "Methods for Dilution Susceptibility Tests for Bacteria that Grow Aerobically" (incorporado en este documento por referencia). El compuesto se sometió a ensayo en diluciones al doble en serie en el intervalo de 0,06 a 64 µg/ml. En el análisis se evaluó un panel de 12 cepas. Este panel consistía en las cepas de laboratorio: Staphylococcus aureus Oxford, Staphylococcus aureus WCUH29, Enterococcus faecalis I, Enterococcus faecalis 7, Haemophilus influenzae Q1, Haemophilus influenzae NEMC1, Moraxella catarrhalis 1502, Streptococcus pneumoniae 1629, Streptococcus pneumoniae N1387, Streptococcus pneumoniae N1387, E. coli 7623 (AcrABEFD+) y E. coli 120 (AcrAB-). La concentración inhibidora mínima (MIC) se determinó como la menor concentración de compuesto que inhibía el crecimiento visible. Se empleó un lector de espejo para ayudar en la determinación del punto final de MIC.


Todas las publicaciones, incluyendo, pero no limitándose a las patentes y solicitudes de patentes, citadas en esta memoria descriptiva se incorporan a ella por referencia como si se hubiera indicado específica e individualmente para cada publicación individual que la misma se incorpora por referencia en este documento como si se hubiera expuesto por completo.

La descripción anterior describe totalmente la invención incluyendo sus realizaciones preferidas. Modificaciones y mejoras de las realizaciones descritas específicamente en este documento están dentro del alcance de las siguientes reivindicaciones. Se cree que, sin elaboración adicional, un experto en la técnica puede, empleando la descripción precedente, emplear la presente invención en toda su extensión. Por tanto los ejemplos de este documento han de interpretarse como meramente ilustrativos y de ninguna manera una limitación del alcance de la presente invención. Las realizaciones de la invención en las que se reivindica una propiedad o privilegio exclusivo se definen como sigue.

**REIVINDICACIONES**

1. Un compuesto según la fórmula (1):

En un aspecto de la presente invención, se proporciona un compuesto de fórmula (1):



(1)

en donde:

R se selecciona del grupo que consiste en:

alquilo $C_{2-6}$ (opcionalmente sustituido con alcoxi, halógeno, o alquilsulfanilo $C_{1-3}$); alquenilo $C_{2-6}$ (opcionalmente sustituido con alcoxi, halógeno, o $C_{1-3}$ alquilsulfanilo); alquinilo $C_{2-6}$ (opcionalmente sustituido con alcoxi, halógeno, o alquilsulfanilo $C_{1-3}$); carbociclo $(CH_2)_n$—$C_{3-6}$ (opcionalmente sustituido con alcoxi, halógeno, o alquilsulfanilo $C_{1-3}$); y $(CH_2)_n$—R4, en donde R4 se selecciona del grupo que consiste en fenilo, furano, benzofurano, tiofeno, benzotiofeno, tetrahidrofurano, tetrahidropirano, dioxano, 1,4-benzodioxano o benzo[1,3]dioxol; R4 esta opcionalmente sustituido con uno o más sustituyentes seleccionados entre Cl, Br, I, alquilo $C_{1-3}$ (opcionalmente sustituido con uno a tres F) y alcoxi $C_{1-2}$ (opcionalmente sustituido con uno a tres F)};

R1 y R2 se seleccionan independientemente del grupo que consiste en:

hidrógeno, alquilo sustituido con $C_{1-3}$, alquenilo sustituido con $C_{2-3}$, alquinilo sustituido con $C_{2-3}$, carbociclo sustituido con $(CH_2)_n$—$C_{3-6}$, arilo, heteroarilo, y heterociclo;


Y representa O, $CH_2$ o un enlace covalente; y

n es un número entero de 0 a 2;

o una sal, solvato, o uno de sus derivados funcionales fisiológicalmente funcionales.

2. Un compuesto según la reivindicación 1, en el que $R_2$ representa hidrógeno;

3. Un compuesto según la reivindicación 2, con la siguiente configuración absoluta:



o una sal, solvato o uno de sus derivados fisiológicamente funcionales.

4. Un compuesto según la reivindicación 3, seleccionado del grupo que consiste en:
N-hidroxi-N-[(R)-2-(N'-piridin-2-il-hidrazinocarbonil)-heptil]-formamida.
N-hidroxi-N-{(R)-2-[N'-(3-metoxi-fenil)-hidrazinocarbonil]-heptil}-formamida.
N-hidroxi-N-{(R)-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-formamida.
N-{(R)-2-[N'-(4-ciano-fenil)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.
N-{(R)-2-[N'-(2,6-dimetil-pirimidin-4-il)- hidrazinocarbonil]-heptil}-N-hidroxi-formamida.
N-hidroxi-N-[(R)-2-(N'-quinoxalin-2-il-hidrazinocarbonil)-heptil]-formamida.
N-hidroxi-N-((2*R*)-2-{N'-(3,4-dihidro-quinoxalin-2-il)- hidrazinocarbonil)-heptil]-formamida.
N-hidroxi-N-{(R)-2-[N'-(1,3,4-trimetil-1H-pirazolo[3,4-b]piridin-6-il)- hidrazinocarbonil)-heptil]-formamida.
4-(N'-{(R)-2-[(Formil-hidroxi-amino)-metil]-heptanoil}-hidrazino)-benzenosulfonamida.
N-hidroxi-N-((2*R*)-2-(ciclohexilmetil)-3-oxo-3-{N'-[4-(trifluorometil)-pirimidin-2-il}-hidrazino}-propil]-formamida.
N-hidroxi-N-((2*R*)-2-(ciclopentilmetil)-3-oxo-3-{N'-[4-(trifluorometil)-pirimidin-2-il}-hidrazino}-propil]-formamida.

N-{(R)-2-[N'-(Dimetil-trifluorometil-pirimidin-4-il)-hidrazinocarbonil]-heptil}-formamida.
N-hidroxi-N-{(R)-2-[N'-(6-trifluorometil-piridazin-3-il)-hidrazinocarbonil]-heptil}-formamida.
N-hidroxi-N-{(R)-2-[N'-(6-trifluorometil-pirimidin-4-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(5-metil-[1,2,4]triazolo[1,5-a]pirimidin-7-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(9H-purin-6-il)-hidrazinocarbonil]-heptil}-formamida.

N-{(R)-2-[N'-(5-ciano-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-((2*R*)-2-{[N'-(pirimidin-2-il)-hidrazino]carbonil}-heptil)-formamida.

N-hidroxi-N-((2*R*)-2-(ciclobutilmetil)-3-oxo-3-{N'-[4-(trifluorometil)-pirimidin-2-il]-hidrazino}-propil)-formamida.

N-hidroxi-N-{(R)-2-[N'-(6-imidazol-1-il-pirimidin-4-il)- hidrazinocarbonil]-heptil}-formamida.

N-[(R)-2-(N'-Benzo[1,2,4]triazin-3-il-hidrazinocarbonil)-heptil]-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(7-metoxi-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(1-metil-1H-pirazolo[3,4-d]pirimidin-6-il)-hidrazinocarbonil]-heptil}-formamida.

N-((R)-2-{N'-[6-(5-Cloro-piridin-3-il-oxi)-piridazin-3-il]-hidrazinocarbonil}heptil)-N-hidroxi-formamida.

N-hidroxi-N-[(2*R*)-2-({N'-[6-(1*H*-pirrol-1-il)-3-piridazinil]-hidrazino}-carbonil)-heptil]-formamide.

N-hidroxi-N-[(2*R*)-2-({N'-(9-metil-9*H*-purin-6-il)-hidrazino]-carbonil}-heptil)-formamida.

N-hidroxi-N-{(R)-2-[N-({6-morfolin-4-il}-9H-purin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-{(R)-2-[N'-(6-Fluoro-piridin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-((2*R*)-2-{[N'-(1-metil-1*H*-pirazolo[3,4-*d*]pirimidin-4-il)-hidrazino]-carbonil}-heptil)-formamida.

N-{(R)-2-[N'-(4-Amino-6-isopropil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(2,5-Dimetil-4-nitro-2H-pirazol-3-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(3-Cloro-1-metil-1H-pirazolo[3,4-d]pirimidin-6-il)-hidrazinocarbonil]-heptil}-n-hidroxi-formamida.

N-{(R)-2-[N'-(6-Dimetilamino-9H-purin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-[(2*R*)-4-cicloropropil-2-({N-[4-(trifluorometil)-pirimidin-2-il]-hidrazino}-carbonil)-butil]-formamida.

N-hidroxi-N-((2*R*)-2-(ciclopropilmetil)-3-oxo-3-{N-[4-(trifluorometil)-pirimidin-2-il]-hidrazino}-propil)-formamida.

N-hidroxi-N-{(R)-2-[N-metil-N-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-formamida.

éster metílico del ácido 2-(N-{(R)-2-[(Formil-hidroxi-amino)-metil]-heptanoil}-hidrazino)-4-trifluorometil-pirimidina-5-carboxílico.

ácido 2-(N-{(R)-2-[(Formil-hidroxi-amino)-metil]-heptanoil}-hidrazino)-4-trifluorometil-pirimidina-5-carboxílico.

N-{(R)-2-[N-(5-fluoro-4-metoxi-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-[N-(4-Dimetilamino-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N- hidroxi-formamida.

N-hidroxi-N-{(2*R*)-2-[(N-{6-[(2-hidroxietil)amino]-1,3-dihidro-2*H*-purin-2-ilideno}-hidrazino)-carbonil]-heptil}-formamida.

N-{(R)-2-[N-(5-Fluoro-4-morfolin-4-il-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-[N-(5-Fluoro-4-metilamino-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

dimetilamida del ácido 2-(N-{(R)-2-[(Formil-hidroxi-amino)-metil]-heptanoil}-hidrazino)-4-trifluorometil-pirimidina-5-carboxílico.

N-hidroxi-N-{(R)-2-[N-(3-oxo-3,4-dihidro-quinoxalin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-{(R)-2-Butoxi-2-[N-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-etil}-N-hidroxi-formamida.

(2-fluoro-fenil)-amida del ácido 2-(N-{(R)-2-[(Formil-hidroxi-amino)-metil]-heptanoil}-hidrazino)-4-trifluorometil-pirimidina-5-carboxílico.

ter-butilamida del ácido 2-(N-{(R)-2-[(Formil-hidroxi-amino)-metil]-heptanoil}-hidrazino)-4-trifluorometil-pirimidina-5-carboxílico.

N-hidroxi-N-((R)-2-{N-[(1-piperidin-1-il-metanoil)-trifluorometil-pirimidin-2-il]-hidrazinocarbonil}-heptil)-formamida.

N-{(R)-2-[N'-(5-ciano-4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-[(2*R*)-2-({N'-[9-(4,4,4-trifluorobutil)-1,9-dihidro-2*H*-purin-2-ilideno]-hidrazino}-carbonil)-heptil]-formamida.

N-hidroxi-N-((R)-2-{N'-[(1-morfolin-4-il-metanoil)-trifluorometil-pirimidin-2-il]-hidrazinocarbonil}-heptil)-formamida.

benzilamida del ácido 2-(N'-{(R)-2-[(Formil-hidroxi-amino)-metil]-heptanoil}-hidrazino)-4-trifluorometil-pirimidina-5-carboxílico.

N-hidroxi-N-[(2*R*)-3-[N'-(1,2,4-benzotriazin-3-il)-hidrazino]-2-(ciclohexilmetil)-3-oxopropil]-formamida.

N-hidroxi-N-((2*R*)-2-(ciclohexilmetil)-3-{N'-[7-(metiloxi)-1,2,4-benzotriazin-3-il)-hidrazino}-3-oxopropil)-formamida.

2-[2-((2R)-2-{[Formil(hidroxi)amino]metil}heptanoil)hidrazino]-N-metil-N-2-piridinil-4-(trifluorometil)-5-pirimidinecarboxamida.

2-[2-((2R)-2-{[Formil(hidroxi)amino]metil}heptanoil)hidrazino]-N-metil-N-fenil-4-(trifluorometil)-5-pirimidinecarboxamida.

morfolin-4-ilamida del ácido 2-[2-((2R)-2-{[Formil(hidroxi)amino]metil}heptanoil)hidrazino)-4-trifluorometil-pirimidina-5-carboxílico.

N-hidroxi-N-((R)-2-{N'-[(N'-fenil-hidrazinocarbonil)-trifluorometil-pirimidin-2-il]-hidrazinocarbonil}-heptil)-formamida.

piperidin-1-ilamida del ácido 2-(N'-{(R)-2-[(Formil-hidroxi-amino)-metil]-heptanoil}-hidrazino)-4-trifluorometil-pirimidina-5-carboxílico.

pirrol-1-ilamida del ácido 2-(N'-{(R)-2-[(Formil-hidroxi-amino)-metil]-heptanoil}-hidrazino)-4-trifluorometil-pirimidina-5-carboxílico.

N-{(R)-2-[N'-(Dimetilamino-fluoro-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-((R)-2-{N'-[(Etil-metil-amino)-fluoro-pirimidin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-hidroxi-N-((2R)-2-(ciclopentilmetil)-3-{N'-[7-(metiloxi)-1,2,4-benzotriazin-3-il]-hidrazino}-3-oxopropil)-formamida.

N-hidroxi-N-{(R)-2-[N'-(1-metil-1H-benzoimidazol-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-{(R)-2-[N'-(4-Azetidin-1-il-5-fluoro-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(4-Ciclopropilamino-5-fluoro-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-[(R)-2-(N'-Benzo[1,2,4]triazin-3-il-hidrazinocarbonil)-3-ciclopentil-propil]-N- hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(morfolin-4-il-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-[(R)-2-(N'-{[2-hidroxi-etil)-metil-amino]-trifluorometil-pirimidin-2-il}-hidrazinocarbonil)-heptil]-formamida.

N-hidroxi-N-((R)-2-(N'-[(4-metil-piperazin-1-il)-trifluorometil-pirimidin-2-il]-hidrazinocarbonil)-heptil]-formamida.

N-hidroxi-N-((2R)-2-(ciclohexilmetil)-3-{N'-[4-(ciclopropilamino)-5-fluoro-pirimidin-2-il]hidrazino}-3-oxopropil)-formamida.

N-hidroxi-N-((2R)-2-(ciclopentilmetil)-3-{N'-[4-(ciclopropilamino)-5-fluoro-pirimidin-2-il]hidrazino}-3-oxopropil)-formamida.

N-hidroxi-N-[(2R)-3-{N'-[4-(azetidin-1-il)-5-fluoro-pirimidin-2-il]-hidrazino}-2-(ciclopentilmetil)-3-oxopropil]-formamida.

N-hidroxi-N-[(2R)-5-metil-2-({N'-[4-(trifluorometil)-pirimidin-2-il]-hidrazino}-carbonil)-hexil]-formamida.

N-[(R)-2-(N'-Benzo[1,2,4]triazin-3-il-hidrazinocarbonil)-5-metil-hexil]-N-hidroxi-formamida.

N-hidroxi-N-[(2R)-5-metil-2-({N'-[7-(metiloxi)-1,2,4-benzotriazin-3-il]-hidrazino}-carbonil)-hexil]-formamida.

N-{(R)-2-[N'-(7-Cloro-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-((2R)-2-(ciclopentilmetil)-3-{N'-[4-(morfolin-4-il)-6-(trifluorometil)-pirimidin-2-il]-hidrazino}-3-oxopropil)-formamida.

N-hidroxi-N-((2R)-2-(ciclopentilmetil)-3-{N'-[4-[(2-hidroxietil)-(metil)-amino]-6-(trifluorometil)-pirimidin-2-il]-hidrazino}-3-oxopropil)-formamida.

N-hidroxi-N-[(2R)-6-metil-2-({N-[4-(trifluorometil)-pirimidin-2-il]-hidrazino}-carbonil)-heptil]-formamida.

N-hidroxi-N-((2R)-2-{[N-(1,2,4-benzotriazin-3-il)-hidrazino]-carbonil-6-metilheptil-formamida.

N-hidroxi-N-{(R)-2-[N-(5-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-formamida.

N-((R)-2-{N-[(4-Etil-piperazin-1-il)-trifluorometil-pirimidin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N-(piperazin-1-il-trifluorometil-pirimidin-2-il)- hidrazinocarbonil]-heptil}-formamida.

N-{(R)-2-[N-(7-Fluoro-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-[(2R)-2-({N-[4-(4-etil-1-piperazinil)-6-(trifluorometil)-pirimidin-2-il]-hidrazino}-carbonil)-6-metilheptil]-formamida.

N-hidroxi-N-[(2R)-6-metil-2-({N-[4-(piperazin-1-il)-6-(trifluorometil)-pirimidin-2-il]-hidrazino}-carbonil)-heptil]-formamida.

N-hidroxi-N-[(2R)-6-metil-2-({N-[4-(4-metil-piperazin-1-il)-6-(trifluorometil)-pirimidin-2-il]-hidrazino}-carbonil)-heptil]-formamida.

N-hidroxi-N-((2R)-2-{[N-[7-cloro-1,2,4-benzotriazin-3-il)hidrazino]carbonil}-6-metilheptil)-formamida.

N-hidroxi-N-((2R)-6-metil-2-{[N-(5-metil-1,2,4-benzotriazin-3-el)-hidrazino]-carbonil}-heptil)-formamida.

N-hidroxi-N-((2R)-6-{[N-(7-fluoro-1,2,4-benzotriazin-3-il)-hidrazino]-carbonil}-6-metilheptil-formamida.

N-hidroxi-N-((R)-2-{N-[(2-metoxi-etilamino)-trifluorometil-pirimidin-2-il]-hidrazinocarbonil}-heptil)-formamida.

N-hidroxi-N-[(2R)-6-metil-2-({N-[7-(metiloxi)-1,2,4-benzotriazin-3-il]-hidrazino}-carbonil)-heptil]-formamida.

N-hidroxi-N-[(R)-2-(N-{[4-(2-hidroxi-etil)-piperazin-1-il]-trifluorometil-pirimidin-2-il}-hidrazinocarbonil)-heptil]-formamida.

N-hidroxi-N-((R)-2-(N-[(4-pirimidin-2-il-piperazin-1-il)-trifluorometil-pirimidin-2-il]hidrazinocarbonil}-heptil)-formamida.

N-hidroxi-N-((R)-2-(N'-[(2-hidroxi-etilamino)-trifluorometil-pirimidin-2-il]-hidrazinocarbonil}-heptil)-formamida.

N-hidroxi-N-{(R)-2-[N'-(7-trifluorometil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(6-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(2R)-2-(ciclopentilmetil)-3-[N'-(5-metil-1,2,4-benzotriazin-3-il)hidrazino]-3-oxopropil}-formamida.

N-hidroxi-N-[(2R)-2-({N'-[4-(trifluorometil)-pirimidin-2-il]-hidrazino}-carbonil)-octil]-formamida.

N-hidroxi-N-((2R)-2-{[N'-(1,2,4-benzotriazin-3-il)hidrazino]-carbonil}-octil)-formamida.

N-hidroxi-N-[(2R)-2-({N'-[7-(metiloxi)-1,2,4-benzotriazin-3-il)-hidrazino}carbonil]-octil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(7-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-formamida.

N-{(R)-2-[N'-(6-Cloro-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(5-metoxi-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(1-metil-2-oxo-1,2-dihidro-piridin-4-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-((R)-2-{N'-[(N'piridin-2-il-hidrazino)-trifluorometil-pirimidin-2-il]-hidrazinocarbonil}-heptil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(4-metil-6-morfolin-4-il-pirimidin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-((R)-2-{N'-[4-(4-Etil-piperazin-1-il)-6-metil-pirimidin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-{(R)-2-[N'-(4,6-Dimetil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(4-trifluorometil-piridin-2-il)-hidrazinocarbonil]-heptil}-formamide.

N-hidroxi-N-[(R)-2-(N'-isoquinolin-1-il-hidrazinocarbonil)-heptil]-formamida.

N-hidroxi-N-[(R)-2-(N'-quinolin-2-il-hidrazinocarbonil)-heptil]-formamida.

N-{(R)-2-[N'-(1-Benzil-2-oxo-1,2-dihidro-piridin-4-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(4-oxo-4H-pirido[1,2-a][1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(4-metil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-{(R)-2-[N'-(1-Butil-2-oxo-1,2-dihidro-piridin-4-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(9-metil-4-oxo-4H-pirido[1,2-a][1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(6-oxo-4-trifluorometil-1,6-dihidro-pirimidin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(metil-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(5-trifluorometil-piridin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-{(R)-2-[N'-(6-Etoxi-piridin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-[(R)-2-[N'-pirido[2,3-e]-[1,2,4]triazin-3-il-hidrazinocarbonil)-heptil]-formamida.

N-((R)-2-[N'-[1-(1-Etil-propil)-2-oxo-1,2-dihidro-piridin-4-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-hidroxi-N-((R)-2-{N'-[2-oxo-1-(3-trifluorometil-benzil)-1,2-dihidro-piridin-4-il]-hidrazinocarbonil}-heptil-formamida.

N-hidroxi-N-{(R)-2-[N'-(4-metil-piridin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(6-metoxi-piridin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(2-oxo-1-quinolin-8-il-metil-1,2-dihidro-piridin-4-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-[(R)-2-(N'-{2-oxo-1-[2-(5,6,7,8-tetrahidro-[1,8]naftiridin-2-il)-etil]-dihidro-piridin-4-il}-hidrazinocarbonil)-heptil]-formamida.

N-{(R)-2-[N'-(4,6-Bis-etilamino-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(Bis-dimetilamino-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(4,6-Di-morfolin-4-il-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-((R)-2-{N'-[4-(4-metil-piperazin-1-il)-6-propilamino-[1,3,5]triazin-2-il]-hidrazinocarbonil]-heptil)-formamida.

N-{(R)-2-[N'-(Dimetilamino-morfolin-4-il-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(6-metil-piridin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-((R)-2-{N'-[5-(5-fenil-[1,3,4]oxadiazol-2-il)-piridin-2-il]-hidrazinocarbonil}-heptil)-formamida.

N-{(R)-2-[N'-(7-ter-Butil-1,4-dioxo-1,2,3,4-tetrahidro-pirido[3,4-d]piridazin-5-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-((R)-2-{N'-[4-Etilamino-6-(4-metil-[1,4]diazepan-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-((R)-2-{N'-[4-Etilamino-6-(4-etil-piperazin-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(6-trifluorometil-piridin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(4-metil-6-morfolin-4-il-metil-pirimidin-2-il)- hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(4-metil-6-morfolin-4-il[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(2R)-2-(ciclopentilmetil)-3-[N'-(4,6-dimetil-2-pirimidinil)-hidrazino]-3-oxopropil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(4-metil-6-pirrolidin-1-il-metil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(4-Dimetilaminometil-6-metil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-((R)-2-{N'-[4-metil-6-(4-metil-piperazin-1-il-metil)-pirimidin-2-il]-hidrazinocarbonil}-heptil)-formamida.

N-hidroxi-N-{(R)-2-[N'-(5-metil-piridin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-((R)-2-{N'-[Dimetilamino-(4-metil-[1,4]diazepan-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(4-metil-6-pirrolidin-1-il-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-((R)-2-{N'-[4-metil-6-)4-pirrolidin-1-il-piperidin-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-formamida.

N-((R)-2-{N'[(Etil-metil-amino)-metil-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-((R)-2-{N'-[(4-(4-Etil-piperazin-1-il)-6-metil-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-hidroxi-N-[(2R)-7,7,7-trifluoro-2-({N'-[4-(trifluorometil)-pirimidin-2-il]-hidrazino}-carbonil)-heptil]-formamida.

N-hidroxi-N-[(2R)-7,7,7-trifluoro-2-({N'-(5-metil-1,2,4-benzotriazin-3-il)-hidrazino]-carbonil}-heptil)-formamida.

N-hidroxi-N-[(2R)-7,7,7-trifluoro-2-({N'-(7-metil-1,2,4-benzotriazin-3-il)-hidrazino]-carbonil}-heptil)-formamida.

N-hidroxi-N-{(R)-2-[N'-(4-metilamino-6-morfolin-4-il-[1,3,5]-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-((R)-2-{N'-[4-(4-Etil-piperazin-1-il)-6-metilamino-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-{(R)-2-[N'-(4-Etilamino-6-morfolin-4-il-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(4,6,7-trimetil-7,8-dihidro-pterin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(4,6,7-trimetil-pteridin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(metoximetoximetil-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-((R)-2-{N'-[4-metil-6-(1-piperidin-1-il-metanoil)-pirimidin-2-il]-hidrazinocarbonil]-heptil)-formamida.

ciclopropilamida del ácido 2-(N'-{(R)-2-[(Formil-hidroxi-amino)-metil]-heptanoil}-hidrazino)-6-metil-pirimidine-4-carboxílico.

diisopropilamida del ácido 2-(N'-{(R)-2-[(Formil-hidroxi-amino)-metil]-heptanoil}-hidrazino)-6-metil-pirimidine-4-carboxílico.

N-{(R)-2-[N'-(5-ciano-piridin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(4,6-Dietil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-4-Ciclopentil-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-butil}-N-hidroxi-formamida.

N-{(R)-4-Ciclopentil-2-[N'-(7-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-butil}-N-hidroxi-formamida.

N-{(R)-4-Ciclopentil-2-[N'-(5-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-butil}-N-hidroxi-formamida.

N-hidroxi-N-((R)-2-{N'[6-(4-metil-piperazin-1-ilmetil)-piridin-2-il]-hidrazinocarbonil}-heptil)-formamida.

N-((R)-2-{N'-[5-(4,6-Dimetoxi-pirimidin-2-il)-piridin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-{(R)-2-[N'-(Dietilamino-metil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}- N-hidroxi-formamida.

N-hidroxi-N-[(R)-2-(N'-{[(2-metoxi-etil)-metil-amino]-metil-[1,3,5]triazin-2-il}-hidrazinocarbonil)-heptil]-formamida.

N-((R)-2-{N'-[4-(2,6-Dimetil-morfolin-4-il)-6-metil-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-{(R)-2-[N'-(5-Fluoro-4-metil-6-morfolin-4-il-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(4-Etil-6-morfolin-4-il-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(Etil-metil-amino)-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-((R)-2-{N'-[4-Etil-6-(4-etil-piperazin-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-((R)-2-{N'-[5-Fluoro-4-metil-6-(4-metil-piperazin-1-il)-pirimidin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-{(R)-2-[N'-(Dimetilamino-etil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-((R)-2-{N'-[5-Fluoro-4-metil-6-(4-metil-[1,4]diazepan-1-il)-pirimidin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-{(R)-4-Ciclopentil-2-[N'-(morfolin-4-il-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-butil}-N-hidroxi-formamida.

N-[(R)-2-(N'-{Etil-[(2-metoxi-etil)-metil-amino]-[1,3,4]triazin-2-il}-hidrazinocarbonil)-heptil]-N-hidroxi-formamida.

N-{(R)-2-[N'-(Dimetilamino-metil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(Ciclopropilamino-6-metil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-Ciclohexil-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-etil}-N-hidroxi-formamida.

N-{(R)-2-Ciclohexil-2-[N'-(7-metoxi-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-etil}-N-hidroxi-formamida.

N-{(R)-2-Ciclohexil-2-[N'-(5-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-etil}-N-hidroxi-formamida.

N-{(R)-4,4-Dimetil-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-pentil}-N-hidroxi-formamida.

N-{(R)-4,4-Dimetil-2-[N'-(7-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-pentil}-N-hidroxi-formamida.

N-{(R)-4,4-Dimetil-2-[N'-(5-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-pentil}-N-hidroxi-formamida.

N-{(R)-4,4-Dimetil-2-[N'-(morfolin-4-il-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-pentil}-N-hidroxi-formamida.

N-((R)-2-{N'-[Etil-(metil-piridin-2-il-amino)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-{(R)-2-[N'-(4-Ciclopropilamino-6-etil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-[(R)-2-[N'-(5-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-3-(1-metil-ciclopentil)-propil]-formamida.

N-hidroxi-N-[(R)-2-[N'-(7-metoxi-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-3-(1-metil-ciclopentil)-propil]-formamida.

N-hidroxi-N-{(R)-3-(1-metil-ciclopentil)-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-propil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(4-isopropil-6-morfolin-4-il-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(2R)-2-(ciclopentilmetil)-3-[N'-(4-metil-2-pirimidinil)-hidrazino]-3-oxopropil}-formamida.

N-hidroxi-N-[(2R)-6,6,6-trifluoro-2-({N'-[4-(trifluorometil)-pirimidin-2-il]-hidrazino}-carbonil)-hexil]-formamida.

N-{(R)-2-[N'-(5,7-Dimetil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(3,6-Dimetil-pirazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-((R)-2-{N'-[4-(4-Etil-piperazine-1-il)-6-isopropil-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-{(R)-2-[N'-(4-Dimetilamino-6-isopropil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(metil-trifluorometil-piridin-2-il)-hidrazinocarbonil]-heptil}-formamida.

2N'-{(R)-2-[(Formil-hidroxi-amino)-metil]-heptanoil}-hidrazino)-6,N,N-trimetil-isonicotinamida.

N-hidroxi-N[(2R)-2-({N'-[3-amino-6-(trifluorometil)-piridin-2-il]-hidrazino}-carbonil)-heptil]-formamida.

N-hidroxi-N-[(R)-2-(N'-{4-isopropil-6-[(2-metoxi-etil)-metil-amino]-[1,2,4]triazin-2-il}-hidrazinocarbonil)-heptil]-formamida.

N-{(R)-3-Ciclopentil-2-[N'-(4-etil-6-morfolin-4-il-6-propil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-propil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(4-morfolin-4-il-6-propil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-((R)-2-{N'-[4-(4-Etil-piperazin-1-il)-6-propil-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-{(R)-5,5-Dimetil-2-[N'(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.

N-{(R)-5,5-Dimetil-2-[N'-(7-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.

N-{(R)-5,5-Dimetil-2-[N'-(5-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.

N-{(R)-5,5-Dimetil-2-[N'-(morfolin-4-il-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.

N-{(R)-4-Etil-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.

N-{(R)-4-Etil-2-[N'-(7-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.

N-{(R)-4-Etil-2-[N'-(morfolin-4-il-trifluorometil-pirimidin-2-il-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.

N-((R)-3-Ciclopentil-2-{N'-[4-etil-6-(4-etil-piperazin-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-propil)-N-hidroxi-formamida.

N-((R)-3-Ciclopentil-2-{N'-[4-ciclopropilamino-6-etil-[1,3,5]triazin-2-il]-hidrazinocarbonil]-propil}-N-hidroxi-formamida.

N-{(R)-4-Etil-2-[N'-(5-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.

N-hidroxi-N-[(R)-2-(N'-{[(2-metoxi-etil)-metil-amino]-propil-[1,3,5]triazin-2-il}-hidrazinocarbonil-heptil]-formamida.

N-{(R)-2-[N'-(Dimetilamino-propil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(4-Etil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(4-isopropil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-{(R)-2-[N'-(4-Ciclopropil-6-morfolin-4-il[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-[(2R)-2-({N'-[4-(piridin-2-il)-pirimidin-2-il]-hidrazino}-carbonil)-heptil]-formamida.

N-((R)-2-{N'-[4-Ciclopropil-6-(4-etil-piperazin-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-{(R)-2-[N'-(Ciclopropil-dimetilamino-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-((R)-2-{N'-[Ciclopropil-(etil-metil-amino)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-{(R)-2-[N'-(4-Ciclopropil-6-pirrolidin-1-il[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(4,6-Diciclopropil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-[(R)-2-[N'-(5-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-3-(2-metil-ciclopentil)-propil]-formamida.

N-[(R)-2-[N'-(Dimetilamino-etil-[1,3,5]triazin-2-il)-hidrazinocarbnil]-3-(2-metil-ciclopentil)-propil]-formamida.

N-hidroxi-N-[(R)-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-3-(2-metil-ciclopentil)-propil]-formamida.

N-{(R)-2-[N'-(5-Etil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-{(2R)-2-(ciclopentilmetil)-3-[N'-(7-metil-1,2,4-benzotriazin-3-il)-hidrazino]-3-oxopropil}-formamida.

N-hidroxi-N-[(2R)-2-(ciclopentilmetil)-3-(N'-{4-etil-6-[etil(metil)amino]-1,3,5-triazin-2-il}-hidrazino)-3-oxopropil]-formamida.

N-hidroxi-N-((2R)-2-(ciclopentilmetil)-3-{N'[4-(dimetilamino)-6-etil-1,3,5-triazin-2-il]-hidrazino}-3-oxopropil)-formamida.

N-((R)-2-{N'-[4-Etil-6-(4-isopropil-piperazin-1-il)-[1,3,5]triazin-2.il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-hidroxi-N-[(2R)-3-[N'-(6-cloro-1,2,4-benzotriazin-3-il)-hidrazino]-2-(ciclopentilmetil)-3-oxopropil]-formamida.

N-{(R)-4,4-Dimetil-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.

N-{(R)-4,4-Dimetil-2-[N'-(7-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.

N-{(R)-4,4-Dimetil-2-[N'-(5-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.

N-{(R)-4,4-Dimetil-2-[N'-(morfolin-4-il-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(5-fenil-[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-formamida.

N-{(R)-2-[N'-(4-Etil-6-morfolin-4-il-pirimidin-2-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.

N-((R)-2-{N'-[4-Etil-6-(4-metil-piperazin-1-il)-pirimidin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-{(R)-2-[N'-(5-Etil-4-metil-pirimidin-2-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.

N-((R)-2-{N'-[4-Etil-6-(4-propil-piperazin-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-hidroxi-N-((R)-2-{N'-[6-(4-pirimidin-2-il-piperazin-1-il-metil)-piridin-2-il]-hidrazinocarbonil{-heptil)-formamida.

N-hidroxi-N-((R)-2-{N'-[6-(3-[1,2,4]triazol-1-il-metil-[1,2,4]triazol-1-il)-piridin-2-il]-hidrazinocarbonil{-heptil)-formamida.

N-{(R)-3-Biciclo[2.2.1]Pet-7-il-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.

N-{(R)-3-Biciclo[2.2.1]Pet-7-il-2-[N'-(morfolin-4-il-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.

N-hidroxi-N-[(R)-2-(N'-piridin-3-il-hidrazinocarbonil)-heptil]-formamida.

Yoduro de 4-{4-Etil-6-[2((2R)-2-{[formil(hidroxi)amino[-metil}-heptanoil)-hidrazino]-1,3,5-triazin-2-il}-1-metil-1-propilpiperazin-1-io.

N-{(R)-3-Biciclo[2.2.1]hept-7-il-2-[N'-(5-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-hexil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(4-Azetidin-1-il-6-etil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-Ciclopentil-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-etil}-N-hidroxi-formamida.

N-{(R)-2-Ciclopentil-2-[N'-(morfolin-4-il-4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-etil}-N-hidroxi-formamida.

N-{(R)-2-Ciclopentil-2-[N'-(4-metil-piridin-2-il)-hidrazinocarbonil]-etil}-N-hidroxi-formamida.

N-{(R)-2-Ciclopentil-2-[N'-(dimetilamino-etil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-etil}-N-hidroxi-formamida.

N-{(R)-2-Ciclopentil-2-[N'-(7-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-etil}-N-hidroxi-formamida.

N-{(R)-2-Ciclopentil-2-[N'-(5-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-etil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(5-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-2-(4-metil-ciclohexil)-etil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(7-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-2-(4-metil-ciclohexil)-etil}-formamida.

N-hidroxi-N-{(R)-2-(4-metil-ciclohexil)-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-etil}-formamida.

N-hidroxi-N-{(R)-2-(4-metil-ciclohexil)-2-[N'-(morfolin-4-il-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-etil}-formamida.

N-hidroxi-N-{(R)-2-(4-metil-ciclohexil)-2-[N'-(4-metil-piridin-2-il)-hidrazinocarbonil]-etil}-formamida.

N-{(R)-2-[N'-(Dimetilamino-etil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-2-(4-metil-ciclohexil)-etil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(6,7-Dihidro-5H-ciclopentapirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-((R)-2-[N'-[4-Etil-6-((S)-2-hidroximetil-pirrolidin-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil]-hetil)-N-hidroxi-formamida.

N-{(R)-2-[N'-(Dimetilamino-piridin-3-il-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(Dimetilamino-piridin-4-il-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-N'-(5,6,7,8-tetrahidro-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-formamida.

N-{(R)-2-[N'-(5,6-Dietil-[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-[5-(4-hidroxi-fenil)-[1,2,4]triazin-3-il]-hidrazinocarbonil}-heptil)-formamida.

N-[(R)-2-(N'-{[(2-Dimetilamino-etil)-metil-amino]-etil-[1,3,5]triazin-2-il}-hidrazinocarbonil)-heptil]-N-hidroxi-formamida.

N-{(R)-2-[N'-(2-Dimetilamino-quinazolin-4-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-[5-(3-metanosulfonil-4,6-dimetil-piridin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-((R)-2-{N'-[4-Etil-6-(3-hidroxi-piperidin-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-[(R)-2-(N'-[4,5']Bipirimidinil-2-il-hidrazinocarbonil)-heptil]-N-hidroxi-formamida.

N-((R)-2-{N'-[(Ciclopropil-metil-amino)-etil-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-((R)-2-{N'-[4-Etil-6-((R)-3-hidroxi-pirrolidin-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-hidroxi-N-[(R)-2-(N'-[3,3']Bipiridinil-5-il-hidrazinocarbonil)-heptil]-formamida.

N-hidroxi-N-[(R)-2-(N'-[5-morfolin-4-il-piridin-3-il)-hidrazinocarbonil)-heptil]-formamida.

N-hidroxi-N-{(R)-2-[N'-(4-piridin-3-il-pirimidin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(5,6,7,8-tetrahidro-quinazolin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-[(R)-2-(N'-{[Ciclopropil-1-(1-metil-piperidin-4-il)-amino]-etil-]1,3,5]triazin-2-il}-hidrazinocarbonil)-heptil]-N-hidroxi-formamida.

N-((R)-2-{N'-[4-((R)-3-Dimetilamino-pirrolidin-1-il)-6-etil-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-hidroxi-N-[(R)-2-(N'-[5-(1H-pirrol-2-il)-piridin-3-il]-hidrazinocarbonil)-heptil]-formamida.

N-hidroxi-N-[(R)-2-(N'-[(4-metil-piperazin-1-il)-trifluorometil-pirimidin-4-il]-hidrazinocarbonil)-heptil]-formamida.

N-hidroxi-N-[(R)-2-(N'-(5-Furan-3-il-piridin-3-il)-hidrazinocarbonil)-heptil]-formamida.

N-{(R)-5,5-Dimetil-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-5,5-Dimetil-2-[N'-(7-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-5,5-Dimetil-2-[N'-(4-metil-piridin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-Cicloheptil-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-etil}-N-hidroxi-formamida.

N-{(R)-2-Cicloheptil-2-[N'-(4-metil-piridin-2-il)-hidrazinocarbonil]-etil}-N-hidroxi-formamida.

N-{(R)-2-Cicloheptil-2-[N'-(dimetilamino-etil-[1,3,5]triazin-2-il)-hidrazinocarbonil]-etil}-N-hidroxi-formamida.

N-{(R)-2-Cicloheptil-2-[N'-(7-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-etil}-N-hidroxi-formamida.

N-((R)-2-{N'-[4-Etil-6-(4-hidroxi-piperidin-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-{(R)-5,5-Dimetil-2-[N'-(5-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(4-Dimetilamino-quinazolin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(4-piridin-4-il-pirimidin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-((R)-2-{N'-[4-(3-hidroximetil-fenil)-pirimidin-2-il]-hidrazinocarbonil}-heptil)-formamida.

N-hidroxi-N-((R)-2-{N'-[4-(4-hidroximetil-fenil)-pirimidin-2-il]-hidrazinocarbonil}-heptil)-formamida.

N-((R)-2-{N'-[4-Etil-6-(3-metoxi-piperidin-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(7-metil-benżo[1,2,4]triazin-3-il)-hidrazinocarbonil]-2-(4-metil-ciclohexil)-etil}-formamida.

N-[(R)-2-{N'-[Etil-(etil-metilamino)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-2-)-metil-ciclohexil)-etil}-N-hidroxi-formamida.

N-[(R)-2-{N'-[Etil-(etil-metilamino)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-2-)-metil-ciclohexil)-etil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(7-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-2-(4-metil-ciclohexil)-etil}-formamida.

N-((R)-2-{N'-[4-(2,6-Dimetoxi-fenil)-pirimidin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-((R)-2-{N'-[4-Etil-6-((R)-3-metoxi-pirrolidin-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-((R)-2-{N'-[4-Etil-6-(4-metoxi-piperidin-1-il)-[1,3,5]triazin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-hidroxi-N-[(R)-2-(N'-(6-pirrolidin-1-il-pirimidin-4-il)-hidrazinocarbonil)-heptil]-formamida.

N-hidroxi-N-[(R)-2-(N'-[6-(4-metil-piperazin-1-il)-pirimidin-4-il])-hidrazinocarbonil)-heptil]-formamida.

N-{(R)-2-[N'-(6-Dimetilamino-pirimidin-4-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(Piridin-4-il-trifluorometil-pirimidin-4-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(Piridin-3-il-trifluorometil-pirimidin-4-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-2-[N'-(2-Etilamino-6-trifluorometil-pirimidin-4-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-((R)-2-{N'-[5-(4-metoxi-fenil)-[1,2,4]triazin-3-il]-hidrazinocarbonil}-heptil)-formamida.

N-hidroxi-N-((R)-2-{N'-[4-(2,3,4-trimetoxi-fenil)-pirimidin-2-il]-hidrazinocarbonil}-heptil)-formamida.

N-{(R)-4,4-Dimetil-2-[N'-(4-trifluorometil-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-4,4-Dimetil-2-[N'-(7-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-4,4-Dimetil-2-[N'-(5-metil-benzo[1,2,4]triazin-3-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(R)-4,4-Dimetil-2-[N'-(4-metil-piridin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(6-morfolin-4-il-pirimidin-4-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-[(R)-2-(N'-{5-[4-(2-hidroxi-etoxi)-fenil]-[1,2,4]triazin-3-il}-hidrazinocarbonil)-heptil]-formamida.

N-{(R)-2-[N'-(4-Furan-2-il-pirimidin-2-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-((R)-2-{N'-[4-(3,5-Dimetil-isoxazol-4-il)-pirimidin-2-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(4-metil-1-oxi-piridin-2-il)-hidrazinocarbonil]-heptil}-formamida.

Ácido 2-(N'-{(R)-2-[(Formil-hidroxi-amino)-metil]-heptanoil}-hidrazino)-6-metil-nicotínico.

N-hidroxi-N-{(R)-2-[N'-(3-metoxi-piridin-2-il)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(2R)-2-[(N'-{4-[4-(metilsulfonil)fenil]-pirimidin-2-il}-hidrazino)-carbonil]-heptil}-formamida.

N-hidroxi-N-[(2R)-2-({N'-[4-(furan-3-il)-pirimidin-2-il]-hidrazino}-carbonil)-heptil]-formamida.

N-[(2R)-2-({N'-[4-(2-aminofenil)-pirimidin-2-il]-hidrazino}-carbonil)-heptil]-N-hidroxi-formamida.

N-hidroxi-N-[(2R)-2-({N'-[5-(5-metil-1,3,4-oxadiazol-2-il)-4-(trifluorometil)-pirimidin-2-il]-hidrazino}-carbonil)-heptil]-formamida.

N-hidroxi-N-[(2R)-2-(ciclopentilmetil)-3-{N'-[5-(5-metil-1,3,4-oxadiazol-2-il)-4-(trifluorometil(-pirimidin-2-il]-hidrazino}-3-oxopropil)-formamida.

N-[(2R)-2-({N'-[6-(dimetilamino)-2-metil-pirimidin-4-il]-hidrazino}-carbonil)-heptil]-N-hidroxi-formamida.

N-[(2R)-2-({N'-[2-Ciclopropil-6-(dimetilamino)-pirimidin-4-il]-hidrazino}-carbonil)-heptil]-N-hidroxi-formamida.

N-hidroxi-N-[(2R)-4-(2-tienil)-2-({N'-[4-(trifluorometil)-pirimidin-2-il]-hidrazino}-carbonil)-butil]-formamida.

N-hidroxi-N-[(2R)-2-{[N'-(4-metil-pirimidin-2-il)hidrazino]carbonil}-4-(2-tienil)-butil]-formamida.

N-[(2R)-2-[(N'{4-Etil-6-[etil(metil)amino]-1,3,5-triazin-2-il}-hidrazino)-carbonil]-4-(2-tienil)butil]-N-hidroxi-formamida.

N-hidroxi-N-((2R)-3-oxo-2-(2-tienilmetil)-3-{N'[4-(trifluorometil)-pirimidin-2-il]-hidrazino}-propil)-formamida.

N-hidroxi-N-[(2R)-3-[N'(4-metil-pirimidin-2-il)hidrazino]-3-oxo-2-(2-tienilmetil)-propil]-formamida.

N-[(2R)-3-(N'{4-Etil-6-[etil(metil)amino]-1,3,5-triazin-2-il}hidrazino)-3-oxo-2-(2-tienilmetil)-propil]-N-hidroxi-formamida.

N-hidroxi-N-[(2R)-2-({N'[2-metil-6-(piridin-2-il)-pirimidin-4-il]-hidrazino}-carbonil)-heptil]-formamida.

N-hidroxi-N-[(2R)-2-({N'[6-(piridin-2-il-metil)-piridazin-3-il]-hidrazino}-carbonil)-heptil]-formamida.

N-hidroxi-N-[(2R)-2-({N'[2-metil-6-(morfolin-4-il)-pirimidin-4-il]-hidrazino}-carbonil)-heptil]-formamida.

N-hidroxi-N-[(2R)-2-({N'[6-(morfolin-4-il)-2-(trifluorometil)-pirimidin-4-il]-hidrazino}-carbonil)-heptil]-formamida.

N-hidroxi-N-{(2R)-2-[(N'{4-[metil-(piridin-2-il)-amino]-pirimidin-2-il}-hidrazino)-carbonil]-heptil}-formamida.

N-hidroxi-N-((2R)-2-(ciclopentilmetil)-3-{N'[4-ciclopropil-6-(dimetilamino)-1,3,5-triazin-2-il]-hidrazino}-3-oxopropil)-formamida.

éster *ter*-butílico del ácido *N*-Benzo[1,3]dioxol-5-il-metil-hidrazinacarboxílico.

N-[(2R)-2-(N'Benzo[1,3]dioxol-5-il-metil-hidrazinocarbonil)-heptil]-N-hidroxi-formamida.

N-{(2R)-2-[N'(2,3-Dihidro-[1,4]dioxino[1,2-b]piridin-7-il-metil)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(2R)-2-[N'(4-Dimetilamino-benzil)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-((R)-2-{N'[2-(5,6,7,8-tetrahidro-[1,8]naftiridin-2-il)-etil]-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-[(R)-2-(N'quinolin-2-il-metil-hidrazinocarbonil)-heptil]-formamida.

N-hidroxi-N-{(R)-2-[N'(1,2,3,4-tetrahidro-quinolin-2-il-metil)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-[(R)-2-(N'-quinolin-6-il-metil-hidrazinocarbonil)-heptil]-formamida.

N-[(2R)-2-(N'-Benzofuran-2-il-metil-hidrazinocarbonil)-heptil]-N-hidroxi-formamida.

N-[(2R)-2-(N'-Ciclopropilmetil-hidrazinocarbonil)-heptil]-N-hidroxi-formamida.

N-{(2R)-2-[N'-(6-Fluoro-4H-benzo[1,3]dioxin-8-il-metil)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(4-metoxi-benzil)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(2-metoxi-benzil)-hidrazinocarbonil]-heptil}-formamida.

N-hidroxi-N-{(R)-2-[N'-(tetrahidro-furan-3-il-metil)-hidrazinocarbonil]-heptil}-formamida.

N-[(2R)-2-(N'-Furan-3-il-metil-hidrazinocarbonil)-heptil]-N-hidroxi-formamida.

N-{(2R)-2-[N'-(2,3-Dihidro-benzo[1,4]dioxin-6-il-metil)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-{(2R)-2-[N'-(2,3-Dihidro-benzo[1,4]dioxin-2-il-metil)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(2-fenoxi-etil)-hidrazinocarbonil]-heptil}-formamida.

N-{(2R)-2-[N'-((S)-2,3-Dihidroxi-propil)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-hidroxi-N-{(R)-2-[N'-(5-metil-isoxazol-3-il-metil)-hidrazinocarbonil]-heptil}-formamida.

N-((R)-2-{N'-[1-(1-Benzo[1,3]dioxol-5-il-metanoil)-piperidin-4-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-((R)-2-{N'-[1-(1-Benzofuran-2-il-metanoil)-piperidin-4-il]-hidrazinocarbonil}-heptil)-N-hidroxi-formamida.

N-hidroxi-N-[(R)-2-(N'-{1-[1-(7-metoxi-benzofuran-2-il)-metanoil]-piperidin-4-il}-hidrazinocarbonil)-heptil]-formamida.

N-{(R)-2-[N'-(1-Benzil-piperidin-4-il)-hidrazinocarbonil]-heptil}-N-hidroxi-formamida.

N-[(R)-2-(N'-{1-[1-(3,4-Dicloro-fenil)-metanoil]-piperidin-4-il}-hidrazinocarbonil)-heptil]-N-hidroxi-formamida.

N-[(R)-2-(N'-{1-[1-(2,3-Dicloro-fenil)-metanoil]-piperidin-4-il}-hidrazinocarbonil)-heptil]-N-hidroxi-formamida.

N-hidroxi-N-[(R)-2-(N'-{1-[1-(4-metil-piperazin-1-il)-metanoil]-pentil}-hidrazinocarbonil)-heptil]-formamida.

N-[(R)-2-(N'-Benzil-hidrazinocarbonil)-heptil]-N-hidroxi-formamida

5. Un método para tratar una infección bacteriana administrando a un sujeto que necesita tratamiento un compuesto según la reivindicación 1.

312

## RESUMEN DE LA DESCRIPCIÓN

Se proporcionan nuevos inhibidores de PDF y nuevos métodos para su empleo.

5

# PATENT COOPERATION TREATY

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:
SOMA G. SIMON
SMITHKLINE BEECHAM CORPORATION
COPORATE INTELLECTUAL PROPERTY,UW2220
709 SWEDELAND ROAD, P.O. BOX 1539
KING OF PRUSSIA, PA 19406-0939

# PCT

## NOTIFICATION OF TRANSMITTAL OF INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Rule 71.1)

| Date of Mailing (day/month/year) | 01 SEP 2004 |
|---|---|

| Applicant's or agent's file reference | IMPORTANT NOTIFICATION |
|---|---|
| P51358 | |

| International application No. | International filing date (day/month/year) | Priority date (day/month/year) |
|---|---|---|
| PCT/US03/17054 | 30 May 2003 (30.05.2003) | 31 May 2002 (31.05.2002) |

Applicant

SMITHKLINE BEECHAM CORPORATION

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.

2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.

3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices)(Article 39(1))(see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

2004 SEP -3 P

| Name and mailing address of the IPEA/US | Authorized officer |
|---|---|
| Mail Stop PCT, Attn: IPEA/US<br>Commissioner for Patents<br>P.O. Box 1450<br>Alexandria, Virginia 22313-1450 | BERNARD DENTZ |
| Facsimile No. (7023) 305- 3230 | Telephone No. (703) 389-1235 |

Form PCT/IPEA/416 (July 1992)

PATENT COOPERATION TREATY

# PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

**(PCT Article 36 and Rule 70)**

| Applicant's or agent's file reference<br>P51358 | FOR FURTHER ACTION | See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416) |
|---|---|---|
| International application No.<br>PCT/US03/17054 | International filing date (day/month/year)<br>30 May 2003 (30.05.2003) | Priority date (day/month/year)<br>31 May 2002 (31.05.2002) |

International Patent Classification (IPC) or national classification and IPC

IPC(7): A61K 31/16, 31/18, 31/44, 31/50, 31/505, 31/495; C07C 243/22, 311/16; C07D 213/77, 237/22, 239/42, 2 and US Cl.: 514/247, 249, 275, 303, 353, 604, 614; 544/224, 297, 356; 546/119, 306; 564/81, 151

Applicant

SMITHKLINE BEECHAM CORPORATION

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 3 sheets, including this cover sheet.

   ☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

   These annexes consist of a total of — sheets.

3. This report contains indications relating to the following items:

   - I ☒ Basis of the report
   - II ☐ Priority
   - III ☐ Non-establishment of report with regard to novelty, inventive step and industrial applicability
   - IV ☐ Lack of unity of invention
   - V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
   - VI ☐ Certain documents cited
   - VII ☐ Certain defects in the international application
   - VIII ☐ Certain observations on the international application

| Date of submission of the demand | Date of completion of this report |
|---|---|
| 18 November 2003 (18.11.2003) | 11 February 2004 (11.02.2004) |
| Name and mailing address of the IPEA/US<br>Mail Stop PCT, Attn: IPEA/US<br>Commissioner for Patents<br>P.O. Box 1450<br>Alexandria, Virginia 22313-1450<br>Facsimile No. (703)305-3230 | Authorized officer<br>Bernard Dentz<br>Telephone No. 703 308-1235 |

Form PCT/IPEA/409 (cover sheet)(July 1998)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/US03/17054

315

## I. Basis of the report

1. With regard to the elements of the international application:*

☒ the international application as originally filed.

☒ the description:
pages 1-114 as originally filed
pages NONE, filed with the demand
pages NONE, filed with the letter of _____.

☒ the claims:
pages 115-137, as originally filed
pages NONE, as amended (together with any statement) under Article 19
pages NONE, filed with the demand
pages NONE, filed with the letter of _____.

☐ the drawings:
pages NONE, as originally filed
pages NONE, filed with the demand
pages NONE, filed with the letter of _____.

☐ the sequence listing part of the description:
pages NONE, as originally filed
pages NONE, filed with the demand
pages NONE, filed with the letter of _____.

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.
These elements were available or furnished to this Authority in the following language _____ which is:

☐ the language of a translation furnished for the purposes of international search (under Rule23.1(b)).

☐ the language of publication of the international application (under Rule 48.3(b)).

☐ the language of the translation furnished for the purposes of international preliminary examination(under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

☐ contained in the international application in printed form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. ☐ The amendments have resulted in the cancellation of:

☐ the description, pages NONE

☐ the claims, Nos. NONE

☐ the drawings, sheets/fig NONE

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

** Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).*
*** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.*

International application No.
PCT/US03/17054

316

**V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. STATEMENT

| | | | |
|---|---|---|---|
| Novelty (N) | Claims | 1-5 | YES |
| | Claims | | NO |
| Inventive Step (IS) | Claims | 1-5 | YES |
| | Claims | | NO |
| Industrial Applicability (IA) | Claims | 1-5 | YES |
| | Claims | | NO |

2. CITATIONS AND EXPLANATIONS

Claims 1-5 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest the instant N-hydroxyformamides

Claims 1-5 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claimed can be made or used in industry.

---------- NEW CITATIONS ----------

# PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY

To:
SOMA G. SIMON
SMITHKLINE BEECHAM CORPORATION
CORPORATE INTELLECUTAL PROPERTY , UW2220
709 SWEDELAND ROAD, P.O. BOX 1539
KING OF PRUSSIA, PA 19406-0939

# PCT

NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT OR THE DECLARATION

(PCT Rule 44.1)

| | |
|---|---|
| | Date of Mailing (*day/month/year*) 02 OCT 2003 |
| Applicant's or agent's file reference P51358 | FOR FURTHER ACTION See paragraphs 1 and 4 below |
| International application No. PCT/US03/17054 | International filing date (*day/month/year*) 30 May 2003 (30.05.2003) |
| Applicant SMITHKLINE BEECHAM CORPORATION | |

1. ☒ The applicant is hereby notified that the international search report has been established and is transmitted herewith.

   **Filing of amendments and statement under Article 19:**
   The applicant is entitled, if he so wishes, to amend the claims of the international application (see Rule 46):

   **When?** The time limit for filing such amendments is normally two months from the date of transmittal of the international search report.

   **Where?** Directly to the International Bureau of WIPO, 34, chemin des Colombettes 1211 Geneva 20, Switzerland, Facsimile No.: (41-22) 740.14.35

   **For more detailed instructions,** see the notes on the accompanying sheet.

2. ☐ The applicant is hereby notified that no international search report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

3. ☐ With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

   ☐ the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.

   ☐ no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. **Reminders**

   Shortly after 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90 *bis*.1 and 90 *bis*.3, respectively, before the completion of the technical preparations for international publication.

   Within 19 months from the priority date, but only in respect of some designated Offices, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later); otherwise the applicant must, within 20 months from the priority date, perform the prescribed acts for entry into the national phase before those designated Offices.

   In respect of other designated Offices, the time limit of 30 months (or later) will apply even if no demand is filed within 19 months.

   See the Annex to Form PCT/IB/301 and, for details about the applicable time limits, Office by Office, see the *PCT Applicant's Guide*, Volume II, National Chapters and the WIPO Internet site.

| | |
|---|---|
| Name and mailing address of the ISA/US<br>Mail Stop PCT, Attn: ISA/US<br>Commissioner for Patents<br>P.O. Box 1450<br>Alexandria, Virginia 22313-1450<br>Facsimile No. (703)305-3230 | Authorized officer<br>Bernard Dentz<br>Telephone No. 703 308-1235 |

Form PCT/ISA/220 (April 2002) *(See notes on accompanying sheet)*

# PATENT COOPERATION TREATY

# PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

| Applicant's or agent's file reference P51358 | FOR FURTHER ACTION | see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below |
|---|---|---|
| International application No. PCT/US03/17054 | International filing date (*day/month/year*) 30 May 2003 (30.05.2003) | (Earliest) Priority Date (*day/month/year*) 31 May 2002 (31.05.2002) |
| Applicant SMITHKLINE BEECHAM CORPORATION | | |

This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of ~~1~~ sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. **Basis of the Report**
   a. With regard to the language, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.
   ☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).
   b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing:
   ☐ contained in the international application in written form.
   ☐ filed together with the international application in computer readable form.
   ☐ furnished subsequently to this Authority in written form.
   ☐ furnished subsequently to this Authority in computer readable form.
   ☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
   ☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.
2. ☐ Certain claims were found unsearchable (See Box I).
3. ☐ Unity of invention is lacking (See Box II).
4. With regard to the title,
   ☒ the text is approved as submitted by the applicant.
   ☐ the text has been established by this Authority to read as follows:

5. With regard to the abstract,
   ☒ the text is approved as submitted by the applicant.
   ☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the drawings to be published with the abstract is Figure No. ____
   ☐ as suggested by the applicant. ☐ None of the figures
   ☐ because the applicant failed to suggest a figure.
   ☐ because this figure better characterizes the invention.

# INTERNATIONAL SEARCH REPORT

International application No.
PCT/US03/17054

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) : A61K 31/16, 31/18, 31/44, 31/50, 31/505, 31/495; C07C 243/22, 311/16; C07D 213/77, 237/22, 239/42, 2
US CL : 514/247, 249, 275, 303, 353, 604, 614; 544/224, 297, 356; 546/119, 306; 564/81, 151

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)
U.S. : 514/247, 249, 275, 303, 353, 604, 614; 544/224, 297, 356; 546/119, 306; 564/81, 151

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
CAS ONLINE-Structure search

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|---|---|---|
| A ,P | WO 02/070541 A2 (XIANG ET AL) 12 SEPTEMBER 2002. | 1-5 |

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

| Date of the actual completion of the international search | Date of mailing of the international search report |
|---|---|
| 15 August 2003 (15.08.2003) | 02 OCT 2003 |
| Name and mailing address of the ISA/US<br>Mail Stop PCT, Attn: ISA/US<br>Commissioner for Patents<br>P.O. Box 1450<br>Alexandria, Virginia 22313-1450<br>Facsimile No. (703)305-3230 | Authorized officer<br>Bernard Dentz<br>Telephone No. 703 308-1235 |

Form PCT/ISA/210 (second sheet) (July 1998)

320

SUPERINDUSTRIA Y COMERCIO
Radicacion : 04120865 00000000 Folios: 315
Fecha (AMD): 2004-11-29 17:36:04
Tramite : 811 PCT-PATENT 379 FASE NACI 411 PRESENTA
Dependencia: 2020 DIVISION DE NUEVAS CREACIONES

# REQUISITOS NECESARIOS PARA PRESENTACION Y AGILIZACION DEL TRAMITE

| | USUARIO | RADICADOR |
|---|---|---|
| **PATENTE DE INVENCIÓN** *MODELO DE UTILIDAD* | (✓) | (✓) |
| - Indicación de que se solicita la concesión de una patente. | (✓) | (✓) |
| - Datos de identificación del solicitante o de la persona que se presenta la solicitud. | (✓) | (✓) |
| - Descripción de la invención. | (✓) | (✓) |
| - Dibujos de ser estos pertinentes. | (✓) | (✓) |
| - Comprobante de Pago de las tasas establecidas. | | |
| **COMPLETA** (✓) **INCOMPLETA** | ( ) | ( ) |
| **DISEÑO INDUSTRIAL** ( ) | | |
| - Indicación de que se solicita el registro de Diseño Industrial | ( ) | ( ) |
| - Datos de identificación del solicitante o de la persona que presenta | ( ) | ( ) |
| - la solicitud. | | |
| - Representación gráfica o fotográfica del Diseño Industrial o muestra del Material que incorpora el diseño. | ( ) | ( ) |
| Comprobante de pago de las tasas establecidas | ( ) | ( ) |
| **COMPLETA** ( ) **INCOMPLETA** | ( ) | ( ) |
| **ESQUEMA DE TRAZADO** ( ) | | |
| - Indicación de que solicita el registro de un Esquema de trazado. | ( ) | ( ) |
| - Datos de identificación del solicitante o de la persona que presenta La solicitud. | ( ) | ( ) |
| Representación gráfica del esquema de trazado | ( ) | ( ) |
| Comprobante de pago de las tasas establecidas. | ( ) | ( ) |
| **COMPLETA** ( ) **INCOMPLETA** | ( ) | ( ) |

**Firma Responsable:**

**Fecha:**

321

321

Industria y Comercio
SUPERINTENDENCIA

2020
Bogotá D C

Doctor(a)
**CARLOS R. OLARTE**
Apoderado(a)
SMITHKLINE BEECHAM CORPORATION

Oficio N° 11333

**ASUNTO:**

| | |
|---|---|
| Radicación N° | 04-120065 |
| Solicitud internacional | PCT/US03/17054 |
| Fecha inicio fase nacional | 31/12/2004 |
| Trámite | 011 |
| Evento | 379 |
| Actuación | 430 |
| Folios | 001 |

Como resultado del examen de forma, realizado con fundamento en el artículo 38 de la Decisión 486 de la Comisión de la Comunidad Andina, artículo 27 del Tratado de Cooperación en Materia de Patentes (PCT), regla 51 bis del Reglamento y Circular Única de la Superintendencia de Industria y Comercio, se le comunica que:

- La solicitud no contiene copia del documento en que consta la cesión del derecho de patente del inventor al solicitante o a su causante (Art. 26-k) Decisión 486).
- El solicitante debe presentar un nuevo título, que permita identificar la materia de la cual trata la solicitud, ya que el relacionado no se encuentra con la precisión necesaria para identificar claramente el objeto de la solicitud de patente (Regla 4.3 PCT, Art. 27, 27 Decisión 486, Circular Única 5.2.9).

En cumplimiento de lo dispuesto por el artículo 39 de la Decisión 486, se le requiere para que dentro del término de dos meses siguientes a la fecha de notificación del presente oficio, complete los requisitos anteriormente enunciados. En caso de no dar cumplimiento al presente requerimiento, la solicitud se considerará abandonada y perderá su prelación.

Notifíquese el presente oficio conforme a lo dispuesto en el numeral 5.2, literal e), del capítulo quinto del título primero de la Circular Única N° 10 de 2001.

**ALIX CARMENZA CESPEDES DE VERGEL**
Jefe de la División de Nuevas Creaciones.

El anterior requerimiento fue notificado por fijación en lista de fecha,
10 DIC. 2004

202044

Sede Centro: Carrera 13 No. 27-00 Pisos 2, 5, 7 y 10
Conmutador: 3 820840 Fax: 3 505220
Sede CAN: Tr. 40A No. 38-50 3153265 al 69
Fax: 3 505220. Línea 9800-910 165
Web: www.sic.gov.co e-mail: info@sic.gov.co
Bogotá D.C. - Colombia